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2   Key messages 
Key messages 
This Health Technology Assessment was commissioned by the “National 
system for the introduction of new health technologies within the specialist 
health service”. The aim of this report was to assess the effect and cost-ef-
fectiveness of the disease modifying medicines used in Norway for patients 
with relapsing remitting multiple sclerosis (dimethyl fumarate, terifluno-
mide, interferon beta, peg-interferon, glatiramer acetate, natalizumab, fin-
golimod, and alemtuzumab). 
 
The key results are:  
 
 We identified 37 randomised clinical trials. The quality of the available 
evidence ranged from very low to high.  
 
 Alemtuzumab 12 mg had the best effect on annual relapse (for medicines 
we had evidence of high quality). Dimethyl fumarate 240 mg twice daily 
and fingolimod oral 0.5 mg were the most effective against disability 
progression (for medicines we had evidence of high quality). 
 
 Our results indicated that interferon beta-1a 44 mcg and peg-interferon 
beta-1a were associated with more withdrawal due to adverse events 
than placebo. The examined treatments had no effect on mortality 
compared to placebo. 
 
 Our health economic analysis, examining all multiple sclerosis 
treatment alternatives, indicated that alemtuzumab was more effective 
(in terms of quality-adjusted life-years (QALY)) and less costly than the 
other treatment alternatives. We did several scenario analyses and the 
cost-effectiveness results were robust to variations in the model 
assumptions. 
 
 The results of a scenario analysis that excluded alemtuzumab (the 
dominant strategy), showed that three treatments alternatives 
(interferon beta-1b (Extavia), peg-interferon beta-1a and natalizumab) 
could be cost-effective depending on the willingness-to-pay (WTP) per 
QALY. Assuming a WTP below NOK 1,000,000, interferon beta-1b 
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(Extavia) was 40% likely to be the most cost-effective treatment, followed by peg-
interferon beta-1a (30% likely). 
 
 The results of our model analysis showed that there is some degree of uncertainty 
regarding the input parameters. More research on efficacy and epidemiological 
data would have the greatest impact on reducing decision uncertainty. 
 
 Our bugdet impact analysis based on the results of our cost-effectiveness analysis, 
the drugs’ adverse events profile, and current clinical practice showed that there 
is a substantial potential for cost saving.  
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Executive summary 
Background 
Several disease-modifying therapies are available for the treatment of multiple scle-
rosis, but the comparative clinical effectiveness of these medicines is unclear. Further-
more, the cost-effectiveness of the different treatments has not been investigated in a 
Norwegian setting. To ensure the most appropriate multiple sclerosis management, it 
is important to assess effectiveness and cost-effectiveness of disease modifying med-
icines used for multiple sclerosis.  
 
Objective 
The aim of this project was to compare the effect and cost-effectiveness of the disease 
modifying medicines used for multiple sclerosis in Norway. 
 
Methods 
We conducted a systematic review based on the following conditions: Evidence should 
come from randomised controlled trials (RCTs) with study populations that included 
men and women aged 18 years or older were eligible. Modifying medicines used for 
multiple sclerosis were our intervention of interest (dimethyl fumarate, terifluno-
mide, interferon beta, peg-interferon, glatiramer acetate, natalizumab, fingolimod, 
and alemtuzumab). We included studies that compared these medicines to placebo or 
to each other. We examined the following endpoints: annual relapse, disability pro-
gression, mortality, serious adverse events, withdrawal from the study due to adverse 
events, hospitalisations, and health related quality of life.   
 
We systematically searched the literature for previously published health technology 
assessment reports or systematic reviews that answered our objectives, and met our 
inclusion criteria. We conducted a systematic review of randomised controlled trials 
to supplement the evidence of previously published health technology assessments.  
 
Two persons independently examined the risk of bias of included studies using the 
Norwegian Knowledge Centre for the Health Services methods. These are based on 
Cochrane methodology. 
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We summarised the evidence from the randomised clinical trials quantitavely through 
network meta-analyses of data on direct and indirect evidence on all relevant com-
parisons.  
 
Two persons independently assessed the quality of the evidence for each selected end-
point. We used GRADE (Grading of recommendations Assessment, Development, 
and Evaluation) to assess our confidence in the effect estimates.  
 
In order to assess the cost-effectiveness of disease-modifying therapies in patients di-
agnosed with relapsing-remitting multiple sclerosis, we developed a decision analytic 
model. The economic model was developed in the form of a cost-utility analysis and 
included treatments approved and available in Norway. The model structure and all 
assumptions were adapted to the Norwegian setting based on Norwegian clinical 
practice. Efficacy estimates were taken from our network meta-analyses. Transitional 
probabilities were derived from published sources and clinical experts’ opinions. 
Quality of life data were extracted from published studies based on a systematic re-
view of the literature. The costs of medications were based on prices obtained through 
the Drug procurement cooperation (LIS), and other costs were based on official Nor-
wegian unit prices. 
 
We performed probabilistic sensitivity analyses, designed as a Monte Carlo simula-
tion with 10,000 iterations, to explore the uncertainty surrounding our results. 
 
Results 
All examined treatments were more effective than placebo against annual relapse. The 
effect was best for alemtuzumab 12 mg (based on high quality evidence). Fingolimod 
oral 0.5 mg and dimethyl fumarate 240 mg twice daily were also associated with a 
reduction in annualised relapse rate. For disability progression, dimethyl fumarate 
240 mg twice daily and fingolimod 0.5 mg were more effective than placebo (high 
quality evidence). 
 
For withdrawal due to adverse events, the conclusion is unclear due to the low quality 
of the available evidence. However, our results indicate that interferon beta-1a 44 
mcg, and peg-interferon beta-1a are associated with more withdrawal due to adverse 
events than placebo. 
 
For the outcomes change in expanded disability status scale, serious adverse events, 
and mortality; we did not assess the quality of the available evidence. Our results in-
dicate that interferon beta-1a 30 mcg is associated with a reduction in expanded dis-
ability status scale. Interferon beta-1a 30 mcg is associated with fewer serious adverse 
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events. Finally, our results showed that none of the examined treatments increased or 
decreased mortality compared to placebo. 
 
Our health economic analysis indicated that alemtuzumab dominated all other dis-
ease-modifying therapies, as it was more effective in terms of quality-adjusted life-
years (QALY) and less costly than the other treatment alternatives.  
 
A scenario analysis that excluded alemtuzumab (the dominant strategy) showed that 
three treatment alternatives (interferon beta-1b (Extavia), peg-interferon beta-1a and 
natalizumab) could be cost-effective depending on the willingness-to-pay (WTP) 
threshold. Interferon beta-1b was likely to be the cost-effective choice for a WTP per 
QALY below NOK 1,658,000. Peg-interferon was the cost-effective option for a WTP 
from NOK 1,658,450 to NOK 1o,619,960, and natalizumab was the cost-effective al-
ternative for a WTP above NOK 10,619,960. Assuming a WTP below NOK 1,000,000 
per QALY, interferon beta-1b (Extavia) was approximately 40% likely to be the most 
cost-effective treatment, followed by peg-interferon beta-1a (approximately 30% 
likely).  
 
The results of probabilistic analysis showed that there is some degree of uncertainty 
regarding the input parameters. More research on efficacy and epidemiologic input 
parameters would have the greatest impact on reducing decision uncertainty.  
 
We performed several scenario analyses to test the uncertainty around the model as-
sumptions. The results showed that, while there were numerical changes to the incre-
mental cost-effectiveness ratio, the cost-effectiveness results were robust to variations 
in the model assumptions and the conclusions of the analysis would not change. 
 
Our bugdet impact analysis based on the results of our cost-effectiveness analysis, the 
drugs’ adverse events profile, and current clinical practice showed that there is a 
substantial potential for cost saving.  
 
Discussion 
We used a systematic methodology to search for evidence, extract data, and assess the 
risk of bias of studies and quality of evidence for important outcomes. The systematic 
review included evidence on both established and emerging treatments. We examined 
the effect of these treatments on clinical endpoints relevant for patients with multiple 
sclerosis. We have analysed direct and indirect evidence through network meta-anal-
yses. The consistency of results using different methods indicates that our results are 
robust. 
 
Our systematic review has some limitations, due more to the weakness of the available 
evidence than to the methods used in this report. These limitations are related to the 
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paucity and quality of the available evidence, and to the methodologies used in the 
included randomised controlled trials. 
 
We used a probabilistic Markov-model, considered the appropriate approach for sim-
ulating the natural history of multiple sclerosis. The model structure and all assump-
tions have been adapted to the Norwegian setting based on Norwegian clinical prac-
tice with close assistance of experts in this field. 
 
For transitional probabilities, we did not find Norwegian data that were compatible 
with the developed model, so these were based on estimates reported in the published 
literature. 
 
Study designs of published trials did not permit separate analyses of first and second 
line treatments, or conclusions regarding the sequential use of first and second line 
treatments. Therefore, we did not perform separate cost-effectiveness analyses for 
first or second line treatments. In addition, based on expert opinion, we did not in-
clude combination therapy in our model, as it is not relevant to current Norwegian 
clinical practice. 
 
Conclusion 
Alemtuzumab 12 mg had the best effect against annual relapse. Dimethyl fumarate 
240 mg twice daily and fingolimod oral 0.5 mg were the most effective against disa-
bility progression. Results indicate that some treatments are associated with more 
withdrawals due to adverse events than placebo. Our results showed that the exam-
ined treatments had no effect on mortality. 
 
Our health economic analysis indicated that alemtuzumab was more effective and less 
costly than the other treatment alternatives. A scenario analysis that excluded 
alemtuzumab indicated that three treatment alternatives (interferon beta-1b (Exta-
via), peg-interferon beta-1a and natalizumab) could be cost-effective depending on 
the WTP. For a WTP below NOK 1,000,000 per QALY, interferon beta-1b (Extavia) 
was approximately 40% likely to be the most cost-effective treatment, followed by 
peg-interferon beta-1a (approximately 30% likely). 
 
The results of probabilistic analysis showed that there is some degree of uncertainty 
regarding the input parameters. More research on efficacy and epidemiologic input 
parameters would have the greatest impact on reducing decision uncertainty.  
 
Our budget impact analysis showed that there is a substantial potential for cost sav-
ing. 
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Hovedfunn (norsk) 
Denne fullstendige metodevurderingen ble bestilt av «Nasjonalt system for 
innføring av nye metoder i spesialisthelsetjenesten». Målet var å sammen-
ligne effekt, sikkerhet og kostnadseffektivitet av sykdomsmodifiserende le-
gemidler som brukes for multippel sklerose i Norge (dimetylfumarat, 
teriflunomid, interferon beta, peginterferon, glatirameracetat, natali-
zumab, fingolimod og alemtuzumab). 
 
Hovedfunnene er:  
 
 Vi identifiserte 37 randomiserte kontrollerte studier og kvaliteten på 
dokumentasjon varierte fra veldig lav til høy. 
 
 Basert på sammenligninger hvor kvaliteten på dokumentasjonen var 
høy kan vi si at alemtuzumab 12 mg hadde den beste effekten mot 
årlig tilbakefall, og at dimetylfumarat 240 mg to ganger om dagen 
og fingolimod 0.5 mg var de mest effektive mot sykdomsprogresjon. 
 
 Våre resultater indikerer at interferon beta-1a 44 mcg, og peginter-
feron beta-1a var assosiert med høyere frafall på grunn av bivirk-
ninger enn placebo. Våre resultater viste ingen av behandlingene 
hadde effekt på dødelighet. 
 
 Vår helseøkonomiske analyse indikerte at alemtuzumab var bedre 
og mindre kostnadskrevende enn de andre behandlingsalternati-
vene. Vi utførte flere scenarioanalyser for å teste usikkerheten rundt 
forutsetninger ved modellen, men konklusjonene endret seg ikke. 
 
 En scenarioanalyse hvor alemtuzumab (den dominante strategien) 
ble ekskludert, viste at tre behandlingsalternativer (interferon beta-
1b (Extavia), peginterferon beta-1a og natalizumab) kunne være 
kostnadseffektive, avhengig av betalingsvilje per vunnet kvalitetjus-
tert leveår (QALY).  Ved å anta en betalingsvilje under en million 
kroner per vunnet QALY, var interferon beta-1b (Extavia) trolig den 
mest kostnadseffektive behandlingen (ca. 40 %), etterfulgt av 
peginterferon beta-1a (ca. 30 %).  
 
Tittel: 
Fullstendig metodevurdering av 
legemidler ved multippel 
sklerose  
------------------------------------------ 
Publikasjonstype: 
Metodevurdering 
En metodevurdering er 
resultatet av å 
- innhente 
- kritisk vurdere og 
- sammenfatte 
relevante forskningsresultater 
ved hjelp av forhåndsdefinerte 
og eksplisitte metoder. 
 
Minst ett av følgende tillegg 
er også med: 
helseøkonomisk evaluering, 
vurdering av konsekvenser for 
etikk, jus, organisasjon eller 
sosiale forhold  
------------------------------------------ 
Svarer ikke på alt: 
- Ingen studier utenfor de 
eksplisitte inklusjonskriteriene 
- Ingen anbefalinger  
------------------------------------------ 
Hvem står bak denne 
rapporten? 
Folkhelseinstuttet har skrevet 
rapporten på oppdrag fra  
Nasjonalt system for innføring 
av nye metoder i spesialist- 
helsetjenesten 
------------------------------------------ 
Når ble litteratursøket 
utført? 
Søk etter studier ble avsluttet  
november 2015 
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 Vår modellanalyse viste at det er en viss grad av usikkerhet knyttet til parame-
terne brukt i analysen. Mer forskning på effekt av legemidlene eller bedre epi-
demiologiske data fra norske registre ville hatt størst innvirkning på å redu-
sere beslutningsusikkerhet. 
 
 Vår budsjettkonsensanalyse basert på resultatene av vår kostnadseffektivitets-
analyse, bivirkninger knyttet til behandlingsalternativene og dagens kliniske 
praksis viste at det er et betydelig potensial for å redusere kostnadene knyttet 
til MS-behandling i spesialisthelsetjenesten. 
 
 10   Sammendrag (norsk) 
Sammendrag (norsk) 
Fullstendig metodevurdering av legemidler ved multippel sklerose  
 
Bakgrunn 
Det finnes flere sykdomsmodifiserende legemidler godkjent til bruk ved multippel 
sklerose, men en fullstendig sammenligning av den kliniske effektiviteten på tvers av 
alle disse har ikke vært gjort. Kostnadseffektiviteten av de ulike behandlingene er hel-
ler ikke blitt undersøkt i en norsk setting.  
 
Problemstilling 
Målet vårt var å sammenligne effekt, sikkerhet og kostnadseffektivitet av sykdoms-
modifiserende legemidler som brukes for multippel sklerose i Norge.  
 
Metode 
Vi utførte en systematisk oversikt, hvor vi inkluderte randomiserte kontrollerte stu-
dier på personer over 18 år med multippel sklerose behandlet med følgende legemid-
ler: dimetylfumarat, teriflunomid, interferon beta, peginterferon, glatirameracetat, 
natalizumab, fingolimod og alemtuzumab. Vi inkluderte studier som sammenlignet 
disse medisinene med placebo eller med hverandre. Vi undersøkte følgende kliniske 
endepunkt: årlig attakk, sykdomsprogresjon, dødelighet, alvorlige bivirkninger, fra-
fall fra studien på grunn av bivirkninger, sykehusinnleggelser og helserelatert livskva-
litet.  
 
Vi søkte etter publiserte Health Technology Assessment (HTA) rapporter og systema-
tiske oversikter som besvarte vår problemstilling. Deretter søkte vi etter randomiserte 
kontrollerte studier for å supplere kunnskapsgrunnlaget med informasjon publisert 
etter søkedato i den nyeste, mest omfattende HTA rapporten vi identifiserte.  
 
To personer undersøkte uavhengig av hverandre kvaliteten på den inkluderte HTA-
rapporten og risiko for systematiske skjevheter i de supplerende studiene. Vi oppsum-
merte kliniske resultater gjennom nettverks meta-analyser som baserer seg på både 
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direkte og indirekte sammenligninger. Til slutt brukte vi GRADE (Grading av anbefa-
linger Assessment, Development, and Evaluation) for å vurdere kvaliteten på doku-
mentasjonen og vår vår tillit til effektestimatene.  
 
For å vurdere kostnadseffektiviteten av de sykdomsmodifiserende legemidlene hos 
pasienter med relapsing-remitting multippel sklerose, utviklet vi en helseøkonomisk 
modell (Markov-modell). Modellstruktur og alle forutsetninger ble tilpasset norsk kli-
nisk praksis. Effektestimatene ble tatt fra vår systematiske gjennomgang av klinisk 
effekt og sikkerhet. Overgangssannsynligheter ble hentet fra publiserte kilder og sup-
plert med opplysninger fra kliniske eksperter. Livskvalitetsdata ble hentet fra publi-
serte studier indentifisert gjennom en systematisk gjennomgang av litteratur. Kost-
nader på medisiner ble basert på priser fra Legemiddelinnkjøpssamarbeidet (LIS), og 
andre kostnader var basert på norske kilder. Vi utførte probabilistiske sensitivitets-
analyser, utformet som en Monte Carlo-simulering med 10,000 gjentakelser, for å 
analysere usikkerheten i våre resultater.  
 
Resultat 
Alle undersøkte legemidler var mer effektive enn placebo mot årlig attakk. Effekten 
var best for alemtuzumab 12 mg (basert på evidens av høy kvalitet). For sykdomspro-
gresjon var dimetylfumarat og fingolimod mer effektivt enn placebo (evidens av høy 
kvalitet).  
 
For frafall på grunn av bivirkninger var det lavere kvalitet på tilgjengelig dokumenta-
sjon, noe som knytter mer usikkerhet til resultatene. Men våre resultater indikerer at 
både interferon beta-1a 44 mcg, og peginterferon beta-1a begge er assosiert med høy-
ere frafall på grunn av bivirkninger enn placebo.  
 
Vi vurderte ikke kvaliteten på tilgjengelig dokumentasjon om endring i uførhetssta-
tusskalaen EDSS (expanded disabliltity symptom scale), alvorlige bivirkninger og 
dødsfall. Våre resultater tyder på at interferon beta-1a 30 mcg var relatert til en re-
duksjon i EDSS nivå. Interferon beta-1a 30 mcg var assosiert med færre alvorlige bi-
virkninger. Til slutt, viser våre resultater at ingen av de undersøkte behandlinger ga 
økt dødelighet sammenlignet med placebo.  
 
Vår helseøkonomiske analyse indikerte at alemtuzumab dominerte alle andre syk-
domsmodifiserende behandlinger. Alemtuzumab var både mer effektiv og mindre 
kostnadskrevende enn de andre behandlingsalternativene.  
 
Resultatene av en scenarioanalyse hvor alemtuzumab (den dominante strategien) ble 
ekskludert, viste at tre behandlingsalternativer (interferon beta-1b (Extavia), peg-
interferon beta-1a og natalizumab) kunne være kostnadseffektive, avhengig av beta-
lingsvilje per vunnet kvalitetjustert leveår (quality-adjusted life-years, QALY). Forut-
satt en betalingsvilje (Willingness to pay, WTP) lavere enn 1 658 000 kroner per 
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QALY, vil Interferon beta-1b sannsynligvis være et kostnadseffektivt valg. For en WTP 
mellom 1 658 450 og 1o 619 960 kroner var peginterferon et kostnadseffektivt alter-
nativ, og for en WTP over 10 619 960 kroner var natalizumab et kostnadseffektivt al-
ternativ. Ved å anta en betalingsvilje på under 1 000 000 kroner per vunnet QALY var 
interferon beta-1b (Extavia) trolig den mest kostnadseffektive behandlingen (ca. 
40%), fulgt av peginterferon beta-1a (ca. 30%).  
 
Sannsynlighetsanalyser viste at det er usikkerhet knyttet til parameterne benyttet i 
modellen. Mer forskning på effekt av legemidlene eller bedre epidemiologiske data fra 
norske registre ville hatt størst innvirkning på å redusere beslutningsusikkerhet. 
 
Vi utførte flere scenarioanalyser for å teste usikkerheten rundt ulike helseøkonmiske 
modellforutsetninger. Selv om det var numeriske endringer i resultater, så var resul-
tatene for kostnadseffektivitet robuste og konklusjonene fra analysen endret seg ikke.  
 
Vår budsjettkonsensanalyse basert på resultater av kostnadseffektivitetsanalysen vår, 
bivirkninger knyttet til behandlingsalternativene og dagens kliniske praksis viste at 
det er et betydelig potensial for å redusere kostnadene knyttet til MS-behandling i 
spesialisthelsetjenesten. 
 
Diskusjon 
Vi brukte internasjonalt anerkjente metoder for å systematisk oppsummere kunn-
skapsgrunnlaget og fokuserte på kliniske endepunkter som er relevante for pasienter 
med multippel sklerose. Konsistente resultater ved bruk av direkte, indirekte eller 
nettverksanalyser viser at våre resultater er pålitelige.  
 
Vår systematiske gjennomgang har noen begrensninger. De er hovedsakelig knyttet 
til at det er få studier eller rapporterte utfall for enkelte av sammenligningene og me-
todiske uklarheter i de inkluderte randomiserte kontrollerte studiene.  
 
Vi brukte en probabilistisk Markov-modell, som er ansett for å være den beste måten 
å simulere sykdomsforløpet til multippel sklerose på. Modellens struktur og alle for-
utsetninger er tilpasset norske forhold og klinisk praksis med tett bistand fra eksper-
ter på feltet. Der vi ikke fant norske data som kunne brukes i modellen benyttet vi 
overgangssannsynligheter fra publisert litteratur.  
 
Måten de publiserte kliniske studiene er utført på gjør det vanskelig å undersøke 
første- og andrelinje behandlinger hver for seg, eller å konkludere på sekvensiell bruk 
av ulike behandlinger. Vi utførte derfor ikke separate kostnadseffektivitetsanalyser 
for første- eller andrelinjebehandlinger. Som følge av ekspertuttalelser, gjorde vi hel-
ler ikke analyser for kombinasjonsbehandling siden det ikke er relevant for norsk kli-
nisk praksis i dag.  
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Konklusjon 
Basert på dokumentasjon av høy kvalitet kan vi si at alemtuzumab 12 mg hadde den 
beste effekten mot årlig tilbakefall og at fingolimod oral 0,5 mg og dimetylfumarat 
240 mg to ganger daglig hadde den beste effekten mot sykdomsprogresjon. Resulta-
tene tyder på at noen behandlinger er forbundet med mer frafall på grunn av bivirk-
ninger enn placebo. De inkluderte intervensjonene hadde ingen effekt på dødelighet.  
 
Vår helseøkonomiske analyse indikerte at alemtuzumab var både mer effektiv og 
mindre kostnadskrevende enn de andre behandlingsalternativene.  
 
En scenarioanalyse hvor alemtuzumab ble ekskludert viste at tre behandlingsalterna-
tiver (interferon beta-1b (Extavia), peginterferon beta-1a og natalizumab) kunne være 
kostnadseffektive, avhengig av betalingsvilje per vunnet QALY. Ved å anta en beta-
lingsvilje under en million kroner per vunnet QALY, var trolig interferon beta-1b (Ex-
tavia) den mest kostnadseffektive behandlingen (ca. 40 %), fulgt av peginterferon 
beta-1a (ca. 30 %). 
 
Resultatene av sannsynlighetsanalysen viste at det er en viss grad av usikkerhet knyt-
tet til de ulike parameterne inkludert i analysen. Mer forskning på effekt og epidemi-
ologiske data vil ha størst innvirkning på å redusere usikkerheten rundt beslutningen.  
 
Vår budsjettkonsensanalyse viste at det er et betydelig potensial for å redusere kost-
nadene knyttet til MS-behandling i spesialisthelsetjenesten. 
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Glossary and abbreviations 
CI Confidence interval. A measure of uncertainty around the results of a 
statistical analysis that describes the range of values within which we can 
be reasonably sure that the true mean effect lies.  Wider intervals indi-
cate lower precision; narrow intervals, greater precision.  
CIS Clinical isolated syndrome 
CNS Central nervous system 
CUA Cost-utility analysis. An economic evaluation where health conse-
quences are measured in QALYs. 
EDSS Expanded disability status scale 
EQ-5D European Quality of Life-5 Dimensions. EQ-5D is a standardized 
instrument for use as a measure of health outcome. 
EVPI  Expected value of partial perfect information 
GRADE Grading of recommendations Assessment, Development, and 
Evaluation 
HTA Health Technology Assessment 
Healthcare 
perspective 
Economic evaluation from a healthcare perspective will consider only the 
costs and consequences specifically related to the healthcare sector (di-
rect costs), e.g. staff costs, capital costs, drug acquisition costs. 
ICER Incremental cost-effectiveness ratio. The ratio of the difference in 
costs between two alternative health technologies to the difference in  
effectiveness between these two technologies. 
E
C
EffectEffect
CostCost
ICER 


comparatoroninterventi
comparatoroninterventi  
MRI Magnetic resonance imaging 
MS Multiple sclerosis 
NHB Net Health Benefit. In a decision-making process, a positive NHB 
suggests that the intervention represents good value for money 

CENHB   
NMB Net Monetary Benefit. In a decision-making process, a positive NMB 
suggests that the intervention represents good value for money. 
CENMB    
Odds The odds of an event happening is defined as the probability that an 
event will occur divided by the probability that the event will not occur. 
 15   Sammendrag (norsk) 
OR Odds ratio. The ratio of the odds of an outcome in one treatment group 
divided by the odds of the same outcome in a different treatment group. 
PPMS Primary progressive multiple sclerosis 
PSA Probabilistic sensitivity analysis. An analysis of the uncertainty re-
lated to all parameters in a decision analytic model. Typically performed 
by Monte Carlo simulation, hence by drawing values from probability 
distributions for all parameters simultaneously 
QALY Quality-adjusted life-year. A measure of health outcomes that com-
bines quantity and quality of life by assigning to each year of life a weight 
from 1 (perfect health) to 0 (state judged equivalent to death) dependent 
on the individual's health related quality of life during that year 
RCT Randomised controlled trial. An experiment in which investigators 
use randomisation to allocate participants into the groups that are being 
compared. Usually allocation is made at the level of individuals, but 
sometimes it is done at group level e.g. by schools or clinics. This design 
allows assessment of the relative effects of interventions. 
RRMS Relapsing-remitting multiple sclerosis 
RR Relative risk / risk ratio. The relative risk is the absolute risk (AR) in 
the intervention group divided by the AR in the control group. It is to be 
distinguished from odds ratio (OR), which is the ratio of events over 
non-events in the intervention group over the ratio of events over non-
events in the control group. 
SPMS Secondary progressive multiple sclerosis 
SR Systematic review. A review of a clearly formulated question that uses 
systematic and explicit methods to identify, select, and critically appraise 
relevant research, and to collect and analyse data from the studies that 
are included in the review. Statistical methods (meta-analysis) may or 
may not be used to analyse and summarise the results of the included 
studies. 
Statistically  
significant 
Means that the findings of a study are unlikely to have arisen because of 
chance. Significance at the commonly cited 5% level (P < 0.05) means 
that the observed difference or greater difference would occur by chance 
in only 1/20 similar cases. Where the word "significant" or "significance" 
is used without qualification in the text, it is being used in this statistical 
sense. 
SUCRA Surface under the cumulative ranking curve 
WTP (λ) Willingness to pay. A pre-specified limit of what society is willing to 
pay for a given health unit (e.g. QALY or life year). In Norway it is com-
mon to use NOK 500 000 per QALY or life year in economic evaluations. 
 16   Table of contents   
Table of contents 
KEY MESSAGES 2 
EXECUTIVE SUMMARY 4 
Background 4 
Objective 4 
Methods 4 
Results 5 
Discussion 6 
Conclusion 7 
HOVEDFUNN (NORSK) 8 
SAMMENDRAG (NORSK) 10 
Bakgrunn 10 
Problemstilling 10 
Metode 10 
Resultat 11 
Diskusjon 12 
Konklusjon 13 
TABLE OF CONTENTS 16 
PREFACE 18 
OBJECTIVE 19 
BACKGROUND 20 
The epidemiology of multiple sclerosis 20 
The clinical course and diagnosis of multiple sclerosis 21 
Treatment alternatives 22 
Introduction to Economic Evaluations of Health Care Programmes 25 
Priority setting criteria 26 
CLINICAL EVALUATION – METHODS 28 
Criteria for considering studies for this review 28 
Literature search 29 
Selection and assessment of publications 30 
Data collection and analysis 31 
 17   Table of contents   
Grading the quality of evidence 34 
CLINICAL EVALUATION - RESULTS 36 
Result of literature search 36 
Effects of intervention(s) 45 
ECONOMIC EVALUATION-METHODS 64 
General 64 
Population, interventions and model structure 64 
Model Parameters 68 
ECONOMIC EVALUATION – RESULTS 81 
Incremental cost–effectiveness estimates 81 
Value of information analysis 86 
Scenario analyses 87 
Budget impact 90 
DISCUSSION 98 
Summary of key findings 98 
Quality of the evidence 99 
Strengths and weaknesses 100 
Consistency 104 
CONCLUSION AND IMPLICATIONS ON PRACTICE 105 
Need for further research 106 
REFERENCES 107 
APPENDIX 115 
Appendix 1: Literature search strategy 115 
Appendix 2: Description of included studies 124 
Appendix 3: Excluded studies and reasons for exclusions 162 
Appendix 4 Ongoing studies and other potential relevant literature 169 
Appendix 5: GRADE evaluation of comparisons 171 
Appendix 6: Full network meta-analysis results 210 
Appendix 7: Results for direct pairwise meta-analyses 216 
Appendix 8 Monitorings costs 219 
Appendix 9 Scenario analyses 225 
 18  Preface 
Preface 
This project was commissioned by the “National system for the introduction of new 
health technologies within the specialist health service”, that wanted us to examine 
the effect and cost-utility of the disease modifying medicines used for patients with 
relapsing remitting multiple sclerosis in Norway. The results will be used as scientific 
documentation for price negotiations, and guidelines development. 
 
Elisabeth Couto was lead reviewer for the clinical evaluation and Vida Hamidi led the 
health economic evaluation. Rune Midgard and Torbjørn Wisløff performed peer re-
view of the report. We thank Elisabeth Gulowsen Celius and Elisabeth Farbu for clin-
ical expertise and input in the report, and Bjørn Svendsen for his contribution on cost 
information. 
 
The project group consisted of: 
 Couto, Elisabeth, (project leader), senior researcher 
 Hamidi Vida, senior researcher 
 Ringerike Tove, senior researcher 
 Odgaard-Jensen, Jan, senior advisor 
 Harboe, Ingrid, research librarian  
 Klemp, Marianne, head of Health economics and drugs unit  
 
We would like to thank Elisabeth Gulowsen Celius, Elisabeth Farbu, Rune Midgard, 
Bjørn Svendsen, and Torbjørn Wisløff for their expertise in this project.  The Norwe-
gian Institute of Public Health assumes final responsibility for the content of this re-
port. 
 
The aim of this report is to support well-informed decisions in health care that lead to 
improved quality of services. The evidence should be considered together with other 
relevant issues, such as clinical experience and patients’ preferences. 
 
 
Signe Flottorp 
Department director 
Marianne Klemp 
Research director 
Elisabeth Couto 
Lead reviewer, 
Clinical evaluation 
Vida Hamidi 
Lead health economist 
 
 19  Objective 
Objective  
Overall objective 
 To examine the effect and cost-utility of the disease modifying medicines used 
for patients with relapsing remitting multiple sclerosis in Norway. 
 
Specific objectives 
 To conduct a systematic review to assess the efficacy and safety of the different 
disease modifying medicines used for multiple sclerosis with regard to clinical 
important endpoints 
 To carry out a health economic evaluation ascertaining cost-utility of the 
disease modifying medicines used for patients with relapsing remitting 
multiple sclerosis.  
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Background  
Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous sys-
tem (CNS) with secondary neurodegeneration (1). It affects nerves in the brain and 
spinal cord by damaging the myelin sheath that covers the axon part of the nerve cells. 
The myelin sheath protects and aids signal transduction, therefore, when damaged, it 
affects the transfer of timely and correct information from the CNS to the peripheral 
part of the nervous system (1-3).  
 
 
The epidemiology of multiple sclerosis 
MS is one of the most common causes of disability in young adults (4). In 2013, a 
systematic review summarised MS incidence and prevalence estimates reported by 
123 studies that used a range of different data sources (5). Prevalence and incidence 
estimates tended to be higher in Northern countries, and in more recently published 
studies. Incidence surveys show an increase in MS incidence in later years (6). Re-
ported annual incidence rates are 1.9 (95% confidence interval: 1.2-2.6) for the period 
1953 to 1957, and 8.5 (7.3.9.7) for 1978 to 2007 (7). Increase in MS incidence could be 
due, to some extent, to changes in methods and criteria used for MS diagnosis (6). In 
Europe, the prevalence of MS is twice as high in women than in men (5). Incidence 
rates are generally also higher in women (5). A study, using data from the National 
Patient Registry, the Norwegian MS registry, and Biobank data estimated crude prev-
alence rates of 203/100,000 (95% confidence interval 199 – 207) overall, 280 (247-
287) for women, and 126 (122-130) for men (8).  
 
The disease usually starts around the age of 30 (range 20-40), and prevalence rates 
peak at around 50 (6). The median time to death is around 30 years from disease 
onset, representing a reduction in life expectancy of 5 to 10 years (1).  
 
The aetiology of MS is not well understood. Geographical variations in MS prevalence 
and incidence could be due to differences in genes and environment. To date, most 
commonly reported risk factors for MS are exposure to Epstein Barr virus, cigarette 
smoking, low sunlight exposure and vitamin D levels and genetic predisposition (1, 9-
11).  
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The clinical course and diagnosis of multiple sclerosis 
Clinical manifestations depend on the affected area of the CNS. Symptoms reflect an 
involvement of motor, sensory, visual and autonomic systems (1). Symptoms evolve 
over time. MS appears in several degrees of severity from a mild form (with few at-
tacks) to a more progressive disease that is potentially highly disabling and that im-
pacts on the quality of life of patients and their families (1, 12). 
 
Appropriate MS diagnosis allows early disease management. Different diagnosis cri-
teria have been used over the years, leading to possible differences in MS diagnosis 
with time. The revised McDonald criteria are the most commonly used for MS diag-
nosis nowadays. National guidelines, such as British (NICE) and Norwegian guide-
lines, recommend the use of the revised McDonald criteria for MS diagnosis (12, 13). 
 
To be diagnosed with MS, patients should have at least one clinical attack (demye-
linating event in the CNS with duration of symptoms of more than 24 hours in the 
absence of fever or infection) corroborated by findings on neurological examination, 
visual evoked potential response or findings on magnetic resonance imaging (MRI) 
consistent with demyelination in the CNS (T2 lesion or T1 gadolinium-enhancing le-
sion). In addition, exclusion of other possible diagnoses is essential for the diagnosis 
of MS. 
 
MS is classified as (1, 13): 
 
 Clinical isolated syndrome (CIS): one attack and objective clinical evidence of 
one lesion.  
 Relapsing-remitting MS (RRMS): objectively established disease as with two 
or more clinical attacks and localisaton of two or more lesions in the CNS. It 
is characterised by episodes of acute worsening of function followed by partial 
or complete recovery (14). 85 to 90% of patients present with RRMS (11). 
Aproximately half of the patients with RRMS will develop secondary 
progressive MS (15). 
 Secondary progressive MS (SPMS): About 30-40% of the prevalent MS 
population have SPMS. It is associated with disease progression without 
clinical attacks and of highly variable degrees (16). 
 Primary progressive MS (PPMS): at least one year of disease progression and 
characteristic findings on MRI and/or positive findings in cerebrospinal fluid. 
 
Disease progression is most commonly assessed by relapse rate and disease progres-
sion. The gradual increasing level of disability is often measured with the Expanded 
Disability Status Scale (EDSS), an ordinal scale ranging from 0 (normal clinical sta-
tus) to 10 (death due to MS) in steps of 0.5 points (17). 
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Treatment alternatives 
Disease-modifying medicines are the standard treatment for patients with MS. It is 
possible to treat both the underlying disease, relapses and MS-related symptoms. Dis-
ease modifying drugs may inhibit the inflammatory process to prevent progression 
and reduce disabilities due to the disease. The different treatment options have dif-
ferent mechanisms of action, routes of administration, approved indications and 
other differences influencing their use. The various medications are presented in Ta-
ble 1.  
 
Due to safety issues, some of these treatments are used as first line treatments (dime-
thyl fumarate, teriflunomide, interferon beta, peg-interferon, glatiramer acetate), and 
others as second line treatments (natalizumab, fingolimod, and alemtuzumab) ac-
cording to different national guidelines (18).  
 
Disease-modifying treatments are expensive. The use of MS medicines has been de-
scribed as “uneven” with “questionable effects on the long-term accumulation of dis-
ability and disease progression” (1). Currently a number of new disease-modifying 
therapies are available for the treatment of MS, but it is uncertain whether the new 
medicines are cost-effective in the Norwegian setting. To insure proper MS manage-
ment, it is important to assess the effectiveness and cost-effectiveness of disease mod-
ifying medicines used for MS.  
 
This report was ordered by the “National system for the introduction of new health 
technologies within the specialist health service”, and will be used for price negotia-
tions and guidelines development. 
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Table 1. Overview of included interventions 
Intervention 
Medication name 
First authorisation date in Norway 
Administration form and 
recommended dose 
Approved indication 
Alemtuzumab 
(Lemtrada) 
Sept.2013 
- 12 mg concentrate for solution for infusion 
- 12 mg/day for 5 consecutive days, then after 12 
months: 12 mg/day for 3 consecutive days. 
Diluted and i.v. over approximately 4 hours 
Adult patients with relapsing remitting multiple sclerosis 
(RRMS) with active disease defined by clinical or imaging 
features 
Dimethyl fumarate 
(Tecfidera) 
Jan. 2014 
-120 or 240 mg gastro-resistant hard capsules 
- 240 mg twice daily  
Adult patients with relapsing remitting multiple sclerosis 
Fingolimod 
(Gilenya) 
March 2011 
- 0,5 mg hard capsules 
 
- 0,5 mg once daily 
- High disease activity despite treatment with at least one 
disease modifying therapy 
- Rapidly evolving severe relapsing remitting multiple 
sclerosis 
Glatiramer acetat 
(Copaxone) 
Februar 2004 
April 2015 (40 mg) 
- 20 mg/ml Solution for Injection, Pre-filled 
Syringe 
- 20 mg of glatiramer acetate (one pre-filled 
syringe), administered as a subcutaneous 
injection once daily 
- 40 mg of glatiramer acetate administered 
three times weekly 
- Patients experienced a well-defined first clinical episode, 
determined to be at high risk of developing clinically definite 
multiple sclerosis  
- Ambulatory patients with relapsing, remitting multiple 
sclerosis w/≥2 attacks of neurological dysfunction over the 
preceding two-year period. 
Interferon beta-1a 
(Avonex) 
May 2011 
- 30 micrograms (6 million IU) powder and 
solvent for solution for injection 
- 30 micrograms (1 ml solution), by 
intramuscular (IM) injection once a week 
-Relapsing multiple sclerosis w/≥2 relapses in the previous 
three years without evidence of continuous progression 
between relapses 
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Interferon beta-1a 
(Rebif) 
June 2010 
- 22 micrograms (6 million IU) solution for 
injection in pre-filled syringe 
- 44 micrograms given three times per week by 
subcutaneous injection 
Relapsing multiple sclerosis, w/≥2 acute exacerbations in the 
previous two years 
Peg-interferon beta-1a  
(Plegridy) 
July 2014 
- 125 micrograms injected subcutaneously every 
2 weeks 
Adult patients for the treatment of relapsing remitting 
multiple sclerosis 
Interferon beta-1b 
(Betaferon) 
August 2008 
- 250 microgram (8.0 million IU) /ml, powder 
and solvent for solution for injection [300 
microgram (9.6 million IU) per vial] 
- 250 microgram (8.0 million IU), contained in 
1 ml of the reconstituted solution, to be injected 
subcutaneously every other day 
 
- Patients with a single demyelinating event with an active 
inflammatory process (…)determined to be at high risk of 
developing clinically definite multiple sclerosis  
- Patients with relapsing-remitting multiple sclerosis w/≥2 
relapses within the last two years 
-Patients with secondary progressive multiple sclerosis with 
active disease, evidenced by relapses. 
Interferon beta-1b 
(Extavia) 
June 2006 
See: interferon beta-1b (Betaferon) above  Adults and adolescents from 12-17 years of age. 
Indication similar to Interferon beta-1b (Betaferon) above 
Natalizumab 
(Tysabri) 
June 2006 
- 300 mg concentrate for solution for infusion 
- 300 mg by i.v over approximately 1 hour, once 
every 4 weeks 
- Adult patients with relapsing remitting multiple sclerosis  
-High disease activity despite treatment with a 
betainterferon or glatiramer acetate 
-Rapidly evolving severe relapsing remitting multiple 
sclerosis  
Teriflunomide 
(Aubagio) 
Aug.2013 
- 14 mg film-coated tablets 
- 14 mg once daily, swallowed whole with some 
water 
Adult patients with relapsing remitting multiple sclerosis 
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Introduction to Economic Evaluations of Health Care Pro-
grammes  
The basic task of any economic evaluation is to identify, measure and compare costs 
and consequences of the alternatives under consideration in an incremental analy-
sis—one in which the differences in costs are compared with differences in conse-
quences (19). Results of economic evaluations can be expressed as an incremental 
cost-effectiveness ratio (ICER), which is defined by the following equation: 
 
 
 
Because the health care sector, like the society in general, is restricted by scarce re-
sources and budget constraints, economic evaluations are important tools for decision 
makers facing questions of how to prioritize treatments and maximize health benefits 
using scarce resources. For an economic evaluation to be meaningful in a decision 
making process, the ICER must be judged with regard to a ceiling ratio that reflects 
the decision maker’s maximum willingness to pay (WTP) for a health gain. The deci-
sion rule for an economic evaluation can therefore be expressed as 
 
   
 
where λ equals WTP, and means that if the ICER of an intervention is below the ceiling 
ratio, introducing the intervention represents good value for money. Because the 
ICER has poor statistical properties, ICERs are often rearranged to express either in-
cremental net monetary benefit (INMB) or incremental net health benefit (INHB), 
which yields the following decision rules related to INMB or INHB.  
 
INMB: λ•∆E - ∆C > 0 
 
INHB: ∆E – (∆C/λ) > 0 
 
 
An intervention can in other words be considered cost-effective if it yields a positive 
INHB or INMB. 
 
Economic evaluations are often based on decision models (such as decision trees, 
Markov models, etc.) that calculate results based on various input parameters in the 
model. Because there are always uncertainties related to the values of these parame-
ters, sensitivity analysis is an important feature of any economic evaluation based on 
a decision model framework. In short, sensitivity analysis illustrates how much the 
results vary when model parameters are changed.  
 
E
C
EffectEffect
CostCost
ICER 


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Probabilistic sensitivity analysis (PSA) is a kind of sensitivity analysis. The advantage 
of PSA is that it makes it possible to take the uncertainties of all of the model-param-
eters into account simultaneously. The basic approach in PSA is to assign appropriate 
probability distributions to the model-parameters, which makes it possible to replace 
the “fixed” values of the parameters with values generated by random draws from the 
distributions. Doing this repeatedly, with a specified number of iterations, makes it 
possible to estimate the probabilities that alternative interventions are cost-effective 
subject to different ceiling values of WTP. The calculation is based on the alternative 
that renders the highest values of NMB or NHB. Results from PSAs are often pre-
sented as scatter plots, which show point estimates of the ICER for all iterations in the 
cost-effectiveness plane, and also as cost-effectiveness acceptability curves (CEACs), 
which show the probability of the alternatives being cost-effective subject to changing 
values of WTP. 
 
Another result from PSA is the expected value of perfect information (EVPI). This 
number indicates the value to society to have more accurate information about the 
decision, given a WTP. If EVPI for a given population seems large, it might be of in-
terest to determine for which parameters it would be most useful to obtain additional 
data. Expected value of perfect information for parameters is a more time-consuming 
analysis that can help determine for which single parameters or groups of parameters 
it is most cost-effective to conduct new research.  
 
In short, making a model probabilistic means that it is possible to estimate the uncer-
tainty associated with a decision to implement alternative interventions, and it pro-
vides a possibility of estimating the value of collecting additional information from 
new research. 
 
Priority setting criteria 
According to Norwegian policy documents (20) , a treatment should be prioritized if 
the following criteria are met:  
 
 The disease is severe: A disease is considered severe to the degree that it causes 
pain and discomfort, loss of physical, psychological and social function and if it 
limits the individual in his or her daily activities. Severity is also evaluated 
according to the risk increase the disease entails in terms of death, disability and 
discomfort, if treatment is postponed. 
 
 The treatment is effective: The patient should be expected to benefit from 
treatment in terms of longevity or improved quality of life of certain duration. The 
treatment effectiveness should also be well documented. 
 
 The treatment is cost-effective: The additional costs of the treatment should be 
reasonable compared to the additional benefits. 
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It should be mentioned that there is no academic or political consensus regarding 
what constitutes a reasonable relationship between incremental costs and effects in 
Norway. For this reason, we use a range of potential willingness-to-pay (WTP) values 
throughout our report.   
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Clinical evaluation – Methods 
Criteria for considering studies for this review 
Type of studies 
We searched for published health technology assessment (HTA) reports or systematic 
reviews (SR) of randomised controlled trials (RCT). We included only reports and re-
views of high quality that fitted our inclusion criteria. We supplemented the evidence 
with data from recently published RCTs. 
 
Type of participants (Population of interest) 
Suitable studies included men and women aged 18 and above diagnosed with MS. El-
igible MS diagnosis was RRMS. CIS patients were not included in this report; how-
ever, Appendix 3 lists identified studies that included CIS patients. We excluded stud-
ies with patients with primary progressive MS and radiologically isolated syndrome. 
Studies that included both eligible patients, and patients from our exclusion criteria 
were included if results were presented separately for each type of patients (so that 
we could extract results for patients who fitted our inclusion criteria).  
 
Types of interventions  
The following medicines were the interventions of interest: dimethyl fumarate, teri-
flunomide, interferon beta, peg-interferon, glatiramer acetate, natalizumab, fin-
golimod, and alemtuzumab.  
 
Comparisons  
Eligible comparison groups were either placebo or one of the medicines listed above. 
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Types of outcome measures 
The outcomes of interest were:  
 
Primary outcomes 
‐ Clinical relapses 
‐ Disability progression measured using the EDSS 
‐ Mortality 
‐ Serious adverse events 
Secondary outcomes: 
‐ Withdrawal from study due to adverse events 
‐ Stay at hospitals  
‐ Health related quality of life measured with EQ-5D  
  
Literature search 
The research librarian (in collaboration with the project team) conducted a peer-re-
viewed literature search using index terms (Medical Subject Headings and EMTREE 
terms) and free text terms relating to the population and the interventions of interest. 
The last date of the literature search was 9/11/2015. Full literature search strategies 
are presented in Appendix 1. We did not use any language restrictions in the literature 
search. 
 
We searched the following databases:  
 Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid 
MEDLINE(R) 
 Embase 
 Cochrane Library; Cochrane Database of Systematic Reviews, Other Reviews, 
Technology Assessments, Cochrane Central Register of Controlled Trials 
(Central) 
 Centre for Reviews and Dissemination; DARE, HTA 
 ISI web of Science 
 PubMed (epub ahead of print) 
 Epistemonikos 
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We searched also the following websites:  
 Canadian Agency for Drugs and Technologies in Health (CADTH) 
 Agency for Healthcare Research and Quality (AHRQ),  
 FinOHTA- Finnish Office for Health Technology Assessment 
 Statens beredning för medicinsk utvärdering (SBU) 
 EUnetHTA POP database (POP = Planned and Ongoing Projects) 
 PROSPERO – Centre for Reviews and Dissemination 
We checked bibliographies of selected articles for additional publications meeting our 
inclusion criteria. Finally, we searched the WHO ICTRP and ClinicalTrials.gov to 
identify relevant ongoing or unpublished trials.  
We contacted the companies with marketing authorization in Norway for the MS 
medicines included in order to get additional information.  
 
Selection and assessment of publications 
Selection of publications 
Unless stated otherwise, two persons independently carried out the selection pro-
cesses.  
 
Selection of HTA or SR reports 
Two persons read titles and abstracts retrieved by the literature search, and excluded 
obviously irrelevant literature. Based on information provided in abstracts, one per-
son organised the publications depending on how many medicines were apparently 
examined. Abstracts looking at two, three, or more than three drugs were grouped 
together. If we lacked information in the abstract to know which medicine were as-
sessed, articles were classified in the “several drugs category” (more than three drugs). 
One person sorted all abstracts in the “several drugs category” according to the date 
of publication from the newest to the oldest. Two persons read full-text articles of the 
“several drugs category” by publication chronological order (from newest to oldest). 
Hence, we were able to include the most recently published HTA report that met all 
our inclusion criteria. 
 
Selections of RCT publications 
Two persons examined all titles and abstracts retrieved by the literature search for 
possibly relevant RCTs published after the selected HTA, and excluded obviously ir-
relevant titles and abstracts. Two persons read full-text articles of selected publica-
tions. We included articles that met our inclusion criteria. The same process was used 
to select publications sent by companies having market authorization for MS medi-
cines in Norway. 
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Throughout the selection process, any disagreement was discussed to reach an agree-
ment.  
 
 
Assessment of included publications 
Quality assessment of selected HTA 
We assessed the quality of the SR part of the identified HTA using the checklist for SR 
in the handbook of The Norwegian Knowledge Centre for the Health Services (21). 
 
Risk of bias of RCTs  
We did not perform risk of bias assessments for the RCTs included in the selected high 
quality HTA report. Instead, we report the risk of bias assessments conducted by the 
HTA authors. The domains of risk of bias assessed in the HTA report were similar to 
the Cochrane Collaboration tool for assessing risk of bias (22) (randomization, allo-
cation concealment, double-blinding, baseline characteristics similarity, outcome 
measures, withdrawals, use of intention-to-treat analysis, and source of funding). 
For the newer RCTs that we supplemented, we used the Norwegian Knowledge Centre 
for the Health Services tool to assess risk of bias (23). That tool is based on  Cochrane 
risk of bias tool (22).  
 
The assessment of risk of bias of included RCTs was carried out by one person and 
checked by another. For the evaluation of risk of bias provided by the HTA report, one 
author extracted the assessment data, and another verified the data. Any disagree-
ments were discussed to reach consensus.  
 
 
Data collection and analysis 
Data extraction  
One person extracted predefined data from the selected publications, and a second 
checked the data extraction for accuracy.  
 
Data extraction from HTA/SR 
We extracted the following data from the selected HTA report: publication infor-
mation (authors, publication details), date of the literature search, characteristics of 
included studies (study design, origin, setting, comparisons and endpoints investi-
gated, follow-up range of included studies), and information on quality assessment.  
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Data extraction from RCTs 
We extracted the following data from included RCTs: information on publication (au-
thors , publication details); RCT description (clinical trial identification, design and 
setting, source of funding); participants characteristics (age and gender, MS diagno-
sis, inclusion and exclusion criteria, and baseline characteristics); description of in-
tervention and comparison groups (numbers of participants in each group, doses, ad-
ministration method); and outcomes (primary and secondary endpoints assessed, 
definitions used, length of follow-up, measurements of outcomes such as number of 
events, means, corresponding standard deviations).  
 
For RCTs included in the HTA, for each individual RCT, we extracted the data re-
ported in the HTA publication. To assess accuracy, one person compared the infor-
mation given by the HTA report with the original study publication of seven randomly 
chosen RCTs. All the data presented in the HTA were identical to the original publi-
cations. For RCTs identified after the HTA literature search, we extracted the data 
from the primary publications. 
 
 
Statistical analyses and presentation of results 
Measures of treatment effect 
We expressed the comparative effectiveness of the treatments as the relative risk (RR) 
for dichotomous outcomes, annualised rate ratios (ARR) for count data and the mean 
difference (MD) for continuous outcomes. For all outcomes 95% confidence intervals 
(CI) or credible intervals (CrI) were calculated for the RR, ARR, MD. The credible 
interval is the Bayesian analogue to confidence intervals used in traditional fre-
quentist statistical approaches. We considered a difference to be "significant" if the 
CrI did not include RR =1 or MD=0. 
 
For count data (number of relapses), we used a Poisson regression based approach to 
obtain the annualised rate ratios (ARR) from the total number of relapses and patient-
years of follow-up.  
 
Dealing with missing data 
For the endpoint “number of relapses” we performed imputations to derive needed 
values where included trials did not report the total number of relapses or exposure 
time (person-years). Missing number of total relapses were derived using the expo-
sure time (person-years) and the reported mean ARR values. For missing exposure-
time (in person-years), the values were imputed using treatment duration and num-
ber of patients completing the study (100% was assumed in cases where the percent-
age of completers was not reported).  
 
For disability progression, measured as a dichotomous outcome, we assumed that 
participants who dropped out experienced the event (a likely scenario). For all other 
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endpoints, we did not perform imputations for missing data. We based the statistical 
analyses on the intention to treat principle (all participants analysed in the group to 
which they were allocated, and all available data included in the analyses).  
 
The statistical analysis was based on binomial likelihoods (dichotomous outcomes), 
poisson likelihoods (count outcomes), and normal likelihood (continuous outcomes), 
with vague priors for the trial baselines, basic parameters (normal distribution with 
mean 0 and standard deviation 0.0001) and the random effects standard deviation 
(uniformly distributed in the interval 0 to 2), and takes the correlation structure in-
duced by multi-arm trials into account. We used a random effects model. We checked 
for incoherence between direct and indirect evidence by "node-splitting" (24). We cal-
culated the direct and indirect estimates of effect and the corresponding Bayesian "P-
values" for incoherence.  
 
We ranked the different treatments in terms of their likelihood of leading to the best 
results for each primary endpoint. We based the rankings on the surface under the 
cumulative ranking curve (SUCRA) (25). We interpreted the rankings cautiously tak-
ing into account the quality of evidence.  
 
We performed sensitivity analyses where participants who dropped out were excluded 
from the analyses of the sustained disability progression, to base the analyses only on 
the available data. 
  
Data synthesis 
First, we conducted pairwise meta-analyses for each available outcome and, for each 
identified intervention vs. control group comparison. This was done using a tradi-
tional frequentist statistical approach assuming random effects models using the soft-
ware RevMan 5.3. Hereafter, we refer to this method as the “pairwise comparisons 
method”. Further, we combined direct and indirect evidence, and performed a net-
work-meta-analysis (19). For that, we used a Bayesian method based on Markov 
Chain Monte Carlo simulation. This method is, hereafter, referred to as the “network 
meta-analysis approach”. This was done using Winbugs version 1.4.3 (Imperial Col-
lege and MRC, UK). 
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Grading the quality of evidence 
Two review authors assessed independently the quality of the evidence for each se-
lected outcome. We used Grading of recommendations Assessment, Development, 
and Evaluation (GRADE) to assess the quality of the direct evidence, indirect evi-
dence, and the combined evidence from the NMA (26).  
 
First, we graded the evidence for all comparisons with available direct evidence. Then, 
we graded the comparisons for which we had indirect evidence. To grade the indirect 
evidence, we considered the direct evidence that contributed to that indirect evidence. 
For example, the indirect evidence comparing a medicine A with a medicine C might 
have been obtained with direct evidence comparing medicines A and B, and B with C. 
The grade of the indirect evidence for the comparison A and C was based on the grade 
of the direct evidence on A and B, and B and C. The grade of the indirect evidence on 
A versus C was the lowest grade of all the direct evidence that contributed to that com-
parison. 
 
To select the direct evidence that might have contributed to the indirect evidence, we 
chose the evidence that involved fewest head-to-head comparisons. For example, for 
indirect evidence comparing A to C, one might also have evidence comparing A to D, 
D to E and E to C. This example involves three head-to-head comparisons compared 
to the two presented above (A with B, and B with C). The indirect evidence with fewer 
head-to-head comparisons is referred to as first order loops. If more than one first 
order loops were available, we chose the loop with the lowest available quality. This 
was a conservative approach.  
 
For a specified comparison, the grade of the network meta-analysis evidence was the 
highest GRADE between the direct and indirect evidence for that comparison. 
 
Due to time constraint, we graded the quality of the evidence only for annual relapse 
rate, disability progression (when examining disability progression as a dichotomous 
variable: considering whether someone had been less disabled or not when using a 
certain treatment) and withdrawal due to adverse events. The first two outcomes were 
the two outcomes used in the economic evaluation. Withdrawal due to adverse events 
is also an important outcome as it measures the risk of adverse event(s) outweighing 
the benefit of the treatment to the point of causing withdrawal from treatment.  
 
GRADE provides specific criteria to consider when rating the quality of evidence. This 
includes the strength of the study design, possible risk of bias, imprecision and incon-
sistency of the estimates, and indirectness and magnitude of effect, dose response gra-
dient and potential confounding factors. The overall quality of the evidence was clas-
sified as high, moderate, low, or very low for each outcome. The definition for each 
category is described in the following table.  
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Table 2. Definition of each category for GRADE  
 
Grade Definition 
High We are very confident that the true effect lies close to that of the 
estimate of effect 
Moderate We are moderately confident in the effect estimate: The true effect 
is likely to be close to the estimate of effect, but there is a possibility 
that it is substantially different 
Low Our confidence in the effect estimate is limited: The true effect may 
be substantially different from the estimate of the effect 
Very low We have very little confidence in the effect estimate: The true effect 
is likely to be substantially different from the estimate of effect  
 
 
 
  
36 
 
Clinical evaluation - Results 
Result of literature search 
Results of the search and selection process  
We selected the evidence for this report in two stages, first identifying relevant SRs or 
HTA reports (Figure 1), and then supplementing the evidence of the identified HTA 
with more up to date information (Figure 2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Flow diagram for the selection of possible systematic reviews (SR) or 
health technology assessment (HTA) reports 
 
 
Abstracts for possible SR/HTA reports 
identified through database searching 
(n = 277)
Abstracts for possible SR/HTA reports 
identified through other sources 
(n = 1)
Total number of abstracts for possible SR/HTA re-
ports (n = 278) 
Excluded full-text articles 
(n = 18) 
Full-text articles assessed for 
eligibility (n = 19) 
Included HTA report 
(n = 1) 
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When looking for possible SR or HTA reports, the literature search retrieved 277 rec-
ords, and we found one extra record. After abstract selection, and assessing 19 full-
text articles, we included one HTA. This was a recent HTA report (literature search 
carried out in October 2013).  To supplement the HTA’s information with more up to 
date evidence, we searched for additional RCTs published from 2013 to the last date 
of our literature search (9/11/2015). 
 
The literature search for RCTs identified 644 records. We supplemented this search 
with two records identified in reference lists, and one RCT provided by a pharmaceu-
tical company. After the selection process, we included fifteen publications on eleven 
RCTs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Flow diagram for the selection of possible randomised clinical trials 
(RCT) published after the included health technology assessment report 
 
  
Abstracts for possible RCTs 
identified through database searching 
(n = 644) 
Abstracts for possible RCTs 
identified through other sources 
(n =  2) 
Total number of abstracts for possible RCTs 
(n = 646) 
Excluded full-text articles (n = 72) 
Conference abstract (55) 
Clinically isolated syndrome (6) 
Inappropriate study design (7) 
Other reasons (8) 
Full-text articles assessed for 
eligibility (n = 85) 
Relevant RCT publications 
(n = 14) 
(14 publications on 11 RCTs) 
Included RCT publications 
(n=15) 
(15 publications of 11 RCTs) 
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Included studies 
The included health technology assessment report 
Some of the evidence presented in this report was extracted from a previously pub-
lished HTA report (27). This publication is described in Table 3. It summarised evi-
dence from RCTs assessing mono- and combination therapies of MS-medicines. We 
included data from 26 RCTs (only the RCTs that examined MS monotherapies). The 
participants were RRMS patients, with a mean age ranging between 29 and 41 years 
old. They were followed for a period ranging from 16 weeks to 3.5 years, and were in 
majority women.  
 
Table 3. Characteristics of the included HTA report 
 
Date of literature search October 2013 
Study types included RCTs (Number of included monotherapy RCTs: 26) 
Participants  - All studies included patients with RRMS. One study in-
cluded patients with clinically isolated syndrome (CIS), 
one study included patients with progressive-relapsing 
MS (PRMS), one study included patients with secondary-
progressive, and one study included patients with second-
ary-progressive MS and progressive-relapsing MS.  
- Randomized sample size: 75 to 1430.  
- Female participants: 64% to 84% 
- Mean age: 29 to 41 years 
Intervention (number of 
unique RCTs) 
Alemtuzumab (three) 
Dimethyl fumarate (two) 
Fingolimod (three) 
Glatiramer acetate (eight) 
Interferon beta-1a subcutaneous (nine) 
Interferon beta-1a intramuscular (nine) 
Interferon beta-1b (five) 
Natalizumab (one) 
Teriflunomide (two) 
Comparison Placebo 
One of the drugs listed above 
Outcome - Relapse 
- Disability progression 
- MRI lesions 
- Adverse events 
- Serious adverse events 
- Withdrawal due to adverse events 
- Quality of life 
Follow-up 16 weeks to 3.5 years. 
Quality assessment This publication was assessed to be of high quality 
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The included primary studies 
We present an overview of RCTs that constitute our evidence base in Table 4. Further 
details on both the primary studies included in the above-mentioned HTA report, and 
those we identified are provided in Appendix 2.  
Altogether, we included 37 studies; 26 from the selected HTA report (27), and 11 RCTs 
from our supplementary search. All RCTs included RRMS patients. Treatment histo-
ries varied, with 11 RCTs confined to treatment-naive patients, 4 included treatment 
experienced participants, 11 combined treatment naïve and treatment experienced 
patients, and treatment history was unclear in 9 studies. We had information for 39 
comparisons including active treatments versus placebo, and active treatments com-
pared with each other. 
 
Many of the published studies did not examine medications separating first- and sec-
ond- line treatments. Studies compared first-line treatments and second-line treat-
ments (28-32). Other studies examined first-line treatments in patients who had 
taken other medications before (33-36). Two studies investigated second-line treat-
ments in a population that comprised treatment naive patients (i.e. patients who had 
not received a first-line treatment) (37, 38). 
 
Excluded studies 
Excluded studies and reasons for exclusion are presented in Appendix 3. 
 
Ongoing studies and other relevant literature 
We searched the WHO ICTRP and ClinicalTrials.gov to identify relevant ongoing or 
unpublished trials. The result of this search is presented in Appendix 4.  
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Table 4. Characteristics of included randomised clinical trials 
 
 
Name (publication) (reference) 
Study design 
Intervention versus comparison (n=number random-
ised) 
Treatment  
history 
Follow-up 
CAMMS223 (2008)(28) 
Rater-blinded, in 49 centres in Europe 
and US 
- Alemtuzumab 12 mg IV q.d., 5 consecutive days at 1st month, 3 
consecutive days at months 12 and 24 (n = 113)  
- Alemtuzumab 24 mg IV q.d. (n = 110) 
- Interferon beta-1a 44 mcg SC t.i.w. (n = 111) 
Treatment-
naive 
3 years 
CARE-MS I(2012) (29) 
A rater-blinded, in 101 centres in 16 
countries including Europe, Canada, 
and US. 
 
- Alemtuzumab 12 mg IV q.d., 5 consecutive days at month 0, 3 
consecutive days at month 12 (n = 386) 
- Interferon beta-1a 44 mcg SC t.i.w. (n = 195) 
Treatment-
naive 
2 years 
CARE MS II (2008)(28) 
Rater-blinded, in 194 academic medi-
cal centres and clinical practices in 23 
countries including Europe, Canada, 
and US. 
- Alemtuzumab 12 mg IV q.d., 5 consecutive days at month 0, 3 
consecutive days at month 12 (n=436) 
Alemtuzumab 24 mg IV q.d., 5 consecutive days at month 0, 3 
consecutive days at month 12 (n=173) 
- Interferon beta-1a 44 mcg SC t.i.w. (n=231) 
Treatment-
experienced 
2 years 
DEFINE (2012)(33) 
Double-blind, in 28 countries includ-
ing Europe, Canada, and US 
- Dimethyl fumarate 240 mg oral twice daily (n = 410) [total 480 
mg/day] 
- Dimethyl fumarate 240 mg oral three times daily (n = 416) [total 
720 mg/day] 
- Placebo (n = 408) 
Mixed 2 years 
CONFIRM (2012) (34) 
Rater-blinded, in 200 research sites in 
28 countries including Europe and 
North America 
- Dimethyl fumarate 240 mg b.i.d, (n=359) 
- Dimethyl fumarate 240 mg three times daily (n=345), subcuta-
neous daily injections of 20 mg of glatiramer acetate for 96 weeks 
(n=350) 
- Placebo (n=363) 
Mixed 2 years 
mg=milligrams, mcg=micrograms, SC= subcutaneous; q.d.= once daily, q.w.=. once weekly, t.i.w.= three times weekly, IM= intra muscular 
  
41 
 
Name (publication) (reference) 
Study design 
Intervention versus comparison (n=number random-
ised) 
Treatment  
history 
Follow-up 
FREEDOMS (2010) (37) 
Double-blind, multi-centre in Aus-
tralia, Canada, Europe, and South Af-
rica (138 centers in 22 countries) 
- Fingolimod oral 0.5 mg q.d. (n = 425)  
- Fingolimod oral 1,25 mg q.d. (n = 429) 
- Placebo (n = 418) 
Mixed 2 years 
TRANSFORMS (2010) (38) 
Double-blind, in 172 centres in 18 
countries including Canada, Australia, 
Europe, and US. 
- Fingolimod oral 0.5 mg q.d. (n=431) 
- Fingolimod oral 1.25 mg q.d. (n=426) 
- Interferon beta-1a 30 mcg IM q.w. (n=435) 
Mixed 1 year 
Saida et al. (2012) (39) 
Double-blind, multicentre in Japan 
- Fingolimod oral 0.5 mg q.d. (n=57) 
- Fingolimod oral 1.25 mg q.d. (n=57 
- Placebo (n=57) 
Unclear 6 months 
FREEDOMS II (2014)(40, 41) 
Double-blind, in 117 academic and ter-
tiary referral centres in 8 countries, 
most patients included in the USA 
- Fingolimod 0.5 mg oral q.d. (n=358) 
- Fingolimod 1.25 mg oral q.d. (n=370) 
- Placebo (n=355) 
Unclear 2 years 
Johnson et al. (1995) (42) 
Double-blind, in 11 centres in the US 
- Glatiramer acetate 20 mg SC q.d (n =125) 
- Placebo (n=126) 
Treatment-
naive 
2 years 
Comi et al. (2001)(43) 
Double-blind, in 7 countries 
- Glatiramer acetate 20 mg SC q.d. (n=119) 
- Placebo (n=120) 
Unclear 9 months 
REGARD (2008)(44) 
Open-label, rater-masked. 81 centres 
in 14 countries including Canada, 
South America, and Europe 
- Glatiramer acetate 20 mg SC q.d. (n=378) 
- Interferon beta-1a 44 mcg SC t.i.w. (n=386) 
Treatment-
naive 
96 weeks 
BECOME (2009) (45) 
Rater-blinded, in one centre in the US 
- Glatiramer acetate 20 mg SC q.d. (n = 39) 
- Interferon beta-1b 250 mcg SC every other day (n = 36) 
Treatment-
naive 
2 years 
mg=milligrams, mcg=micrograms, SC= subcutaneous; q.d.= once daily, q.w.=. once weekly, t.i.w.= three times weekly, IM= intra muscular   
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Name (publication) (reference) 
Study design 
Intervention versus comparison (n=number random-
ised) 
Treatment  
history 
Follow-up 
BEYOND (2009)(46) 
A rater-blinded,  in 198 centres in 26 
countries worldwide. 
- Glatiramer acetate 20 mg SC q.d. (n = 448) 
- Interferon beta-1b 250 mcg SC every other day (n = 897)  
- Interferon beta-1b 500 mcg SC every other day (n = 899) 
Treatment-
naive 
2 to 3,5 
years 
Calabrese et al. (2012)(47) 
Rater-blinded, single-centre in Italy 
- Glatiramer acetate 20 mg SC q.d. (n = 55) 
- Interferon beta-1a 44 mcg SC t.i.w. (n = 55)  
- Interferon beta-1a 30 mcg IM q.w. (n = 55) 
Unclear 2 years 
GALA (2013)(35)  
Double-blind study, in 142 sites in 17 
countries 
- Glatiramer acetate sc 40mg (1ml) tiw (n=943) 
- Placebo (n=461) 
Mixed 1 year 
CombiRx (2013) (48) 
Double-blind, in 68 sites, both private 
practice and academic, in the USA and 
Canada 
- Interferon beta-1a 30µg IM q.d and glatiramer acetate (GA) 20mg 
q.d (n=499) (not considered)) 
- Glatiramer acetate 20mg q.d (n=259) 
- Interferon beta-1a 30µg IM q.w (n=250) 
- These interventions were compared one with another 
Treatment-
naïve 
3 years 
 
 
 
 
MSCRG (1996)(49) 
Double-blind, in 4 centres in the US 
- Interferon beta-l a 30 mcg IM q.w. (n=158) 
- Placebo (n=143) 
Treatment-
naive 
2 years 
EVIDENCE (2002)(50) 
Rater-blinded, in 56 centres in Eu-
rope, Canada, and US. 
- Interferon beta-1a 30 mcg IM q.w. (n = 338) 
- Interferon beta-1a 44 mcg SC t.i.w. (n = 339) 
Unclear 24 weeks 
INCOMIN (2002) (51) 
Open label, rater-masked, in 15 cen-
tres in Italy 
- Interferon beta-1a 30 mcg IM q.w. (n = 92) 
- Interferon beta-1b 250 mcg SC every other day (n = 96) 
Treatment-
naive 
2 years 
Clanet et al. (2002) (52) 
Double-blind, dose-comparison study. 
In 38 centers in Europe 
- Interferon beta-1a 30 mcg IM once weekly (n=402) 
- Interferon beta-1a 60 mcg IM once weekly N=(400) 
 
Unclear At least 3 
years 
mg=milligrams, mcg=micrograms, SC= subcutaneous; q.d.= once daily, q.w.=. once weekly, t.i.w.= three times weekly, IM= intra muscular  
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Name (publication) (reference) 
Study design 
Intervention versus comparison (n=number random-
ised) 
Treatment  
history 
Follow-up 
Kappos et al. (2011) (36) 
79 centres in 20 countries in North 
America, east-central Europe, Asia, 
western Europe, and Latin America. 
- Ocrelizumab 600 mg IV day 1 and 15 (n=55, not our scope) 
- Ocrelizumab 600 mg IV day 1 and 15 (n=55, not our scope) 
- Interferon beta-1a 30 mcg IM q.d. (n=55) 
- Placebo (n=54) 
Mixed 24 weeks 
Mokhber et al. (2013) (53) 
Single center in Iran 
- Interferon beta-1a (Avonex ) 30 mcg once per week IM injection; 
(n=23) 
- Interferon beta-1a (Rebif) 44 mcg t.i.w. SC injection; (n=23) 
- Interferon beta-1a (Betaferon) 0.25 mg every other day SC injec-
tion (n=23) 
Treatment-
naive 
1 year 
BRAVO (2014) (54) 
In 18 countries  
- Laquinimod 0.6 mg capsule q.d. (n=434)[not our scope] 
- Interferon beta-1a IM 30 mcg once-weekly injection (n = 447) 
- Placebo (matching laquinimod) (n = 450) 
Mixed 2 years 
PRISMS (1998) (55) 
Double-blind, in 22 centres in 9 coun-
tries including Australia, Canada, and 
Europe 
- Interferon beta-1a 22 mcg SC t.i.w.(n=189) 
- Interferon beta-1a 44 mcg SC t.i.w. (n=184) 
- Placebo (n=187) 
Treatment-
naive 
2 years 
IMPROVE (2010) (56) 
Double-blind, multi-centre, multi-
country in European countries. 
- Interferon beta-1a 44 mcg SC t.i.w. (n = 120) 
- Placebo (n = 60) 
Unclear 16 weeks 
IFNB-MS (1993) (57) 
Multi-centre Canada and the US. 
- Interferon beta-1b 250 mcg SC every other day (n = 124)  
- Interferon beta-1b 50 mcg SC every other day (n=125) 
- Placebo (n = 123) 
Treatment-
naïve 
3 years 
Etemadifar et al. (2006)(58) 
Rater-blinded, neurology outpatient 
clinics in Iran 
- Interferon beta-1b 250 mcg SC every other day (n = 30) 
- Interferon beta-1a 30 mcg IM q.w. (n = 30) 
- Interferon beta-1a 44 mcg SC t.i.w. (n = 30) 
Unclear 2 years 
ADVANCE study(2014) (59) 
Double-blind, in 26 countries, in 
north/south America, Europe, India 
- Peg-interferon beta-1a 125 mcg SC once every 2 weeks (n=512) 
- Peg-interferon beta-1a 125 mcg SC once every 4 weeks (n=500) 
- Placebo (n=500) 
Mixed 2 years 
mg=milligrams, mcg=micrograms, SC= subcutaneous; q.d.= once daily, q.w.=. once weekly, t.i.w.= three times weekly, IM= intra muscular   
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Name (publication) (reference) 
Study design 
Intervention versus comparison (n=number random-
ised) 
Treatment  
history 
Follow-up 
AFFIRM (2006) (60) 
Double-blind, in 99 centres in Europe, 
North America, Australia, and New 
Zealand. 
- Natalizumab 300 mg IV every 4 weeks (n = 627) 
- Placebo (n = 315) 
Unclear 2 years 
Gobbi et al (2013) (31) 
Rater blinded. One centre, Switzer-
land. 
- Continue on natalizumab 300 mg IV q.m. (n=10) 
- Switch to interferon beta-1b 250 mcg every other day (n=9) 
Treatment 
experienced 
1 year 
RESTORE (2014) (61) 
Randomized partially, in North Amer-
ica and Europe 
- Natalizumab 300 mg IV every 4 weeks (n=45) 
- Alternate immunomodulatory therapy (n=88) (not our scope) 
- Placebo IV every 4 weeks (n=42) 
Treatment 
experienced 
24 weeks 
Zecca et al. (2014) (32) 
Rater-blinded, parallel-group study, 
single center, Switzerland 
- Continue Natalizumab monthly intravenous (i.v.) 300 mg (n=10) 
- De-escalate to interferon beta-1b subcutaneous (s.c.) 250 mcg 
every other day (n=9) 
Treatment 
experienced 
1 year 
O’Connor et al (2006) (62) 
Double-blind. Centres in Canada 
- Teriflunomide oral 7 mg q.d.(n=61) 
- Teriflunomide oral 14 mg q.d.(n=57 
- Placebo (n=61) 
Treatment-
naive 
36 weeks 
TEMSO (2011) (63, 64) 
Double-blind, in 127 centres in 21 
countries including Canada, Europe, 
and US. 
- Teriflunomide oral 7 mg q.d. (n=365) 
- Teriflunomide oral 14 mg q.d. (n=358) 
- Placebo (n=363) 
Mixed 108 weeks 
TOWER (2014) (65) 
Double-blind, in 189 centres mainly 
hospital-based sites in 26 countries 
- Teriflunomide 14 mg once daily (n=372) 
- Teriflunomide 7 mg once daily (n=408) 
- Placebo once daily (n=389) 
Mixed Up to 48 
weeks 
TENERE (2014) (66) 
Rater-blinded study, multicentre 
study 
- Teriflunomide 14 mg oral once daily (n=111) 
- Teriflunomide 7 mg oral once daily (n=109) 
- Interferon beta-1a 44mcg s.c three times/week (n=104) 
Mixed Up to 48 
weeks 
mg=milligrams, mcg=micrograms, SC= subcutaneous; q.d.= once daily, q.w.=. once weekly, t.i.w.= three times weekly, IM= intra muscular 
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Effects of intervention(s) 
We describe here the effects of the examined MS disease modifying medicines on out-
comes. 
 
The GRADE evaluation is described in detail in Appendix 5. Results of the full network 
meta-analysis for all possible comparisons for all outcomes are given in Appendix 6.  
 
 
Annualised relapse rate 
We present here the results obtained using the “network meta-analysis approach” 
(Bayesian method). We found similar results using the “pairwise comparison method” 
(Frequentist approach). Those results are presented in Appendix 7. 
 
Figure 3 shows the available network of evidence for annualised relapse rate. The 
thickness of the line is proportional to the amount of evidence for that comparison. In 
total, 19 MS treatment strategies and placebo were examined. 
 
 
Figure 3. Evidence network for annualised relapse rate 
 
 
 
  
46 
 
Active treatments versus placebo 
Fifteen treatments were compared to placebo (Table 5). Results from direct, and in-
direct evidence, and from the whole network are consistent (except for teriflunomide 
oral 7 mg). All active treatments examined were more effective than placebo against 
relapse. The highest effect against annual relapse was seen for alemtuzumab 12 mg IV 
q.d. When considering results we had high quality evidence for, the relative risk for 
annual relapse ranged between 0.29 (95% CI: 0.23; 0.35) for alemtuzumab 12 mg IV 
q.d, and 0.86 (0.7 to 1.06) for interferon beta-1a 60 mcg IM q.w, compared to placebo.  
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Table 5. Relative risk for annual relapse for active MS treatments compared to placebo 
 
  Direct evidence Indirect evidence Network meta-analysis 
Interventions RR (95% CI) GRADE RR (95% CI) GRADE RR (95% CI) GRADE 
Interferon beta-1a 22  mcg 0.69 (0.57 to 0.83) Moderate NA NA 0.69 (0.57 to 0.83) Moderate 
Interferon beta-1a 30  mcg 0.76 (0.65 to 0.89) High 0.87 (0.75 to 1.01) Moderate 0.82 (0.73 to 0.91) High 
Interferon beta-1a 44  mcg 0.67 (0.54 to 0.80) High 0.61 (0.52 to 0.72) Very low 0.64 (0.56 to 0.72) High 
Glatiramer acetate 20mg 0.70 (0.60 to 0.82) High 0.60 (0.52 to 0.70) Moderate 0.65 (0.59 to 0.73) High 
Glatiramer acetate 40mg 0.66 (0.52 to 0.82) High NA NA 0.66 (0.52 to 0.82) High 
Dimethyl fumarate 240 mg 2.i.d 0.5 (0.42 to 0.6) High NA NA 0.5 (0.42 to 0.6) High 
Dimethyl fumarate 240 mg t.i.d 0.5 (0.42 to 0.6) High NA NA 0.5 (0.42 to 0.6) High 
Teriflunomide oral 7 mg 0.73 (0.64 to 0.84) High 1.12 (0.78 to 1.57) Moderate 0.77 (0.68 to 0.9) High 
Teriflunomide oral 14 mg 0.67 (0.58 to 0.78) High 0.57 (0.39 to 0.83) Low 0.67 (0.58 to 0.77) High 
Fingolimod oral 0.5 mg  0.49 (0.41 to 0.57) High 0.38 (0.27 to 0.51) Moderate 0.46 (0.39 to 0.54) High 
Fingolimod oral 1.25 mg  0.43 (0.37 to 0.51) High 0.53 (0.39 to 0.84) Moderate 0.45 (0.39 to 0.53) High 
Peg-interferon beta-1a 125 mcg 1/ 2 w 0.65 (0.49 to 0.85) High NA NA 0.65 (0.49 to 0.85) High 
Peg-interferon beta-1a 125 mcg 1/4 w 0.73 (0.56 to 0.95) High NA NA 0.73 (0.56 to 0.95) High 
Natalizumab 0.30 (0.25 to 0.36) Moderate 0.0002 (0.00 to 0.07) Very low 0.3 (0.24 to 0.36) Moderate 
Interferon beta-1b 250 mcg  0.65 (0.51 to 0.83) Moderate 0.67 (0.55 to 0.79) Very low 0.66 (0.57 to 0.76) Moderate 
Alemtuzumab 24 mg IV q.d. NA NA 0.16 (0.1 to 0.25) Low 0.16 (0.1 to 0.25) Low 
Alemtuzumab 12 mg IV q.d NA NA 0.29 (0.23 to 0.35) High 0.29 (0.23 to 0.35) High 
Interferon beta-1b 500mcg SC 1/2 d NA NA 0.62 (0.51 to 0.74) Moderate 0.62 (0.51 to 0.74) Moderate 
Interferon beta-1a 60 mcg IM q.w. NA NA 0.86 (0.7 to 1.06) High 0.86 (0.7 to 1.06) High 
RR= relative ratio, CI= confidence interval, mg= milligrams, mcg= micrograms, SC= subcutaneous, IM= intra muscular, q.d.= once daily, q.w.=once weekly, t.i.w.= three times 
weekly, 2.i.d= two times daily, t.i.d= three times daily, 1/2 w=once every 2 weeks, 1/4 w=once every 4 weeks, 1/2 d= once every two days, NA=Not applicable (no available data). 
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Active treatments compared with each other 
We had information on 24 head-to-head comparisons of active treatments (Table 6). 
Most results (except interferon beta-1a 44mcg versus alemtuzumab 24 mg and inter-
feron beta-1a 22 mcg; and for teriflunomide oral 7 mg versus interferon beta-1a 44 
mcg) were similar for direct, and indirect evidence, and for the whole network.  When 
considering statistically significant results for which we had high quality of evidence, 
we found that some treatments were more effective than others against relapses: in-
terferon beta-1a 44 mcg was less effective than alemtuzumab 12 mg (RR; 95% CI= 
2.21; 1.90 to 2.64). Fingolimod oral 0.5 mg and fingolimod oral 1.25 mg performed 
better than interferon beta-1a 30 mcg, with RRs (95% CI) of 0.57 (0.47 to 0.67) and 
0.55 (0.47 to 0.66), respectively. Furthermore, dimethyl fumarate 240 mg two times 
and three times daily were more effective than glatiramer acetate 20mg, with RRs of 
0.77 (0.63 to 0.93) and 0.77 (0.64 to 0.93), respectively. 
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Table 6. Relative risk for annual relapse for active MS treatments compared to others for comparisons with available direct evidence 
 
 
RR= relative ratio, CI= confidence interval, mg= milligrams, mcg= micrograms, SC= subcutaneous, IM= intra muscular, q.d.= once daily, q.w.=once weekly, t.i.w.= three times 
weekly, 2.i.d= two times daily, t.i.d= three times daily, 1/2 w=once every 2 weeks, 1/4 w=once every 4 weeks. 
 NE= Not estimable (Estimate of difference for direct evidence is not estimable due to 0 events in the Natalizumab group) 
Interv ention Com parison RR (95% CI) GRADE RR (95% CI) GRADE RR (95% CI) GRADE
Alemtuzumab 24 mg Alemtuzumab 12 mg 0.55 (0.35 to 0.86) Low NA NA 0.55 (0.35 to 0.86) Low
Interferon beta-1a 44  mcg Alemtuzumab 12 mg 2.21 (1 .9 to 2.64) High NA Low 2.21  (1 .9 to 2.64) High
Interferon beta-1a 44  mcg Interferon beta-1a 22  mcg 0.68 (0.56 to 0.83) Moderate 0.43 (0.33 to 0.55) Moderate 0.92 (0.7 6 to 1 .11) Moderate
Interferon beta-1a 44  mcg Interferon beta-1a 30  mcg 0.7 6 (0.63 to 0.93) High 0.7 9 (0.65 to 0.95) Very  low 0.7 8 (0.68 to 0.89) High
Interferon beta-1a 60  mcg Interferon beta-1a 30  mcg 1.05 (0.88 to 1 .25) Moderate NA NA 1.05 (0.88 to 1 .25) Moderate
Glatiramer acetate 20mg Interferon beta-1a 30  mcg 0.7 9 (0.61  to 1 .02) Moderate 0.80 (0.69 to 0.93) Moderate 0.8 (0.7  to 0.91) Moderate
Fingolimod oral 0.5 mg Interferon beta-1a 30  mcg 0.48 (0.35 to 0.64) High 0.60 (0.50 to 0.7 3) Moderate 0.57  (0.47  to 0.67 ) High
Fingolimod oral 1 .25 mg Interferon beta-1a 30  mcg 0.63 (0.46 to 0.90) High 0.52 (0.43 to 0.63) Moderate 0.55 (0.47  to 0.66) High
Interferon beta-1b 250 mcg Interferon beta-1a 30  mcg 0.7 1  (0.53 to 0.91) Moderate 0.85 (0.7 1  to 1 .03) Very  low 0.81 (0.69 to 0.93) Moderate
Glatiramer acetate 20mg Interferon beta-1a 44 mcg 1.02 (0.83 to 1 .28) Moderate 0.98 (0.82 to 1 .18) Very  low 1.02 (0.9 to 1 .18) Moderate
Teriflunomide oral 7  mg Interferon beta-1a 44 mcg 1.7 2 (1 .24 to 2.44) Moderate 1 .13 (0.93 to 1 .34) Low 1.21 (1 .02 to 1 .47 ) Moderate
Teriflunomide oral 14 mg Interferon beta-1a 44 mcg 0.91  (0.62 to 1 .36) Low 1.06 (0.89 to 1 .31) Moderate 1 .04 (0.87  to 1 .27 ) Moderate
Interferon beta-1b 250 mcg Interferon beta-1a 44 mcg 0.81  (0.46 to 1 .43) Very  low 1.00 (0.83 to 1 .18) Moderate 1 .03 (0.88 to 1 .22) Moderate
Ddimethyl fumarate 240 mg 2.i.d Glatiramer acetate 20mg 0.59 (0.38 to 0.90) High 0.63 (0.40 to 0.98) Moderate 0.7 7  (0.63 to 0.93) High
Dimethy l fumarate 240 mg t.i.d Glatiramer acetate 20mg 0.53 (0.35 to 0.7 9) High 0.7 8 (0.50 to 1 .25) Moderate 0.7 7  (0.64 to 0.93) High
Interferon beta-1b 250 mcg Glatiramer acetate 20mg 1.07  (0.90 to 1 .27 ) Moderate 0.92 (0.7 5 to 1 .14) Very  low 1.01 (0.88 to 1 .16) Moderate
Interferon beta-1b 500 mcg Glatiramer acetate 20mg 0.95 (0.8 to 1 .12) Moderate NA NA 0.95 (0.8 to 1 .12) Moderate
Dimethy l fumarate 240 mg t.i.d Dimethy l fumarate 240 mg 2.i.d 1.01  (0.82 to 1 .23) Moderate NA NA 1.01 (0.82 to 1 .23) Moderate
Teriflunomide oral 14 mg Teriflunomide oral 7  mg 0.86 (0.7 4 to 1 .) Moderate NA NA 0.86 (0.7 4 to 1 .) Moderate
Fingolimod oral 1 .25 mg Fingolimod oral 0.5 mg 0.98 (0.83 to 1 .17 ) Moderate NA NA 0.98 (0.83 to 1 .17 ) Moderate
Peginterferon beta-1a 125 mcg 1/4 w Peginterferon beta-1a 125 mcg 1/2 w 1 .13 (0.84 to 1 .52) Moderate NA NA 1.13 (0.84 to 1 .52) Moderate
Interferon beta-1b 250 mcg Natalizumab NE Very  low 2.17  (1 .7 1  to 2.7 6) Moderate 2.22 (1 .7 6 to 2.81) Moderate
Interferon beta-1b 500 mcg Interferon beta-1b 250 mcg 0.93 (0.8 to 1 .1) Moderate NA NA 0.93 (0.8 to 1 .1) Moderate
Direct ev idence Indirect evidence Network m eta-analy sis
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Disability progression 
We examined, first, disability progression as a dichotomous variable, considering 
whether someone had been less disabled or not when using a certain treatment. The 
results obtained using the “network meta-analysis approach” are presented here. 
These results are consistent with results found with the “pairwise comparison 
method”. The “pairwise comparison method” results are presented in Appendix 7. 
 
The network of evidence available for disability progression is presented in Figure 4. 
We had evidence for 18 treatment strategies and placebo. 
 
 
Figure 4. Evidence network for disability progression  
 
Active treatments versus placebo 
Table 7 compares results obtained when considering direct, indirect evidence and the 
whole network. It shows that results were similar. Seventeen treatments were com-
pared to placebo. For four of these, we had high quality evidence, and they were all 
more effective than placebo against disability progression. The network meta-analysis 
RRs for disability progression were 0.65 (95% CI: 0.49; 0.85) for dimethyl fumarate 
240 mg two times daily, 0.68 (0.52; 0.89) for dimethyl fumarate 240 mg three times 
daily, 0.71 (0.55; 0.90) for fingolimod oral 0.5 mg, and 0.71 (0.56; 0.90) for fin-
golimod oral 1.25 mg.  
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Table 7. Relative risk for disability progression for active MS treatments compared to placebo 
 
 
RR= relative ratio, CI= confidence interval, mg= milligrams, mcg= micrograms, SC= subcutaneous, IM= intra muscular, q.d.= once daily, q.w.=once weekly, t.i.w.= three times 
weekly, 2.i.d= two times daily, t.i.d= three times daily, 1/2 w=once every 2 weeks, 1/4 w=once every 4 weeks. 
 
  
Interventions RR (95% CI) GRADE RR (95% CI) GRADE RR (95% CI) GRADE
Interferon beta-1a 22  mcg 0.84 (0.61 to 1.19) Low NA NA 0.84 (0.61 to 1.19) Low
Interferon beta-1a 30  mcg 0.68 (0.50 to 0.95) Moderate 0.88 (0.66 to 1.20) Low 0.8 (0.65 to 0.99) Moderate
Interferon beta-1a 44  mcg 0.70 (0.48 to 1.04) Low 0.86 (0.59 to 1.30) Low 0.77 (0.6 to 1.01) Low
Glatiramer acetate 20mg 0.88 (0.61 to 1.21) Low 0.70 (0.51 to 0.94) Low 0.78 (0.63 to 0.96) Low
Dimethyl fumarate 240 mg two times daily 0.65 (0.49 to 0.85) High NA NA 0.65 (0.49 to 0.85) High
Dimethyl fumarate 240 mg three times daily 0.68 (0.52 to 0.89) High NA NA 0.68 (0.52 to 0.89) High
Teriflunomide oral 7 mg 0.8 (0.55 to 1.13) Low NA NA 0.8 (0.55 to 1.13) Low
Teriflunomide oral 14 mg 0.73 (0.51 to 1.05) Low NA NA 0.73 (0.51 to 1.05) Low
Fingolimod oral 0.5 mg 0.75 (0.56 to 0.98) High 0.56 (0.32 to 0.91) Low 0.71 (0.55 to 0.9) High
Fingolimod oral 1.25 mg 0.70 (0.52 to 0.92) High 0.81 (0.48 to 1.31) Low 0.71 (0.56 to 0.9) High
Peginterferon beta-1a 125 mcg once every 2 wks 0.61 (0.36 to 0.98) Low NA NA 0.61 (0.36 to 0.98) Low
Peginterferon beta-1a 125 mcg once every 4 wks 0.62 (0.38 to 1.01) Low NA NA 0.62 (0.38 to 1.01) Low
Natalizumab 0.59 (0.42 to 0.84) Moderate NA NA 0.59 (0.42 to 0.84) Moderate
Interferon beta-1b 250 mcg 0.77 (0.50 to 1.17) Low 0.67 (0.43 to 0.95) Low 0.72 (0.54 to 0.92) Low
Alemtuzumab 12 mg IV q.d NA NA 0.4 (0.27 to 0.6) Low 0.4 (0.27 to 0.6) Low
Alemtuzumab 24 mg IV q.d NA NA 0.36 (0.16 to 0.74) Very low 0.36 (0.16 to 0.74) Very low
Interferon beta-1b 500 mcg SC 1/2 d. NA NA 0.79 (0.56 to 1.1) Low 0.79 (0.56 to 1.1) Low
Direct evidence Indirect evidence Network meta-analysis
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Active treatments compared with each other 
We obtained similar results when comparing active treatments with each other using 
direct and indirect evidence, and the evidence from the whole network (except for 
interferon beta-1b 250 mcg  versus  interferon beta-1a 30 mcg) (Table 8). We had 
evidence of very low to moderate quality (Table 8). Only two of the network meta-
analysis comparisons showed statistically significant differences between treatments. 
interferon beta-1a 44 mcg was less effective against disability progression than 
alemtuzumab 12 mg and 24 mg, with RRs of 1.95 (95% CI: 1.45; 2.59) (evidence of 
moderate quality) and 2.15 (1.10; 4.55) (evidence of very low quality), respectively. 
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Table 8. Relative risk for disability progression for active MS treatments compared to others for comparisons with available direct evidence 
 
 
RR= relative ratio, CI= confidence interval, mg= milligrams, mcg= micrograms, SC= subcutaneous, IM= intra muscular, q.d.= once daily, q.w.=once weekly, t.i.w.= three times 
weekly, 2.i.d= two times daily, t.i.d= three times daily, 1/2 w=once every 2 weeks, 1/4 w=once every 4 weeks. 
 
  
Interv ention Com parison RR (95% CI) GRADE RR (95% CI) GRADE RR (95% CI) GRADE
Alemtuzumab 24 mg Alemtuzumab 12 mg 0.85 (0.4 to 1.65) Very low NA NA 0.85 (0.4 to 1.65) Very low
Interferon beta-1a 44  mcg Alemtuzumab 12 mg 1.95 (1.45 to 2.59) Moderate NA NA 1.95 (1.45 to 2.59) Moderate
Interferon beta-1a 44  mcg Alemtuzumab 24 mg 2.15 (1.1 to 4.55) Very low NA NA 2.15 (1.1 to 4.55) Very low
Interferon beta-1a 44  mcg Interferon beta-1a 22  mcg 0.92 (0.65 to 1.3) Low NA NA 0.92 (0.65 to 1.3) Low
Interferon beta-1a 44  mcg Interferon beta-1a 30  mcg 0.89 (0.55 to 1.38) Low 1.04 (0.72 to 1.50) Low 0.97 (0.73 to 1.3) Low
Interferon beta-1a 60  mcg Interferon beta-1a 30  mcg 0.99 (0.71 to 1.39) Low NA NA 0.99 (0.71 to 1.39) Low
glatiramer acetate 20mg Interferon beta-1a 30  mcg 1.18 (0.81 to 1.75) Low 0.87 (0.64 to 1.17) Low 0.98 (0.76 to 1.23) Low
Fingolimod oral 0.5 mg Interferon beta-1a 30  mcg 0.72 (0.42 to 1.17) Low 0.96 (0.68 to 1.33) Low 0.89 (0.65 to 1.16) Low
Fingolimod oral 1.25 mg Interferon beta-1a 30  mcg 0.99 (0.58 to 1.60) Low 0.85 (0.59 to 1.19) Low 0.89 (0.66 to 1.18) Low
Interferon beta-1b 250 mcg Interferon beta-1a 30  mcg 0.44 (0.23 to 0.82) Low 1.07 (0.81 to 1.43) Low 0.9 (0.65 to 1.17) Low
glatiramer acetate 20mg Interferon beta-1a 44 mcg 0.75 (0.46 to 1.21) Low 1.17 (0.82 to 1.65) Low 1.01 (0.75 to 1.33) Low
dimethyl fumarate 240 mg two times daily glatiramer acetate 20mg 0.78 (0.52 to 1.18) Low 0.80 (0.51 to 1.18) Low 0.83 (0.61 to 1.15) Low
dimethyl fumarate 240 mg three times daily glatiramer acetate 20mg 0.79 (0.53 to 1.16) Low 0.88 (0.59 to 1.36) Low 0.88 (0.64 to 1.18) Low
Interferon beta-1b 250 mcg glatiramer acetate 20mg 1.04 (0.74 to 1.46) Moderate 0.74 (0.48 to 1.09) Low 0.92 (0.69 to 1.16) Moderate
Interferon beta-1b 500 mcg glatiramer acetate 20mg 1.01 (0.74 to 1.36) Moderate NA NA 1.01 (0.74 to 1.36) Moderate
dimethyl fumarate 240 mg three times daily dimethyl fumarate 240 mg two times daily 1.06 (0.78 to 1.42) Low NA NA 1.06 (0.78 to 1.42) Low
Teriflunomide oral 14 mg Teriflunomide oral 7 mg 0.92 (0.64 to 1.35) Low NA NA 0.92 (0.64 to 1.35) Low
Fingolimod oral 1.25 mg Fingolimod oral 0.5 mg 1.01 (0.78 to 1.32) Moderate NA NA 1.01 (0.78 to 1.32) Moderate
Peginterferon beta-1a 125 mcg once every 4 wks Peginterferon beta-1a 125 mcg once every 2 wks 1.02 (0.61 to 1.74) Low NA NA 1.02 (0.61 to 1.74) Low
Interferon beta-1b 500 mcg Interferon beta-1b 250 mcg 1.1 (0.84 to 1.51) Moderate NA NA 1.1 (0.84 to 1.51) Moderate
Direct evidence Indirect evidence Network Meta-analysis
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Withdrawal due to adverse events 
We present here the results obtained using the “network meta-analysis approach”. 
Those are consistent with results found with the “pairwise comparison method”. The 
“pairwise comparison method” results are presented in Appendix 7. 
 
Figure 5 presents the network of evidence available for the outcome withdrawal due 
to adverse events. This network included information on 19 different treatments strat-
egies and placebo. 
 
Figure 5. Evidence network for withdrawal due to adverse events
 
 
Active treatments versus placebo 
Table 9 presents results estimated through direct and indirect evidence, and through 
the whole network. Results are consistent (except for interferon beta-1b 250 mcg). We 
had evidence for 19 treatments versus placebo. The quality of the evidence considered 
for the whole network was of very low to moderate quality. Four treatments were sta-
tistically significantly more associated with withdrawal due to adverse events than 
placebo. We found RRs for withdrawal due to adverse events of 2.20 (95% CI: 1.29-
3.97) for interferon beta-1a 44 mcg (low quality evidence), of 2.21 (1.42; 3.58) for fin-
golimod oral 1.25 mg (moderate quality), and of 3.57 (1.27; 11.14) and 3.47 (1.25 to 
10.9) for peg-interferon beta-1a 125 mcg once every 2 and 4 weeks, respectively (low 
quality evidence). 
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Table 9. Relative risk for withdrawal due to adverse events for active MS treatments compared to placebo 
 
 
RR= relative ratio, CI= confidence interval, mg= milligrams, mcg= micrograms, SC= subcutaneous, IM= intra muscular, q.d.= once daily, q.w.=once weekly, t.i.w.= three times 
weekly, 2.i.d= two times daily, t.i.d= three times daily, 1/2 w=once every 2 weeks, 1/4 w=once every 4 weeks. 
  
Interventions RR (95% CI) GRADE RR (95% CI) GRADE RR (95% CI) GRADE
Interferon beta-1a 22  mcg 1.68 (0.5 to 5.98) Low NA NA 1.68 (0.5 to 5.98) Low
Interferon beta-1a 30  mcg 1.73 (0.82 to 3.87) Low 1.12 (0.61 to 2.10) Low 1.33 (0.85 to 2.17) Low
Interferon beta-1a 44  mcg 5.32 (1.09 to 41.63) Low 1.98 (1.10 to 3.61) Low 2.2 (1.29 to 3.97) Low
Glatiramer acetate 20mg 1.22 (0.64 to 2.66) Low 1.15 (0.54 to 2.42) Low 1.17 (0.74 to 1.94) Low
Glatiramer acetate 40mg 2.5 (0.86 to 8.29) Low NA NA 2.5 (0.86 to 8.29) Low
Dimethyl fumarate 240 mg 2.i.d. 1.24 (0.74 to 2.13) Low NA NA 1.24 (0.74 to 2.13) Low
Dimethyl fumarate 240 mg t.i.d 1.25 (0.74 to 2.13) Low NA NA 1.25 (0.74 to 2.13) Low
Teriflunomide oral 7 mg 1.54 (0.89 to 2.51) Low 0.89 (0.32 to 2.44) Low 1.37 (0.82 to 2.21) Low
Teriflunomide oral 14 mg 1.70 (1.02 to 3.01) Low 1.29 (0.47 to 3.44) Low 1.53 (0.96 to 2.54) Low
Fingolimod oral 0.5 mg 1.49 (0.86 to 2.50) Low 1.48 (0.65 to 3.55) Low 1.54 (0.98 to 2.52) Low
Fingolimod oral 1.25 mg 1.93 (1.18 to 3.14) Moderate 3.26 (1.52 to 7.22) Low 2.21 (1.42 to 3.58) Moderate
Peginterferon beta-1a 125 mcg 1/2 w 3.57 (1.27 to 11.14) Low NA NA 3.57 (1.27 to 11.14) Low
Peginterferon beta-1a 125 mcg 1/4 w 3.47 (1.25 to 10.9) Low NA NA 3.47 (1.25 to 10.9) Low
Natalizumab 1.22 (0.5 to 2.74) Low NA NA 1.22 (0.5 to 2.74) Low
Interferon beta-1b 250 mcg 0.07 (0.003 to 0.48) Low 1.64 (0.68 to 4.36) Low 0.84 (0.4 to 1.87) Low
Alemtuzumab 24 mg IV q.d NA NA 0.54 (0.17 to 1.54) Very low 0.54 (0.17 to 1.54) Very low
Alemtuzumab 12 mg IV q.d NA NA 0.61 (0.25 to 1.47) Low 0.61 (0.25 to 1.47) Low
Interferon beta-1b 500 mcg SC 1/2 d NA NA 1.37 (0.52 to 3.92) Low 1.37 (0.52 to 3.92) Low
Interferon beta-1a 60 mcg IM q.w NA NA 1.9 (0.79 to 4.81) Low 1.9 (0.79 to 4.81) Low
Direct evidence Indiret evidence Network meta-analysis
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Active treatments compared with each other 
Results using direct and indirect evidence, and evidence from the whole network were 
similar in terms of direction of the association and magnitude (Table 10). The quality 
of the evidence ranged from very low to moderate. Only two of the network meta-
analysis comparisons showed statistically significant results. Patients withdrew more 
due to adverse events with interferon beta-1a 44 mcg than with alemtuzumab 12 and 
24 mg (RRs of 3.6 (95% CI: 1.88; 7.33), and 4.08 (1.69; 11.42), respectively). The cor-
responding quality of the evidence was moderate and very low. 
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Table 10. Relative risk for withdrawal due to adverse events for active MS treatments compared to each other 
 
 
RR= relative ratio, CI= confidence interval, mg= milligrams, mcg= micrograms, SC= subcutaneous, IM= intra muscular, q.d.= once daily, q.w.=once weekly, t.i.w.= three times 
weekly, 2.i.d= two times daily, t.i.d= three times daily, 1/2 w=once every 2 weeks, 1/4 w=once every 4 weeks. 
 
  
Intervention Comparison RR (95% CI) GRADE RR (95% CI) GRADE RR (95% CI) GRADE
Alemtuzumab 24 mg Alemtuzumab 12 mg 0.88 (0.3 to 2.31) Low NA NA 0.88 (0.3 to 2.31) Low
Interferon beta-1a 44  mcg Alemtuzumab 12 mg 3.6 (1.88 to 7.33) Moderate NA NA 3.6 (1.88 to 7.33) Moderate
Interferon beta-1a 44  mcg Alemtuzumab 24 mg 4.08 (1.69 to 11.42) Very low NA NA 4.08 (1.69 to 11.42) Very low
Interferon beta-1a 44  mcg Interferon beta-1a 22  mcg 1.31 (0.4 to 4.36) Low NA NA 1.31 (0.4 to 4.36) Low
Interferon beta-1a 44  mcg Interferon beta-1a 30  mcg 1.15 (0.43 to 3.10) Low 2.09 (0.98 to 4.57) Low 1.65 (0.91 to 3.08) Low
Interferon beta-1a 60  mcg Interferon beta-1a 30  mcg 1.43 (0.66 to 3.11) Low NA NA 1.43 (0.66 to 3.11) Low
glatiramer acetate 20mg Interferon beta-1a 30  mcg 0.61 (0.22 to 1.67) Low 1.02 (0.53 to 2.03) Low 0.88 (0.51 to 1.55) Low
Fingolimod oral 0.5 mg Interferon beta-1a 30  mcg 1.28 (0.52 to 3.44) Low 1.17 (0.58 to 2.29) Low 1.16 (0.65 to 2.04) Low
Fingolimod oral 1.25 mg Interferon beta-1a 30  mcg 2.44 (1.09 to 5.68) Low 1.41 (0.73 to 2.59) Low 1.66 (0.94 to 2.91) Low
Interferon beta-1b 250 mcg Interferon beta-1a 30  mcg 6.27 (0.79 to 172.3) Low 0.41 (0.16 to 0.93) Low 0.63 (0.28 to 1.44) Low
glatiramer acetate 20mg Interferon beta-1a 44 mcg 0.88 (0.36 to 1.94) Low 0.37 (0.17 to 0.77) Low 0.53 (0.29 to 0.96) Low
Teriflunomide oral 7 mg Interferon beta-1a 44 mcg 0.40 (0.14 to 1.00) Low 0.75 (0.34 to 1.42) Low 0.62 (0.31 to 1.12) Low
Teriflunomide oral 14 mg Interferon beta-1a 44 mcg 0.54 (0.20 to 1.38) Low 0.76 (0.35 to 1.57) Low 0.69 (0.37 to 1.28) Low
dimethyl fumarate 240 mg two times daily glatiramer acetate 20mg 1.18 (0.49 to 2.84) Low 0.96 (0.37 to 2.36) Low 1.07 (0.56 to 1.92) Low
dimethyl fumarate 240 mg three times daily glatiramer acetate 20mg 1.15 (0.52 to 2.56) Low 0.98 (0.35 to 2.53) Low 1.07 (0.56 to 1.93) Low
Interferon beta-1b 250 mcg glatiramer acetate 20mg 0.91 (0.37 to 2.27) Low 0.49 (0.14 to 1.63) Low 0.72 (0.35 to 1.49) Low
Interferon beta-1b 500 mcg glatiramer acetate 20mg 1.16 (0.46 to 3.05) Low NA NA 1.16 (0.46 to 3.05) Low
dimethyl fumarate 240 mg three times daily dimethyl fumarate 240 mg two times daily 1.01 (0.58 to 1.73) Low NA NA 1.01 (0.58 to 1.73) Low
Teriflunomide oral 14 mg Teriflunomide oral 7 mg 1.12 (0.73 to 1.85) Moderate NA NA 1.12 (0.73 to 1.85) Moderate
Fingolimod oral 1.25 mg Fingolimod oral 0.5 mg 1.43 (0.94 to 2.21) Moderate NA NA 1.43 (0.94 to 2.21) Moderate
Peginterferon beta-1a 125 mcg once every 4 wks Peginterferon beta-1a 125 mcg once every 2 wks 0.98 (0.41 to 2.37) Low NA NA 0.98 (0.41 to 2.37) Low
Interferon beta-1b 500 mcg Interferon beta-1b 250 mcg 1.63 (0.66 to 4.11) Low NA NA 1.63 (0.66 to 4.11) Low
Directe evidence Indirecte evidence Network meta-analysis
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Change in Expanded Disability Scale 
Here, we examined disability progression in a continuous manner; that is by estimat-
ing the change in EDSS. We did not grade the quality of the evidence for this outcome. 
We present here results for active treatments versus placebo. We compare results ob-
tained though the “network meta-analysis approach” and the “pairwise comparison 
method”. 
 
The network of the evidence for change in EDSS included 12 treatment strategies and 
placebo (Figure 6).  
 
Figure 6. Network of evidence for change in expanded disability status scale 
 
 
 
Active treatments versus placebo 
Twelve different treatments were compared to placebo in the network meta-analysis 
(Table 11). Four treatments were statistically significantly more effective than placebo 
against disability progression: alemtuzumab 24 mg (mean difference=-0.91 (95% CI:-
1.48; -0.4), alemtuzumab 12 mg (-06 (-1.02; -0.24)), interferon beta-1b 250 mcg every 
other day (-0.58 (-0.94; -0.22)), and interferon beta-1a 44 mcg three times a week (-
0.28 (-0.58; -0.02).  
 
When comparing results obtained through “network meta-analysis approach” and 
“pairwise comparison method”, we found a difference in the magnitude and statistical 
significance of the effect for the comparison interferon beta-1a 30 mcg versus placebo 
(Table 11). The mean difference in change in EDSS score was -0.59 (-0.86 to -0.32) 
when considering pairwise comparisons, and -0.22 (-0.48 t0 0.02) for the network 
meta-analysis estimates. For the other treatments strategies, a similar magnitude of 
effect was seen. 
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Table 11. Change in expanded disability status scale for MS treatments com-
pared to placebo for direct pairwise comparisons and network evidence 
 
 
CI= confidence interval, mg= milligrams, mcg= micrograms, SC= subcutaneous, IM= intra muscular, 
q.d.= once daily, q.w.=once weekly, t.i.w.= three times weekly, 2.i.d= two times daily, t.i.d= three times 
daily, 1/2 w=once every 2 weeks, 1/4 w=once every 4 weeks. SUCRA= surface under the cumulative 
ranking curve. 
 
 
Serious adverse events 
We present here results for active treatments versus placebo. We did not grade the 
quality of the evidence for this outcome. We compare results obtained though the 
“network meta-analysis approach” and the “pairwise comparison method”. 
 
  
Network meta-analysis Pairwise comparison
Interventions Mean difference SUCRA Mean difference
Alemtuzumab 24 mg IV q.d -0.91  (-1 .48 to -0.4) 0.98
Alemtuzumab 12 mg IV q.d -0.6 (-1 .02 to -0.24) 0.86
Interferon beta-1b 250 mcg SC every  other day -0.58 (-0.94 to -0.22) 0.85
Interferon beta-1a 44 mcg SC t.i.w -0.28 (-0.58 to -0.02) 0.56  -0.24 (-0.48 to 0.00)
Interferon beta-1a 22 mcg SC t.i.w -0.27  (-0.7 1  to 0.15) 0.52 -0.25 (-0.51  to  0.01)
Interferon beta-1a 60 mcg IM q.w -0.25 (-0.7 6 to 0.24) 0.49
Fingolimod oral 1 .25 mg  -0.22 (-0.47  to 0.04) 0.46 -0.15 (-0.25 to -0.05)
Interferon beta-1a 30 mcg IM q.w -0.22 (-0.48 to 0.02) 0.46 -0.59 (-0.86 to -0.32)
Teriflunomide oral 14 mg -0.14 (-0.56 to 0.27 ) 0.35 -0.14 (-0.27  to -0.01)
Fingolimod oral 0.5 mg -0.16 (-0.41  to 0.1 ) 0.35 -0.08 (-0.20 to 0.03)
glatiramer acetate 20mg q.d -0.13 (-0.4 to 0.11) 0.31 -0.03 (-0.12 to 0.06)
Teriflunomide oral 7  mg -0.05 (-0.47  to 0.36) 0.23 -0.05 (-0.18 to 0.08)
Placebo 0 0.10
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The evidence network available for serious adverse events is presented in Figure 7. 
 
 
Figure 7. Network of evidence for serious adverse events 
 
 
Active treatments versus placebo 
Through the network meta-analysis, we had information for 17 treatments (Table 12). 
When considering all the available evidence comparing active treatments and pla-
cebo, based on the confidence intervals, no statistically significant difference was seen 
between results obtained through pairwise comparisons and network meta-analysis 
results. However, for the network meta-analysis results no treatments were found to 
increase statistically significantly serious adverse events compared to placebo. Results 
from the “pairwise comparison method” showed that peg-interferon beta-1a 125 mcg 
once every 4 and 2 weeks were associated with more serious adverse events than pla-
cebo, with RRs of 1.55 (95% CI: 1.12-2.14) and 1.66 (1.21- 2.28), respectively. 
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Table 12. Relative risk for serious adverse events for MS treatments compared to 
placebo for direct pairwise comparisons and network evidence 
 
 
RR= relative ratio, CI= confidence interval, mg= milligrams, mcg= micrograms, SC= subcutaneous, 
IM= intra muscular, q.d.= once daily, q.w.=once weekly, t.i.w.= three times weekly, 2.i.d= two times 
daily, t.i.d= three times daily, 1/2 w=once every 2 weeks, 1/4 w=once every 4 weeks. SUCRA= surface 
under the cumulative ranking curve. 
 
 
Mortality 
We present here results for active treatments versus placebo. We compare results ob-
tained though the “network meta-analysis approach” and the “pairwise comparison 
method”. 
  
Network meta-analysis Pairwise comparison
Intervention Relative ratio (95% CI) SUCRA Relative ratio (95% CI)
Alemtuzumab 12 mg IV q.d 0.67 (0.37 to 1.28) 0.80
Interferon beta-1b 250 mcg SC every other day 0.66 (0.35 to 1.26) 0.80
Dimethyl fumarate 240 mg three times daily 0.72 (0.49 to 1.07) 0.76 0.73 (0.59 to 0.91)
Interferon beta-1a 30 mcg IM q.w 0.77 (0.54 to 1.13) 0.70 0.65 (0.44 to 0.97)
Glatiramer acetate 20mg q.d 0.78 (0.54 to 1.14) 0.68 0.99 (0.50 to 1.97)
Alemtuzumab 24 mg IV q.d 0.79 (0.42 to 1.53) 0.64
Dimethyl fumarate 240 mg two times daily 0.81 (0.56 to 1.19) 0.64 0.82 (0.67 to 1.01)
Natalizumab 0.81 (0.49 to 1.39) 0.62 0.80 (0.62 to 1.03)
Interferon beta-1a 44 mcg SC t.i.w 0.86 (0.52 to 1.46) 0.54
Interferon beta-1b 500 mcg SC every other day 0.93 (0.49 to 1.8) 0.47
Fingolimod oral 0.5 mg 0.96 (0.68 to 1.39) 0.45 0.98 (0.67 to 1.42)
Glatiramer acetate 40mg t.i.w 0.99 (0.49 to 2.04) 0.44 0.98 (0.59 to 1.63)
Placebo 1 0.39
Teriflunomide oral 7 mg 1.03 (0.71 to 1.51) 0.37 1.02 (0.79 to 1.32)
Teriflunomide oral 14 mg 1.07 (0.73 to 1.54) 0.33 1.14 (0.89 to 1.46)
Fingolimod oral 1.25 mg  1.22 (0.87 to 1.77) 0.20 1.18 (0.73 to 1.91)
peginterferon beta-1a 125 mcg once every 4 weeks 1.55 (0.88 to 2.74) 0.11 1.55 (1.12 to 2.14)
Peginterferon beta-1a 125 mcg once every 2 weeks 1.67 (0.94 to 2.94) 0.07 1.66 (1.21 to 2.28)
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Figure 8 illustrates the network of evidence available for mortality. In total, 19 treat-
ment strategies and placebo were examined. 
 
Figure 8. Evidence network for mortality 
 
 
 
 
Active treatments versus placebo 
Table 13 reports results for nineteen treatments compared to placebo. Estimates ob-
tained through “pairwise comparison method” and “network meta-analysis approach” 
are statistically consistent. None of the examined treatments were associated with a 
higher risk for mortality than placebo.  
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Table 13. Relative risk for mortality for MS treatments compared to placebo for 
direct pairwise comparisons and network evidence 
 
 
RR= relative ratio, CI= confidence interval, mg= milligrams, mcg= micrograms, SC= subcutaneous, 
IM= intra muscular, q.d.= once daily, q.w.=once weekly, t.i.w.= three times weekly, 2.i.d= two times 
daily, t.i.d= three times daily, 1/2 w=once every 2 weeks, 1/4 w=once every 4 weeks. SUCRA= surface 
under the cumulative ranking curve. 
 
 
Stay at hospitals 
Very few studies reported on stay at hospitals. Therefore, we could not summarise 
quantitatively the results for this endpoint. 
 
  
Network meta-analysis Pairwise comparison
Intervention Relative ratio (95% CI) SUCRA Relative ratio (95% CI) 
Fingolimod oral 0.5 mg 0.1 (0. to 2.57) 0.80 0.20 (0.01 to 4.09)
Interferon beta-1b 500 mcg SC every other day 0.08 (0. to 5.9) 0.79
Glatiramer acetate 40mg t.i.w 0.08 (0. to 3.54) 0.79 0.16 (0.01 to 4.00)
Interferon beta-1b 250 mcg SC every other day 0.07 (0. to 6.65) 0.79
Peginterferon beta-1a 125 mcg once every 4 weeks 0.4 (0.01 to 10.22) 0.61 0.50 (0.05 to 5.50)
Peginterferon beta-1a 125 mcg once every 2 weeks 0.41 (0.01 to 8.87) 0.61 0.49 (0.04 to 5.37)
Dimethyl fumarate 240 mg two times daily 0.52 (0.04 to 5.34) 0.59 1.00 (0.10 to 9.62)
Fingolimod oral 1.25 mg  0.52 (0.02 to 6.76) 0.58 0.49 (0.04 to 5.35)
Dimethyl fumarate 240 mg three times daily 0.89 (0.09 to 8.41) 0.47 1.64 (0.20 to 13.27)
Interferon beta-1a 44 mcg SC t.i.w 0.97 (0.06 to 17.15) 0.47 0.34 (0.01 to 8.26)
Glatiramer acetate 20mg q.d 0.9 (0.11 to 7.85) 0.47 1.03 (0.06 to 16.47)
Teriflunomide oral 14 mg 0.94 (0.02 to 37.74) 0.46 0.94 (0.06 to 15.00)
Placebo 1 0.44
Interferon beta-1a 22 mcg SC t.i.w 1.6 (0.07 to 34.77) 0.37 0.99 (0.06 to 15.70)
Alemtuzumab 24 mg IV q.d 2.08 (0.04 to 125.5) 0.34
Interferon beta-1a 60 mcg IM q.w 2.28 (0.03 to 222.1) 0.34
Interferon beta-1a 30 mcg IM q.w 2.1 (0.26 to 24.45) 0.29 2.86 (0.30 to 27.43)
Teriflunomide oral 7 mg 2.59 (0.12 to 82.51) 0.29 2.08 (0.19 to 22.79)
Alemtuzumab 12 mg IV q.d 2.81 (0.08 to 168.2) 0.27
Natalizumab 4.34 (0.16 to 2761.) 0.22 2.52 (0.12 to 52.25)
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Economic evaluation-Methods 
General 
In order to assess the health economic effectiveness of different disease-modifying 
medicines for patients with RRMS, we performed a cost-utility analysis (CUA). The 
relevant costs were expressed in 2015 Norwegian kroner (NOK), and effects were ex-
pressed in quality-adjusted life-years (QALYs). Both costs and effects were discounted 
using an annual discount rate of 4% as recommended by the Norwegian Ministry of 
Finance and guidelines for health economic evaluation in the health sector (67). 
 
The analysis was carried out from a healthcare perspective. The healthcare perspec-
tive is relevant for prioritisation of interventions within a fixed budget if the aim of 
the decision maker is to maximize health (no expansion of the budget is assumed). 
The methodological guidelines for economic evaluation in the health sector recom-
mend a societal perspective that includes consequences for all parts of the economy, 
including time costs, the deadweight loss of taxation, any productivity changes, and 
excluding transfers such as value added tax. This perspective is more appropriate if 
an expansion of the budget is assumed and in settings where prioritization of inter-
ventions across sectors of the economy is relevant (e.g. for public health interven-
tions).  
 
We expressed the results as mean incremental cost-effectiveness ratio (ICER) from 
10,000 runs of the model in base-case. We handled uncertainties in model parameters 
by performing probabilistic sensitivity analyses, designed as a Monte Carlo simula-
tion, with 10,000 iterations. 
 
Population, interventions and model structure  
Population 
In the economic evaluation, we assumed that a typical RRMS patient population in 
Norway has an average age of 30 years at diagnosis, and 68% are female.  
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Interventions 
There are currently 12 disease-modifying therapies approved and available for RRMS 
patients in Norway (based on clinical experts’ opinion). All these active treatment op-
tions were included in our analysis (Table 14).  
 
Table 14. Available treatments included in the health economic analysis 
Interventions 
Alemtuzumab 12 mg (Lemtrada) 
Dimethyl fumarate 240 mg (Tecifidera) 
Fingolimod 0.5 mg (Gilenya) 
Glatiramer acetate 20 mg (Copaxone)* 
Interferon beta-1a 30 mcg (Avonex) 
Interferon beta-1a 22 mcg (Rebif) 
Interferon beta-1a 44 mcg (Rebif) 
Interferon beta-1b 250 mcg (Betaferon) 
Interferon beta-1b 250 mcg (Extavia) 
Natalizumab 300 mg/15 mL (Tysabri) 
Peg-interferon beta-1a 125 mcg (Plegridy) 
Teriflunomide 14 mg (Aubagio) 
  mg: milligram; mL: millilitre; mcg: microgram 
* Glatiramer acetate 40 mg 3 times per week was discussed in the discussion section.  
 
Because of lack of clinical data exploring the sequential use of different treatment 
options following the failure of first-line treatments or switching, we assumed that 
patients could not switch between treatments in the model. 
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Model structure 
In order to assess the cost-utility of different disease-modifying therapies in patients 
diagnosed with RRMS, a decision analytic model was developed in TreeAge pro ® 
2015. The model is of the Markov type, in which a cohort of patients is followed over 
a given period of time. A Markov model was considered appropriate, as multiple scle-
rosis is a chronic condition requiring continuous treatment (68, 69). 
 
We developed the model based on a previously published report with similar objec-
tives as ours (27). The validity of the model structure and assumptions to the Norwe-
gian context have been discussed and evaluated by two independent clinical experts 
experienced in treating patients with RRMS in Norway. The model structure and all 
assumptions were adapted to the Norwegian setting, and took into consideration Nor-
wegian clinical practice. 
 
The model simulates the natural history of MS using the state transition methodology 
(Figure 9). Health states were defined according to the Kurtzke EDSS (70). EDSS is a 
clinical rating scale ranging from 0 to 10. EDSS 0-2.5 refers to patients with no or few 
limitations in mobility, and EDSS 10 refers to death due to MS. Disability status was 
modelled from 0 to 10 for RRMS and from 2 to 10 for SPMS (70).  
 
During one cycle, all patients could remain in the current health state, progress to the 
next more severe state, transition to a secondary-progressive health state, or die (Fig-
ure 9). Patients with an EDDS scale of five or lower could also improve to a less severe 
state, and stop treatment. Improvement in lower health states was modelled by as-
suming that a maximum of 2 EDSS-point improvements could be achieved (71). Pa-
tients would discontinue treatment once they progress to an EDSS of six or SPMS 
(based on clinical experts’ opinion).  
 
In the base-case analysis, we assumed no treatment effect once patients progress to 
an EDDS of six. It is also documented that with advancing disease (EDSS>6) less re-
lapses occur (71). We, therefore, assumed that relapses would occur only in patients 
with EDSS of five or lower. 
 
We assessed the costs and utilities associated with different treatment options over 
20 years for the base case analysis (based on experts’ opinion). Alternatives horizons 
of 10 years and 30 years were considered in scenario analyses. We used a cycle length 
of the model of one year, meaning that any transitions between different states could 
happen only once a year. Patients could be in only one of the pre-defined states at any 
time. Upon completion of each cycle, patients could, depending on transition proba-
bilities, transfer to another state or remain in the same state until death or the end of 
the simulation. Each state and event is associated with specific health outcomes and 
costs. Death is modelled as an absorbing state. Once an individual makes a transition 
into the absorbing state, no further incurred costs or health outcome are included in 
the analysis.  
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Figure 9. Model structure  
EDSS: Expanded Disability Status Scale; RRMS: relapsing-remitting multiple scle-
rosis; SMPM: Secondary-progressive multiple sclerosis 
Note: Patients with EDSS over 5 can also progress to SPMS. Mild or moderate and 
severe relapses can occur in EDSS below 6 as events.  
 
Disease-modifying therapies are usually initiated in patients with an EDSS score 
lower than 5, and mostly for patients with an EDSS score between 1 and 3 (clinical 
expert opinion and (72)). EDSS distributions used in our analysis are presented in 
Table 15. 
 
Table 15. EDSS distribution 
EDSS score Distributions (%) Standard error 
0 5.10 0.003 
1 24.60 0.013 
2 29.30 0.015 
3 24.70 0.013 
4 12.70 0.006 
≥ 5 3.60 0.002 
  EDSS: Expanded Disability Status Scale 
  Source: Nixon et.al 2014 (72) 
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Model Parameters 
The model was created as a probabilistic model. This means that all uncertain param-
eters (efficacy, costs, epidemiological data, etc.) were modelled as probability distri-
butions rather than point estimates. This was done to facilitate probabilistic sensitiv-
ity analysis.  The sources and methods used to derive the model parameters are de-
scribed below. First, we describe how we estimated the natural history transitional 
probabilities, then we describe how we incorporated into the model the clinical effect 
estimates (obtained through the systematic review (SR) and the network meta-analy-
sis). Finally, we describe the methods used to calculate costs, and quality of life esti-
mates.  
 
Key model assumptions 
Based on reporting of withdrawals in studies included in our SR, we set annual treat-
ment discontinuation rate at 15% for the first two years in the base case analysis. This 
rate is also applicable to the Norwegian context according to the experts’ opinion. A 
previous study showed that the proportion of patients who discontinued treatment 
and the degree of treatment adherence were similar across different treatment op-
tions (73). We therefore assumed the same discontinuation rate across all treatment 
options. We assumed no discontinuation after two years (expert opinion). Any pa-
tients who discontinues therapy subsequently progress according to natural history 
rates with no additional cost of therapy. 
 
We assumed that treatments have no survival benefit. The annual risk of other mor-
tality causes is, therefore, assumed to be the same as the normal population. We col-
lected age and gender specific Norwegian all-cause mortality data from Statistics Nor-
way (74). A weighted average was calculated based on the assumption that 68% of 
RRMS patients were female.  
  
Natural history transitional probabilities  
We did not find Norwegian data that were compatible to the developed model, so the 
transitional probabilities had to be based on estimates reported in the published lit-
erature. However, the transferability of the data to the Norwegian context were criti-
cally discussed and modified based on expert advice. 
 
Disability progression 
Probabilities for disability progression within RRMS health states, transitioning from 
RRMS to SPMS, as well as disability progression within SPMS health states were de-
rived from a large 25- year patient-level cohort study (untreated patients) undertaken 
in London, Ontario, Canada (75, 76). The reported data were eligible for our model 
and used by the several previously published economic studies (27, 77).  
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Instantaneous hazard rates for disability progression without disease-modifying ther-
apy were calculated from the Ontario dataset using the formula below (76), and are 
presented in the Tables 16-18. 
 
λi ൌ Number	of	people	leaving	state	i∑ ݀ݑݎܽݐ݅݋݊	݅݊	ݏݐܽݐ݁	݅௡௝ୀଵ  
where n is the number of individuals, j is each individual leaving state i, and i= 
EDSS sate 0 to 10. 
 
All rates were transformed into transition probabilities for use in the model (78). All 
natural history probabilities were incorporated in the model as beta distributions 
 
Table 16. Progression rates within RRMS health states 
EDSS score Estimates (per person-year) Variance 
0 0.144 0.00007 
1 0.075 0.00003 
2 0.152 0.00006 
3 0.272 0.00025 
4 0.450 0.00166 
5 0.485 0.00213 
6 0.283 0.00104 
7 0.342 0.00450 
8 0.105 0.00139 
9 0.167 0.02778 
  EDSS: Expanded Disability Status Scale 
   Source: (27, 76) 
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Table 17. Progression rates from RRMS to SPMS  
EDSS score Estimates (per person-year) Variance 
0 0.004 0.000002 
1 0.002 0.000001 
2 0.029 0.000012 
3 0.102 0.000094 
4 0.199 0.000735 
5 0.256 0.001126 
6 0184 0.000676 
7 0.237 0.000312 
8 0.066 0.000866 
9 0.167 0.027778 
  EDSS: Expanded Disability Status Scale; SPMS: Secondary-progressive multiple sclerosis 
  Source: (27, 76) 
 
Table 18. Progression rates within SPMS health states 
EDSS score Estimates (per person-year) Variance 
2 0.370 0.00370 
3 0.385 0.00129 
4 0.594 0.00280 
5 0.349 0.00088 
6 0.241 0.00029 
7 0.186 0.00024 
8 0.107 0.00015 
9 0.093 0.00038 
  EDSS: Expanded Disability Status Scale; SPMS: Secondary-progressive multiple sclerosis 
  Source: (27, 76) 
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Improvements in MS disability 
Based on a large study, Tremlett and co-workers concluded that improvements in MS 
disability over one or two years were not unusual (71). The result of the study indicated 
that 8.3% of patients had an improvement of at least 1 point in the EDDS scale after 
one year, and 2.2% showed greater than or equal to 2-point improvements. We con-
sidered a maximum of two EDSS-point improvements in the model. The rates of an-
nual disability improvements were used in the model only for the EDSS states lower 
than 6. 
 
Relapse rate 
There were no available Norwegian data on annual relapse rate compatible to our 
model. We considered therefore the best available sources. Annual relapse rates have 
been estimated based on Ontario cohort data (76), and published evidence suggested 
that the frequency of relapse is affected by a patient’s age and disease duration (a de-
crease over time) (79, 80). Based on Ontario cohort data, the mean relapse rate after 
two years since disease onset was reported to be 0.835 and 1.423 for patients in EDSS 
0 to 2 and 3+, respectively (76). These estimates were adjusted such that the patients 
enter the model with an average time since disease onset of five years and onwards 
(based on the studies included in our systematic review). More detailed information 
about the estimation of annual relapse rate can be found in the Canadian HTA report 
(27). These annual relapse rates were judged applicable to the Norwegian context by 
our clinical experts. 
 
We used a Gamma distribution for annual relapse rates based on the assumption that 
events with a known average rate occur in a fixed interval of time.  
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Table 19. Annual relapse rates 
Year since MS 
onset Base estimate Standard error 
For patients with a EDSS 0 to 2.5 
5 0.712 0.343 
10 0.623 0.335 
15 0.571 0.331 
20 0.534 0.327 
25 0.506 0.325 
For patients with a EDSS 3 to 5.5 
5 1.255 0.386 
10 1.101 0.374 
15 1.011 0.367 
20 0.947 0.362 
25 0.897 0.358 
  EDSS: Expanded Disability Status Scale 
  Source: (27) 
 
Based on published literature and expert opinion, we assumed that 23% of relapses 
were severe (81). In addition, we assumed that the average length of mild or moderate 
relapses was of 45 days. For severe relapse, it was of 90 days (27, 81).  
 
Clinical efficacy parameters in the model 
Clinical efficacy data for the model were the data presented in the “Clinical evaluation- 
results” section of this report. These were the results obtained through the network 
meta-analysis of the included trials. In the health economic model, we included the 
estimates on relapse rates and disability progression. These efficacy estimates were 
modelled by applying the relative risk for each treatment compared to best supportive 
care “no treatment”, to the transitional probabilities based on the natural history of 
the disease for untreated patients.    
 
We added the relative risks to the model as probability distributions. We used log-
normal distributions, according to the methodology described by Briggs and co-au-
thors (78). Standard errors for the log-normal distributions were calculated based on 
confidence intervals for efficacy estimates. The estimates of the calculations of distri-
butions for efficacy parameters used in the model are presented in Tables 20 and 21. 
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Based on expert opinion, we considered a reduction in treatment effect over time. Full 
effect of treatments is assumed to be 100% for the first four years, 75% from year 5 -
10, and 50% beyond 10 years. 
 
Treatment effect on disability progression 
The relative risks of sustained disability progression were multiplied to the transi-
tional probabilities of patients moving to higher health states, as well as to progression 
to SPMS health states.  
 
We assumed that patients transitioned as natural history of disease transitional prob-
abilities between SPMS health state. That is treatments had no effect on the transition 
between SPMS states. Patients who withdraw treatment will progress according to 
transitional probabilities for natural disability progression, but will retain any previ-
ously accrued benefits. 
 
Table 20. Efficacy estimates for disability progression (log-normal distribution) 
Interventions 
RR of sustained 
disability progression 
Ln (RR) SE 
Alemtuzumab 12 mg (Lemtrada) 0.36 -1.02 0.39 
Dimethyl fumarate 240 mg (Tecifidera) 0.65 -0.43 0.14 
Fingolimod 0.5 mg (Gilenya) 0.71 -0.34 0.13 
Glatiramer acetate 20 mg * (Copaxone) 0.78 -0.25 0.11 
Interferon beta-1a 30 mcg (Avonex) 0.80 -0.22 0.11 
Interferon beta-1a 22 mcg (Rebif) 0.84 -0.17 0.17 
Interferon beta-1b 250 mcg (Betaferon) 0.72 -0.33 0.14 
Interferon beta-1b 250 mcg (Extavia) 0.72 -0.33 0.14 
Natalizumab 300 mg/15 mL (Tysabri) 0.59 -0.53 0.18 
Peg-interferon beta-1a 125 mcg (Plegridy) 0.61 -0.49 0.26 
Teriflunomide 14 mg (Aubagio) 0.73 -0.31 0.18 
  RR: relative risk; SE: standard error; mg: milligram; mL: millilitre; mcg: microgram  
* We did not find any documentation for glatiramer acetate 40 mg. 
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Treatment effect on relapses 
The expected number of relapses for each treatment alternative were estimated in the 
model by multiplying the treatment effect on the relapse rates for each treatment al-
ternative (Table 21) to the average number of relapses experienced with “no treat-
ment”.  
 
Table 21. Efficacy estimates for annual relapse (log-normal distribution) 
Interventions 
RR of annual 
relapse rate 
Ln (RR) SE 
Alemtuzumab 12 mg (Lemtrada) 0.29 -1.24 0.11 
Dimethyl fumarate 240 mg 
(Tecifidera) 0.50 -0.69 0.09 
Fingolimod 0.5 mg (Gilenya) 0.46 -0.78 0.08 
Glatiramer acetate 20 mg * 
(Copaxone)  0.65 -0.43 0.05 
Interferon beta-1a 30 mcg 
(Avonex) 0.82 -0.20 0.06 
Interferon beta-1a 22 mcg (Rebif) 0.69 -0.37 0.10 
Interferon beta-1a 44 mcg (Rebif) 
 0.64 -0.45 0.06 
Interferon beta-1b 250 mcg 
(Betaferon) 0.66 -0.42 0.07 
Interferon beta-1b 250 mcg 
(Extavia) 0.66 -0.42 0.07 
Natalizumab 300 mg/15 mL 
(Tysabri) 0.30 -1.20 0.10 
Peg-interferon beta-1a 125 mcg 
(Plegridy) 0.65 -0.43 0.14 
Teriflunomide 14 mg (Aubagio) 0.67 -0.40 0.07 
RR: relative risk; SE: standard error; mg: milligram; mL: millilitre; mcg: microgram  
* Glatiramer acetate 40 mg RR: 0.66 SE: 0.11 
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Treatment-related adverse events 
Generally, disease-modifying therapies are well tolerated. Our systematic review 
showed no statistically significant differences between the therapies for serious ad-
verse events. Moreover, most of the adverse events related to the RRMS treatments 
were transient, and some of them may potentially be related to the disease process 
(e.g. depression). We have therefore not included adverse events (except for Progres-
sive multifocal leukoencephalopathy (PML)) in the model based on the assumption 
that the costs and disutility associated with adverse events would not have a signifi-
cant impact on the results. However, some of the differences for resource use related 
to the adverse events have been considered when estimating of monitoring costs as-
sociated with each of the treatment strategies. For more information, see Appendix 8. 
 
Natalizumab has been reported to be associated with the development of PML, which 
is a rare but serious infectious or inflammatory disease. PML is a viral infection (JC-
virus) leading to inflammation and finally demyelination,  often resulting in severe 
disability or death (82). A study from 2013 found a risk of developing PML of 2.84 
cases per 1000 patients who received natalizumab for MS (83). It was also reported 
that 22% of the reported natalizumab-associated PML patients died (83). The costs 
and reduction in quality of life associated with PML is addressed in the next sections.  
 
It should be mentioned that recently PML has also been reported in a small number 
of patients treated with other disease-modifying therapies, such as dimethyl fumurate 
and fingolimod. Due to insufficient data, we included PML only for natalizumab in 
the model.  
 
Costs 
An annual cost per patient associated with different treatment alternatives was calcu-
lated for each health state and event in the model. The costs included in the model are 
drug costs, monitoring costs associated with the use of drugs, costs related to MS pa-
tients care (excluding drugs) at different EDSS levels, and costs related to the treat-
ments of relapses and PML.  
 
All costs were measured in 2015 Norwegian kroner (NOK) (based on the consumer 
price index for the first four months of 2015 (74)). The uncertainty surrounding cost 
parameters were assessed by using gamma distribution. 
 
Annual drug costs 
Drug costs were calculated based on the maximum pharmacy retail prices that we re-
ceived from the Drug procurement cooperation (LIS). The annual drug cost was esti-
mated based on recommended doses (LIS), and are presented in Table 22. 
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Table 22. Drug costs per patient inclusive VAT 
Drug 
Dosage and recommended 
treatment regimen a 
Dosage form a 
LIS price 
(NOK) a 
Pills/ 
syringes per  
package a 
Annual drug 
cost (NOK) 
Alemtuzumab 
(Lemtrada) 
12 mg/1.2 ml per day for 5 
days, 12 mg/1.2 ml per day 
for 3 days after one year (IV) 
Vial 63,757.09 1 
318,785 (5 days 
first year), 
191,271 (3 days 
second year) b 
Dimethyl fumarate 
(Tecifidera) 
120 mgx2 for 7 days, 
 
 240mg x2 /dag 
Capsule 
3,256.12 (start 
package) 
12,936.70 
14 
 
56 
168,670 
Fingolimod  (Gilenya) 0.5 mg/day Capsule 15,125.39 28 197,170 
Glatiramer acetate 
(Copaxone) c 
20mg/mL 
I syringe/day (SC) 
Pre-filled 
Syringe 
6,702.38 28 87,370 
Interferon beta-1a 
(Avonex) 
30 mcg/0.5 ml 
Once per week (IM) 
Pre-filled 
Syringe 
8,021.97 4 104,286 
Interferon beta-1a 
(Rebif) 
22 mcg/0.5 ml 
3 times per week (IM) 
Pre-filled syringe 
or autoinjector 
7,027.32 12 91,355 
Interferon beta-1a 
(Rebif) 
 
44 mcg/0.5 ml 
3 times per week (IM) 
Pre-filled syringe 
or autoinjector 
8,904.26 12 115,755 
Interferon beta-1b 
(Betaferon) 
250 mcg /mL every other day 
(SC) 
Powder for injec-
tion 
4,937.05 (start 
package) 
5,513.18 
1 
 
15 
66,318 
Interferon beta-1b 
(Extavia) 
250 mcg /mL every other day 
(SC) 
Powder for injec-
tion 
4,950.14 15 60,062 
Natalizumab (Tysabri) 300 mg/15 mL 
Every four weeks (IV) 
Vial 14,757.51 1 191,848 
Peg-interferon  
beta-1a (Plegridy) 
63 mcg/0.5 ml (first dose), 94 
mcg/0.5 ml (second dose), 
125 mcg/0.5 ml every 14 days 
(SC) 
Prefilled syringe 
8,820.69 (start 
package) 
8,820.69 
 
1 (63 mcg) and 
1 (94 mcg) 
 
2 
114,669 
Teriflunomide 
(Aubagio) 14 mg/day Tablet 24,249.21 84 105,369 
IM: intramuscular; IV: intravenous; mcg: microgram; mg: milligram; SC: subcutaneous 
a Source: Drug procurement cooperation (LIS) 2015. 
b The majority of patients receiving Alemtuzumab would not need new treatment after 5 year 
treatment. It was assumed that 20% of patients need extra treatment (12 mg/day for 3 days) 
(84).  
C  Glatiramer acetate 40 mg/ml 3 times per week: LIS price 2015: 6702,38 (12 syringes per  
package). Annual drug cost was estimated to be NOK 87,131.  
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Monitoring costs associated with the use of medicines 
Monitoring costs associated with use of medicines were calculated based on the esti-
mates that we received from the drug procurement cooperation (LIS). The monitoring 
costs were estimated separately for the first and second year. Based on the infor-
mation from clinical experts, we calculated the monitoring costs beyond the second 
year. The estimated monitoring costs are summarized in Table 23 and Appendix 8. 
 
Table 23. Monitoring costs associated with each of the treatments*  
 Drug 1. year 2. year Beyond 2. year 
Alemtuzumab a (Lemtrada) 22,735 14,573 
8307 (3.-5.year) 
7075 (+5.year) 
Dimethyl fumarate (Tecifidera) 11,550 7075 7075 
Fingolimod (Gilenya) 17,912 7075 7075 
Glatiramer  acetate (Copaxone) 11,550 7075 7075 
Interferon beta-1a 30 mcg (Avonex) 19,266 14,791 7075 
Interferon beta-1a  22 mcg (Rebif) 19,266 14,791 7075 
Interferon beta-1a 44 mcg (Rebif) 19,266 14,791 7075 
Interferon beta-1b (Betaferon) 19,266 14,791 7075 
Interferon beta-1b (Extavia) 19,266 14,791 7075 
Natalizumab (Tysabri) 33,240 27,725 27,725 
Peg-interferon beta-1a (Plegridy) 19,266 14,791 7075 
Teriflunomide (Aubagio) 12,894 7523 7523 
* All costs were updated to 2015 costs. 
a The majority of patients receiving alemtuzumab would not need new treatment after 5 –
year treatment. It was assumed that 20% of patients need extra treatment (12 mg/day for 3 
days) (84).  
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Costs associated with MS care (exclusive costs associated with inter-
ventions) 
The costs associated with different health states (EDSS levels) were obtained from a 
Norwegian study (85). This was a survey study carried out in Hordaland county in 
2013 including 546 MS patients. The costs related to diagnosis, treatment, nursing 
care, assistive devices and equipment were included in the cost calculation.  
 
The costs of mild or moderate and severe relapse were estimated based on the survey 
carried out by Svendsen in 2013 (85). The difference between the monthly costs for 
patients who had experienced relapse and for those who had not experienced relapse 
were estimated to be approximately NOK 14,600.  
 
The cost associated to different EDSS states and relapse are presented in Table 24. 
 
Table 24. Costs associated to different EDSS states a 
EDSS Direct costs b (NOK) 
0 18,046 
1 36,901 
2 51,297 
3 126,145 
4 147,554 
5 329,743 
6 564,928 
7 689,224 
8 1,380,296 
9 1,393,636 
Cost per relapse c  
Mild/ moderate 21,906 
Severe  43,812 
EDSS: Expanded Disability Status Scale 
a  Estimated costs associated to different EDSS states in Norway (2013) (85). All costs were 
updated in 2015 NOK (based on the consumer price index for the first four months of 
2015 (74)). 
b  Including VAT   
c  It was assumed that the average length of mild or moderate relapse and severe relapse 
would be 45 and 90 days, respectively (27, 81). 
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We assumed that most of the patients who developed PML needed treatment at hos-
pital. The costs were estimated based on prices from the Norwegian DRG system 
(DRG code 421; personal communication by dr.med Elisabeth Gulowsen Celius). Pa-
tients who survived PML also needed 3-6 months extra treatments at rehabilitation 
centres. We assumed NOK 3,000 cost per day for stay at rehabilitation centre (86).  
 
Health-related Quality of Life 
In order to obtain utility weights, we performed a systematic search for published val-
ues. For consistency, and as the use of different utility instruments would yield differ-
ent results, we focused on values based on EQ-5D, the most commonly used instru-
ment (87). 
 
In the base-case, we used the utility values reported by Orme and co-workers (88). 
The study was a cross sectional study of people comprising all course of MS (RRMS, 
SPMS and PPMS) from the United Kingdom. Based on the systematic search on 
health related quality of life data, this is the only study that presented the utility asso-
ciated with each EDSS state, SPMS and relapse by using the EQ-5D method.  
  
As Orme and colleagues did not make a distinction between mild or moderate and 
severe relapse, we assumed that the reported disutility was for mild or moderate re-
lapses. Therefore, the ratio between disutility associated with mild or moderate re-
lapse and severe relapse estimated by Prosser and co-workers (81) was applied to es-
timate the disutility associated with severe relapse. As mentioned, it was assumed that 
the average length of mild or moderate relapse and severe relapse would be 45 and 90 
days, respectively (27, 81). 
 
We assumed a disutility of 0.4 (0.3-0.5) assigned to the year a patient experienced 
PML (89). 
    
Beta or log-normal distributions were used for utility values used in the model. The 
mean values and standard errors of the utility (QALY) weights used in our model are 
presented in the Table 25. 
 
We did not identify reliable data on the probable effect on patients’ utility of the dif-
ferent methods of administrating the medication. Therefore, the possible disutility 
associated with injections is not included in the model. 
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Table 25. Quality of life data (base-case) 
Parameter Utility weight 95% CL Probability distribution 
EDSS 0 0.870 0.782 0.958 Beta 
EDSS 1 0.799 0.799 0.617 Beta 
EDSS 2 0.705 0.705 .0523 Beta 
EDSS 3 0.574 0.574 0.384 Beta 
EDSS 4 0.610 0.610 0.428 Beta 
EDSS 5 0.518 0.518 0.338 Beta  
EDSS 6 0.460 0.277 0.641 Beta 
EDSS 7 0.297 0.112 0.481 Beta 
EDSS 8 -0.049 -0.235 -0.138 Log-normal 
EDSS 9 -0.195 -0.428 -0.039 Log-normal 
SPMS a -0.045  -0.076 -0.014 Beta or Log-normal 
Disutility associated 
with mild or moderate 
relapse 
-0.071 -0.096 -0.046 Log-normal 
Disutility associated 
with severe relapse b -0.236 -0.295 -0.174 Log-normal 
Disability associated 
with PML c -0.40 -0.30 -0.50 Log-normal 
CI: confidence interval; EDSS: Expanded Disability Status Scale; SPMS: Secondary Progressive MS  
a Assumed fixed utility decrement over the corresponding RRMS EDSS state utility values. 
b It was estimated based on the data reported by Orme et al. (88) and Prosser et al. (81). 
c Ref:(89) 
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Economic evaluation – Results 
We calculated costs and effectiveness (in terms of QALYs), for all relevant disease 
modifying therapies used for RRMS based on simulations of the model. We used 
10,000 iterations in the Monte Carlo analyses. Our assessment of cost-effectiveness 
will reflect a range of potential willingness to pay (WTP) values per gained QALY.  
 
Incremental cost–effectiveness estimates  
The results of the base-case analysis are presented in Table 26. Over a 20-year time 
horizon, alemtuzumab dominated all other alternative treatments, i.e. it was both 
more effective and less costly.  
 
Table 26: Results of the base-case cost-effectiveness analysis (discounted) 
Drugs 
Total costs 
(NOK) 
Effects 
(QALYs) 
Incremental 
cost (NOK) 
Incremental 
 effect 
(QALYs) 
ICER 
(NOK/QALY) 
Alemtuzumab (Lemtrada) 4,897,903 8.05   Dominant 
Interferon beta-1b (Extavia) 6,031,551 7.40 1,133,647 -0.64 Dominated by alemtuzumab 
Interferon 
beta-1b (Betaferon) 6,088,153 7.40 1,190,250 -0.64 
Dominated by 
alemtuzumab 
Glatiramer acetate 20mg (Copax-
one)* 6,253,728 7.31 1,355,825 -0.73 
Dominated by 
alemtuzumab 
Peg-interferon  
beta-1a 
 (Plegridy) 
6,310,586 7.56 1,412,682 -0.48 Dominated by alemtuzumab 
Teriflunomide (Aubagio) 6,337,489 7.38 1,439,586 -0.67 Dominated by alemtuzumab 
Interferon  
beta-1a  22 mcg (Rebif) 6,498,571 7.21 1,600,667 -0.84 
Dominated by 
alemtuzumab 
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QALY: quality-adjusted life year; ICER: incremental cost-effectiveness ratio  
 * Based on effect estimates and annual drug costs, it is highly probable that 
glatiramer acetate 40 mg 3 times per week will be as cost-effective as glatiramer 
acetate 20 mg per day (given all the other parameters are the same). 
 
Monte Carlo simulations with 10,000 draws from the input distributions are shown 
in Figure 10. Simulations for alemtuzumab show that alemtuzumab was more effec-
tive and less costly relative to other treatments. All other interventions were domi-
nated by alemtuzumab. The results of the probabilistic sensitivity analysis also 
showed that alemtuzumab was more likely to be the most cost-effective strategy 
(above 90%) for all values of WTP. 
 
 
Figure 10. Cost-effectiveness scatter-plot; mcg: microgram; mg: milligram 
 
The results presented above show that alemtuzumab was the most cost-effective strat-
egy and dominated all other treatment strategies.  
Interferon beta-1a 30 mcg (Avonex) 6,533,915 7.27 1,636,012 -0.77 Dominated by alemtuzumab 
Interferon 
beta-1a 44 mcg (Rebif) 6,574,606 7.32 1,676,702 -0.72 
Dominated by 
alemtuzumab 
Dimethyl fumarate (Tecifidera) 6,707,787 7.52 1,809,884 -0.52 Dominated by alemtuzumab 
Natalizumab (Tysabri) 6,983,132 7.63 2,085,228 -0.41 Dominated by alemtuzumab 
Fingolimod  (Gilenya) 7,041,216 7.43 2,143,313 -0.62 Dominated by alemtuzumab 
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In order to show the cost-effectiveness of other treatment strategies relative to each 
other, we excluded alemtuzumab (the dominate strategy) and conducted a separate 
analysis of the remaining interventions. The results (for all treatment strategies, ex-
cept alemtuzumab) are presented in Table 27 and Figure 11.  
 
Discarding alemtuzumab, natalizumab was the most effective treatment regarding 
QALYs (7.63),  followed by peg-interferon beta-1a (7.56). Interferon beta-1a 22 mcg 
was the least effective strategy (7.21).  
 
Fingolimod was the most expensive treatment (NOK 7,050,000), followed by 
natalizumab (NOK 6,984,840). Interferon beta-1b (Extavia) was the least expensive 
treament (NOK 6,033,330) and was, therefore, used as a reference. 
 
Three treatment strategies were not dominated by the other interventions. The incre-
mental cost per QALY for peg-interferon beta-1a versus interferon beta-1b (Extavia) 
was NOK 1,658,450. The incremental cost per QALY for natalizumab versus peg-in-
terferon beta-1a was NOK 10,620,000.  
 
Interferon beta-1b (Betaferon) was dominated by interferon-1b (Extavia); glatiramer 
acetate was dominated by interferon beta-1b (Extavia and Betaferon), while terifluno-
mide was dominated by interferon beta-1b (Extavia and Betaferon) and peg-inter-
feron beta-1a. 
 
Interferon beta-1a (Rebif and Avonex) was dominated by peg-interferon beta-1a, in-
terferon beta-1b (Extavia and Betaferon), teriflunomide, and glatiramer acetate.  
Dimethyl fumarate was dominated by peg-interferon beta-1a, while fingolimod was 
dominated by natalizumab, peg-interferon beta-1a and dimethyl fumarate.  
 
Table 27. Results of the base-case cost-effectiveness analysis (all interventions except 
alemtuzumab) (discounted) 
Drugs 
Total 
costs 
(NOK) 
Effects 
(QALYs) 
Versus Interferon beta-1b 250 mg (Extavia) 
Sequential ICER 
(NOK/QALY) Incremental 
cost (NOK) 
  Incremental 
effect (QALYs) 
ICER 
(NOK/QALY) 
Interferon  
beta-1b (Extavia) 
6,033,328 7.40    
 
Peg-interferon  
beta-1a 
 (Plegridy) 
6,308,924 7.56 275,597 0.17 1,658,451 1,658,451 
Natalizumab 
(Tysabri) 
6,984,843 7.63 951,515 0.23 4,140,203 10,619,960 
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QALY: quality-adjusted life year; ICER: incremental cost-effectiveness ratio; mcg: mi-
crogram; mg: milligram  
* Based on effect estimates and annual drug costs, it is highly probable that glatiramer ace-
tate 40 mg 3 times per week will be as cost-effective as glatiramer acetate 20 mg per day 
(given all the other parameters are the same). 
 
 
Dominated therapies 
Interferon 
beta-1b (Beta-
feron) 
6,089,587 7.40 56,259 - 
Dominated by 
interferon beta-
1b (Extavia) 
Dominated by interferon 
beta-1b (Extavia) 
Glatiramer ace-
tate 20 mg (Co-
paxone) * 
6,256,047 7.31 222,720 -0.09 Dominated  
Dominated by interferon 
beta-1b (Extavia) and in-
terferon beta-1b (Beta-
feron) 
Teriflunomide 
(Aubagio) 
6,332,443 7.38 299,116 -0.02 Dominated 
Dominated by interferon 
beta-1b (Extavia), inter-
feron beta-1b (Betaferon) 
and peg-interferon beta-
1a 
Interferon  
beta-1a  22 mcg 
(Rebif) 
6,497,728 7.21 464,401 -0.19 Dominated 
Dominated by  interferon 
beta-1b (Extavia), inter-
feron beta-1b (Betaferon), 
peg-interferon beta-1a, 
glatiramer acetate and 
teriflunomide 
Interferon beta-
1a 30 mcg 
(Avonex) 
6,539,464 7.27 506,137 -0.13 Dominated 
Dominated by  interferon 
beta-1b (Extavia), inter-
feron beta-1b  (Beta-
feron), peg-interferon 
beta-1a, glatiramer ace-
tate and teriflunomide 
Interferon 
beta-1a 44 mcg 
(Rebif) 
6,573,653 7.32 540,325 -0.08 Dominated 
Dominated by interferon 
beta-1b (Extavia), inter-
feron beta-1b (Betaferon), 
peg-interferon beta-1a, 
glatiramer acetate and 
teriflunomide 
Dimethyl 
fumarate 
(Tecifidera) 
6,710,845 7.52 677,517 0.12 5,746,659 
Dominated peg-interferon 
beta-1a  
Fingolimod  
(Gilenya) 
7,040,995 7.42 1,007,668 0.02 43,827,412 
Dominated by peg-inter-
feron beta-1a, dimethyl 
fumarate and natalizumab  
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The incremental cost versus incremental effectiveness (QALY), when all treatment 
strategies, except alemtuzumab are included in the analysis, is presented in Figure 11. 
As mentioned, three interventions, interferon beta-1b (Extavia), peg-interferon beta-
1a and natalizumab were undominated strategies. The line from interferon beta-1b 
(Extavia) to peg-interferon beta-1a and to natalizumab represent the cost-effective-
ness frontier. It means that at different WTP, these three strategies could be consid-
ered the most cost-effective. The incremental cost per QALY of peg-interferon beta-
1a compared with interferon beta-1b (Extavia) is estimated to be NOK 1,658,000, 
meaning interferon beta-1b (Extavia) could be considered the cost-effective treatment 
if WTP for QALY is less than NOK 1,658,000. For WTP between NOK 1,658,000 and 
NOK 10,620,000, peg-interferon beta-1a is the cost-effective treatment. If WTP is 
above 10,620,000, then natalizumab is the cost-effective treatment. The other treat-
ments were dominated by the treatment comprising in the frontier. Therefore, they 
were not considered to be cost-effective.  
 
 
Figure 11. Cost-effectiveness graph (all interventions except alemtuzumab); mcg: mi-
crogram; mg: milligram; INf: interferon 
 
We performed a Monte Carlo simulation with 10,000 draws from the input distribu-
tions and we varied the WTP from NOK 0 to NOK 2,000,000. The cost-effectiveness 
acceptability curves in Figure 12 show the probability of the alternatives being cost-
effective subject to different levels of WTP. If one assumes maximum WTP per QALY 
is NOK 500,000, interferon beta-1a (Extavia) was the most cost-effective treatment 
strategy (47%), followed by peg-interferon beta-1a (27%) and teriflunomide (13%). 
With a WPT per QALY of NOK 1,000,000, interferon beta-1b (Extavia) was the most 
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cost-effective (36%) followed by peg-interferon beta-1a (34%) and teriflunomide 
(14%). However, as presented in the cost-effectiveness scatterplot (Figure 10) and Ta-
ble 27, total QALYs of included interventions (except alemtuzumab) overlapped, 
which indicates the uncertainty regarding the gain in QALYs.  
 
 
Figure 12. Cost-effectiveness acceptability curve (all interventions except alemtuzumab) 
WTP willingness to pay; mcg: microgram; mg: milligram 
 
Value of information analysis 
We performed an analysis of the expected value of perfect information (EVPI) on all 
uncertain parameters to explore the uncertainty surrounding specific groups of pa-
rameters and show which group has the most impact on the results. EVPI analyses 
were performed with 100x500 iterations. The EVPI of different groups of parameters 
(costs, efficacy, QALYs and probabilities) are presented in Figure 13. 
 
At a WTP of NOK 400,000 per QALY, probabilities data (Norwegian epidemiological 
data) had the highest EVPI. For values of WTP above NOK 1,000,000 per QALY, the 
results indicate that the treatment efficacy data have the greatest impact on decision 
uncertainty. These results suggest that if new research is to be undertaken (for WTP 
above NOK 1,000,000), additional information on efficacy data would contribute 
most to reducing the uncertainty surrounding the decision about which treatment 
modality is most cost-effective. 
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Figure 13. Expected value of partial perfect information per patient for different groups of 
parameters; QALY: quality-adjusted life year; WTP: willingness to pay; INMB: incremen-
tal net monetary benefit 
 
Scenario analyses 
In addition to the probabilistic sensitivity analysis, we performed several scenario 
analyses to test the uncertainty around the model assumptions and some of the input 
parameters.  
 
“No treatment” was our common comparator in the network meta-analyses, and 
therefore was included in the health economics model. As additional information, we 
presented the cost-effectiveness of all treatment strategies compared to “no treat-
ment” as a scenario analysis. The results are presented in Table 28. They showed that 
alemtuzumab remained the dominant strategy (less costly and more effective). Inter-
feron beta-1b (Extavia and Betaferon) had ICERs below NOK 500,000 per QALY. Peg-
interferon beta-1a had ICER between NOK 500,000-800,000 per QALY. Teriflino-
mide and glatiramer acetate had ICERs between NOK 1,000,000- 1,500,000 per 
QALY. Dimethyl fumarate and natalizumab had ICERs between 1,500,000-
1,800,000 per QALY. Interferon beta-1a (22mcg, 44 mcg and 30 mcg) and fingolimod 
had ICERs above NOK 2,000,000 per QALY.  
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Table 28. Cost-effectiveness of disease-modifying therapies compared to “no treatment” 
(discounted) 
QALY: quality-adjusted life year; ICER: incremental cost-effectiveness ratio  
* Based on effect estimates and annual drug costs, it is highly probable that glatiramer 
acetate 40 mg 3 times per week will be as cost-effective as glatiramer acetate 20 mg per day 
(given all the other parameters are the same). 
 
 
Drugs 
Total costs 
(NOK) 
Effects 
(QALYs) 
Incremental 
cost (NOK) 
Incremental 
 effect (QALYs) 
ICER 
(NOK/QALY) 
No treatment 5,900,815 7.00    
Alemtuzumab 
(Lemtrada) 
4,897,903 8.05 -1,002,911 1.05 Dominant 
Interferon  
beta-1b (Extavia) 
6,031,551 7.40 130,736 0.40 326,841 
Interferon 
beta-1b (Beta-
feron) 
6,088,153 7.40 187,339 0.40 468,346 
Glatiramer acetate 
(Copaxone) * 
6,253,728 7.31 352,914 0.31 1,138,431 
Peg-interferon  
beta-1a 
 (Plegridy) 
6,310,586 7.56 409,771 0-56 731,734 
Teriflunomide 
(Aubagio) 
6,337,489 7.38 436,675 0.38 1,149,144 
Interferon  
beta-1a  22 mcg 
(Rebif) 
6,498,571 7.21 597,756 0.21 2,846,458 
Interferon beta-1a 
30 mcg (Avonex) 
6,533,915 7.27 633,101 0.27 2,344,817 
Interferon 
beta-1a 44 mcg 
(Rebif) 
6,574,606 7.32 673,791 0.32 2,105,598 
Dimethyl fumarate 
(Tecifidera) 
6,707,787 7.52 806,973 0.52 1,551,870 
Natalizumab 
(Tysabri) 
6,983,132 7.63 1,082,317 0.63 1,717,964 
Fingolimod  
(Gilenya) 
7,041,216 7.43 1,140,402 0.43 2,652,097 
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In the base-case analysis, we assumed that once patients progress to EDSS=6 or 
SPMS, they would not receive MS treatment anymore. A scenario analysis was con-
ducted varying the EDSS levels where treatment would be discontinued. The results 
of scenario analysis showed that ICERs were reduced when considering a stopping 
rule at EDSS=7 (Appendix 9.1). We also assumed a stopping rule without considering 
SPMS progression. As we did not consider any treatment benefit for SPMS patients in 
our model, a scenario analysis without considering treatment discontinuation with 
the progression to SPMS resulted in much higher ICERs.  
 
A time horizon of 20 years was considered in the base-case analysis. We performed a 
scenario analysis where the time horizon varied within the range of 10 years. A time 
horizon of 30 years resulted in lower ICERs (Appendix 9.2), and the scenario analysis 
indicated that a time horizon of 10 years would increase the ICERs.  
 
We also conducted a scenario analysis where the starting age was changed within the 
range of 10 years. Scenario analysis showed that variation in the starting age had a 
very small potential impact on the results. However, treating younger patients would 
slightly decrease the ICERs.  
 
For base-case analysis, we assumed disability improvements (a maximum of 2 EDSS-
level). We performed a scenario analysis where no improvement in EDSS were mod-
elled. ICERs were not very sensitive to this assumption. However, “no improvement” 
in EDSS-level resulted in slightly lower ICERs (Appendix 9.3).   
 
The annual rate of treatment discontinuation was assumed to be 15% in the base-case 
analysis. Based on our systematic review the rate varied between 0 and 33%. We con-
ducted two scenario-analyses where the annual rate of treatment discontinuation was 
considered to be 0 and 30%, respectively. The scenario analyses showed that discon-
tinuation rate did not have a significant impact on the results. 
 
Utility values reported by Orme and co-workers (88) were used in the base-case anal-
ysis, as it was the only study that presented the utility associated with EDSS-states, 
SPMS and relapse by using a generic preference-based instrument (EQ-5D). We per-
formed a scenario analysis based on utility values reported by Svendsen and co-
worker (90). Utility values were calculated based on data from 423 Norwegian pa-
tients by using the EQ-5D method (Table 29). 
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Table 29. Quality life data reported by Svendsen et al. (90) 
 EDSS 1 EDSS 2 EDSS 3 EDSS 4 EDSS 5 EDSS 6 EDSS 7 EDSS 8 EDSS 9 
Quality 
of life 
0.800 0.757 0.701 0.617 0.536 0.443 0.211 0.142 0.56 
 
The use of different quality of life data resulted in different QALYs gained (higher 
QALYs for all interventions). However, the conclusion remained the same as in the 
base-case analysis. The results are presented in Appendix 9.4. 
 
It has been reported that more patients (about 22-28%) than we assumed may need 
three cycles of alemtuzumab during the 5-year period (and some patients may need 
four (about 8-10% of patients) or five cycles (1.5%) of alemtuzumab). The scenario 
analysis was performed by varying the probability of patients who need more than 2 
cycles of alemtuzumab. The results showed that alemtuzumab still was the dominant 
strategy.  
 
Budget impact 
The prevalence of MS in Norway is estimated to be 203 per 100,000 people (8). Ap-
proximately 85%-90% of patients with MS are estimated to have RRMS from onset of 
disease (11). We assumed that about 50% of these patients are eligible for disease 
modifying therapies, based on a Norwegian study (91). Based on these assumptions, 
we have estimated the number of eligible patients for disease- modifying therapies for 
the next 5 years (Table 30).  
 
Table 30. Number of patients eligible for disease-modifying therapies 
 2015 * 2016 2017 2018 2019 2020 
Number of 
patients 
4610 4650 4690 4740 4780 4830 
*The population used in the analysis was 5,165,802 which was the population in Norway in 1. 
January 2015. It was assumed that the population of Norway increases about 50,000 annu-
ally (74) 
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The market shares for disease-modifying therapies for the last three years is presented 
in Figure 14 and Table 31, based on sales data (defined daily dose; DDD) (Farmastat). 
As results show, in the past few years the oral MS-medicines won market share from 
non-oral treatment alternatives.  
 
 
 
Figure 14. Sales data for disease-modifying therapies in DDD (Farmastat) DDD:  de-
fined daily dose; Sales data for 2015 were estimated based on data from the first half of 
2015. 
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Table 31. Current market shares for disease-modifying therapies in DDD (Farmastat) 
Drugs 2013 2014 2015 a 
Alemtuzumab (Lemtrada) 0% 2% 4% 
Dimethyl fumarate (Tecifidera) 0 % 10% 17% 
Fingolimod  (Gilenya) 14% 18% 18% 
Glatiramer acetate (Copaxone) 20% 14% 11% 
Interferon beta-1a 30 mcg (Avonex) 12% 8% 6% 
Interferon beta-1a 22 mcg (Rebif) 5% 4% 3% 
Interferon beta-1a 44 mcg (Rebif) 21% 14% 10% 
Interferon beta-1b (Betaferon) 5% 3% 2% 
Interferon  beta-1b (Extavia) 5% 4% 3% 
Natalizumab (Tysabri) 17% 16% 14% 
Peg-interferon  beta-1a  (Plegridy) b 0% 0% 0% 
Teriflunomide (Aubagio) 1% 9% 13% 
DDD:  defined daily dose 
a Estimated based on data from the first half of 2015. 
b Peg-interfron beta-1a: DDD 2013=0, DDD 2014= 70, DDD 2015=337 
 
The market share forecasts for the next five years were estimated based on the results 
of our cost-effectiveness analysis and the drugs’ adverse events. We also took under 
consideration the current practice where there is a trend in favour of oral medicines. 
The results were presented in Table 32. 
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Table 32: Forecasted marked shares for disease-modifying therapies  
Drugs 2016 2017 2018 2019 2020 
Alemtuzumab (Lemtrada) 15% 19% 24% 31% 33% 
Dimethyl fumarate (Tecifidera) 13% 13% 12% 11% 10% 
Fingolimod  (Gilenya) 13% 12.5% 12% 12% 12% 
Glatiramer acetate (Copaxone) 7% 6% 5% 4% 3% 
Interferon beta-1a 30 mcg (Avonex) 4% 3% 2% 1% 1% 
Interferon beta-1a 22 mcg (Rebif) 2% 1.5% 1% 0% 0% 
Interferon beta-1a 44 mcg (Rebif) 8% 5% 3% 1% 1% 
Interferon beta-1b (Betaferon) 2% 1% 1% 0% 0% 
Interferon  beta-1b (Extavia) 9% 9% 9% 9% 9% 
Natalizumab (Tysabri) 12% 12% 12% 12% 12% 
Peg-interferon beta-1a (Plegridy) 4% 4% 4% 4% 4% 
Teriflunomide (Aubagio) 14% 14% 15% 15% 15% 
 
The budget impact was calculated based on the same cost inputs (drug costs, moni-
toring costs associated with use of drugs) used in the cost-effectiveness model (see 
Tables 22 and 23). All estimations are based on 2015-price. The results of the budget 
impact analysis for the next five years (2016 was assumed as a starting point) are 
shown in Tables 33-35. Table 33 presented estimated costs based on current practice, 
while Table 34 presented estimated costs based on future practice (based on data from 
Table 32). Estimated costs based on future practice compared to estimated costs 
based on current practice were presented in Table 35. 
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Table 33. Estimated costs* based on current practice 
Drugs 2016 2017 2018 2019 2020 
Alemtuzumab 
(Lemtrada) 
70,957,237 43,384,319 5,405,710 5,381,873 5,488,448 
Dimethyl fumarate 
(Tecifidera) 
143,409 155 140,972,076 142,482,533 143,676,691 145,187,149 
Fingolimod  
(Gilenya) 
179,884,866 172,095,248 173,949,176 175,396,174 177,250,102 
Glatiramer acetate 
(Copaxone) 
49,276,655 47,406,610 47,916,734 48,315,953 48,826,077 
Interferon beta-1a 
30 mcg (Avonex) 
33,691,593 32,727,302 30,916,393 31,174,127 31,502,362 
Interferon  
beta-1a 22 mcg 
(Rebif) 
13,167,637 12,733,796 11,927,325 12,026,598 12,153,335 
Interferon 
beta-1a 44 mcg 
(Rebif) 
60,609,419 59,065,448 56,138,239 56,606,768 57,202,424 
Interferon 
beta-1b (Beta-
feron) 
6,899,458 6,588,894 6,022,076 6,071,961 6,136,109 
Interferon  
beta-1b (Extavia) 
12,465,793 11,852,383 10,737,660 10,826,455 10,940,936 
Natalizumab 
(Tysabri) 
149,923 462 147,436,954 149,016,551 150,265,611 151,,845,208 
Peg-interferon  
beta-1a 
(Plegridy) 
104,602 101,908 96,806 97,614 98,642 
Teriflunomide 
(Aubagio) 
69,119,685 66,483,177 67,198,605 67,758,440 68,473,868 
Total  789,509,563 740,848,115 701,807,807 707 598 265 715,104,659 
* Undiscounted costs, included VAT 
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Table 34. Estimated costs* based on future practice   
Drugs 2016 2017 2018 2019 2020 
Alemtuzumab 
(Lemtrada) 
190,987,053 184,889,553 29,099,797 37,421,494 40,624,633 
Dimethyl fumarate 
(Tecifidera) 
109,173,395 107,318,114 100,124,293 92,549,822 85,020,717 
Fingolimod  
(Gilenya) 
130,374,387 119,931,479 116,374,524 117,342,587 118,582,892 
Glatiramer acetate 
(Copaxone) 
32,322,524 26,653,617 22,450,355 18,109,921 13,725,845 
Interferon beta-1a 
30 mcg (Avonex) 
23,098,927 16,828,357 10,598,126 5,343,239 5,429,044 
Interferon  
beta-1a 22 mcg 
(Rebif) 
10,346,880 7,504,483 4,686,134 0 0 
Interferon 
beta-1a 44 mcg 
(Rebif) 
50,464,321 30,736,743 17,528,081 5,891,457 5,953,451 
Interferon 
beta-1b (Beta-
feron) 
8,018,439 3,828,753 3,499,380 0 0 
Interferon  
beta-1b (Extavia) 
33,464,841 31,818,121 28,832,186 29,063,982 29,371,310 
Natalizumab 
(Tysabri) 
126,211,185 124,112,685 125,447,714 126,499,219 127,828,983 
Peg-interferon  
beta-1a 
(Plegridy) 
25,030,165 24,385,660 23,164,869 23,358,184 23,603,988 
Teriflunomide 
(Aubagio) 
77,266,215 74,318,964 80,484,336 81,154,855 82,011,729 
Total 816,758,333 752,326,530 562,289,795 536,734,760 532,152,591 
* Undiscounted costs, included VAT 
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Table 35. The results of the budget impact; estimated costs based on future practice com-
pared to estimated costs based on current practice   
Drugs 2016 2017 2018 2019 2020 
Alemtuzumab 
(Lemtrada) 
120,029,816 141,505,234 23,694,087 32,039,621 35,136,185 
Dimethyl fumarate 
(Tecifidera) 
-34,235,760 -33,653,961 -42,358,241 -51,126,869 -60,166,432 
Fingolimod  
(Gilenya) 
-49,510,480 -52,163,769 -57,574,651 -58,053,587 -58,667,210 
Glatiramer acetate 
(Copaxone) 
-16,954,131 -20,752,993 -25,466,378 -30,206,032 -35,100,232 
Interferon beta-1a 
30 mcg (Avonex) 
-10,592,666 -15,898,945 -20,318,267 -25,830,888 -26,073,319 
Interferon  
beta-1a  22 mcg 
(Rebif) 
-2,820,756 -5,229,314 -7,241,192 -12,026,598 -12,153,335 
Interferon 
beta-1a 44 mcg 
(Rebif) 
-10,145,097 -28,328,706 -38,610,158 -50,715,312 -51,248,973 
Interferon 
beta-1b (Beta-
feron) 
1,118,981 -2,760,140 -2,522,696 -6,071,961 -6,136,109 
Interferon  
beta-1b (Extavia) 
20,999,048 19,965,738 18,094,526 18,237,527 18,430,374 
Natalizumab 
(Tysabri) 
-23,712,276 -23,324,269 -23,568,837 -23,766,392 -24,016,225 
Peg-interferon  
beta-1a 
(Plegridy) 
24,925,563 24,283,752 23,068,062 23,260,569 23,505,346 
Teriflunomide 
(Aubagio) 
8,146,530 7,835,788 13,285,731 13,396,415 13,537,861 
Total 27,248,771 11,478,415 -139,518,013 -170,863,506 -182,952,068 
 
The budgetary impact for the next 5 years is difficult to predict. The prediction de-
pends on several factors, including any change in current clinical practice, the relative 
drug prices and the number of patients eligible for different treatment alternatives.  
 
For budget impact analysis, we mainly assumed that alemtuzumab, the more effective 
and less costly treatment alternative, would capture higher market share in the future. 
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The results presented in Table 35 showed that in the first two years, there will be ad-
ditional costs compared to costs estimated based on current practice. However, our 
results indicated that costs would decrease after the first two years and there is a po-
tential for cost-savings. Overall, the potential cost-savings over a 5-year period were 
estimated to be NOK 454,606,000 compared to the costs estimated for current prac-
tice. 
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Discussion 
In this HTA, we have systematically reviewed the literature on the clinical effect of 
disease modifying medicines used for multiple sclerosis. The evidence base comprised 
findings from 37 RCTs. Furthermore, we performed an economic evaluation to exam-
ine the cost-effectiveness of these disease-modifying medicines in a Norwegian set-
ting.  
 
Summary of key findings 
Key findings of the clinical evaluation 
All examined treatments were more effective than placebo against annual relapse. The 
strongest effect was seen for alemtuzumab 12 mg. Fingolimod oral 1.25 mg and dime-
thyl fumarate 240 mg two times a day were also associated with a reduction in annu-
alised relapse rate.  
 
For disability progression, there is high quality evidence showing that dimethyl 
fumarate 240 mg twice daily and fingolimod oral 0.5 mg are more effective than pla-
cebo. For withdrawal due to adverse events, the lower quality of the available evidence 
provides unclear conclusion. Results indicate that some treatments are associated 
with more withdrawal due to adverse events than placebo, such as interferon beta-1a 
44 mcg, and all regimens of peg-interferon beta-1a mcg. 
 
For change in disability status, serious adverse events and mortality, we did not access 
the quality of the available evidence. Therefore, one cannot conclude on how reliable 
results are for these outcomes. Our results indicate that interferon beta-1a 30 mcg is 
related to a negative progression in disability status scale. Finally, our results did not 
show that examined treatments increased mortality. 
 
  
Key findings of economic evaluation 
Our health economic analysis indicated that alemtuzumab was more effective and less 
costly than the other treatment alternatives dominating all other disease-modifying 
therapies.  
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A scenario analysis that excluded alemtuzumab (the dominant strategy) showed that 
natalizumab was the most effective (in terms of QALYs), and interferon beta-1a 22 mg 
was the least effective treatment. Fingolimod was the most expensive strategy and 
interferon beta-1b was the least expensive alternative. The results also showed that 
only three treatment alternatives (interferon beta-1b (Extavia), peg-interferon beta-
1a and natalizumab) could be cost-effective depending on the willingness-to-pay 
(WTP) threshold. Interferon beta-1b was likely to be the cost-effective choice for a 
WTP per QALY below NOK 1,658,000. Peg-interferon was the cost-effective option 
for a WTP from NOK 1,658,450 to NOK 1o,619,960, and natalizumab was the cost-
effective alternative for a WTP above NOK 10,619,960. Assuming a WTP below NOK 
1,000,000 per QALY, interferon beta-1b (Extavia) was approximately 40% likely to 
be the most cost-effective treatment, followed by peg-interferon beta-1a (approxi-
mately 30% likely).  
 
The scenario analysis where all treatment alternatives were compared to “no treat-
ment” indicated that alemtuzumab remained the dominant strategy. Interferon beta-
1b had ICERs below NOK 500,000 per QALY. The ICER for peg-interferon compared 
to “no treatment” was NOK 731,730. Other treatment options had ICERs over NOK 
1,000,000 per QALY. The treatment costs (included drug costs and monitoring costs 
associated with each treatment) had an impact on the ICERs.  
 
The results of probabilistic analysis showed that there is some degree of uncertainty 
regarding the input parameters. More research on efficacy and epidemiologic input 
parameters would have the greatest impact on reducing decision uncertainty.  
 
In addition to our probabilistic sensitivity analysis, we performed several scenario 
analyses to test the uncertainty around the model assumptions. The results showed 
that, while there were numerical changes to the ICERs, the cost-effectiveness results 
were robust to variations in the model assumptions and the conclusions of the analy-
sis would not change. 
 
Our bugdet impact analysis based on the results of our cost-effectiveness analysis, the 
drugs’ adverse events profile, and current clinical practice showed that there is a 
substantial potential for cost saving.  
 
Quality of the evidence  
Quality of the evidence of the systematic review 
We included a HTA of high quality. We updated the information with more recently 
published RCTs with generally low risk of bias.  
 
We chose a conservative approach in grading the quality of the evidence. This implies 
that one can rely on the evidence we judged to be of high quality. We had evidence of 
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high quality only for annual relapse rates and disability progression. This implies that 
results on other outcomes are less reliable.  
 
Quality of the economic evaluation 
Our cost-effectiveness analysis showed that there is some degree of uncertainty 
around the estimates. This was mainly due to uncertainty in the efficacy data, followed 
by probabilities estimates.  
 
Strengths and weaknesses  
Strengths of the systematic review 
We used an internationally recognised methodology to systematically search the evi-
dence, extract the data, access bias of studies and the quality of evidence. While the 
focus of this report was MS treatments used in Norway, we included evidence for 
treatments that are both used in Norway and not to get a bigger network of evidence 
for medicines relevant to the Norwegian setting.  Our network of evidence includes 
information on treatments that have been used for some years, and on emerging treat-
ments.  
 
Limitations of the systematic review 
Many of the limitations of this report are related to the available evidence, and are not 
inherent to the methodology used in this report.  
 
The available evidence differs by treatments according to how long these have been 
on the market, with newer treatments having a smaller amount of information.  
 
Most MS medications are only approved for RRMS patients. The systematic review 
includes, therefore, only studies of RRMS patients. As RRMS patients represent the 
largest proportion of MS patients, the results of our report are relevant to the majority 
of MS patients in Norway. Furthermore, there is no reason to believe that the effect of 
these medications are different depending on if one treats after the first relapse (CIS 
scenario) or if the treatment is initiated after the second relapse (e.g. definite clinical 
MS including RRMS patients). Results related to newer medications carry more un-
certainty. As MS diagnosis has changed through the years, studies conducted at a dif-
ferent time might differ in terms of the MS population included. Therefore, when 
comparing older with newer MS treatments, differences in results could partly be due 
to differences in patient population. Furthermore, follow-up time of newer medicines 
is usually shorter, and some serious adverse events might only occur after a longer use 
of the medicine. One should bear this in mind when interpreting results. 
 
Through network meta-analysis, one can infer on the relationship between two treat-
ments if those treatments were compared to a common comparator in RCTs. For such 
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an inference to be accurate, the contributing RCTs should be very similar regarding 
patient population and outcome definition, measurement and reporting. Treatment 
history among patients varied across the trials, being either unclear, treatment naive, 
treatment experienced or a mixture. However, different statistical analyses provided 
similar results, and results were consistent when considering direct evidence, indirect 
evidence or the evidence from the whole network. 
 
The available evidence does not allow to investigate separately first and second line 
treatments. Most published studies did not examine first and second medications sep-
arately. Indeed, some studies have compared first and second line treatments. Fur-
thermore, in some case, first-line treatments have been investigated in patients who 
had taken other medications before, hence considered as second line treatments. Fi-
nally, studies considered second-line treatments in a population that comprised pa-
tients who had not received any treatment before, and were therefore tested as first-
line treatments. We, therefore, present results for all MS treatments together (inde-
pendent of them being used as first or second line treatments). However, patients who 
use a first and a second treatment might differ, and discrepancies in treatments effi-
cacy might be due to disparity in patients.  
 
The clinical endpoints covered in the systematic review (clinical relapse and disability 
progression) are important clinical outcomes in MS. Magnetic resonance imaging 
(MRI) is a surrogate endpoint and, therefore, was not examined. However, a previous 
published HTA report described that the available evidence on MRI was of poorer 
quality compared to clinical relapse and disability progression (27). The population 
of studies examining MRI populations were usually smaller, and it is unclear how 
these populations were selected (27). Therefore, any conclusions on MS medicines use 
on that surrogate outcome would have a higher degree of uncertainty. 
 
Some outcome definitions differed from one study to the other. For example, disabil-
ity progression was measured as disability progression confirmed at 3 months, or con-
firmed at 6 months, or at two years, or as a change compared to baseline EDSS. Pa-
tients EDSS classification might also differ between studies. 
 
The lengths of the included studies were relatively short with a maximum follow-up 
time of 3.5 years. Therefore, our results cannot conclude on the long-term effect of 
examined medicines. Observational follow-up studies, with a longer follow-up time 
have been published, and could be used to estimate the longer-term effect of MS med-
icines.  
 
All these limitations would not only have an impact on the clinical effect results but 
could also influence the health economic evaluation results that incorporated some of 
the clinical effect results into the health economic model.  
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Strengths of the health economic model 
We performed the economic evaluation of disease- modifying therapies based on a 
thorough systematic review of the literature, and estimates of treatment effect ob-
tained through a network meta-analysis. We used a probabilistic Markov-model, con-
sidered the appropriate approach for simulating the natural history of multiple scle-
rosis. This model was previously used in a high quality HTA report. The model struc-
ture and all assumptions have been adapted to the Norwegian setting based on Nor-
wegian clinical practice with close assistance of experts in this field. 
 
Limitations of the health economic model 
To model real life is very complex; hence, any simulation is a simplification. We have 
tried to find the most robust and best evidence available but limitations associated 
with the data, and the simplifications of our health economic model should be consid-
ered when interpreting the results.  
 
Data from Norwegian MS-registry or Norwegian cohort studies should ideally be used 
in the model. However, we were not able to identify data sources that were compatible 
to the developed model. The transitional probabilities were therefore based on esti-
mates reported in the published literature. Those were also used in previous health 
economic studies. Data on annual relapse rate were uncertain. Indeed, we were not 
able to identify any study that linked rates of annual relapse to different EDSS-scores 
by disease duration.  
 
We found a Norwegian study from 1996 where EDSS distributions in the cohort pa-
tients were reported (92). 22.6% of the patients in this study had EDSS scores over 
4.5 (6.4% of patients scored between 8 and 9.5). However, based on clinical experts’ 
opinion, disease-modifying therapies are usually initiated in patients with an EDSS 
score less than 5, and most commonly for patients with an EDSS score between 1 and 
3. Therefore, EDSS distributions used in our model were based on published litera-
ture of large cohort studies where over 91% of patients had EDSS scores less than 5. 
 
The network meta-analyses were not performed separately for first and second line 
treatments. Therefore, we did not perform separate cost-effectiveness analyses for 
these two types of treatments. In addition, based on expert opinion, we did not include 
combination therapy in our model, as it is not relevant to Norwegian clinical practice 
at present. 
 
There is lack of documentation regarding the long-term effect of the newer drugs. 
Further research could change current estimates and consequently the health eco-
nomic results.  
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In our report, we assumed that 20% of patients might need three cycles of 
alemtuzumab during a 5-year period. However, it has been reported that this propor-
tion might be higher (22 to 28% of patients), and that some patients may need four 
cycles (about 8 to 10% of patients), or five cycles (1.5%) of alemtuzumab. We per-
formed a scenario analysis by varying the proportion of patients who need more than 
2 cycles of alemtuzumab during a 5-year period. The results showed that 
alemtuzumab still was the dominant strategy.  
 
We assumed fixed discontinuation rate across all treatment alternatives for the first 
two years. We performed scenario analyses to test different discontinuation rates. The 
results showed that discontinuation rate did not have a significant impact on the re-
sults. 
 
We assumed that the average length of mild or moderate relapses was 45 days, and 
90 days for severe relapses. The duration of the relapse might be shorter depending 
on the response to the treatment with corticosteroids. We conducted a scenario anal-
ysis where the average length of moderate and severe relapse were 21 days and 45 
days. Although some changes in the results were observed, the conclusion remain the 
same. 
 
The results of our systematic review showed no significant differences between the 
therapies for serious adverse events. However, the risk of developing progressive mul-
tifocal leukoencephalopathy (PML) associated with natalizumab, even if it is rare, was 
considered important, and, therefore, included in the model. We assumed that the 
costs and disutility related to other adverse events would not have a significant impact 
on the results. It should also be mentioned that recently PML has also been reported 
in some patients treated with other disease-modifying therapies, such as dimethyl fu-
murate and fingolimod.  
 
The costs associated with inpatient treatment of PML were estimated based on prices 
from the Norwegian DRG system (DRG code 421). As the costs of inpatient treatment 
of PML might be underestimated, we performed a scenario analysis where the costs 
were 100% increased. As the risk of developing PML is low, the correction factor had 
no significant impact on the cost-effectiveness results. 
 
We performed the health economic evaluation from a health care perspective. The 
health care perspective is relevant for prioritisation of interventions within a fixed 
budget if the aim of the decision maker is to maximize health.  
 
Glatiramer acetate 20 mg was included in the base-case analysis. Based on the results 
from our systematic review regarding relative rates of annual relapse and relative risk 
of disability progression, and also the estimated annual drug costs, it is highly proba-
ble that glatiramer acetate 40 mg 3 times per week will be as cost-effective as glati-
ramer acetate 20 mg per day (given that all the other parameters are the same). 
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Due to the uncertain evidence regarding the potential added value of peroral drug 
administration and the probable effect of the different methods of administrating the 
medication on patients’ utility, we did not include these parameters in the model. 
 
The budget impact estimates were based on several factors that can vary such as dis-
ease prevalence and incidence, current clinical practice, drug and healthcare. The 
market share forecasts for the next five years in our analysis were estimated based on 
the results of our cost-effectiveness analysis and the drugs’ adverse events. We also 
took under consideration the current practice where there is a trend in favour of oral 
medicines.  
 
Consistency  
 
Consistency of the systematic review with other publications 
Our results are consistent with the results of the Canadian HTA report on drug ther-
apies for RRMS (27), although we included more up to date evidence, and also evi-
dence on more MS treatments. Our results are also consistent with a recently pub-
lished Cochrane systematic review (93). 
 
Consistency of the economic evaluation with other studies 
While several cost-effectiveness studies have examined disease-modifying therapies 
for RRMS patients, to date, only the Canadian report (27) has compared almost all 
drugs in one analysis, as we have done in this report. However, it should be mentioned 
that peg-interferon beta-1a was not included in the Canadian report, and the pricing 
of alemtuzumab and teriflunomide was not available in Canada at the time the anal-
yses were conducted. Therefore, they were not included in the Canadian base-case 
analysis.  
 
The Canadian base-case analysis showed that glatiramer acetate was the most cost-
effective treatment unless willingness to pay exceeded CAD 118,242 per QALY. Be-
tween CAD 118,242- CAD 425,655, interferon beta-1b was the most cost-effective 
treatment, between CAD 425,655- CAD 872,972 it was dimethyl fumarate, and above 
CAD 872,972, it was natalizumab.  It is difficult to compare our results to the Canadian 
results, as we included more treatment strategies, and used different input data (effi-
cacy, costs and quality of life data). 
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Conclusion and implications on 
practice 
All examined treatments were more effective than placebo against annual relapse. The 
strongest effect was seen for alemtuzumab 12 mg. Fingolimod oral 0.5 mg and 
dimethyl fumarate 240 mg two times a day were also associated with a reduction in 
annualised relapse rate. For disability progression, direct evidence of high quality 
indicated that dimethyl fumarate 240 mg twice daily and fingolimod oral 0.5 mg were 
more effective than placebo. For withdrawal due to adverse events, the lower quality 
of the available evidence provides unclear conclusion. Results indicate that some 
treatments are associated with more withdrawal due to adverse events than placebo, 
such as interferon beta-1a 44 mcg, and all regimens of peg-interferon beta-1a mcg. 
These results should be considered bearing in mind that some of them are first line 
treatments while others are used as second line treatments, and may not be relevant 
to whole type of MS patients. 
 
Our health economic analysis indicated that alemtuzumab dominated all other dis-
ease-modifying therapies, as it was more effective and less costly than the other treat-
ment alternatives.  
 
A scenario analysis that excluded alemtuzumab (the dominant strategy) showed that 
three treatment alternatives (interferon beta-1b (Extavia), peg-interferon beta-1a and 
natalizumab) could be cost-effective depending on the willingness-to-pay (WTP) 
threshold. Interferon beta-1b was likely to be the cost-effective choice for a WTP per 
QALY below NOK 1,658,000. Peg-interferon was the cost-effective option for a WTP 
from NOK 1,658,450 to NOK 1o,619,960, and natalizumab was the cost-effective al-
ternative for a WTP above NOK 10,619,960. Assuming a WTP below NOK 1,000,000 
per QALY, interferon beta-1b (Extavia) was approximately 40% likely to be the most 
cost-effective treatment, followed by peg-interferon beta-1a (approximately 30% 
likely).  
 
Our budget impact analysis showed that there is a substantial potential for cost sav-
ing.  
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Need for further research 
The length of included RCTs is relatively short with a maximum of 3.5 years. We need 
longer studies to be able to conclude on the longh term efficacy and safety of MS med-
icines. 
 
Study designs of published studies do not allow to investigate separately first and sec-
ond line treatments, or to conclude on the sequential use of first and second line treat-
ments. It is difficult to conclude which medicine is most effective when interested only 
in first or second line treatments. To address this, future studies should use appropri-
ate study design that fits the type of the investigated treatment. For example, first line 
treatments should be examined as first-line (i.e. in treatment naïve patients), and sec-
ond line treatments should be investigated as second-line treatments (that is in treat-
ment experienced patients).  
 
There is some degree of uncertainty regarding the health economic model input pa-
rameters. More research on efficacy and epidemiologic input parameters would have 
the greatest impact on reducing decision uncertainty.  
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 Appendix 
Appendix 1: Literature search strategy 
Search strategy - Drugs for multiple sclerosis 
 
Databases:  Ovid MEDLINE(R), Embase (Ovid). Cochrane Library: Cochrane Da-
tabase of Systematic Reviews, Other Reviews (DARE), Cochrane Cen-
tral Register of Controlled Trials (Central), Health Technology As-
sessments (HTA), Economic Evaluations (NHS EED). 
Centre for Reviews and Dissemination: DARE, HTA, NHS EED. 
Web of Science, PubMed, SweMed+, SBU, Google scholar, PROS-
PERO.  
Date:  2015.02.26. 
  2015.11.09 updated search for RCT 
Study designs:  Systematic Review using Ovids search filter "reviews (maxim-
izes specificity)" and text words: ((systematic* or literature) adj2 (re-
view* or overview*)) in title or abstract. Search fliter Ovids "therapy 
(maximizes specificity)" and search filters for RCT’s from Cochrane 
Handbook, chapter 6.4.11.1/2. 
Limits:  2013-2015 - Randomized controlled trials  
Results:  1613 records (277 SR + 729 RCT +607 Econ. Eval.) without duplicates  
  277 SR 
  729 RCT (644 + 85 in update search) 
  607 Economic evaluations 
Searched by:  Ingrid Harboe, research librarian 
 
 
 
Search strategies: 
Databases:  Embase 1974 to 2015 February 25,   
Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations, 
Ovid MEDLINE(R) Daily, Ovid MEDLINE(R) and Ovid 
OLDMEDLINE(R) 1946 to Present 
Date:   2015.02.25 
Codes:  Embase:   oemezd  
  MEDLINE: pmoz 
  SR  
Results:  816 RCT  + 69 (update search) 
# Searches Results 
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1 Multiple sclerosis/ or Multiple sclerosis, chronic progressive/ or Multiple 
sclerosis, relapsing-remitting/ or Neuromyelitis Optica/ use pmoz [Medline] 
130140 
2 Multiple sclerosis/ use oemezd [Embase] 84701 
3 ((multiple or disseminated) adj sclerosis).tw. 124063 
4 (sclerosis multiplex or Neuromyelitis Optica).tw. 5340 
5 ((progressive or relapsing or remitting or aggressive or inflammatory or ac-
tive) adj MS).tw. 
9306 
6 (SPMS or PPMS or RRMS).tw. 7859 
7 MS.ti. 48528 
8 or/1-7 195757 
9 Fumaric acid dimethyl ester/ use oemezd 1068 
10 (dimethyl fumarate* or dimethylfumarate*).tw. 1054 
11 Teriflunomide/ use oemezd 1128 
12 teriflunomide.tw. 502 
13 Interferon-beta/ use pmoz 7464 
14 Beta interferon/ use oemezd 17923 
15 (interferon adj1 beta*).tw. 16726 
16 Glatiramer/ use oemezd 5518 
17 (glatirameracetat* or glatiramer acetat*).tw. 3213 
18 Natalizumab/ use oemezd 5744 
19 natalizumab.tw. 3941 
20 Fingolimod/ use oemezd 4436 
21 fingolimod.tw. 2150 
22 Alemtuzumab/ use oemezd 10765 
23 alemtuzumab.tw. 5127 
24 or/9-23 57825 
25 8 and 24 19920 
26 limit 25 to "reviews (maximizes specificity)" 229 
27 ((systematic* or literature) adj2 (review* or overview*)).ti,ab. 347467 
28 25 and 27 236 
29 or/26,28 352 
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30 limit 29 to yr="1995 -Current" 350 
31 exp animals/ 37620453 
32 humans/ 29132069 
33 31 not (31 and 32) 8488384 
34 25 not 33  19194 
35 limit 34 to "therapy (maximizes specificity)" 1986 
36 randomized controlled trial.pt. use pmoz  385465 
37 controlled clinical trial.pt. use pmoz 88645 
38 randomized.ti,ab. use pmoz 331972 
39 placebo.ab. use pmoz 158299 
40 clinical trials as topic.sh. use pmoz 170938 
41 randomly.ab. use pmoz 224453 
42 trial.ti. use pmoz 133387 
43 or/36-42 940316 
44 34 and 43 1211 
45 randomized controlled trial/ use oemezd 363421 
46 crossover-procedure/ use oemezd 41657 
47 double-blind procedure/ use oemezd 120547 
48 single-blind procedure/ use oemezd 19566 
49 randomized.ab. use oemezd 417485 
50 placebo.ab. use oemezd 206226 
51 randomly.ab. use oemezd 282429 
52 trial.ti. use oemezd 176165 
53 or/45-52 974635 
54 34 and 53 2056 
55 35 or 44 or 54 3363 
56 limit 55 to yr="2013 -Current" 816 
57 (eq5d or eq-5d or euroqol or euro qol or euroqol-eq-5d or eq-5d-euroqol or 
eq-5d-3L or eq-5d-5L).mp.  
12866 
58 (quality adjusted life or quality-adjust-life).mp. 26318 
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59 (qaly* or qald* or qale* or qtime* or qali*).mp. 15888 
60 57 or 58 or 59 40089 
61 25 and 60 249 
62 limit 61 to yr="2013 -Current" 69 
63 remove duplicates from 56  692 
64 "Cost Benefit Analysis"/  128162 
65 "Cost Effectiveness Analysis"/ 165316 
66 "Cost Minimization Analysis"/ 44712 
67 "Cost Utility Analysis"/ 67265 
68 (cost* adj2 (analys* or benefit* or effective* or minim* or utilit*)).tw. 246501 
69 cba.tw. 19501 
70 cea.tw. 41311 
71 cua.tw. 1829 
72 Economic Evaluation/ 71524 
73 Health economics/ 34220 
74 (health economic? or economic evaluation?).tw. 24738 
75 Pharmacoeconomics/ 8587 
76 ((pharmacoeconomic? or pharmac*) adj economic?).tw. 863 
77 (15D or HRQoL or health-related quality of life instrument).mp.  23802 
78 or/60,64-77  541256 
79 25 and 78 799 
80 Cost-Benefit Analysis/ 128162 
81 (cost* adj2 (analys* or benefit* or effective* or minim* or utilit*)).tw. 246501 
82 cba.tw. 19501 
83 cea.tw. 41311 
84 cua.tw. 1829 
85 Economics, Medical/ 42830 
86 (health economic? or economic evaluation?).tw. 24738 
87 Economics, Pharmaceutical/ 8587 
88 (pharmac* adj economic?).tw. 863 
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89 pharmacoeconomic?.tw. 8935 
90 Technology Assessment, Biomedical/ 19671 
91 technology assessment?.tw. 8787 
92 (15D or HRQoL or health-related quality of life instrument).mp.  23802 
93 or/60,80-92  489726 
94 25 and 93  736 
95 79 or 94  840 
96 remove duplicates from 95 698 
97 96 not 63 654 
98 97 use oemezd 606 
99 97 use pmoz 48 
 
 
100 limit 56 to yr="2015 -Current" 69 
101 remove duplicates from 100 62 
102  101 use oemezd 7 
103 101 use pmoz 55 
 
Database: Cochrane Library 
Date Run: 2015.02.26.  
Results: 24 Cochrane Reviews (Reviews and Protocols),  
20 Other Reviews,  
37 Technology Assessments  
41 Economic Evaluations 
 181 Clinical trials + 29 (update search) 
 
ID Search         Hits 
#1 MeSH descriptor: [Multiple Sclerosis] this term only   1378 
#2 MeSH descriptor: [Neuromyelitis Optica] this term only  5 
#3 MeSH descriptor: [Multiple Sclerosis, Chronic Progressive] this term only 152 
#4 MeSH descriptor: [Multiple Sclerosis, Relapsing-Remitting] this term only 426 
#5 ((multiple or disseminated) next sclerosis) or (sclerosis next multiplex) or  
"neuromyelitis optica" or "MS" or SPMS or PPMS or RRMS:ti,ab,kw 21763 
#6 #1 or #2 or #3 or #4 or #5       21761 
#7 (dimethyl fumarate* or dimethylfumarate*):ti,ab,kw    63 
#8 teriflunomide*:ti,ab,kw        45 
#9 MeSH descriptor: [Interferon-beta] this term only   524 
#10 (interferon next beta*):ti,ab,kw      1005 
#11 (glatiramer aceta* or glatirameraceta*):ti,ab,kw    205 
#12 natalizumab:ti,ab,kw        135 
#13 fingolimod:ti,ab,kw        128 
#14 alemtuzumab:ti,ab,kw        251 
#15 #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14    1589 
#16 #6 and #15         1150 
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#17 #16 in Cochrane Reviews (Reviews and Protocols), Other Reviews,  
Technology Assessments and Economic Evaluations  122 
#18 #16 Publication Year from 2013 to 2015, in Trials   181 
#19 #16 Publication Year from 2015 to 2015, in Trials   29 
 
 
Database: Centre for Reviews and Dissemination (CRD) 
Date:  2015.02.26. 
Results: 84 DARE, HTA 
 46 NHS EED (Econ. eval.) 
Line  Search Hits 
1 MeSH DESCRIPTOR Multiple Sclerosis 201 
2 MeSH DESCRIPTOR Multiple Sclerosis, Chronic Progressive 12 
3 MeSH DESCRIPTOR Multiple Sclerosis, Relapsing-Remitting 60 
4 MeSH DESCRIPTOR Neuromyelitis Optica 1 
5 ((multiple sclerosis OR disseminated sclerosis OR sclerosis multi-
plex OR "neuromyelitis optica")) 
408 
6 ((MS OR SPMS OR PPMS OR RRMS)) 808 
7 #1 OR #2 OR #3 OR #4 OR #5 OR #6 1052 
8 ((dimethyl fumarate* or dimethylfumarate*)) 12 
9 (teriflunomide*) 8 
10 MeSH DESCRIPTOR Interferon-beta 68 
11 ((interferon next beta*)) 94 
12 ((glatiramer aceta* or glatirameraceta*)) 32 
13 (natalizumab) 34 
14 (fingolimod) 22 
15 (alemtuzumab) 34 
16 #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 178 
17 #7 AND #16 129 
18 (#17) IN DARE, HTA 83 
19 (#17) IN NHSEED 46 
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Database: PubMed 
Date: 2015.02.26 
Results: 10 Reviews 
 7 RCT + 11 (update search) 
Search: 
SR: 
((((multiple sclerosis[MeSH Terms]) OR (("multiple sclerosis" OR "disseminated 
sclerosis" OR "sclerosis multiplex" OR "neuromyelitis optica")) OR "MS" OR SPMS 
OR PPMS OR RRMS))))  
AND  
((((((((("dimethyl fumarate"[Title/Abstract] OR dimethylfumarate[Title/Ab-
stract]))) OR teriflunomide[Title/Abstract]) OR (("interferon beta"[Title/Abstract] 
OR interferon-beta[Title/Abstract]))) OR (("glatiramer aceta"[Title/Abstract] OR 
glatirameraceta[Title/Abstract]))) OR natalizumab[Title/Abstract]) OR fin-
golimod[Title/Abstract]) OR alemtuzumab[Title/Abstract]))  
AND review AND Pubstatusaheadofprint 
RCT: 
(((randomized[Title/Abstract] OR randomly[Title/Abstract]))) AND (((((multiple 
sclerosis[MeSH Terms]) OR (("multiple sclerosis" OR "disseminated sclerosis" OR 
"sclerosis multiplex" OR "neuromyelitis optica")) OR "MS" OR SPMS OR PPMS OR 
RRMS)))) AND ((((((((("dimethyl fumarate"[Title/Abstract] OR dime-
thylfumarate[Title/Abstract]))) OR teriflunomide[Title/Abstract]) OR (("interferon 
beta"[Title/Abstract] OR interferon-beta[Title/Abstract]))) OR (("glatiramer ac-
eta"[Title/Abstract] OR glatirameraceta[Title/Abstract]))) OR natalizumab[Ti-
tle/Abstract]) OR fingolimod[Title/Abstract]) OR alemtuzumab[Title/Abstract])) 
AND pubstatusaheadofprint) 
 
 
 
Web of Science 
Date: 2015.02.26 
Results: 11 clinical trials 
 53 reviews  
# 16 66 #15 AND #14 
Timespan=2013-2015 
Search language=Auto   
# 15 Approxi-
mately 
6,298,345 
YEAR PUBLISHED: (2013-2015) 
Timespan=2013-2015 
Search language=Auto   
# 14 730 #2 AND #1 
Refined by: Databases: ( WOS ) AND Databases: ( WOS ) 
AND DOCUMENT TYPES: ( CLINICAL TRIAL ) 
Timespan=1995-2015 
Search language=Auto   
# 13 Approxi-
mately 
14,598 
#2 AND #1 
Refined by: Databases: ( WOS ) AND Databases: ( WOS ) 
Timespan=1995-2015 
Search language=Auto   
# 12 11 #9 AND #4 
Refined by: Databases: ( WOS ) AND DOCUMENT 
TYPES: ( CLINICAL TRIAL ) 
Timespan=2013-2015 
Search language=Auto   
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# 11 50 #9 AND #4 
Refined by: Databases: ( WOS ) 
Timespan=2013-2015 
Search language=Auto   
# 10 50 #9 AND #4 
Timespan=2013-2015 
Search language=Auto   
# 9 Approxi-
mately 
113,246 
TOPIC: (("randomized controlled trial" or randomized* or ran-
domly or "controlled clinical trial")) OR TITLE: (("randomized 
controlled trial" or randomized* or randomly or "controlled 
clinical trial")) 
Timespan=2013-2015 
Search language=Auto   
# 8 53 #5 AND #4 
Refined by: Databases: ( WOS ) AND DOCUMENT 
TYPES: ( REVIEW ) 
Timespan=1995-2015 
Search language=Auto   
# 7 68 #5 AND #4 
Refined by: Databases: ( WOS ) 
Timespan=1995-2015 
Search language=Auto   
# 6 68 #5 AND #4 
Timespan=1995-2015 
Search language=Auto   
# 5 Approxi-
mately 
181,139 
TOPIC: (systematic* review*) OR TITLE: (systematic* re-
view*) 
Timespan=1995-2015 
Search language=Auto   
# 4 Approxi-
mately 
14,598 
#2 AND #1 
Refined by: Databases: ( WOS ) 
Timespan=1995-2015 
Search language=Auto   
# 3 Approxi-
mately 
15,657 
#2 AND #1 
Timespan=1995-2015 
Search language=Auto   
# 2 Approxi-
mately 
266,458 
TOPIC: (("dimethyl fumarate" OR dimethylfumarate OR teri-
flunomide OR interferon OR glatirameraceta* OR "glatiramer 
aceta" OR natalizumab OR alemtuzumab)) OR TITLE: (("di-
methyl fumarate" OR dimethylfumarate OR teriflunomide OR 
interferon OR glatirameraceta* OR "glatiramer aceta" OR na-
talizumab OR alemtuzumab)) 
Timespan=1995-2015 
Search language=Auto   
# 1 Approxi-
mately 
113,294 
TOPIC: (("multiple sclerosis" OR "disseminated sclerosis" OR 
"sclerosis multiplex" OR "neuromyelitis optica")) OR TI-
TLE: (("multiple sclerosis" OR "disseminated sclerosis" OR 
"sclerosis multiplex" OR "neuromyelitis optica")) 
Timespan=1995-2015 
Search language=Auto   
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Database: PROSPERO 
Date: 2015.02.20. 
Results: 1 
Search:  multiple sclerosis  
 
 
Database: SweMed+ 
Date: 2015.02.20. 
Results: 8  
Search:  Multiple sclerosis AND 
("dimethyl fumarate" OR dimethylfumarate OR teriflunomide OR  interferon 
OR glatirameraceta* OR  "glatiramer aceta*" OR natalizumab OR 
alemtuzumab) 
 
 
Webpage: SBU  
Date: 2015.02.20. 
Results: 0  
Search: Multipel sckleros 
 
 
Webpage: Google scholar 
Date: 2015.02.20. 
Results: 2 
Search:  
"Multiple sclerosis" AND name of the intervention drugs AND "technology assess-
ment" AND allintitle 
"Multiple sclerosis" AND name of the intervention drugs AND “systematic review" 
AND allintitle 
 
 
 
 
 
 
 
 
  
 
 
 
 
124 
Appendix 2: Description of included studies 
 
 
Notes on the following tables:  
 Unless otherwise stated, the baseline characteristics described are those of all 
participants in the study 
 Unless otherwise stated, the statistics presented for age and Expanded Disability 
Status Scale (EDSS) are means (+/-standard deviation) 
 The following tables are presented by alphabetic order of the medicine 
considered as the intervention of interest. 
 List of abbreviations used in tables:  
 IV= intravenous; 
 IM= intra muscular 
 SC= subcutaneous;  
 mg = milligram 
 mcg=micrograms 
 q.d.= once daily 
 q.w.= once weekly 
 t.i.w.= three times weekly 
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Alemtuzumab 
CAMMS223-study 2008, CAMMS223 Trial Investigators (28), included 
(incl.) in Khai et al. (27) 
RCT identification NCT00050778 
Study setting Rater-blinded, randomized controlled trial in 49 centres in Europe 
and US 
Participants  Eligibility criteria: Diagnosis of RRMS (McDonald criteria) with an 
onset of symptoms no more than 36 months before the time of 
screening, EDSS = 0 to 3.0; had one or more enhancing lesions on 
MRI; with ≥ 2 relapses during the previous 2 years.  
Key exclusion criteria: Previous disease-modifying treatment; pres-
ence of serum antithyrotropin-receptor antibodies.  
Baseline characteristics: Age 32+/-8; 64% female; EDSS 2,0+/-0.8 
Intervention group Annual alemtuzumab: 
- Alemtuzumab 12 mg IV q.d., 5 consecutive days at 1st month, 3 con-
secutive days at months 12 and 24 (n = 113)  
- Alemtuzumab 24 mg IV q.d. (n = 110)  
Comparison group Interferon beta-1a 44 mcg SC t.i.w. (n = 111)  
Outcome Primary endpoints: Sustained accumulation of disability and rate of 
relapse.  
Secondary endpoints: Proportion of patients with relapse-free MS, 
different MRI outcomes.  
Definitions used for endpoints: Relapses: New or worsening symp-
toms with an objective change in neurologic examination attributa-
ble to MS that lasted 48 hours, that were present at normal body 
temperature, and that were preceded by at least 30 days of clinical 
stability.  
Sustained accumulation of disability: An increase of at least 1.5 
points for patients with baseline score of 0, and at least 1.0 point for 
patients with a baseline score of 1.0 or more; all scores were con-
firmed twice during a 6-month period.  
Follow-up 3 years 
Treatment history Treatment-naive (based on inclusion criteria) 
Comments In September 2005, alemtuzumab therapy was suspended after im-
mune thrombocytopenic purpura developed in three patients, one of 
whom died. Treatment with interferon beta-1a continued throughout 
the study. 
Critical appraisal  
Randomization Adequate 
Allocation concealment Insufficient reporting 
Double-blinding No (rater-blinded) 
Baseline characteristic similarity Yes 
Outcome measures Adequate 
Withdrawals 25% 
ITT Analysis Yes 
Funding Manufacturer 
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CARE (Comparison of Alemtuzumab and Rebif Effi cacy in Multiple 
Sclerosis) MS I- study 2012, Cohen et al. (29), in Khai et al. (27) 
RCT identification NCT00530348 
Study setting A rater-blinded, randomized controlled trial in 101 centres in 16 
countries including Europe, Canada, and US.  
Participants  Eligibility criteria: Age = 18 years to 50 years, diagnosis of RRMS 
(McDonald criteria) with disease duration up to 5 years, EDSS = 0 to 
3.0; had cranial abnormalities on MRI attributable to MS; with ≥ 2 
relapses during the previous 2 years.  
Key exclusion criteria: Progressive disease course, previous MS dis-
ease therapy (apart from corticosteroids), previous immunosuppres-
sive; investigational or monoclonal antibody therapy, clinically sig-
nificant autoimmunity other than MS.  
Baseline characteristics: Age 33+/-8; 65% female; EDSS 2.0+/-0.8 
Intervention group Alemtuzumab 12 mg IV q.d., 5 consecutive days at month 0, 3 con-
secutive days at month 12 (n = 386)  
Comparison group Interferon beta-1a 44 mcg SC t.i.w. (n = 195)  
Outcome Primary endpoints: Relapse rate and time to 6 months sustained ac-
cumulation of disability.  
Secondary endpoints: Proportion of patients with relapse-free, 
change in EDSS, change in MSFC, different MRI outcomes.  
 
Definitions used for endpoints: Relapses: New or worsening neuro-
logic symptoms attributable to MS, lasting at least 48 hours, with py-
rexia, after at least 30 days of clinical stability, with an objective 
change on neurological examination assessed by a masked rater.  
Sustained accumulation of disability: An increase from baseline of 
at least one EDSS point (or ≥ 1.5 points if baseline EDSS score was 
0) confirmed over 6 months.  
Follow-up 2 years 
Treatment history Treatment-naive (based on inclusion criteria).  
Critical appraisal  
Randomization Adequate 
Allocation concealment Adequate 
Double-blinding No (rater-blinded) 
Baseline characteristic similarity Yes 
Outcome measures Adequate 
Withdrawals 9% 
ITT Analysis Yes 
Funding Manufacturer  
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CARE (Comparison of Alemtuzu mab and Rebif Effi cacy in Multiple 
Sclerosis)-MS II study 2012, Coles et al. (30), in Khai et al. (27) 
RCT identification NCT00548405 
Study setting Rater-blinded, randomized controlled trial. 194 academic medical 
centres and clinical practices in 23 countries including Europe, 
Canada, and US.  
Participants  Eligibility criteria: Age = 18 years to 50 years, diagnosis of RRMS 
(McDonald criteria) with disease duration up to 5 years, EDSS = 0 
to 5.0; had cranial and spinal MRI lesions; with ≥ 2 relapses dur-
ing the previous 2 years and at least one in the previous year.  
Key exclusion criteria: Progressive forms of MS, previous cyto-
toxic drug use or investigational therapy, treatment within the 
previous 6 months with natalizumab, methotrexate, azathioprine 
or cyclosporine, and a history of clinically significant autoimmun-
ity other than MS.  
Baseline characteristics: Age: 35 +/-8, 67 female, EDSS: 2.7 +/-
1.2 
Intervention group Alemtuzumab 12 mg IV q.d., 5 consecutive days at month 0, 3 
consecutive days at month 12 (n=436) 
Alemtuzumab 24 mg IV q.d., 5 consecutive days at month 0, 3 
consecutive days at month 12 (n=173) 
Comparison group Interferon beta 1a 44 mcg SC t.i.w. (n=231) 
Outcome Primary endpoints: Relapse rate and time to 6 months sustained 
accumulation of disability.  
Secondary endpoints: Proportion of patients with relapse-free, 
change in EDSS, change in MSFC, different MRI outcomes.  
 
Definitions used for endpoints: Relapses: New or worsening neu-
rologic symptoms attributable to MS, lasting at least 48 hours, 
without pyrexia, after at least 30 days of clinical stability, with an 
objective change on neurological examination.  
Sustained accumulation of disability: An increase from baseline of 
at least one EDSS point (or ≥ 1.5 points if baseline EDSS score was 
0) confirmed over 6 months.  
Follow-up 2 years 
Treatment history Treatment-experienced (based on inclusion criteria). 
Comments The 24 mg per day group was discontinued to aid recruitment, but 
data are included for safety assessments 
Critical appraisal  
Randomization Adequate 
Allocation concealment Adequate 
Double-blinding No (rater blinded) 
Baseline characteristic similarity Yes 
Outcome measures Adequate 
Withdrawals 15% 
ITT Analysis Yes 
Funding Manufacturer  
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Dimetyl fumarate 
DEFINE (Determination of the Efficacy and Safety of Oral Fumarate in 
Relapsing–Remitting MS) study, Gold 2012 (33), in Khai et al. (27) 
RCT identification NCT00420212 
Study setting Randomized, double-blind, placebo controlled trial. 198 sites in 28 
countries including Europe, Canada, and US 
Participants  Eligibility criteria: Age = 18 years to 55 years, diagnosis of RRMS 
(McDonald criteria), EDSS = 0 to 5.0; ≥1 clinically documented re-
lapse within 12 months before randomization, or ≥ 1 gadolinium-en-
hancing lesion within 6 weeks before randomization  
Key exclusion criteria: Progressive forms of MS, another major dis-
ease that would preclude participation in the clinical trial, abnormal 
results on the pre-specified laboratory tests, or recent exposure to con-
traindicated medications 
Baseline characteristics: Age: 38+/-9 years; 74% female; EDSS 
2,4+/-1,2 
Intervention group Dimethyl fumarate 240 mg oral twice daily (480 mg/day) (n = 410) 
Dimethyl fumarate 240 mg oral 3 times daily (720 mg/day) (n = 416)  
Comparison group Placebo (n = 408)  
Outcome Primary endpoint: Patients’ proportion who had a relapse by 2 years  
Secondary endpoints: Different MRI outcomes at 2 years, annualized 
relapse rate, time to progression disability.  
Definitions used for endpoints: Relapses: New or recurrent neuro-
logic symptoms, not associated with fever or infection, that lasted at 
least 24 hours and that were accompanied by new objective neuro-
logic findings according to neurologist's evaluation.  
Disability progression: At least a 1.0-point increase on the EDSS in 
patients with a baseline score of 1.0 or higher or at least a 1.5-point 
increase in patients with a baseline score of 0, with the increased score 
sustained for at least 12 weeks.  
Follow-up 2 years 
Treatment history Mixed (based on baseline characteristics) 
Comments Patients could switch to an approved alternative MS therapy if they 
had completed 48 weeks of blinded treatment, and had at least 1 con-
firmed relapse after 24 weeks, or at any time if they had experienced 
disability progression sustained for 12 weeks. 
Critical appraisal  
Randomization Adequate 
Allocation concealment Adequate 
Double-blinding Yes 
Baseline characteristic similarity Yes 
Outcome measures Adequate 
Withdrawals 23% 
ITT Analysis Yes 
Funding Manufacturer (Biogen) 
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CONFIRM (Comparator and an Oral Fumarate in Relapsing–Remitting 
Multiple Sclerosis) study 2012, Fox et al., (34), in Khai et al. (27) 
RCT identification NCT00451451 
Study setting Rater-blinded, randomized controlled trial. in 200 research sites in 
28 countries including Europe and North America 
Participants  Eligibility criteria: RRMS (McDonald criteria), age 18 to 55 years, 
EDSS 0 to 5 and at least one clinically documented relapse in the 
previous 12 months or at least one gadolinium-enhancing lesion 0 
to 6 weeks before randomization.  
Key exclusion criteria: Progressive forms of multiple sclerosis,11 
other clinically significant illness, prespecified laboratory abnor-
malities, and prior exposure to glatiramer acetate or contraindi-
cated medications  
Baseline characteristics: Age: 37 +/-9, 70% female, EDSS score: 
2.6 +/-1.2 
Intervention group Dimethyl fumarate 240 mg b.i.d, (n=359) 
Dimethyl fumarate 240 mg three times daily (n=345), subcutane-
ous daily injections of 20 mg of glatiramer acetate for 96 weeks 
(n=350) 
Comparison group Placebo (n=363) 
Outcome Primary endpoint: Annualized relapse rate at 2 years.  
Secondary endpoints: Different MRI outcomes at 2 years, disabil-
ity progression.  
Tertiary endpoints: Relative benefits and risks of BG-12 or glati-
ramer acetate versus placebo and the number of gadolinium-en-
hancing lesions at 2 years.  
 
Definitions used for endpoints: Relapses: New or recurrent neuro-
logic symptoms not associated with fever or infection, lasting at 
least 24 hours, accompanied by new objective neurologic findings, 
and separated from the onset of other confirmed relapses by at least 
30 days.  
Disability progression: An increase in the EDSS score of at least 1.0 
point in patients with a baseline score of 1.0 or more or an increase 
of at least 1.5 points in patients with a baseline score of 0, confirmed 
at least 12 weeks later.  
Follow-up 2 years 
Treatment history Mixed (based on reported baseline characteristics) 
Critical appraisal  
Randomization Adequate 
Allocation concealement Adequate 
Double-blinding No 
Baseline characteristic similarity Yes 
Outcome measures Adequate 
Withdrawals 21% 
ITT Analysis Yes 
Funding Manufacturer (Biogen Idec) 
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Fingolimod 
FREEDOMS (FTY720 Research Evaluating Effects of Daily Oral Ther-
apy in Multiple Sclerosis) study, Kappos 2010 (37), in Khai et al. (27) 
RCT identification NCT00289978 
Study setting Double-blind, randomized, placebo-controlled trial multi-centre in 
Australia, Canada, Europe, and South Africa (138 centers in 22 
countries) 
Participants  Eligibility criteria: Age = 18 years to 55 years, diagnosis of RRMS 
(McDonald criteria), EDSS = 0 to 5.5; ≥ 1 relapse in the previous 
year or ≥ 2 relapses in the previous 2 years.  
Key exclusion criteria: Relapse or corticosteroid treatment within 
30 days before randomization, active infection, macular edema, di-
abetes mellitus, immune suppression (drug- or disease-induced), 
or clinically significant systemic disease.  
Baseline characteristics: Age 37+/-9; 70% female; EDSS 2,4+/-1,4 
Intervention group Fingolimod oral 0.5 mg q.d. (n = 425)  
Fingolimod oral 1,25 mg q.d. (n = 429)  
Comparison group Placebo (n = 418)  
Outcome Primary endpoint: Annualized relapse rate.  
Secondary endpoints: Disability progression, time to a first re-
lapse, EDSS change, MSFC change, different MRI outcomes.  
 
Definitions used for endpoints: Relapses: A confirmed relapse con-
stituted symptoms that must have been accompanied by an in-
crease of at least half a point in the EDSS score, of 1 point in each 
of two EDSS functional system scores, or of 2 points in one EDSS 
functional system score (excluding scores for the bowel-bladder or 
cerebral functional systems).  
Disability progression: An increase of 1 point in the EDSS score (or 
half a point if the baseline EDSS score was equal to 5.5), confirmed 
after 3 months, with an absence of relapse at the time of assessment 
and with all EDSS scores measured during that time meeting the 
criteria for disability progression.  
Follow-up 2 years 
Treatment history Mixed (based on reported baseline characteristics) 
Critical appraisal  
Randomization Adequate 
Allocation concealment Adequate 
Double-blinding Yes 
Baseline characteristic similarity Yes 
Outcome measures Adequate 
Withdrawals 19% 
ITT Analysis Yes 
Funding Manufacturer 
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TRANSFORMS (Trial Assessing Injectable Interferon versus FTY720 
Oral in Relapsing–Remitting Multiple Sclerosis) study; Cohen et al. 
2010, (38), in Khai et al. (27) 
RCT identification NCT00340834 
Study setting Double-blind, randomized controlled trial. 172 centres in 18 coun-
tries including Canada, Australia, Europe, and US.  
Participants  Eligibility criteria: Age = 18 years to 55 years; diagnosis of RRMS 
(McDonald criteria), EDSS = 0 to 5.5; had ≥ 1 relapse during the 
previous year or ≥ 2 relapses during the previous 2 years.  
Key exclusion criteria: Documented relapse or corticosteroid treat-
ment within 30 days before randomization; active infection, macu-
lar edema, immunosuppression, and clinically significant coexist-
ing systemic disease.  
Baseline characteristics: Age: 36+/-9; 67% female; EDSS: 2.2 +/-
1.3  
Intervention group Fingolimod oral 0.5 mg q.d. (n=431) 
Fingolimod oral 1.25 mg q.d. (n=426) 
Comparison group Interferon beta-1a 30 mcg IM q.w. (n=435) 
Outcome Primary endpoint: Annualized relapse rate.  
Secondary endpoints: Number of new or enlarged T2-hyperintense 
lesions, time to confirmed disability progression  
 
Definitions used for endpoints: Relapses: New, worsening, or re-
current neurologic symptoms that occurred at least 30 days after 
the onset of preceding relapse, that lasted at least 24 hours without 
fever or infection.  
Disability progression: A one-point increase in the EDSS score (or 
a half-point increase for patients with a baseline score ≥ 5.5) that 
was confirmed 3 months later in the absence of relapse.  
Follow-up 1 year 
Treatment history Mixed (based on reported baseline characteristics) 
Critical appraisal  
Randomization Adequate 
Allocation concealment Adequate 
Double-blinding Yes 
Baseline characteristic similarity Yes 
Outcome measures Adequate 
Withdrawals 11% 
ITT Analysis Yes 
Funding Manufacturer 
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Saida et al. 2012 (39), included in Khai et al. (27) 
RCT identification NCT00537082 
Study setting Double-blind, randomized controlled trial. Multicentre in Japan 
Participants  Eligibility criteria: Age = 18 years to 60 years, diagnosis of RRMS 
(McDonald criteria), EDSS = 0 to 6.0; had ≥ 1 relapse in the previ-
ous year or ≥ 2 relapses in the previous 2 years; ≥ 1 gadolinium-
enhancing lesion within 30 days before study commencement.  
Key exclusion criteria: Primary-progressive MS; relapse or cortico-
steroid treatment within 30 days before randomization; malig-
nancy, macular edema, diabetes mellitus, active infection, immu-
nosuppression, or significant systemic disease; received cladribine, 
cyclophosphamide, mitoxantrone, or other immunosuppressive or 
immunoglobulin medication in the six months before randomiza-
tion, or had plasmapheresis immunoadsorption or IFN beta ther-
apy in the three months before randomization.  
Baseline characteristics: Age: 35 +/-9; 69% female; EDSS: 2.1 +/- 
1.8 
Intervention group Fingolimod oral 0.5 mg q.d. (n=57) 
Fingolimod oral 1.25 mg q.d. (n=57) 
Comparison group Placebo (n=57) 
Outcome Primary endpoint: Percentage of patients free from gadolinium en-
hanced lesions at 3 and 6 months.  
Secondary endpoints: Percentage of patients free from relapse over 
6 months, annualized relapse rate, and other MRI outcomes.  
 
Definitions not reported 
Follow-up 6 months 
Treatment history Unclear (inadequate information to characterise) 
Critical appraisal  
Randomization Insufficient reporting 
Allocation concealment Not reporting 
Double-blinding Yes 
Baseline characteristic similarity Yes 
Outcome measures Adequate 
Withdrawals 14% 
ITT Analysis No 
Funding Manufacturer 
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FREEDOMS II- study (41), not included in Khai et al.(27) 
RCT identification NCT00355134 
Study setting Double-blind, randomised controlled study. In 117 academic and 
tertiary referral centres in 8 countries, most patients from USA 
Participants  Eligibility criteria: diagnosed with relapsing-remitting multiple 
sclerosis according to the 2005 revised McDonald criteria, aged 
18–55 years, one or more confirmed relapses during the preceding 
year (or two or more confirmed relapses during the previous 2 
years), EDSS score of 0–5.5, and had no relapse or steroid treat-
ment within 30 days before randomisation. interferon β or glati-
ramer acetate therapy was stopped at least 3 months before ran-
domisation and natalizumab treatment at least 6 months before 
randomisation. 
Key exclusion criteria: clinically significant systemic disease or im-
mune suppression, active infection or macular oedema, diabetes 
mellitus, or a history of malignancy, and patients with specific car-
diac, pulmonary, or hepatic disorders. 
Baseline characteristics in placebo group: Age: 40+/-8; 81% fe-
male; EDSS: 2.4 +/- 1.3.  
Intervention group Fingolimod 0.5 mg oral q.d. (n=358) 
Fingolimod 1.25 mg oral q.d. (n=370) 
Note: The 1.25 mg dose stopped due to absence of clear added ben-
efits and a higher safety events risk (infections,macular oedema). 
Patients were switched to the 0.5 mg dose in a blinded manner  
Comparison group Placebo (n=355) 
Outcome Primary endpoints: Annualised relapse rates  
Secondary endpoints: Percent brain-volume change , the time to 
first relapse and proportion of relapsefree patients; time to disabil-
ity progression confirmed at6 months, as measured by EDSS; 
change from baseline to the end of study on the MSFC score; and 
effect on MRI.  
Definitions used for endpoints: Relapse: confirmed when accom-
panied by an increase of at least half a step (0・5) on the EDSS, 
an increase of 1 point on two different functional systems of the 
EDSS, or 2 points on one of the functional systems (excluding 
bowel, bladder, or cerebral functional systems). 
Disability progression: 1 point EDSS change [0・5 point if base-
line EDSS was >5・0]) confirmed at 3 months for up to 24 
months. 
Follow-up 2 years 
Treatment history Unclear (inadequate information to characterise) 
Risk of bias 
Random sequence generation Adequate  
Allocation concealment Adequate 
Blinding of participant and personnel Adequate  
Blinding of outcome assessment Adequate  
Incomplete outcome data Intention-to-treat analysis 
Withdrawals: 28% 
Selective reporting None detected 
Other sources of bias Funding: Manufacturer 
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Glatiramer acetate 
Johnson et al., 1995 (42), included in Khai et al. (27) 
RCT identification Not reported 
Study setting Double-blind, randomized, placebo-controlled trial. 11 centres in 
the US 
Participants  Eligibility criteria: RRMS (Poser-criteria), age 18 to 45 years, 
EDSS = 0 to 5.0; had ≥ 2 clinically documented relapses in the 2 
years before entry; onset of the first relapse at least 1 year before 
randomization; and a period of neurologic stability and freedom 
from corticosteroid therapy of at least 30 days prior to entry.  
Key exclusion criteria: Received Glatiramer acetate 1 or previous 
immunosuppressive therapy with cytotoxic chemotherapy (azathi-
oprine, cyclophosphamide, or cyclosporine) or lymphoid irradia-
tion; pregnancy or lactation; insulin-dependent diabetes mellitus, 
positive HIV or HTL V-I serology, evidence of Lyme disease, or re-
quired use of aspirin or chronic nonsteroidal antiinflammatory 
drugs during the course of the trial.  
Baseline characteristics: Age: 34+/-6; 73% female; EDSS 2.6 +/-
1.3 
Intervention group Glatiramer acetate 20 mg SC q.d (n =125)  
Comparison group Placebo (n=126) 
Outcome Primary endpoints: Relapse rate over 24 months, annualized re-
lapse rate, number of relapse over 24 months.  
Secondary endpoints: Proportion of relapse-free patients, median 
time to first relapse, number of relapse per patient, proportion of 
patients with a change in disability, EDSS change, proportion of 
progression-free patients, ambulation index.  
 
Definitions used for endpoints: Relapses: The appearance or reap-
pearance of one or more neurologic abnormalities persisting for at 
least 48 hours and immediately proceeded by a relatively stable or 
improving neurologic state of at least 30 days.  
Disability progression: An increase of at least one full step on the 
EDSS that persisted of at least 3 months.  
Follow-up 2 years 
Treatment history Treatment-naive (based on exclusion criteria, year of study, and 
clinical expert input).  
Critical appraisal  
Randomization Insufficient reporting 
Allocation concealment Not reporting 
Double-blinding Yes 
Baseline characteristic similarity Yes 
Outcome measures Adequate 
Withdrawals 14% 
ITT Analysis Yes 
Funding Manufacturer, public 
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Comi et al., 2001 (43), included in Khai et al. (27) 
RCT identification Not reported 
Study setting Double-blind, randomized controlled study. 29 centres in 6 Euro-
pean countries and Canada.  
Participants  Eligibility criteria: Age = 18 years to 50 years, with relapse-remit-
ting course, a diagnosis of MS for at least 1 year, EDSS = 0 to 5.0; 
≥1 documented relapse in the preceding 2 years, ≥ 1 enhancing le-
sion on screening brain MRI.  
Key exclusion criteria: previous use of glatiramer acetate, oral my-
elin, lymphoid irradiation, the use of immunosuppressant or cyto-
toxic agents in the past 2 years, or the use of azathioprine, cyclo-
sporine, interferons, deoxyspergualine, or chronic corticosteroids 
during the previous 6 months.  
Baseline characteristics in placebo group: Age: 34.0+/-8; % fe-
male not reported; EDSS: 2,4+/-1.2 
Intervention group Glatiramer acetate 20 mg SC q.d. (n=119)  
Comparison group Placebo (n=120)  
Outcome Primary endpoint: Total number of enhancing lesions.  
Secondary endpoints: Other different MRI outcomes.  
Tertiary endpoints: Relapse rate, percentage of patients with re-
lapse-free, steroid courses, relapse-related hospitalizations.  
 
Definitions used for endpoints: Relapses: The appearance of one or 
more new neurological symptoms, or the reappearance of one or 
more previously experienced ones. An event was counted as a re-
lapse only when the patient’s symptoms were accompanied by ob-
jective changes in the neurological examination corresponding to 
an increase of at least 0.5 points on the EDSS, or one grade in the 
score of the two or more functional systems, or two grades in one 
functional system.  
Follow-up 9 months 
Treatment history Unclear (inadequate information to characterize) 
Critical appraisal  
Randomization Adequate 
Allocation concealment Adequate 
Double-blinding Yes 
Baseline characteristic similarity Yes 
Outcome measures Adequate 
Withdrawals 6% 
ITT Analysis Yes 
Funding Manufacturer  
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REGARD (REbif vs Glatiramer Acetate in Relapsing MS Disease) study 
2008, Mikol et al., (44), in Khai et al. (27) 
RCT identification NCT00078338 
Study setting Randomized comparative study. Open-label, rater-masked. 81 cen-
tres in 14 countries (e.g. Canada, South America, and Europe) 
Participants  Eligibility criteria: Adult RRMS patients (McDonald criteria), EDSS 
= 0 to 5.5; had ≥ 1 relapse in the preceding 12 months, and clinically 
stable or neurologically improving during the 4 weeks before ran-
domization.  
Key exclusion criteria: Pregnancy or breastfeeding; treatment with 
steroids or adrenocorticotropic hormone with the previous 4 weeks; 
previous treatment with interferon beta, glatiramer acetate, or 
cladribine; total lymphoid irradiation; plasma exchange within the 
previous 3 months; intravenous gamma-globulin use within the pre-
vious 6 months; cytokine or anti-cytokine therapy within the previ-
ous 3 months; or immunosuppressant use within the past 12 months.  
Baseline characteristics: Age: 37+/-10; 71% female; EDSS: 2.3+/-1.3  
Intervention group Glatiramer acetate 20 mg SC q.d. (n=378) 
Comparison group Interferon beta-1a 44 mcg SC t.i.w. (n=386) 
Outcome Primary endpoint: Time to first relapse over 96 weeks.  
Secondary endpoints: Mean number T2 active lesions, mean num-
ber gadolinium-enhancing lesions, change in T2 lesion volume.  
Tertiary endpoint: Other MRI outcomes, relapse outcomes, disabil-
ity progression.  
 
Definitions used for endpoints: Relapses: New or worsening neuro-
logical symptoms, without fever, that lasted for 48 hours or more and 
accompanied by a change in the Kurtzke Functional Systems Scores.  
Disability progression: Disability progression at the 6-month fol-
low-up visit was confirmed, as follows — if the EDSS score at the 
baseline was 0, then a change of 1.5 points or more was required; if 
the EDSS was 0.5 - 4.5 at baseline, then a change of 1.0 point or more 
was required; and if the EDSS at baseline was 5 points or more, then 
the change required was 0.5 points or more.  
Follow-up 96 weeks 
Treatment history Treatment-naive (based on inclusion criteria, year of study, and clin-
ical expert input).  
Critical appraisal  
Randomization Adequate 
Allocation concealment Adequate 
Double-blinding Yes 
Baseline characteristic similarity Yes 
Outcome measures Adequate 
Withdrawals 18% 
ITT Analysis Yes 
Funding Manufacturer 
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BECOME (Betaseron vs Copaxone in Multiple Sclerosis with Triple-
Dose Gadolinium and 3-Tesla MRI Endpoints) study 2009, Cadavid et 
al.(45), included in Khai et al. (27) 
RCT identification NCT00176592 
Study setting Rater-blinded, randomized controlled trial. In one centre in the US.  
Participants  Eligibility criteria: Age = 18 years to 55 years; treatment-naïve pa-
tients with RRMS (79%) or CIS (21%) suggestive of MS.  
Exclusion criteria: Not reported. 
Baseline characteristics: in interferon beta-1b group: mean 
(range) age 36(18-49); 75% female; EDSS median(range) 2,0 (0-5). 
Intervention group Glatiramer acetate 20 mg SC q.d. (n = 39)  
Comparison group Interferon beta-1b 250 mcg SC every other day (n = 36) 
Outcome Primary endpoints: Different MRI outcomes at 1 and 2 years. Con-
firmed relapse occurrences (annualized relapse rate, percent re-
lapse-free).  
 
Definitions used for: Relapses: All new or worsening symptoms 
lasting ≥ 24 hours and not explained by fever or infection that were 
confirmed by a blinded examining neurologist using worsening 
scores on SNRS or EDSS. : required for relapse confirmation: 1) in-
crease in total EDSS by _0.5 point; 2) increase in the EDSS score 
for one system _2 points; 3) increase in the score of 2 or more EDSS 
systems _1 point; 
Follow-up 2 years 
Treatment history Treatment-naive (based on reported baseline characteristics).  
Critical appraisal  
Randomization Insufficient reporting 
Allocation concealment Not reported 
Double-blinding No (but rater blinded) 
Baseline characteristic similarity Yes 
Outcome measures Adequate 
Withdrawals 15% 
ITT Analysis Yes 
Funding Manufacturer 
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BEYOND (Betaferon Effi cacy Yielding Outcomes of a New Dose) study 
2009, O’Connor et al. (46), included in Khai et al. (27) 
RCT identification NCT00099502 
Study setting A rater-blinded, randomized controlled trial in 198 centres in 26 
countries worldwide. 
Participants  Eligibility criteria: Age = 18 years to 55 years, diagnosis of RRMS 
(McDonald criteria), EDSS = 0 to 5.0; with >=1 relapse in the year 
before entry into the study. 
Key exclusion criteria: Those who had signs or symptoms of other 
diseases not MS; progressive forms of MS; heart disease; treat-
ment-experienced or participated in the previous trials of drug for 
MS; history of severe depression; alcohol or drug misuse; suicide 
attempts; serious or acute live, renal, or bone marrow dysfunction; 
monoclonal gammaglobulinopathy, or uncontrolled epilepsy; con-
traindication or allergy to the drug used in the study; unable to have 
MRI. 
Baseline characteristics in glatiramer acetate group: median 
(range) age 35 (27-43); 68% female; EDSS median (range) 2 (1,5-
3,0) mean 2,28 
Intervention group Glatiramer acetate 20 mg SC q.d. (n = 448)  
Comparison group Interferon beta-1b 250 mcg SC every other day (n = 897)  
Interferon beta-1b 500 mcg SC every other day (n = 899) 
Outcome Primary endpoints: Relapse-based outcomes at year 2 (ARR, days 
to first relapse, proportion relapse-free).  
Secondary endpoints: Confirmed EDSS progression; MS-related 
admission to hospital, MS-related steroid course, different MRI 
outcomes.  
 
Definitions used for endpoints:  Relapses: New or recurrent neuro-
logical abnormalities that were separated by at least 30 days from 
the onset of the preceding event, lasted at least 24 hours, and oc-
curred without fever or infection.  
EDSS progression: Measured as a 1-point change in the score that 
was sustained for 3 months.  
Follow-up 2 to 3,5 years 
Treatment history Treatment-naive (based on inclusion criteria).  
Critical appraisal  
Randomization Adequate 
Allocation concealment Adequate 
Double-blinding No [(rater-blinded), IFN doses double-blinded] 
Baseline characteristic similarity Yes 
Outcome measures Adequate 
Withdrawals 15% 
ITT Analysis Unclear 
Funding Manufacturer 
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Calabrese et al., 2012 (47), included in Khai et al. (27) 
RCT identification Not reported 
Study setting Rater-blinded, randomized controlled trial, single-centre in Italy  
Participants  Eligibility criteria: Age = 18 years to 55 years, diagnosis of RRMS 
(McDonald/Polman criteria), EDSS = 0 to 5.0  
Key exclusion criteria: Those previously treated with immunosup-
pressive drugs.  
Baseline characteristics: Age: 37+/-10 years; 70% female; EDSS 
2,0+/-1,1 
Intervention group Glatiramer acetate 20 mg SC q.d. (n = 55)  
Comparison group Interferon beta-1a 44 mcg SC t.i.w. (n = 55)  
Interferon beta-1a 30 mcg IM q.w. (n = 55)  
Outcome Different MRI outcomes.  
Annualized relapse rate.  
EDSS change.  
 
Definition not stated 
Follow-up 2 years 
Treatment history Unclear (inadequate information to characteristics) 
Comments The publication also includes a group of disease modifying treated 
patients, and disease modifying drug untreated controls 
Critical appraisal  
Randomization Adequate 
Allocation concealment Adequate 
Double-blinding No (rater blinded) 
Baseline characteristic similarity Yes 
Outcome measures Adequate 
Withdrawals 15% 
ITT Analysis No 
Funding Manufacturer 
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GALA (Glatiramer Acetate Low-frequency Administration) study, Khan 
et al., 2013 (35), not included in Khai et al. (27) 
RCT identification  Not reported 
Study setting A randomized, double-blind study was conducted in 142 sites in 17 
countries, including the United States, Bulgaria, Croatia, Germany, 
Poland, Romania, and Ukraine 
Participants  
 
 
Eligibility criteria: 18 to 55 years of age, Confirmed RRMS diagno-
sis (according to the revised McDonald criteria), had an Expanded 
Disability Status Scale (EDSS) score of <=5.5, and were relapse-free 
for >=30 days.  Patients also were required to have >=1 docu-
mented relapse in the 12 months prior to screening, >=2 docu-
mented relapses in the 24 months prior to screening, or 1 docu-
mented relapse between 12 and 24 months prior to screening with 
at least 1 documented T1 gadolinium enhancing lesion in an MRI 
performed within 12 months of screening. 
Key exclusion criteria: Several exclusions criteria based on previ-
ous and/or concurrent treatments.  
Baseline characteristics in placebo group: 38+/-9 years; 68% fe-
male; EDSS 2.7+/-1.2 
Intervention group Glatiramer acetate sc 40mg (1ml) tiw (n=943) 
Comparison group Placebo (n=461) 
Outcome Primary endpoint: Annualised relapse rate 
Secondary outpoints: MRI outcomes 
 
Definition used for relapse: A Relapse was defined as the appear-
ance of >=1 new neurological abnormalities or the reappearance of 
>=1 previously observed neurological abnormalities lasting at least 
48 hours  and preceded by an improving neurological state of at 
least 30 days from the onset of previous relapse. An event was 
counted as a relapse when the patient’s symptoms were accompa-
nied by observed objective neurological changes consistent with an 
increase of >=0.5 points in the EDSS score compared with previous 
evaluation, or an increase of 1 grade in the actual score of >=2 or 
more of the 7 FSs; or an increase of 2 grades in the score of 1 FS, 
compared with the previous assessment.  
Follow-up 12 months (placebo controlled) 
Treatment history Mixed (based on exclusion criteria) 
Risk of bias 
Random sequence generation Low risk 
Allocation concealment Not described, but blinding is adequate. 
Blinding of participant and personnel Low risk 
Blinding of outcome assessment Low risk 
Incomplete outcome data 
 
Low risk 
Analysis performed as ITT  
Selective reporting Not detected 
Other sources of bias Funding: Manufacturer  
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CombiRx study 2013. Lublin et al., (48), included in Khai et al. (27) 
RCT identification NCT00211887 
Study setting A double-blind, randomized, controlled study. 68 sites, both pri-
vate practice and academic, in the USA and Canada 
Participants  Eligibility criteria: Patients with a diagnosis of RRMS by Poser or 
McDonald cirteria, aged 18- 60, EDSS score of 0 to 5.5, at least 2 
exacerbations in the prior 3 years, where 1 exacerbation could be an 
magnetic resonance imaging (MRI) change meeting the 2001 
McDonald MRI criteria for dissemination in time  
Key exclusion criteria: prior history of seizure activity 
Prior use of either interferon or glatiramer acetate 
Baseline characteristics: Age: 38.0 +/- 10, 72% female, EDSS 
score: 2.0 +/- 1.2 
Intervention group Interferon beta-1a 30µg IM q.d and glatiramer acetate (GA) 20mg 
q.d (n=499) (This group was outside our scope) 
Glatiramer acetate 20mg q.d (n=259) 
Interferon beta-1a 30µg IM q.w (n=250) 
Comparison group Interventions were compared one with another 
Outcome Primary endpoint: Annualized relapse rate.  
Secondary endpoints: Disability progression (EDSS change or 
MSFC change), different MRI outcomes.  
 
Definitions used for: Relapses: New or worsening neurologic symp-
toms that lasted at least 24 hours without fever or infection, pre-
ceded by 30 days of stability.  
Disability progression: 1.0 increase in the EDSS from baseline, 
when baseline ≤ 5.0; or an increase of 0.5 from baseline, when 
baseline ≥ 5.5, sustained for 6 months (2 successive quarterly vis-
its), as assessed by the blinded EDSS examiner and confirmed cen-
trally.  
Follow-up 3 years 
Treatment history Treatment-naïve (based on exclusion criteria) 
Critical appraisal 
Randomization Adequate 
Allocation concealement Adequate 
Double-blinding Yes 
Baseline characteristic similarity Yes 
Outcome measures Adequate 
Withdrawals 18% 
ITT analysis Yes 
Funding Public, study agents and placebo provided by man-
ufacturer 
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Interferon beta 1a (im) 
MSCRG (Multiple Sclerosis Collaborative Research Group) study 1996, 
Jacobs et al.(49), included in Khai et al. (27) 
RCT identification Not reported 
Study setting Double-blind randomized controlled trial. 4 centres in the US 
Participants  Eligibility criteria: Age = 18 years to 55 years, diagnosis of relaps-
ing MS (complete and incomplete remissions) (Poser et al.), EDSS 
= 1 to 3.5; had ≥ 2 relapses in previous 3 years, no exacerbations for 
at least 2 months at study entry 
Key exclusion criteria: Prior immunosuppressant or IFN therapy; 
adrenocorticotropic hormone or corticosteroid treatment with 2 
months of entry; pregnancy or nursing; unwillingness to practice 
contraception; presence of chronic-progressive MS, or any disease 
other than MS compromising organ function.  
Baseline characteristics: Age 37+/-7; 73% female; EDSS: 2.4+/-
0.8 
Intervention group Interferon beta-l a 30 mcg IM q.w. (n=158) 
Comparison group Placebo (n=143) 
Outcome Primary endpoint: Time to onset of sustained worsening in disa-
bility.  
Secondary endpoints: Proportion of patients with relapses, annu-
alized relapse rate, different MRI outcomes  
 
Definitions used for endpoints: Relapses: The appearance of new 
neurological symptoms or worsening of pre-existing neurological 
symptoms lasting at least 48 hours in a patient who had been neu-
rologically stable or improving for the previous 30 days, accompa-
nied by objective change on neurological examination.  
Disability progression: Deterioration from baseline by at least 1.0 
point on the EDSS persisting for at least 6 months.  
Follow-up 2 years 
Treatment history Treatment-naive (based on exclusion criteria, year of study, and 
clinical expert input).  
Critical appraisal  
Randomization Adequate 
Allocation concealment Adequate 
Double-blinding Yes 
Baseline characteristic similarity Yes 
Outcome measures Adequate 
Withdrawals 8% 
ITT Analysis Yes 
Funding Public, manufacturer 
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EVIDENCE (EVidence of Interferon Dose-response: European North 
American Comparative Efficacy) study 2002, Panitch et al.(50), in-
cluded in Khai et al. (27) 
RCT identification Not reported 
Study setting Rater-blinded, randomized, placebo-controlled trial in 56 centres 
in Europe, Canada, and US.  
Participants  Eligibility criteria: Age = 18 years to 55 years, IFN-naive patients 
with definite RRMS (Poser et al.), EDSS = 0 to 5.5; ≥ 2 exacerba-
tions of MS in the prior 2 years.  
Key exclusion criteria: use of defined treatments in previous peri-
ods.  
Baseline characteristics in-30 mcg IM q.w group:  Age 37,4 years 
(range 18-55), 74,6%female, EDSS median 2,0 mean 2,3 
Intervention group Interferon beta-1a 30 mcg IM q.w. (n = 338) 
Interferon beta-1a 44 mcg SC t.i.w. (n = 339) 
Comparison group These drugs were compared one with another 
Outcome Primary endpoint: Proportion of patients who were relapse-free at 
24 weeks.  
Secondary endpoints: Relapse, disability, and MRI outcomes at 48 
weeks.  
 
Definitions used for endpoints: Relapses: The appearance of new 
symptoms or worsening of an old symptom, accompanied by an ap-
propriate objective finding on neurologic examination by the 
blinded evaluator, lasting at least 24 hours in the absence of fever 
and preceded by at least 30 days of clinical stability or improve-
ment.  
Disability: Progression by one point on the EDSS scale confirmed 
at a visit 3 or 6 months later without an intervening EDSS value 
that would not meet the criteria for progression.  
Follow-up 24 weeks (treatment for 24 weeks, follow-up until 48 weeks) 
Treatment history Unclear (inadequate information to characterise) 
Critical appraisal  
Randomization Adequate 
Allocation concealment Adequate 
Double-blinding No (rater-blinded) 
Baseline characteristic similarity Yes 
Outcome measures Adequate 
Withdrawals 4% 
ITT Analysis Yes 
Funding Manufacturer 
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INCOMIN (INdependent COMparison of INterferons) study, Durelli et 
al.2002,(51), included in Khai et al. (27) 
RCT identification Not reported 
Study setting Open label, rater-masked, randomized controlled trial in 15 centres 
in Italy  
Participants  Eligibility criteria: Age = 18 years to 50 years, clinically definite 
RRMS (Poser et al.), EDSS = 1-3.5; had two clinically documented 
relapses during the preceding 2 years, and no relapse (and no cor-
ticosteroid treatment) for at least 30 days before the study entry.  
Key exclusion criteria: Previous systemic treatment with IFN beta 
or treatment with other immunosuppressive or immunomodula-
tory drugs (except corticosteroids);  
Baseline characteristics: Age 37+/-8; 65% female; EDSS 2,0+/-0,7 
Intervention group Interferon beta-1a 30 mcg IM q.w. (n = 92)  
Comparison group Interferon beta-1b 250 mcg SC every other day (n = 96)  
Outcome Primary endpoint: Proportions of patients free from relapses dur-
ing 24 months.  
Secondary endpoints: Annualized relapse rate, annualized treated 
relapse rate, proportion of patients free from sustained and con-
firmed progression from disability, EDSS score, time to sustained 
and confirmed progression in disability.  
 
Definitions used for endpoints: Relapses: The occurrence of new 
neurological symptoms or worsening of an old one, with an objec-
tive change of at least one point in Kurtzke Functional System 
Scores, lasting at least 24 hours, without fever, and which followed 
a period of clinical stability or of improvement of at least 30 days.  
Disability progression: An increase in EDSS of at least 1 point sus-
tained for at least 6 months and confirmed at the end of follow-up.  
Follow-up 2 years 
Treatment history Treatment-naive (based on exclusion criteria).  
Critical appraisal  
Randomization Adequate  
Allocation concealment Adequate 
Double-blinding No (rater-masked) 
Baseline characteristic similarity Yes 
Outcome measures Adequate 
Withdrawals 16% 
ITT Analysis Yes 
Funding Public 
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Clanet et al., 2002 (52), included in Khai et al. (27) 
RCT identification Not reported 
Study setting Randomized, double-blind, dose-comparison study. 38 centers in 
Europe 
Participants  Eligibility criteria: Age = 18 years to 55 years, with a relapsing form 
of MS (Poser et al.), EDSS = 2.0 to 5.5; had a clinical diagnosis of 
definite MS; with ≥ 2 relapses within 3 years before randomization.  
Key exclusion criteria: Progressive forms of MS (defined as a con-
tinuous deterioration in neurologic function during the previous 6 
months, without superimposed relapses during the previous 1 
year); had a relapse within 2 months before randomization; preg-
nant or breastfeeding; with history of uncontrolled seizure, suicidal 
ideation, or severe depression; received treatment with IFN beta 
products within 3 months of randomization; investigational prod-
ucts for MS treatment or non-MS indications; chronic immunosup-
pressant therapy or chronic steroid therapy.  
Baseline characteristics: Age; 37+/-8; 68% female; EDSS: 3.6+/- 
1.0;  
Intervention group Interferon beta-1a 30 mcg IM once weekly (n=402) 
Interferon beta-1a 60 mcg IM once weekly N=(400) 
Comparison group The two doses of Interferon beta-1a are compared one with another 
Outcome Primary endpoint: Disability progression.  
Secondary endpoint: Relapse rate, annualized IV steroid use, per-
cent of patients with relapse-free, different MRI outcomes.  
 
Definitions used for endpoints:  Relapses: Not reported.  
Disability progression: Time to a sustained increase of ≥ 1.0 point 
on the EDSS persisting for 6 months for subjects with baseline 
EDSS scores ≤ 4.5, or a 0.5 point increase for subjects with a base-
line EDSS score ≥ 5.0.  
Follow-up At least 3 years 
Treatment history Unclear (inadequate information to characterise) 
Critical appraisal  
Randomization Insufficient reporting 
Allocation concealment Insufficient reporting 
Double-blinding Yes 
Baseline characteristic similarity Yes 
Outcome measures Adequate 
Withdrawals 30% 
ITT Analysis Yes 
Funding Manufacturer 
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Kappos et al., 2011 (36), included in Khai et al. (27) 
RCT identification NCT00676715 
Study setting Randomised controlled study. 79 centres in 20 countries in North 
America, east-central Europe, Asia, western Europe, and Latin 
America. 
Participants  Eligibility criteria: Age = 18 years to 55 years, diagnosis of RRMS, 
EDSS = 1-6.0; had ≥ 2 relapses in previous 3 years.  
Key exclusion criteria: SPMS or PPMS, disease duration more than 
15 years in patients with EDSS of 2 or less; history or presence of 
other neurological systemic autoimmune disorders; treatment with 
rituximab or lymphocyte-depleting therapies; use of lymphocyte 
trafficking disorders within previous 24 weeks; use of beta interfer-
ons, glatiramer acetate, intravenous immunoglobulin, plasmapher-
esis, and immunosuppressive treatments within previous 12 weeks, 
use of systemic glucocorticoids within previous 4 weeks; or intoler-
ance to IFN beta-1a.  
Baseline characteristics in placebo group: Age in years: 38 +/9, 
65% female, mean EDSS score (-/+ SD): 3.2 +/- 1.4 
Intervention group Ocrelizumab 600 mg IV day 1 and 15 (n=55, not our scope) 
Ocrelizumab 600 mg IV day 1 and 15 (n=55, not our scope) 
Interferon beta-1a 30 mcg IM q.d. (n=55) 
Comparison group Placebo (n=54) 
Outcome Primary endpoint: MRI outcomes.  
Secondary endpoints: Annualized relapse rate, proportion of re-
lapse-free patients.  
 
Definitions used for endpoints: Relapses: The occurrence of new or 
worsening neurological symptoms attributable to MS, and imme-
diately preceded by a stable or improving neurological state of at 
least 30 days.  
Disability progression: An increase of 1 point or more from base-
line EDSS score confirmed at the next scheduled examination 3 
months after initial screening.  
Follow-up 24 weeks 
(up to 96 weeks, but after 24 weeks, comparator groups switched 
to ocrelizumab) 
Treatment history Mixed (based on reported baseline characteristics) 
Critical appraisal  
Randomization Insufficient reporting 
Allocation concealment Not reporting 
Double-blinding No 
Baseline characteristic similarity No 
Outcome measures Adequate 
Withdrawals 6% 
ITT Analysis Yes 
Funding Manufacturer 
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Mokhber et al., 2014 (53), not included in Khai et al. (27) 
RCT identification Protocol number: 84393-1 
Study setting Double blind randomized trial, single center in Iran 
Participants  Eligibility criteria: Eligible participants were all new cases of defi-
nite MS according to the revised McDonald criteria, which include 
magnetic resonance imaging, detailed neurological history and ex-
amination, and paraclinical laboratory tests of cerebrospinal fluid 
findings and visual-evoked potential 
Key exclusion criteria: Patients were excluded if they had a history 
of substance abuse or prior treatment with any type of DMTs 
Baseline characteristics: Age 29,+/-8; 65% female; EDSS: 
mean=2.02 
Intervention group Interferon beta-1a (Avonex ) 30 mcg once per week IM injection; 
(n=23) 
Interferon beta-1a (Rebif) 44 mcg t.i.w. SC injection; (n=23) 
Interferon beta-1a (Betaferon) 0.25 mg every other day SC injection 
(n=23) 
Comparison group These drugs were compared one with another 
Outcome Primary endpoint: Cognition status  
Secondary endpoint: EDSS scale  
Follow-up 1 year 
Treatment history Treatment-naive 
Risk of Bias 
Random sequence generation Adequate “The study neurologist (MRA) enrolled 
the participants and allocated the subjects using a 
computer-generated list of random numbers” 
Allocation concealment Yes 
Blinding of participant and person-
nel 
Assessors: yes 
Participants: insufficient reporting 
Blinding of outcome assessment Adequate  
Incomplete outcome data 6% lost to follow-up 
Modified analysis based on available data 
Selective reporting None detected 
Other sources of bias No conflict of interest declared. Funding seem to 
be public “The study was supported by the Vice 
Chancellor of Research at Mashhad University of 
Medical Sciences in Iran (Grant number:84393)” 
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BRAVO (Benefit-Risk Assessment of AVonex and LaquinimOd ) study, 
Vollmer 2014 (54), not included in Khai et al. (27) 
RCT identification NCT00605215 
Study setting A randomized placebo-controlled phase III trial in 155 sites in 18 
countries (including. USA and several European countries) 
Participants  Eligibility criteria: age 18–55 years, diagnosis of RRMS (revised 
McDonald criteria), and EDSS scores of 0–5.5. At least one relapse 
in the previous 12 months, two in the previous 24 months, or one in 
the previous 12–24 months, plus one gadolinium-enhancing (GdE) 
lesion in the previous 12 months.  
Key exclusion criteria: progressive forms of MS; use of glatiramer 
acetate in the previous 2 months; and prior use of natalizumab, 
laquinimod, cladribine, or any interferon beta at any time. 
Baseline characteristics (in placebo group): Age (median and 25-75 
percentile) 37,5 (30,3-45,4); 71,3% female; EDSS (median and 25-75 
percentile) 2.5 (1.5, 3.5) 
Intervention group Laquinimod 0.6 mg capsule q.d. (n=434)[not our scope] 
Interferon beta-1a IM 30 mcg once-weekly injection (n = 447) 
Comparison group Placebo (matching laquinimod) (n = 450) 
Outcome Primary endpoints: Annualized relapse rate (ARR)  
Secondary endpoints: percent change in normalized brain volume 
from baseline to 24 months; changes in disability measured with 
EDSS. Disability (MSFC z-score at 24 months/early termination) 
Exploratory endpoints: confirmed worsening of EDSS scores sus-
tained for 6 months. MRI endpoints: the cumulative numbers at 12, 
24 months of GdE lesions and of new or enlarging ([50 % larger than 
previous scan) T2 lesions 
Definitions used for endpoints: Relapse= appearance of one or more 
new neurological abnormalities, or reappearance of one or more pre-
viously observed neurological abnormalities, in the absence of fever, 
persisting for >= 48 h, preceded by > 30 days of a stable or improving 
condition, and accompanied by at least one of the following: an in-
crease of at least 0.5 point in EDSS score, an increase of one grade in 
the score of two of the seven functional systems (FS) on the EDSS, or 
an increase of two grades in one FS. 
Disability progression: a 1.0 point EDSS increase in EDSS if baseline 
score 0-5.0, or a 0.5 if baseline score was 5.5, for 3 months.  
Follow-up 2 years 
Treatment history Mixed (based on exclusion criteria) 
Risk of bias 
Random sequence generation Low risk  
Allocation concealment Not described. (Assume low risk based on description 
of sequence generation and blinding) 
Blinding of participant and personnel Not for our comparison  
Blinding of outcome assessment Adequate 
Incomplete outcome data Low risk 
Selective reporting None detected 
Other sources of bias Differences in mean T2 lesion volume and GdE lesions at baseline 
between  laquinimod or IFNb-1a groups  
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Interferon beta 1a (sc) 
PRISMS (Prevention of Relapses and Disability by Interferon _beta 1a 
Subcutaneously in Multiple Sclerosis) study1998 (55), in Khai et al. 
(27) 
RCT identification Not reported 
Study setting Double-blind, randomized, controlled trial. 22 centres in 9 coun-
tries including Australia, Canada, and Europe. 
Participants  Eligibility criteria: Adult RRMS patients (Poser et al.), EDSS = 0 
to 5.0; had ≥ 2 relapses in previous 2 years.  
Key exclusion criteria: Previous systemic treatment with IFN, lym-
phoid irradiation, or cyclophosphamide, or with other immuno-
modulatory or immunosuppressive treatments in the preceding 12 
months.  
Baseline characteristics: Age: median (interquartile range) 35 (29-
40); 69% female; EDSS:2.5+/-1.2 
Intervention group Interferon beta-1a 22 mcg SC t.i.w.(n=189) 
Interferon beta-1a 44 mcg SC t.i.w. (n=184) 
Comparison group Placebo (n=187) 
Outcome Primary endpoint: Number of relapses.  
Secondary endpoints: Times to first and second relapse, propor-
tion of relapse-free patients, disability progression, ambulation in-
dex, need for steroid therapy and hospitalization, and disease ac-
tivity under MRI and burden of disease.  
 
Definitions used for endpoints: Relapses: The appearance of a new 
symptom or worsening of an old symptom over at least 24 hours 
that could be attributed to MS activity and was preceded by stability 
or improvement for at least 30 days.  
Disability progression: An increase in EDSS of at least 1 point sus-
tained over at least 3 months.  
Follow-up 2 years 
Treatment history Treatment-naive (based on exclusion criteria, year of study, and 
clinical expert input).  
Critical appraisal  
Randomization Adequate 
Allocation concealment Adequate 
Double-blinding Yes 
Baseline characteristic similarity Yes 
Outcome measures Adequate 
Withdrawals 10% 
ITT Analysis Yes 
Funding Manufacturer 
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IMPROVE (Investigating MRI Parameters with RebifimprOVEd formu-
lation) study 2010, De Stefano et al.,(94), included in Khai et al. (27) 
 
RCT identification NCT00441103 
Study setting Double-blind, randomized, placebo-controlled trial, multi-centre, 
multi-country in European countries.  
Participants  Eligibility criteria: Age = 18 years to 60 years, diagnosis of RRMS 
(McDonald criteria), EDSS = 0 to 5.5; active disease (≥ 1 clinical 
event and ≥ 1 gadolinium-enhancing MRI lesion) within the 6 
months period before randomization.  
Exclusion criteria: Not specified.  
Baseline characteristics: Not reported 
Intervention group Interferon beta-1a 44 mcg SC t.i.w. (n = 120)  
Comparison group Placebo (n = 60)  
Outcome Primary endpoint: Number of combined unique active MRI brain 
lesions at week 16.  
Secondary endpoints: Number of combined unique active le-
sions/patient/scan, other MRI outcomes, relapse rate.  
Follow-up 16 weeks 
Treatment history Unclear (inadequate information to characterise) 
Comments Double-blind phase:16 weeks. After that, patients received Inter-
feron beta-1a, 44 mg sc tiw, for 24 weeks (rater-blind phase). 
The analysis populations for the rater-blind period comprised pa-
tients who completed treatment during the double-blind period 
(Interferon beta-1a, n=12; placebo,n=57). 
Critical appraisal  
Randomization Insufficient reporting 
Allocation concealment Not reporting 
Double-blinding Yes 
Baseline characteristic similarity Not reporting 
Outcome measures Adequate 
Withdrawals Not reporting  
ITT Analysis Yes 
Funding Manufacturer 
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Interferon beta 1b (sc) 
IFNB-MS 1993, (57), included in Khai et al.  (27) 
 
RCT identification Not reported 
Study setting Randomized, placebo-controlled trial Multi-centre Canada and the 
US.  
Participants  Eligibility criteria: Age = 18 years to 50 years, diagnosis of RRMS 
(McDonald criteria), EDSS = 0 to 5.5; had ≥ 2 exacerbations during 
the previous 2 years; clinically stable for at least 30 days before en-
try and received no adrenocorticotrophic hormone or prednisone 
during this period.  
Key exclusion criteria: Prior treatment with azathioprine or cyclo-
phosphamide.  
Baseline characteristics: Age 35+/-7; 70% female; EDSS 2,9+/-1,1 
Intervention group Interferon beta-1b 250 mcg SC every other day (n = 124)  
Interferon beta-1b 50 mcg SC every other day (n=125) 
Comparison group Placebo (n = 123)  
Outcome Primary endpoints: Annualized relapse rate, proportion of relapse-
free patients  
Secondary endpoints: Time to first relapse, relapse duration and 
severity, change in EDSS, MRI outcomes.  
 
Definitions  used for endpoints: Relapses: The appearance of a new 
symptoms or worsening of an old symptom, attributable to MS; ac-
companied by an appropriate new neurologic abnormality; lasting 
at least 24 hours in the absence of fever; and preceded by stability 
or improvement for at least 30 days.  
Disability progression: A patient was considered to have progres-
sion in disability when there was a persistent increase of 1 or more 
EDSS points confirmed on two consecutive evaluations separated 
by at least 3 months.  
Follow-up 3 years 
Treatment history Treatment-naive (based on year of study and clinical expert input).  
Critical appraisal  
Randomization Insufficient reporting 
Allocation concealment Not reporting 
Double-blinding Yes 
Baseline characteristic similarity Yes 
Outcome measures Adequate 
Withdrawals 33% 
ITT Analysis Yes 
Funding Not reporting 
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Etemadifar et al., 2006(58), included in Khai et al. (27) 
 
RCT identification Not reported 
Study setting Rater-blinded, randomized controlled trial, neurology outpatient 
clinics in Iran 
Participants  Eligibility criteria: Age = 15 years to 50 years, diagnosis of relaps-
ing MS (Poser et al.), EDSS = 0 to 5.0; ≥ 2 relapses within the 2-
year period to treatment initiation documented by a neurologist.  
Key exclusion criteria: History of severe allergic or anaphylactic re-
action to any IFN, or to other components of drug formulation; ev-
idence of neurologic, psychiatric, cardiac, endocrinologic, hemato-
logic, hepatic, renal, active malignancy, autoimmune diseases, or 
other chronic disease; history of uncontrolled seizure or suicidal 
ideation or severe depression; lactation and pregnancy.  
Baseline characteristics: Age 29+/-7; 76% female; EDSS 2,0+/-0,9 
Intervention group Interferon beta-1b 250 mcg SC every other day (n = 30) 
Interferon beta-1a 30 mcg IM q.w. (n = 30) 
Interferon beta-1a 44 mcg SC t.i.w. (n = 30) 
Comparison group These drugs were compared one with another 
Outcome Endpoints: Number of relapses, proportion of relapse-free pa-
tients, EDSS scores  
 
Definitions used for endpoints: Relapses: The appearance of a new 
neurologic symptom, or severe deterioration in a pre-existing 
symptom that lasted 24 hours causing the deterioration in the 
EDSS with 1 point.  
Follow-up 2 years 
Treatment history Unclear (inadequate information to characterise) 
Critical appraisal  
Randomization Insufficient reporting 
Allocation concealment Not reporting 
Double-blinding No (rater-blinded) 
Baseline characteristic similarity No 
Outcome measures Adequate 
Withdrawals 0% 
ITT Analysis Yes 
Funding Not reporting 
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Natalizumab 
AFFIRM (Natalizumab Safety and Efficacy in Relapsing Remitting Mul-
tiple Sclerosis) study, Polman et al., 2006 (60), in Khai et al. (27) 
RCT identification NCT00027300 
Study setting Randomized, double-blind, placebo-controlled trial in 99 centres 
in Europe, North America, Australia, and New Zealand.  
Participants  Eligibility criteria: Age = 18 years to 50 years, diagnosis of RRMS 
(McDonald criteria), EDSS = 0 to 5.0; had MRI lesions with MS, 
with ≥1 medially documented relapse within 12 months before the 
study began.  
Key exclusion criteria: relapse within 50 days before administra-
tion of the first dose of the study drug; treatment with specific 
named pharmaceuticals (MS related) 
Baseline characteristics: Age 36+/-8 years; 70% female; EDSS 
2,3+/-1,2 
Intervention group Natalizumab 300 mg IV every 4 weeks (n = 627)  
Comparison group Placebo (n = 315)  
Outcome Primary endpoints: Rate of clinical relapse at 1 year; cumulative 
probability of sustained progression of disability at 2 years.  
Secondary endpoints: Different MRI outcomes at 1 and 2 years; 
proportion of relapse-free patients at 1 year; progression of disabil-
ity at 2 years, measured by MSFC.  
Tertiary endpoints: HRQoL was assessed by SF-36 (PCS and MCS) 
and Subject Global Assessment Visual Analogue Scale.  
 
Definitions used for endpoints: Relapses: New or recurrent neuro-
logic symptoms not associated with fever or infection that lasted for 
at least 24 hours and were accompanied by new neurologic signs 
found by the examining neurologist.  
Sustained progression of disability: An increase of 1.0 or more on 
the EDSS from a baseline score of 1.0 or more or an increase of 1.5 
or more from a baseline score of 0 that was sustained for 12 weeks 
(progression could not be confirmed during a relapse).  
Follow-up 2 years 
Treatment history Unclear (inadequate information to characterise) 
Critical appraisal  
Randomization Adequate 
Allocation concealment Adequate 
Double-blinding Yes 
Baseline characteristic similarity Yes 
Outcome measures Adequate 
Withdrawals 9% 
ITT Analysis Yes 
Funding Manufacturer 
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Gobbi et al. (31), not included in Khai et al. (27) 
RCT identification NCT01144052 
Study setting Randomized controlled study, rater blinded. One centre, Switzer-
land. 
Participants  Eligibility criteria: Patients with RRMS (2005 McDonald’s crite-
ria), aged between 18 and 60 years, who were on natalizumab 
(NTZ) and feared or were at significant risk for progressive multi-
focal leucoencephalopathy (PML) [Risk for PML was defined sig-
nificant in case of NTZ treatment duration equal to or greater than 
12mMonths]. Patients had to be free of disease activity while 
on NTZ (free from relapses and disability progression for at least 6 
months and no gadolinium enhancing lesions on baseline MRI 
Key exclusion criteria: relevant neurologic, internistic or psychiat-
ric disorders; treatment with steroids less than 1 month before 
study entry; treatment with any immunomodulators or immune-
suppressors other than steroids, ACTH* or NTZ in the past year. 
Baseline characterics in NTZ group: Age median (range): 43 (20-
60), 60% female, EDSS score (median (range)): 3 (1.5-3.5) 
Intervention group Continue on natalizumab 300 mg IV q.m. (n=10) 
Comparison group Switch to interferon beta-1b 250 mcg every other day (n=9) 
Outcome Primary endpoint was time to first on-study relapse 
from randomization.  
Secondary endpoints included number of relapses, proportion of 
relapse free patients, severity of relapses (severe relapse was de-
fined by ≥1.5 increase in EDSS score), 3 months confirmed disa-
bility progression (defined by ≥1.0 increase in EDSS score), num-
ber of new T2-hyperintense lesions (nT2L) and Gd+L per patient 
at months 3, 6, 9 and 12. 
Follow-up 1 year 
Treatment history Treatment experienced 
Risk of Bias  
Random sequence genera-
tion 
Adequate 
A monitoring agency prepared the randomization list and 
provided sealed envelopes for treatment allocation. 
Allocation concealment Adequate 
Blinding of participant and 
personnel 
No 
Rater blinded 
Blinding of outcome assess-
ment 
Adequate 
“EDSS and relapses assessment was performed by an ex-
amining neurologist blinded to treatment.” 
Incomplete outcome data Analysis was based on intention to treat. 
Withdrawals: 10.5% 
Selective reporting None detected 
Other sources of bias Several of the authors report funding from one or several 
pharmaceutical companies. 
*ACTH: this abbreviation was not explained in the publication 
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RESTORE-study 2014, Fox et al., (61), not included in Khai et al.  (27) 
RCT identification NCT01071083 
Study setting Randomized, partially placebo-controlled study. 31 sites in North 
America and Europe 
Participants  Eligibility criteria: Patients with RRMS receiving natalizumab, 
aged 18 and 60 years, who had been treated with natalizumab for 
at least 12 months prior to randomization and who had no relapses 
during those 12 months. 
Key exclusion criteria: presence of gadolinium enhancing lesions; 
presence of antinatalizumab antibodies; immunosuppressive treat-
ment within 24 months prior to randomization; treatment with IV 
immunoglobulin, plasmapheresis, or cytapheresis within 12 
months prior to randomization; or treatment with systemic corti-
costeroids within 3 months prior to randomization. 
Baseline characteristics in placebo group: Age: 40 +/- 10; 74% fe-
male; EDSS: 3.3 +/-1.8  
Intervention group Natalizumab 300 mg IV every 4 weeks (n=45) 
Alternate immunomodulatory therapy (IM interferon b-1a, glati-
ramer acetate, or methylprednisolone (n=88) [not included as pa-
tients and their neurologist selected the immunomodulatory ther-
apy on an individual basis; as such, the distribution of patients re-
ceiving IM IFN-b-1a, GA, and MP was not randomized, and the 
groups were unbalanced] 
Comparison group Placebo IV every 4 weeks (n=42) 
Outcome Relapse 
Quality of life’ 
Withdrawal due to adverse events 
Deaths  
 
Definition used: Radiographic and clinical disease activity. Quality 
of life  with Visual Analogue Scale, and Modified Fatigue Impact 
Scale, and cognition (Symbol Digit Modalities Test (SDMT)). Dis-
ability progression with EDSS. 
 
Follow-up 24 weeks (52 weeks but at week 28, patients resumed open-label 
infusions of natalizumab) 
Treatment history Treatment experienced ( all groups received natalizumab at day 0) 
Risk of Bias 
Random sequence generation Adequate 
Allocation concealment Adequate 
For arms natalizumab + placebo 
Blinding of participant and personnel Adequate 
For arms natalizumab + placebo 
Blinding of outcome assessment Adequate 
For arms natalizumab + placebo 
Incomplete outcome data Adequate 
Selective reporting Not detected 
Other sources of bias Funding: manufacturer. 
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Zecca et al., 2014 (32), not included in Khai et al. (27) 
RCT identification NCT1144052, 
Study setting Randomized, rater-blinded, parallel-group study, single center, 
Switzerland 
Participants  Eligibility criteria: Age between 18 and 60, being at significant risk 
for (i.e. NTZ treatment duration equal to or greater than 12 months) 
or fear of PML, and being free of disease activity (free from relapses 
and disability progression for at least 6 months and no gadolinium 
enhancing lesions [Gd + L] on baseline [BL] MRI). RRMS accord-
ing to 2005 McDonald criteria [13] from 2010 to 2011 
Baseline characteristics in Interferon group: Mean (range) 39 (24-
48) ; 33% female (3/9); EDSS median (range) 3,0 (1,5-3,5)  
Intervention group Continue Natalizumab monthly intravenous (i.v.) 300 mg (n=10) 
Comparison group De-escalate to interferon beta 1b subcutaneous (s.c.) 250 mcg every 
other day (n=9) 
Outcome Behavioral assessment of patients included Paced Auditory Serial 
Addition Test, 3 sec (PASAT), Fatigue Scale for Motor and Cogni-
tive functions (FSMC), Functional Assessment of Multiple Sclerosis 
(FAMS), and EuroQuol visual analogue scale (EQ-VAS) 
Follow-up 1 year 
Treatment history Treatment experienced (All patients previously treated with natali-
zumab) 
Risk of bias  
Random sequence generation Unclear/Not described 
Allocation concealment Unclear/Not described 
Blinding of participant and personnel No 
Blinding of outcome assessment Adequate (rater-blinded) 
Incomplete outcome data No 17/19 completed study (reasons listed) 
Selective reporting None detected 
Other sources of bias Some of the authors have received compen-
sation from one or several of pharmaceutical 
companies 
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Peg-interferon 
ADVANCE study 2014, Calabresi et al.,(59), not in Khai et al. (27) 
RCT identification NCT00906399 
Study setting Double-blind, randomized controlled study. 183 neurology prac-
tices in 26 countries, including north and south America, Europe, 
India 
Participants  Eligibility criteria: diagnosis of relapsing-remitting multiple scle-
rosis as defined by the McDonald criteria, aged 18–65 years, a 
EDSS score of 0–5 , and at least two clinically documented re-
lapses in the previous 3 years, with at least one having occurred 
within the past 12 months. 
Key exclusion criteria: pre-specified laboratory abnormalities, and 
previous treatment with interferon for multiple sclerosis for more 
than 4 weeks or discontinuation less than 6 months before baseline 
Baseline characteristics in placebo group: Age: 36+/- 10; 72% fe-
male; EDSS: 2.4 +/-1.2  
Intervention group Peg-interferon beta-1a 125 mcg SC once every 2 weeks (n=512) 
Peg-interferon beta-1a 125 mcg SC once every 4 weeks (n=500) 
Comparison group Placebo (n=500) 
Outcome Primary endpoints: Annualised relapse rate at week 48, based on 
number of relapses.  
Secondary endpoints: The number of new or newly enlarging hy-
perintense lesions on T2-weighted images(relative to baseline 
MRI), proportion of patients who relapsed, and proportion of pa-
tients with disability progression at 48 weeks. 
Tertiary endpoints: Prespecified MRI endpoints at 48 weeks  
Follow-up 2 years, but placebo controlled only for 48 weeks 
Treatment history Mixed (based on exclusion criteria) 
Risk of bias 
Random sequence generation Yes 
Allocation concealment Adequate 
Patients received either study drug or placebo every 2 
weeks to maintain masking; those assigned to receive 
study drug every 4 weeks received alternate injections 
of placebo and peg-interferon beta-1a every 2 weeks 
Blinding of participant and per-
sonnel 
Adequate “ 
Blinding of outcome assess-
ment 
Adequate 
Incomplete outcome data Adequate 
Intention to treat 
Selective reporting None detected 
Other sources of bias Funding: manufacturer 
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Teriflunomide 
O’connor et al., 2006 (62), included in Khai et al. (27) 
RCT identification Not reported 
Study setting Randomized controlled study, double-blind. Centres in Canada 
Participants  Eligibility criteria: Age = 18 years to 65 years, with RRMS (n = 157) 
or secondary-progressive MS with relapses (n = 22) (Poser et al.), 
EDSS = 0 to 6.0; had ≥ 2 documented relapses in previous 3 years, 
and one clinical relapse during the preceding year.  
Key exclusion criteria: Prior treatment with interferon, gamma-
globulin, glatiramer, or other non-corticosteroid immune-modula-
tory therapies in the 4 months prior to the trial.  
Baseline characteristics: Age: 39 +/-; 74% female; , EDSS score: 
(median) 2.3 
Intervention group Teriflunomide oral 7 mg q.d.(n=61) 
Teriflunomide oral 14 mg q.d.(n=57) 
Comparison group Placebo (n=61) 
Outcome Primary endpoint: Number of combined unique active (new and 
persisting) lesions per MRI scan during 36 weeks.  
Secondary endpoints: Other MRI outcomes, number of patients 
experienced relapses, annualized relapse rate, number of relapsing 
patients required a course of steroids, EDSS change.  
 
Definition used for: Relapses: The appearance of a new symptom 
or worsening of an old symptom due to MS lasting 48 hours in the 
absence of fever, preceded by period of stability of at least 30 days 
and accompanied by appropriate changes on neurologic examina-
tion.  
Follow-up 36 weeks 
Treatment history Treatment-naive (based in exclusion criteria, year of study, and 
clinical expert input).  
Comments At baseline 86.9% RRMS, 13.1% secondary progressive 
Critical appraisal  
Randomization Insufficient reporting 
Allocation concealment Not reporting 
Double-blinding Yes 
Baseline characteristic similarity Yes 
Outcome measures Adequate 
Withdrawals 11% 
ITT Analysis Yes 
Funding Manufacturer 
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TEMSO study 2011, O’Connor et al. (63, 64), included in Khai et al. (27) 
RCT identification NCT00134563 
Study setting Double-blind, randomized controlled trial. 127 centres in 21 coun-
tries including Canada, Europe, and US. 
Participants  Eligibility criteria: Age = 18 years to 55 years; diagnosis of RRMS 
(McDonald criteria), EDSS = 0 to 5.5; had ≥ 2 relapses in the pre-
vious 2 years or ≥ 1 relapse during the preceding year, but no re-
lapse in the 60 days before randomization.  
Key exclusion criteria: Had other systemic diseases; pregnant, or 
planned to conceive during the trial period.  
Baseline characteristics: Age 38+/-9; 72% female; EDSS: 2.7+/- 1.3  
Intervention group Teriflunomide oral 7 mg q.d. (n=365) 
Teriflunomide oral 14 mg q.d. (n=358)  
Comparison group Placebo (n=363) 
Outcome Primary endpoint: Annualized relapse rate.  
Secondary endpoints: Disability progression (EDSS change), dif-
ferent MRI outcomes.  
 
Definitions used for endpoints: Relapses: The appearance of a new 
clinical sign or symptom, or clinical worsening of a previous sign or 
symptom that had been stable for at least 30 days and that persisted 
for a minimum of 24 hours in the absence of fever.  
Disability progression: An increase from baseline of at least 1.0 
point in the EDSS score (or at least 0.5 points for patients with a 
baseline EDSS score greater than 5.5) that persisted for at least 12 
weeks.  
Follow-up 108 weeks 
Treatment history Mixed (based on reported baseline characteristics) 
Critical appraisal  
Randomization Adequate 
Allocation concealment Adequate 
Double-blinding Yes 
Baseline characteristic similarity Yes 
Outcome measures Adequate 
Withdrawals 27% 
ITT Analysis Yes 
Funding Manufacturer 
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TOWER-(Teriflunomide Oral in people With relapsing multiplE sclero-
sis) study, Confavreux et al. 2014 (65), not included in Khai et al. (27) 
RCT identification NCT00751881 
Study setting Randomised, double-blind, placebo-controlled in 189 centres 
mainly hospital-based sites in 26 countries 
Participants  Eligibility criteria: ambulatory patients with RMS, aged 18–55 
years, with EDSS scores <=5.5 and >=1 relapse in the previous 12 
months or >=2 relapses in the prior 24 months 
Key exclusion criteria: previously or concomitantly received cyto-
kine therapy, interferon beta, or glatiramer acetate within 3 months 
of randomisation, or had ever used natalizumab or other immuno-
suppressive agents 
Baseline characteristics (in placebo group): Age: 38+/-9; 70% fe-
male; EDSS: 2,7+/-1,4 
Intervention group Teriflunomide 14 mg once daily (n=372) 
Teriflunomide 7 mg once daily (n=408) 
Comparison group Placebo once daily (n=389) 
Outcome Primary endpoints: Annualised relapse rate (number of relapses 
per patient-year) 
Secondary endpoints: time to 12 week sustained accumulation of 
disability; time to fi rst relapse, proportion of patients free from re-
lapses, proportion of patients free of accumulation of disability, and 
change from baseline in EDSS score at week 48, and change in Fa-
tigue Impact Scale (FIS) and Short Form-36 (SF-36) scores at week 
48 and last study visit.  
 
Definitions used for endpoints: Relapse was defined as new or 
worsening clinical signs or symptoms lasting at least 24 h without 
fever. Protocol-defined relapse constituted an increase of either 1 
point in at least two EDSS functional system scores, or 2 points in 
one EDSS functional system score (excluding bowel and bladder 
function, and cerebral function), or 0・5 points in total EDSS score 
from a previous clinically stable assessment time to 12 week sus-
tained accumulation of disability, defined as an increase from base-
line of at least 1 EDSS point (or ≥0・5 points when baseline EDSS 
score was >5・5 points that persisted for at least 12 weeks 
Follow-up Treatment duration in TOWER was variable and ended 48 weeks 
after the last patient was randomized into the study 
Treatment history Mixed (based on exclusion criteria) 
Risk of bias 
Random sequence generation Adequate.  
Allocation concealment Adequate “After a screening phase (up to 4 
weeks), investigators used the allocation se-
quence to randomly assign eligible patients” 
Blinding of participant and personnel Adequate.  
Blinding of outcome assessment Adequate 
Incomplete outcome data Adequate 
Intention to treat analysis 
Selective reporting None detected 
Other sources of bias Funding: manufacturer 
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TENERE-((TErifluNomidE and REbifR) )study, Vermersch et al. 2014 
(66), not included in Khai et al. (27) 
RCT identification NCT00883337 
Study setting Rater-blinded study, randomized multicentre study 
Participants  Eligibility criteria: 18 years of age and older who met McDonald 
criteria for MS,13 had a relapsing clinical course with or without 
progression, and an Expanded Disability Status Scale (EDSS) score 
≤5.5 at screening.14 Patients had to be relapse free for 30 days prior 
to randomisation. 
Key exclusion criteria: several restriction in previous and concom-
itant medications, and relevant illnesses.  
Baseline characteristics (group): Age 37+/-11; 68% female: EDSS 
2,0+/-1,2 
Intervention group Teriflunomide 14 mg oral once daily (n=111) 
Teriflunomide 7 mg oral once daily (n=109) 
Comparison group Interferon beta-1a 44mcg s.c three times/week (n=104) 
Outcome The primary endpoint: time to failure, defined as first occurrence 
of confirmed relapse or permanent treatment discontinuation for 
any cause. Secondary endpoints included ARR, Fatigue Impact 
Scale (FIS) and Treatment Satisfaction Questionnaire for Medica-
tion (TSQM). 
 
Definition used for: Relapse criteria a new clinical sign/symptom 
or clinical worsening of a previous sign/symptom (previously sta-
ble for at least 30 days) that persisted for at least 24 hours without 
fever. required a 1-point increase in each of two FS, a 2-point in-
crease in at least one FS (excluding bowel/bladder and cerebral) or 
an increase of 0.5 points in EDSS score from the previous stable 
assessment. 
Follow-up 48 weeks after the last patient was randomised, resulting in a vari-
able duration of follow-up 
Treatment history Mixed (based on exclusion criteria) 
Risk of bias  
Random sequence generation Unclear, not described 
Allocation concealment Unclear 
Blinding of participant and person-
nel 
No. Double blind for teriflunomide, open-label for 
Interferon beta-1a 
Blinding of outcome assessment Adequate 
Incomplete outcome data 22.4% discontinued treatment due to AEs 
3 patients in IFN did not receive study drug.  
 
Efficacy analyses: intention-to-treat population, 
The safety analysis included all randomized pa-
tients exposed to study medication. 
Selective reporting Unclear 
Other sources of bias Authors declare conflict of interest in form of col-
laboration, employment or other with one or sev-
eral of the pharmaceutical companies 
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Appendix 3: Excluded studies and reasons for exclusions 
Information on the following tables:  
 CIS= Clinical Isolated Syndrome 
 P= population 
 I=Intervention 
 C=Comparator 
 S=Study design 
 Y=Yes (the study fits that criteria) 
 N=No (the study does not fit that criteria) 
 
 
 CIS Publica-
tion 
date 
P I C O S Exclu-
sion/com-
ments 
Corrections to Safety and efficacy of fingolimod in pa-
tients with relapsing-remitting multiple sclerosis 
(FREEDOMS II): A double-blind, randomised, pla-
cebo-controlled, phase 3 trial. [Lancet Neurol 13 
(2014) 545-56]. The Lancet Neurology 
2014;13(6):536. 
      N Exclude 
 
Correction up-
dated in online 
version 
Agius M, Meng X, Chin P, Grinspan A, Hashmonay R. 
Fingolimod therapy in early multiple sclerosis: An ef-
ficacy analysis of the transforms and freedoms studies 
by time since first symptom. CNS Neuroscience and 
Therapeutics 2014;20(5):446-451. 
  N Y Y Y Y Exclude 
subgroups of pa-
tients <3 yrs 
since their first 
MS symptom 
Arnold DL, Calabresi PA, Kieseier BC, Sheikh SI, 
Deykin A, Liu S, et al. Effect of peg-interferon beta-1a 
on MRI measures and freedom from measured dis-
ease activity: 2-year results from the phase 3 AD-
VANCE study. Mult Scler 2014;1):97. 
      N Exclude 
 
Abstract 
 
Arnold DL, Calabresi PA, Kieseier BC, Sheikh SI, 
Deykin A, Zhu Y, Liu S, You X, Sperling B, Hung S. Ef-
fect of peg-interferon beta-1a on MRI measures and 
achieving no evidence of disease activity: results from 
a randomized controlled trial in relapsing-remitting 
multiple sclerosis. BMC Neurol. 2014 Dec 
31;14(1):1058. 
  Y Y Y N  Exclude 
 
ADVANCE 
Combined out-
come of relapse 
and disability 
progression 
Brinar V, Arnold DL, Cohen J, Coles AJ, Fox EJ, 
Hartung HP, et al. Alemtuzumab improves expanded 
disability status scale (EDSS) via effects on functional 
systems: CARE-MS II. Mult Scler 2013;1):283-284. 
      N  Exclude 
 
Abstract 
 
 
Calabresi PA, Kieseier BC, Arnold DL, Balcer L, Boyko 
A, Pelletier J, et al. Clinical efficacy of peg-interferon 
beta-1a in relapsingremitting multiple sclerosis: 2-
year data from the phase 3 ADVANCE study. Mult 
Scler 2014;1):42-43. 
      N Exclude 
 
Abstract 
Cascione M, Gaines C, Fang J, Dangond F, Miller A. 
Early and consistent reduction in relapses among pa-
tients with relapsing-remitting multiple sclerosis re-
ceiving subcutaneous interferon beta-1a: A post-hoc 
analysis of prisms data. Neurology 2014;1). 
      N Exclude 
 
Abstract 
Cascione M, Wynn D, Barbato LM, Pestreich L, 
Schofield L, McCague K. Randomized, open-label 
study to evaluate patient-reported outcomes with fin-
golimod after changing from prior disease-modifying 
therapy for relapsing multiple sclerosis: EPOC study 
rationale and design. J Med Econ 2013;16(7):859-
865. 
     N  Exclude 
The comparator 
is disease-modi-
fying therapies.  
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 CIS Publica-
tion 
date 
P I C O S Exclu-
sion/com-
ments 
Chan A, Phillips JT, Fox RJ, Zhang A, Okwuokenye M, 
Kurukulasuriya NC. Differential recovery from relapse 
between treatment groups in the CONFIRM study of 
delayed-release dimethyl fumarate. Mult Scler 
2014;1):110. 
      N Exclude 
 
Abstract 
 
 
Cofield SS, Gustafson T, Cutter GR, Wolinsky JS, Lu-
blin FD. Physician and participant treatment guesses 
in the double-blind CombiRx study. Mult Scler 
2014;1):111-112. 
      N Exclude 
 
Abstract 
Cohen JA, Belova A, Selmaj K, Wolf C, Oberye JJL, 
Van Den Tweel ERW, et al. Generic glatiramer acetate 
is equivalent to copaxone on efficacy and safety: Re-
sults of the randomized doubleblind GATE trial in 
multiple sclerosis. Mult Scler 2014;1):38-39.  
      N Exclude 
 
Abstract 
 
 
Comi G, Freedman MS, Kappos L, Miller AE, Olsson 
TP, Wolinsky JS, et al. Effect of teriflunomide on lym-
phocyte and neutrophil counts: Pooled analyses from 
four placebo-controlled studies. Mult Scler 
2014;1):93-94.  
      N Exclude 
 
Abstract 
Comi G, Martinelli V, Rodegher M, Moiola L, Leocani 
L, Bajenaru O, et al. Effects of early treatment with 
glatiramer acetate in patients with clinically isolated 
syndrome. Mult Scler 2013;19(8):1074-1083.  
Y       Exclude 
 
Not RRMS pa-
tients 
Comi G, Miller AE, Wolinsky JS, Benamor M, Bauer 
D, Truffinet P, et al. The effect of teriflunomide on 
lymphocyte and neutrophil count in patients with a 
first clinical episode consistent with multiple sclero-
sis: Results from the TOPIC study. J Neurol 
2014;261:S91. 
      N Exclude 
 
Abstract 
Confavreux C, Olsson TP, Comi G, Freedman MS, Mil-
ler A, Wolinsky JS, et al. Teriflunomide hepatic safety 
results: Pooled data from three placebo-controlled 
studies. J Neurol 2013;260:S122. 
      N Exclude 
 
Abstract 
Cutter G, Wolinsky JS, Comi G, Ladkani D, Knappertz 
V, Vainstein A, et al. Comparable clinical and MRI ef-
ficacy of glatiramer acetate 40mg/mL TIW and 
20mg/mL QD: Results of a systematic review and 
meta-analysis. Mult Scler 2014;1):90-91. 
      N Exclude 
 
Abstract 
De Stefano N, Kappos L, Radue EW, Sprenger T, Piani 
Meier D, Haring D, et al. Fingolimod effect on diffuse 
tissue damage is partly independent of its effect on fo-
cal damage in relapsingremitting multiple sclerosis 
patients. Mult Scler 2014;1):379. 
      N Exclude 
 
Abstract 
De Stefano N, Sprenger T, Freedman MS, Cree B, Sor-
mani MP, Haring DA, et al. Including threshold rates 
of brain volume loss in the definition of disease-activ-
ity-free in multiple sclerosis using fingolimod phase 3 
data. Mult Scler 2014;1):196-197. 
      N Exclude 
 
Abstract 
Deykin A, Arnold D, Hung S, Sheikh S, Seddighzadeh 
A, Zhu Y, et al. Interim analysis of 2-year clinical effi-
cacy and safety of peg-interferon beta-1a in patients 
with relapsing-remitting multiple sclerosis: Data from 
the pivotal phase 3 advance study. Neurology 2014;1). 
      N Exclude 
 
Abstract 
Dhib-Jalbut S, Sumandeep S, Valenzuela R, Ito K, Pa-
tel P, Rametta M. Immune response during interferon 
beta-1b treatment in patients with multiple sclerosis 
who experienced relapses and those who were re-
lapse-free in the START study. J Neuroimmunol 
2013;254(1-2):131-140. 
    N  N Exclude 
Re-analysis of 
START study, 
which is obser-
vational with 
only interfreron 
(Betaseron) 
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 CIS Publica-
tion 
date 
P I C O S Exclu-
sion/com-
ments 
Edan G, Kappos L, Montalban X, Polman C, Freed-
man M, Hartung H. Long term impact of early initia-
tion of interferon beta-1B after a first clinical event 
suggestive of multiple sclerosis: Additional relapse 
rate, edss, and msss analyses after 8 years.  2013;80. 
      N Exclude 
 
Abstract 
Fox E, Edwards K, Burch JG, Kim E, Pestreich L, 
McCague K, et al. Treatment satisfaction and clinical 
improvement after switch to fingolimod. J Neurol 
2013;260:S126. 
      N Exclude 
 
Abstract 
Freedman M, Wolinsky J, Comi G, Kappos L, Olsson 
T, Miller A, et al. Long-term safety and efficacy of teri-
flunomide in patients with relapsing forms of multiple 
sclerosis in the TEMSO extension trial. Mult Scler 
2013;1):225.  
      N Exclude 
 
Abstract 
Freedman M, Wolinsky J, Comi G, Kappos L, Olsson 
T, Miller A, et al. Safety and efficacy of teriflunomide 
for up to 9 years in relapsing forms of multiple sclero-
sis: Update of the temso extension trial. Neurology 
2014;1). 
      N Exclude 
 
Abstract 
Freedman MS. Evidence for the efficacy of interferon 
beta-1b in delaying the onset of clinically definite mul-
tiple sclerosis in individuals with clinically isolated 
syndrome. Ther Adv Neurol Disord 2014;7(6):279-
288. 
Y  N    N Exclude 
 
Review not SR 
Freedman MS, Ben-Amor AF, Issard D, Casset-Sema-
naz F. Assessing a tool to predict disease activity in 
patients with multiple sclerosis: A post-hoc analysis of 
clinical trial data on patients treated with subcutane-
ous interferon beta-1a. Mult Scler 2013;1):262. 
      N Exclude 
 
Abstract 
Freedman MS, Stefano N, Barkhof F, Polman CH, 
Comi G, Uitdehaag BMJ, et al. Patient subgroup anal-
yses of the treatment effect of subcutaneous inter-
feron beta-1a on development of multiple sclerosis in 
the randomized controlled REFLEX study. J Neurol 
2014;261(3):490-499. 
Y       Exclude 
 
Not RRMS pa-
tients 
Havrdova E, Gold R, Fox R, Kappos L, Phillips JT, 
Zhang A. BG-12 (dimethyl fumarate) treatment for re-
lapsing-remitting multiple sclerosis (RRMS) increases 
the proportion of patients free of measured clinical 
and neuroradiologic disease activity in the phase 3 
studies.  2013;80. 
      N Exclude 
 
Abstract 
Hung S, Kieseier BC, Arnold DL, Balcer L, Boyko A, 
Pelletier J, et al. Peg-interferon beta-1a provides im-
provements in clinical and radiological disease activ-
ity in relapsing-remitting multiple sclerosis: Year 1 
findings from the phase 3 advance study. Mult Scler 
2014;20 (7):926. 
      N Exclude 
 
Abstract 
Hunter SF, Hunter HM, Kantor D. Phase 1 trial moni-
toring response to alemtuzumab (ALE) in naive and 
ALE-experienced subjects with refractory multiple 
sclerosis (MS). Mult Scler 2013;1):265-266.  
      N Exclude 
 
Abstract 
Hutchinson M, Bar-Or A, Fox RJ, Gold R, Giovannoni 
G, Kita M, et al. Effect of BG-12 (dimethyl fumarate) 
in subgroups of patients with relapsing-remitting 
multiple sclerosis: Findings from Two Phase 3 Studies 
(DEFINE and CONFIRM). Mult Scler 2013;19 
(5):682-683.  
      N Exclude 
 
Abstract 
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 CIS Publica-
tion 
date 
P I C O S Exclu-
sion/com-
ments 
Hutchinson M, Fox RJ, Havrdova E, Kurukulasuriya 
NC, Sarda SP, Agarwal S, et al. Efficacy and safety of 
BG-12 (dimethyl fumarate) and other disease-modify-
ing therapies for the treatment of relapsing-remitting 
multiple sclerosis: A systematic review and mixed 
treatment comparison. Curr Med Res Opin 
2014;30(4):613-627. 
      N Exclude 
 
Systematic re-
view. Date of 
search 
15/11/2012 
 
Hutchinson M, Fox RJ, Phillips JT, Miller DH, Havr-
dova E, Kita M, et al. Efficacy and safety of BG-12 (di-
methyl fumarate) in relapsing-remitting multiple scle-
rosis in the phase 3 CONFIRM study. Mult Scler 
2013;19 (5):683.  
      N Exclude 
 
Abstract 
Kappos L, Cohen J, Collins W, De Vera A, Zhang-Au-
berson L, Ritter S, et al. Fingolimod in relapsing mul-
tiple sclerosis: An integrated analysis of safety find-
ings. Multiple sclerosis and Related Disorders 
2014;3(4):494-504. 
      N Not RCT 
Kappos L, O'Connor PW, Polman CH, Vermersch P, 
Wiendl H, Pace A, et al. Clinical effects of natalizumab 
on multiple sclerosis appear early in treatment course. 
J Neurol 2013;260(5):1388-1395. 
      N Not RCT 
Kaufman M, Cree BA, De Seze J, Fox RJ, Gold R, 
Hartung HP, et al. Radiologic MS disease activity dur-
ing natalizumab treatment interruption: findings from 
RESTORE. J Neurol 2015;262(2):326-336. 
     N  Exclude 
Re-analysis of 
RESTORE study 
and others pla-
cebo groups 
Khan O, Rieckmann P, Boyko A, Selmaj K, Zivadinov 
R. A multinational, multicenter, randomized, placebo-
controlled, double-blind study to assess the efficacy, 
safety, and tolerability of glatiramer acetate 40 mg in-
jection three times a week in subjects with RRMS: Ef-
ficacy and safety results of the gala study. Neurology 
2013;80 (1 MeetingAbstracts). 
      N Exclude 
 
Abstract 
Kita M, Fox R, Phillips JT, Arnold D, Bar-Or A, Yang 
M. Clinical and neuroradiologic efficacy of BG-12 (di-
methyl fumarate) in us patients with relapsing-remit-
ting multiple sclerosis (RRMS): An integrated analysis 
of the phase 3 DEFINE and confirm studies.  2013;80. 
      N Exclude 
 
Abstract 
Leist T, Freedman M, Benamor M, Truffinet P, Du-
kovic D, Comi G. Pooled safety data from four pla-
cebo-controlled teriflunomide studies. Neurology 
2014;1). 
      N Exclude 
 
Abstract 
Leist T, Freedman M, Kappos L, Olsson T, Miller A, 
Wolinsky J, et al. Pooled safety data from three pla-
cebo-controlled teriflunomide studies. Mult Scler 
2013;1):274-275. 
      N Exclude 
 
Abstract 
Leist TP, Freedman MS, Kappos L, Olsson TP, Miller 
AE, Wolinsky JS, et al. Three placebo-controlled teri-
flunomide studies: Pooled safety data. Mult Scler 
2014;20 (7):933-934. 
      N Exclude 
 
Abstract 
Leist TP, Freedman MS, Kappos L, Olsson TP, Miller 
AE, Wolinsky JS, et al. Pooled safety analyses from 
the teriflunomide clinical development program. Mult 
Scler 2014;1):110-111.  
      N Exclude 
 
Abstract 
Lublin F, Cofield S, Cutter G, Salter A, Wang J, Con-
wit R, et al. Edss changes in combirx: Blinded, 7-year 
extension results for progression and improvement. 
Neurology 2013;80 (1 MeetingAbstracts).  
      N Exclude 
 
Abstract 
Lublin F, Cofield S, Cutter G, Salter A, Wang J, Con-
wit R, et al. Relapse activity in the combirx trial: 
Blinded, 7-year extension results. Neurology 2013;80 
(1 MeetingAbstracts). 
      N Exclude 
 
Abstract 
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 CIS Publica-
tion 
date 
P I C O S Exclu-
sion/com-
ments 
Macdonell R, Lublin F, Comi G, Freedman MS, Kap-
pos L, Maurer M, et al. Teriflunomide reduces re-
lapse-related sequelae, severe relapses, hospitalisa-
tions and corticosteroid use: Pooled data from the 
phase 3 TEMSO and TOWER studies. Mult Scler 
2013;1):512-513.  
      N Exclude 
 
Abstract 
Mantia LL, Vacchi L, Rovaris M, Di Pietrantonj C, 
Ebers G, Fredrikson S, et al. Interferon beta for sec-
ondary progressive multiple sclerosis: a systematic re-
view. J Neurol Neurosurg Psychiatry 2013;84(4):420-
426 
  N    N Exclude 
Review of  
Secondary pro-
gressive 
 
Maurer M, Van Wijmeersch B, De Seze J, Meca-Lal-
lana J, Bozzi S, Vermersch P. Significant and mean-
ingful improvement in treatment satisfaction with 
teriflunomide versus subcutaneous IFNB-1A in pa-
tients with relapsing ms results from Tenere. Value 
Health 2014;17 (7):A403. 
      N Exclude 
 
Abstract 
 
 
Mikol D, Freedman MS, Goldman MD, Hartung HP, 
Havrdova E, Jeffery D, et al. Correlations between pa-
tient-reported ambulatory function (MSWS-12) and 
objective disability measurements in SPMS: Analysis 
of ASCEND baseline data. Mult Scler 2014;1):408.  
      N Exclude 
 
Abstract 
Mikol D, Freedman MS, Goldman MD, Hartung HP, 
Havrdova E, Jeffery D, et al. Ascend study of natali-
zumab efficacy on disability in patients with second-
ary progressive multiple sclerosis (SPMS): Baseline 
demographics and disease characteristics. Ann Neurol 
2013;74:S59-S60.  
      N Exclude 
 
Abstract 
Mikol D, Freedman MS, Goldman MD, Hartung HP, 
Havrdova E, Jeffery D, et al. ASCEND study of natali-
zumab efficacy on reducing disability in patients with 
secondary progressive multiple sclerosis: Baseline de-
mographics and disease characteristics. Mult Scler 
2013;1):507-508. 
      N Exclude 
 
Abstract 
Miller A, Kappos L, Comi G, Confavreux C, Freedman 
M, Olsson T. Teriflunomide efficacy and safety in pa-
tients with relapsing multiple sclerosis: Results from 
tower, a second, pivotal, phase 3 placebo-controlled 
study.  2013;80. 
      N Exclude 
 
Abstract 
Miller A, Wolinsky J, Kappos L, Comi G, Freedman M, 
Olsson T, et al. Topic: Efficacy and safety of once-daily 
oral teriflunomide in patients with first clinical epi-
sode consistent with multiple sclerosis. Neurology 
2014;1). 
      N Exclude 
 
Abstract 
Miller A, Wolinsky J, Kappos L, Comi G, Freedman 
MS, Olsson T, et al. TOPIC main outcomes: Efficacy 
and safety of once-daily oral teriflunomide in patients 
with clinically isolated syndrome. Mult Scler 
2013;1):25-26. 
      N Exclude 
 
Abstract 
Miller AE, Wolinsky JS, Kappos L, Comi G, Freedman 
MS, Olsson TP, et al. Oral teriflunomide for patients 
with a first clinical episode suggestive of multiple scle-
rosis (TOPIC): A randomised, double-blind, placebo-
controlled, phase 3 trial. The Lancet Neurology 
2014;13(10):977-986. 
Y       Exclude 
 
TOPIC 
 
Not RRMS pa-
tients 
Montalban X, Barkhof F, Comi G, Hartung HP, Kap-
pos L, Khatri B, et al. Long term efficacy of fingolimod 
in patients with relapsing-remitting multiple sclerosis 
previously treated with interferon b-1a or disease 
modifying therapies: A post hoc analysis of the 
TRANSFORMS 4.5 year extension study. J Neurol 
2013;260:S124-S125. 
      N Exclude 
 
Abstract 
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 CIS Publica-
tion 
date 
P I C O S Exclu-
sion/com-
ments 
Moses H, Freedman M, Kappos L, Miller A, Olsson T, 
Wolinsky J. Pre-DEFINEd subgroups analyses of 
tower, a placebo-controlled phase 3 trial of terifluno-
mide in patients with relapsing multiple sclerosis.  
2013;80.  
      N Exclude 
 
Abstract 
Nabavi M, Abolfazli R, Beladimoghadam N, Shahriari 
S, Hatami-Sadabadi F, Shati M, et al. A randomized 
double blind non-inferiority study of efficacy, safety 
and tolerability of actorif versus rebif in patients with 
relapsing remitting ms. Neuroepidemiology 2013;41 
(3-4):259. 
      N Exclude 
 
Abstract 
 
 
Nagtegaal GJA, Pohl C, Wattjes MP, Hulst HE, Freed-
man MS, Hartung HP, et al. Interferon beta-1b re-
duces black holes in a randomised trial of clinically 
isolated syndrome. Mult Scler 2014;20(2):234-242. 
Y  N   N  Exclude 
 
Not RRMS pa-
tients 
O'Connor P, Lublin F, Wolinsky J, Comi G, Confa-
vreux C, Freedman M. Teriflunomide reduces relapse-
related sequelae, hospitalizations and corticosteroid 
use: A post-HOC analysis of the phase 3 tower study.  
2013;80. 
      N Exclude 
 
Abstract 
Olsson T, Comi G, Freedman M, Miller A, Wolinsky J, 
Truffinet P, et al. Patients free of clinical ms activity in 
temso and tower: Pooled analyses of two phase 3 pla-
cebo-controlled trials. Neurology 2014;1). 
      N Exclude 
 
Abstract 
Pakpoor J, Disanto G, Altmann DR, Pavitt S, Turner 
B, Calado-Marta M, et al. Is there an increased cancer 
risk in people with relapsing multiple sclerosis taking 
cladribine? Mult Scler 2014;1):455. 
      N Exclude 
 
Abstract 
Phillips JT, Fox RJ, Gold R, Havrdova E, Kappos L, 
Raghupathi K, et al. An integrated analysis of safety 
and tolerability of BG-12 (dimethyl fumarate) in pa-
tients with relapsing-remitting multiple sclerosis from 
phase 2 and 3 placebo-controlled studies. J Neurol 
2013;260:S75. 
      N Exclude 
 
Abstract 
Stefano N, Comi G, Kappos L, Freedman MS, Polman 
CH, Uitdehaag BMJ, et al. Efficacy of subcutaneous 
interferon beta-1a on MRI outcomes in a randomised 
controlled trial of patients with clinically isolated syn-
dromes. J Neurol Neurosurg Psychiatry 
2014;85(6):647-653. 
Y  N     Exclude 
 
Not RRMS pa-
tients 
Svenningsson A, Sundstrom P, Salzer J, Vagberg M. 
MS disease activity in RESTORE: a randomized 24-
week natalizumab treatment interruption study. Neu-
rology 2014;83(22):2099-2100. 
      N Exclude 
 
 
Tenenbaum N, Schofield L, Meng X, Kern R. The pre-
ferms study: Evaluating real-world patient retention 
on oral fingolimod compared with injectable disease 
modifying therapies in relapsing-remitting multiple 
sclerosis. Neurology 2014;1). 
      N Exclude 
 
Abstract 
Tolley K, Hutchinson M, Pachner A, Kinter ET, Sper-
ling B, You X, et al. Systematic literature review and 
network meta-analysis of peg-interferon beta-1a and 
injectable therapies for relapsing-remitting multiple 
sclerosis. Mult Scler 2014;1):209. 
      N Exclude 
 
Abstract 
Tunde C. [Natalizumab retreatment: effectiveness and 
long-term safety in multiple sclerosis in the STRATA 
study]. Ideggyogyaszati Szemle 2014;67(7-8):277-279. 
    N   Exclude 
 
Everybody get 
Natalizumab 
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 CIS Publica-
tion 
date 
P I C O S Exclu-
sion/com-
ments 
Twyman C, Montalban X, Arnold D, Cohen J, Coles A, 
Confavreux C, et al. Relapse outcomes with 
alemtuzumab vs IFNB-1A in active relapsing-remit-
ting multiple sclerosis patients who experienced dis-
ease activity while on prior therapy (CARE-MS II). 
Neurology 2013;80 (1 MeetingAbstracts). 
      N Exclude 
 
Abstract 
White JT, Kieseier BC, Newsome SD, Zhu Y, Cui Y, 
Seddighzadeh A, et al. Immunogenicity with peg-in-
terferon beta-1a in patients with relapsing-remitting 
multiple sclerosis: 2-year data from the randomised 
phase 3, multicentre ADVANCE study in relapsing-re-
mitting multiple sclerosis. J Neurol 2014;261:S234. 
      N Exclude 
 
Abstract 
Wolinsky JS, Narayana PA, Nelson F, Datta S, O'Con-
nor P, Confavreux C, et al. Magnetic resonance imag-
ing outcomes from a phase III trial of teriflunomide. 
Mult Scler 2013;19(10):1310-1319. 
     N  Exclude 
 
Not our out-
come 
Wolinsky JS, Truffinet P, Bauer D, Miller AE. Efficacy 
of teriflunomide in patients with early stage MS: Anal-
ysis of the TOPIC study using 2010 McDonald diag-
nostic criteria. Mult Scler 2014;1):109-110. 
      N Exclude 
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Appendix 4 Ongoing studies and other potential relevant litera-
ture 
Below is the list of randomized control trials identifiend on the WHO ICTRP website. 
Due to the lack of information, we could not determine whether these studies fit our 
criteria of selection. These studies may add to the evidence.  
 
1) Retinal Nerve Fiber Layer (RNFL) as measured by Optical Coherence Tomography 
(OCT) to Depict axonal loss in Early RRMS treated with difFEreNt dosage of subCu-
taneous IFN bEta 1a - DEFENCE 
http://apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2009-015007-97-IT 
 
3) Long-Term Safety and Efficacy Study of Oral BG00012 Monotherapy in Relapsing-
Remitting Multiple Sclerosis 
http://apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2008-004753-14-BE 
 
4) ADVANCED MRI STUDY ON INFLAMMATORY AND DEGENRATIVE DAMAGE 
IN MULTIPLE SCLEROSIS - RMaIDSM 
http://apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2008-007162-32-IT 
 
5) A Phase 3 Randomized, Rater- and Dose-Blinded Study Comparing Two Annual 
Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly 
Subcutaneous Interferon Beta-1a (Rebif®) in Patients with Relapsing-Remitting 
Multiple Scleroris Who Have Relapsed On Therapy - CARE MS-II  
http://apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007-001162-32-GB 
 
6) Long-term extension of the multinational, double-blind, placebo controlled study 
EFC6049 (HMR1726D/3001) to document the safety of two doses of teriflunomide (7 
and 14 mg) in patients with multiple sclerosis with relapses  
http://apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2006-003361-14-FI 
 
7) A pilot multi-centre randomised controlled trial of sequential treatment with Mito-
xantrone and Glatiramer Acetate vs. Interferon Beta-1a in early active relapsing re-
mitting Multiple Sclerosis 
http://apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2004-004903-39-GB 
8) Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing 
Forms of Multiple Sclerosis Receiving Tecfidera  
http://apps.who.int/trialsearch/Trial2.aspx?TrialID=NCT02410278 
 
9) Impact of Natalizumab versus Fingolimod on Central Nervous System (CNS) Tis-
sue Damage and Recovery in Active Relapsing-Remitting Multiple Sclerosis (RRMS) 
Subjects  
http://apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2013-004622-29-IT 
10) A study to evaluate the effect of aspirin on flushing in patients with RRMS treated 
with Tecfidera 
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http://apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2013-001895-40-IE 
 
11) Study to investigate the ability of a blood-derived score to select patients with re-
lapsing multiple sclerosis who benefit from treatment with human immune globulin 
http://apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2012-005086-12-AT 
 
12) MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Co-
paxone  
http://apps.who.int/trialsearch/Trial2.aspx?TrialID=NCT01633112 
 
13) A Study of Ocrelizumab in Comparison With Interferon Beta-1a in Patients With 
Relapsing Multiple Sclerosis 
http://apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2010-020315-36-BE 
 
14) A 18-month, open-label, rater-blinded, randomized, multi-center, active-con-
trolled, parallel-group pilot study to assess efficacy and safety of fingolimod (Gilenya) 
in comparison to interferon beta-1b in treating the cognitive symptoms associated to 
relapsing-remitting multiple sclerosis and to assess possible relationship of these ef-
fects to regional brain atrophy 
http://apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2010-023023-19-IT 
 
15) A Study of Ocrelizumab in Comparison With Interferon Beta-1a in Patients With 
Relapsing Multiple Sclerosis 
http://apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2010-020337-99-GB 
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Appendix 5: GRADE evaluation of comparisons 
Interferon beta-1a 22 mcg compared to Placebo for RRMS  
 
Quality assessment № of patients Effect 
Quality Im-portance № of stud-
ies 
Study 
de-
sign 
Risk 
of 
bias 
Incon-
sistency 
Indi-
rectn
ess 
Impre-
cision 
Other 
con-
sider-
ations 
Inter-
feron 
beta-1a 
22 mcg 
Pla-
cebo 
Rela-
tive 
(95% 
CI) 
Absolute 
(95% CI) 
Annualised relapse rate 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  1 
not 
seri-
ous  2 
seri-
ous  3 
none  -/189  -/187  RR 
0.69 
(0.57 
to 
0.83)  
0 fewer per 1000 (from 0 fewer to 0 
fewer)  ⨁⨁⨁◯ 
MODER-
ATE  1 2 3 
 
Disease Progression 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  1 
not 
seri-
ous  2 
very 
seri-
ous  4 5 
none  64/189 
(33.9%)  
77/187 
(41.2%)  
RR 
0.84 
(0.61 
to 
1.19)  
66 fewer per 1000 (from 78 more to 
161 fewer)  ⨁⨁◯◯ 
LOW  1 2 4 5 
 
Withdrawal due to adverse events 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  1 
not 
seri-
ous  2 
very 
seri-
ous  4 5 
none  6/189 
(3.2%)  
2/187 
(1.1%)  
RR 
1.68 
(0.50 
to 
5.98)  
7 more per 1000 (from 5 fewer to 53 
more)  ⨁⨁◯◯ 
LOW  1 2 4 5 
 
MD – mean difference, RR – relative risk  
1. Only one study, not possible to check for inconsistency 
2. Patients were treatment naïve.  
3. For continuous outcomes, a sample size of approximately 400 may not be sufficient to insure prognostic balance (ref GRADE 6 paper). 
4. The confidence interval (CI) includes both no effect, and the 25% threshold for appreciable benefit or harm. This corresponds to a CI that includes 
both 1.00, and 0.75 or 1.25 (ref GRADE 6 paper). 
5. Optimal information size (OIS) not met. For example, at least 200 events are required to meet OIS, based on a 25% relative risk reduction and 
control group risks of approximately 50% or greater (ref GRADE 6 paper). 
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Interferon beta-1a 30 mcg compared to Placebo for RRMS  
  
Quality assessment № of patients Effect 
Quality Im-portance № of stud-
ies 
Study 
de-
sign 
Risk 
of 
bias 
Incon-
sistency 
Indi-
rectn
ess 
Impre-
cision 
Other 
con-
sider-
ations 
Inter-
feron 
beta-1a 
30 mcg 
Pla-
cebo 
Rela-
tive 
(95% 
CI) 
Absolute 
(95% CI) 
Annualised relapse rate 
3  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  
not 
seri-
ous  1 
not se-
rious  
none  -/659  -/647  RR 
0.76 
(0.65 
to 
0.89)  
0 fewer per 1000 (from 0 fewer to 0 
fewer)  ⨁⨁⨁⨁ 
HIGH  1  
Disease Progression 
2  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  
not 
seri-
ous  1 
seri-
ous  2 
none  70/605 
(11.6%)  
96/593 
(16.2%)  
RR 
0.68 
(0.50 
to 
0.95)  
52 fewer per 1000 (from 8 fewer to 
81 fewer)  ⨁⨁⨁◯ 
MODER-
ATE  1 2 
 
Withdrawal due to adverse events 
3  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  
not 
seri-
ous  1 
very 
seri-
ous  2 3 
none  34/659 
(5.2%)  
21/647 
(3.2%)  
RR 
1.73 
(0.82 
to 
3.87)  
24 more per 1000 (from 6 fewer to 
93 more)  ⨁⨁◯◯ 
LOW  1 2 3 
 
MD – mean difference, RR – relative risk  
1. In the minor contributing study patients were treatment naïve.  
2. Optimal information size (OIS) not met. For example, at least 200 events are required to meet OIS, based on a 25% relative risk reduction and 
control group risks of approximately 50% or greater (ref GRADE 6 paper). 
3. The confidence interval (CI) includes both no effect, and the 25% threshold for appreciable benefit or harm. This corresponds to a CI that includes 
both 1.00, and 0.75 or 1.25 (ref GRADE 6 paper). 
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Interferon beta-1a 44 mcg compared to Placebo for RRMS  
  
Quality assessment № of patients Effect 
Quality Im-portance № of stud-
ies 
Study 
de-
sign 
Risk 
of 
bias 
Incon-
sistency 
Indi-
rectn
ess 
Impre-
cision 
Other 
con-
sider-
ations 
Inter-
feron 
beta-1a 
44 mcg 
Pla-
cebo 
Rela-
tive 
(95% 
CI) 
Absolute 
(95% CI) 
Annualised relapse rate 
2  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  
not 
seri-
ous  1 
not se-
rious  
none  -/204  -/247  RR 
0.67 
(0.54 
to 
0.80)  
0 fewer per 1000 (from 0 fewer to 0 
fewer)  ⨁⨁⨁⨁ 
HIGH  1  
Disease Progression 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  2 
not 
seri-
ous  3 
very 
seri-
ous  4 5 
none  54/184 
(29.3%)  
77/187 
(41.2%)  
RR 
0.70 
(0.48 
to 
1.04)  
124 fewer per 1000 (from 16 more 
to 214 fewer)  ⨁⨁◯◯ 
LOW  2 3 4 5 
 
Withdrawal due to adverse events 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  2 
not 
seri-
ous  3 
very 
seri-
ous  4 6 
none  9/184 
(4.9%)  
2/187 
(1.1%)  
RR 
5.32 
(1.09 
to 
41.63)  
46 more per 1000 (from 1 more to 
435 more)  ⨁⨁◯◯ 
LOW  2 3 4 6 
 
MD – mean difference, RR – relative risk  
1. In the major contributing study patients were treatment naïve.  
2. Only one study, not possible to check for inconsistency 
3. Patients were treatment naïve.  
4. Optimal information size (OIS) not met. For example, at least 200 events are required to meet OIS, based on a 25% relative risk reduction and 
control group risks of approximately 50% or greater (ref GRADE 6 paper). 
5. The confidence interval (CI) includes both no effect, and the 25% threshold for appreciable benefit or harm. This corresponds to a CI that includes 
both 1.00, and 0.75 or 1.25 (ref GRADE 6 paper). 
6. The effect estimate and the confidence interval are not robust. Minor variations in number of events would change the results. 
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Glatiramer acetate 20 mg compared to Placebo for RRMS  
  
Quality assessment № of patients Effect 
Quality Im-portance № of stud-
ies 
Study 
de-
sign 
Risk 
of 
bias 
Incon-
sistency 
Indi-
rectn
ess 
Impre-
cision 
Other 
con-
sider-
ations 
Glati-
ramer 
acetate 
20 mg 
Pla-
cebo 
Rela-
tive 
(95% 
CI) 
Absolute 
(95% CI) 
Annualised relapse rate 
3  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  
not 
seri-
ous  1 
not se-
rious  
none  -/595  -/609  RR 
0.70 
(0.60 
to 
0.82)  
0 fewer per 1000 (from 0 fewer to 0 
fewer)  ⨁⨁⨁⨁ 
HIGH  1  
Disease Progression 
2  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  
not 
seri-
ous  2 
very 
seri-
ous  3 4 
none  83/475 
(17.5%)  
93/489 
(19.0%)  
RR 
0.88 
(0.61 
to 
1.21)  
23 fewer per 1000 (from 40 more to 
74 fewer)  ⨁⨁◯◯ 
LOW  2 3 4 
 
Withdrawal due to adverse events 
3  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  
not 
seri-
ous  1 
very 
seri-
ous  3 4 
none  43/595 
(7.2%)  
41/609 
(6.7%)  
RR 
1.22 
(0.64 
to 
2.66)  
15 more per 1000 (from 24 fewer to 
112 more)  ⨁⨁◯◯ 
LOW  1 3 4 
 
MD – mean difference, RR – relative risk  
1. In the minor contributing studies, patients were treatment naïve or had an unclear treatment history.  
2. In the minor contributing study patients were treatment naïve.  
3. Optimal information size (OIS) not met. For example, at least 200 events are required to meet OIS, based on a 25% relative risk reduction and 
control group risks of approximately 50% or greater (ref GRADE 6 paper). 
4. The confidence interval (CI) includes both no effect, and the 25% threshold for appreciable benefit or harm. This corresponds to a CI that includes 
both 1.00, and 0.75 or 1.25 (ref GRADE 6 paper). 
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Glatiramer acetate 40 mg compared to Placebo for RRMS  
  
Quality assessment № of patients Effect 
Quality Im-portance № of stud-
ies 
Study 
de-
sign 
Risk 
of 
bias 
Incon-
sistency 
Indi-
rectn
ess 
Impre-
cision 
Other 
con-
sidera-
tions 
Glati-
ramer 
acetate 
40 mg 
Pla-
cebo 
Rela-
tive 
(95% 
CI) 
Absolute 
(95% CI) 
Annualised relapse rate 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  1 
not 
seri-
ous  
not se-
rious  
none  -/943  -/461  RR 
0.66 
(0.52 
to 
0.82)  
0 fewer per 1000 (from 0 fewer to 0 
fewer)  ⨁⨁⨁⨁ 
HIGH  1  
Withdrawal due to adverse events 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  1 
not 
seri-
ous  
very 
seri-
ous  2 3 
none  29/943 
(3.1%)  
6/461 
(1.3%)  
RR 
2.50 
(0.86 
to 
8.29)  
20 more per 1000 (from 2 fewer to 
95 more)  ⨁⨁◯◯ 
LOW  1 2 3 
 
MD – mean difference, RR – relative risk  
1. Only one study, not possible to check for inconsistency 
2. Optimal information size (OIS) not met. For example, at least 200 events are required to meet OIS, based on a 25% relative risk reduction and 
control group risks of approximately 50% or greater (ref GRADE 6 paper). 
3. The confidence interval (CI) includes both no effect, and the 25% threshold for appreciable benefit or harm. This corresponds to a CI that includes 
both 1.00, and 0.75 or 1.25 (ref GRADE 6 paper). 
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Dimethyl fumarate 240 mg two times daily compared to Placebo for 
RRMS  
  
Quality assessment № of patients Effect 
Quality Im-portance № of stud-
ies 
Study 
de-
sign 
Risk 
of 
bias 
Incon-
sistency 
Indi-
rect
ness 
Impre-
cision 
Other 
con-
sider-
ation
s 
Dimethyl 
fumarate 
240 mg 
two times 
daily 
Pla-
cebo 
Rela-
tive 
(95% 
CI) 
Absolute 
(95% CI) 
Annualised relapse rate 
2  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  
not 
seri-
ous  
not se-
rious  
none  -/769  -/771  RR 
0.50 
(0.42 
to 
0.60)  
0 fewer per 1000 (from 0 fewer to 0 
fewer)  ⨁⨁⨁⨁ 
HIGH   
Disease Progression 
2  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  
not 
seri-
ous  
not se-
rious  
none  113/768 
(14.7%)  
172/771 
(22.3%)  
RR 
0.65 
(0.49 
to 
0.85)  
78 fewer per 1000 (from 33 fewer to 
114 fewer)  ⨁⨁⨁⨁ 
HIGH   
Withdrawal due to adverse events 
2  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  
not 
seri-
ous  
very 
seri-
ous  1 2 
none  109/769 
(14.2%)  
90/771 
(11.7%)  
RR 
1.24 
(0.74 
to 
2.13)  
28 more per 1000 (from 30 fewer to 
132 more)  ⨁⨁◯◯ 
LOW  1 2 
 
MD – mean difference, RR – relative risk  
1. Optimal information size (OIS) not met. For example, at least 200 events are required to meet OIS, based on a 25% relative risk reduction and 
control group risks of approximately 50% or greater (ref GRADE 6 paper). 
2. The confidence interval (CI) includes both no effect, and the 25% threshold for appreciable benefit or harm. This corresponds to a CI that includes 
both 1.00, and 0.75 or 1.25 (ref GRADE 6 paper). 
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Dimethyl fumarate 240 mg three times daily compared to Placebo for 
RRMS  
  
Quality assessment № of patients Effect 
Quality Im-portance № of stud-
ies 
Study 
de-
sign 
Risk 
of 
bias 
Incon-
sistency 
Indi-
rect
ness 
Im-
preci-
sion 
Other 
con-
sider-
ation
s 
Dimethyl 
fumarate 
240 mg 
three 
times 
daily 
Pla-
cebo 
Rela-
tive 
(95% 
CI) 
Absolute 
(95% CI) 
Annualised relapse rate 
2  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  
not 
seri-
ous  
not 
seri-
ous  
none  -/761  -/771  RR 
0.50 
(0.42 
to 
0.60)  
0 fewer per 1000 (from 0 fewer to 0 
fewer)  ⨁⨁⨁⨁ 
HIGH   
Disease Progression 
2  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  
not 
seri-
ous  
not 
seri-
ous  
none  120/761 
(15.8%)  
172/771 
(22.3%)  
RR 
0.68 
(0.52 
to 
0.89)  
71 fewer per 1000 (from 25 fewer to 
107 fewer)  ⨁⨁⨁⨁ 
HIGH   
Withdrawal due to adverse events 
2  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  
not 
seri-
ous  
very 
seri-
ous  1 2 
none  109/760 
(14.3%)  
93/771 
(12.1%)  
RR 
1.25 
(0.74 
to 
2.13)  
30 more per 1000 (from 31 fewer to 
136 more)  ⨁⨁◯◯ 
LOW  1 2 
 
MD – mean difference, RR – relative risk  
1. Optimal information size (OIS) not met. For example, at least 200 events are required to meet OIS, based on a 25% relative risk reduction and 
control group risks of approximately 50% or greater (ref GRADE 6 paper). 
2. The confidence interval (CI) includes both no effect, and the 25% threshold for appreciable benefit or harm. This corresponds to a CI that includes 
both 1.00, and 0.75 or 1.25 (ref GRADE 6 paper). 
  
 
 
 
 
178 
Teriflunomide oral 7 mg compared to Placebo for RRMS  
  
Quality assessment № of patients Effect 
Quality Im-portance № of stud-
ies 
Study 
de-
sign 
Risk 
of 
bias 
Incon-
sistency 
Indi-
rectn
ess 
Impre-
cision 
Other 
con-
sider-
ations 
Teri-
fluno-
mide 
oral 7 
mg 
Pla-
cebo 
Rela-
tive 
(95% 
CI) 
Absolute 
(95% CI) 
Annualised relapse rate 
3  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  
not 
seri-
ous  1 
not se-
rious  
none  -/802  -/806  RR 
0.73 
(0.64 
to 
0.84)  
0 fewer per 1000 (from 0 fewer to 0 
fewer)  ⨁⨁⨁⨁ 
HIGH  1  
Disease Progression 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  2 
not 
seri-
ous  
very 
seri-
ous  3 4 
none  79/365 
(21.6%)  
99/363 
(27.3%)  
RR 
0.80 
(0.55 
to 
1.13)  
55 fewer per 1000 (from 35 more to 
123 fewer)  ⨁⨁◯◯ 
LOW  2 3 4 
 
Withdrawal due to adverse events 
3  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  
not 
seri-
ous  1 
very 
seri-
ous  3 4 
none  97/802 
(12.1%)  
57/806 
(7.1%)  
RR 
1.54 
(0.89 
to 
2.51)  
38 more per 1000 (from 8 fewer to 
107 more)  ⨁⨁◯◯ 
LOW  1 3 4 
 
MD – mean difference, RR – relative risk  
1. In the minor contributing study patients were treatment naïve.  
2. Only one study, not possible to check for inconsistency 
3. Optimal information size (OIS) not met. For example, at least 200 events are required to meet OIS, based on a 25% relative risk reduction and 
control group risks of approximately 50% or greater (ref GRADE 6 paper). 
4. The confidence interval (CI) includes both no effect, and the 25% threshold for appreciable benefit or harm. This corresponds to a CI that includes 
both 1.00, and 0.75 or 1.25 (ref GRADE 6 paper). 
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Teriflunomide oral 14mg compared to Placebo for RRMS  
  
Quality assessment № of patients Effect 
Quality Im-portance № of stud-
ies 
Study 
de-
sign 
Risk 
of 
bias 
Incon-
sistency 
Indi-
rectn
ess 
Impre-
cision 
Other 
con-
sider-
ations 
Teri-
fluno-
mide 
oral 
14mg 
Pla-
cebo 
Rela-
tive 
(95% 
CI) 
Absolute 
(95% CI) 
Annualised relapse rate 
3  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  
not 
seri-
ous  1 
not se-
rious  
none  -/824  -/806  RR 
0.67 
(0.58 
to 
0.78)  
0 fewer per 1000 (from 0 fewer to 0 
fewer)  ⨁⨁⨁⨁ 
HIGH  1  
Disease Progression 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  2 
not 
seri-
ous  
very 
seri-
ous  3 4 
none  72/358 
(20.1%)  
99/363 
(27.3%)  
RR 
0.73 
(0.51 
to 
1.05)  
74 fewer per 1000 (from 14 more to 
134 fewer)  ⨁⨁◯◯ 
LOW  2 3 4 
 
Withdrawal due to adverse events 
3  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  
not 
seri-
ous  1 
very 
seri-
ous  3 5 
none  100/824 
(12.1%)  
57/806 
(7.1%)  
RR 
1.70 
(1.02 
to 
3.01)  
50 more per 1000 (from 1 more to 
142 more)  ⨁⨁◯◯ 
LOW  1 3 5 
 
MD – mean difference, RR – relative risk  
1. In the minor contributing study patients were treatment naïve.  
2. Only one study, not possible to check for inconsistency 
3. Optimal information size (OIS) not met. For example, at least 200 events are required to meet OIS, based on a 25% relative risk reduction and 
control group risks of approximately 50% or greater (ref GRADE 6 paper). 
4. The confidence interval (CI) includes both no effect, and the 25% threshold for appreciable benefit or harm. This corresponds to a CI that includes 
both 1.00, and 0.75 or 1.25 (ref GRADE 6 paper). 
5. The effect estimate and the confidence interval are not robust. Minor variations in number of events would change the results. 
  
 
 
 
 
180 
Fingolimod oral 0.5 mg compared to Placebo for RRMS  
  
Quality assessment № of patients Effect 
Quality Im-portance № of stud-
ies 
Study 
de-
sign 
Risk 
of 
bias 
Incon-
sistency 
Indi-
rectn
ess 
Impre-
cision 
Other 
con-
sider-
ations 
Fin-
golimod 
oral 0.5 
mg 
Pla-
cebo 
Rela-
tive 
(95% 
CI) 
Absolute 
(95% CI) 
Annualised relapse rate 
3  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  
not 
seri-
ous  
not se-
rious  
none  -/840  -/830  RR 
0.49 
(0.41 
to 
0.57)  
0 fewer per 1000 (from 0 fewer to 0 
fewer)  ⨁⨁⨁⨁ 
HIGH   
Disease Progression 
2  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  
not 
seri-
ous  
not se-
rious  
none  124/783 
(15.8%)  
164/773 
(21.2%)  
RR 
0.75 
(0.56 
to 
0.98)  
53 fewer per 1000 (from 4 fewer to 
93 fewer)  ⨁⨁⨁⨁ 
HIGH   
Withdrawal due to adverse events 
3  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  
not 
seri-
ous  
very 
seri-
ous  1 2 
none  104/840 
(12.4%)  
72/830 
(8.7%)  
RR 
1.49 
(0.86 
to 
2.50)  
43 more per 1000 (from 12 fewer to 
130 more)  ⨁⨁◯◯ 
LOW  1 2 
 
MD – mean difference, RR – relative risk  
1. Optimal information size (OIS) not met. For example, at least 200 events are required to meet OIS, based on a 25% relative risk reduction and 
control group risks of approximately 50% or greater (ref GRADE 6 paper). 
2. The confidence interval (CI) includes both no effect, and the 25% threshold for appreciable benefit or harm. This corresponds to a CI that includes 
both 1.00, and 0.75 or 1.25 (ref GRADE 6 paper). 
  
 
 
 
 
181 
Fingolimod oral 1.25 mg compared to Placebo for RRMS  
  
Quality assessment № of patients Effect 
Quality Im-portance № of stud-
ies 
Study 
de-
sign 
Risk 
of 
bias 
Incon-
sistency 
Indi-
rectn
ess 
Im-
pre-
cisio
n 
Other 
con-
sider-
ations 
Fin-
golimod 
oral 1.25 
mg 
Placebo 
Rela-
tive 
(95% 
CI) 
Absolute 
(95% CI) 
Annualised relapse rate 
3  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  
not 
seri-
ous  
not 
seri-
ous  
none  -/853  -/830  RR 
0.43 
(0.37 
to 
0.51)  
0 fewer per 1000 (from 0 fewer to 0 
fewer)  ⨁⨁⨁⨁ 
HIGH   
Disease Progression 
2  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  
not 
seri-
ous  
not 
seri-
ous  
none  119/799 
(14.9%)  
164/773 
(21.2%)  
RR 
0.70 
(0.52 
to 
0.92)  
64 fewer per 1000 (from 17 fewer to 
102 fewer)  ⨁⨁⨁⨁ 
HIGH   
Withdrawal due to adverse events 
3  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  
not 
seri-
ous  
seri-
ous  1 
none  139/853 
(16.3%)  
72/830 
(8.7%)  
RR 
1.93 
(1.18 
to 
3.14)  
81 more per 1000 (from 16 more to 
186 more)  ⨁⨁⨁◯ 
MODERATE  1 
 
MD – mean difference, RR – relative risk  
1. Optimal information size (OIS) not met. For example, at least 200 events are required to meet OIS, based on a 25% relative risk reduction and 
control group risks of approximately 50% or greater (ref GRADE 6 paper). 
  
 
 
 
 
182 
Peg-interferon beta-1a 125 mcg once every two weeks compared to Pla-
cebo for RRMS  
  
Quality assessment № of patients Effect 
Quality Im-portance № of stud-
ies 
Study 
de-
sign 
Risk 
of 
bias 
Incon-
sistency 
Indi-
rect
ness 
Impre-
cision 
Other 
con-
sider-
ations 
Peg-in-
terferon 
beta-1a 
125 mcg 
once 
every 
two 
weeks 
Pla-
cebo 
Rela-
tive 
(95% 
CI) 
Absolute 
(95% CI) 
Annualised relapse rate 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  1 
not 
seri-
ous  
not se-
rious  
none  -/512  -/500  RR 
0.65 
(0.49 
to 
0.85)  
0 fewer per 1000 (from 0 fewer to 0 
fewer)  ⨁⨁⨁⨁ 
HIGH  1  
Disease Progression 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  1 
not 
seri-
ous  
very 
seri-
ous  2 3 
none  31/512 
(6.1%)  
50/500 
(10.0%)  
RR 
0.61 
(0.36 
to 
0.98)  
39 fewer per 1000 (from 2 fewer to 
64 fewer)  ⨁⨁◯◯ 
LOW  1 2 3 
 
Withdrawal due to adverse events 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  1 
not 
seri-
ous  
very 
seri-
ous  2 4 
none  25/512 
(4.9%)  
7/500 
(1.4%)  
RR 
3.57 
(1.27 
to 
11.14)  
36 more per 1000 (from 4 more to 
142 more)  ⨁⨁◯◯ 
LOW  1 2 4 
 
MD – mean difference, RR – relative risk  
1. Only one study, not possible to check for inconsistency 
2. Optimal information size (OIS) not met. For example, at least 200 events are required to meet OIS, based on a 25% relative risk reduction and 
control group risks of approximately 50% or greater (ref GRADE 6 paper). 
3. The effect estimate and the confidence interval are not robust. Minor variations in number of events would change the results. 
4. The effect estimate and the confidence interval are not robust. Minor variations in number of events would change the results. 
  
 
 
 
 
183 
Peg-interferon beta-1a 125 mcg once every four weeks compared to Pla-
cebo for RRMS  
  
Quality assessment № of patients Effect 
Quality Im-portance № of stud-
ies 
Study 
de-
sign 
Risk 
of 
bias 
Incon-
sistency 
Indi-
rect
ness 
Impre-
cision 
Other 
con-
sider-
ations 
Peg-in-
terferon 
beta-1a 
125 mcg 
once 
every 
four 
weeks 
Pla-
cebo 
Rela-
tive 
(95% 
CI) 
Absolute 
(95% CI) 
Annualised relapse rate 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  1 
not 
seri-
ous  
not se-
rious  
none  -/500  -/500  RR 
0.73 
(0.56 
to 
0.95)  
0 fewer per 1000 (from 0 fewer to 0 
fewer)  ⨁⨁⨁⨁ 
HIGH  1  
Disease Progression 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  1 
not 
seri-
ous  
very 
seri-
ous  2 3 
none  31/500 
(6.2%)  
50/500 
(10.0%)  
RR 
0.62 
(0.38 
to 
1.01)  
38 fewer per 1000 (from 1 more to 
62 fewer)  ⨁⨁◯◯ 
LOW  1 2 3 
 
Withdrawal due to adverse events 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  1 
not 
seri-
ous  
very 
seri-
ous  2 4 
none  24/500 
(4.8%)  
7/500 
(1.4%)  
RR 
3.47 
(1.25 
to 
10.90)  
35 more per 1000 (from 4 more to 
139 more)  ⨁⨁◯◯ 
LOW  1 2 4 
 
MD – mean difference, RR – relative risk  
1. Only one study, not possible to check for inconsistency 
2. Optimal information size (OIS) not met. For example, at least 200 events are required to meet OIS, based on a 25% relative risk reduction and 
control group risks of approximately 50% or greater (ref GRADE 6 paper). 
3. The confidence interval (CI) includes both no effect, and the 25% threshold for appreciable benefit or harm. This corresponds to a CI that includes 
both 1.00, and 0.75 or 1.25 (ref GRADE 6 paper). 
4. The effect estimate and the confidence interval are not robust. Minor variations in number of events would change the results 
  
 
 
 
 
184 
Natalizumab 300 mg intravenous every four weeks compared to Placebo 
for RRMS  
  
Quality assessment № of patients Effect 
Quality Im-portance № of stud-
ies 
Study 
de-
sign 
Risk 
of 
bias 
Incon-
sistency 
Indi-
rectn
ess 
Impre-
cision 
Other 
con-
sider-
ations 
Natali-
zumab 
300 mg 
intrave-
nous 
every 
four 
weeks 
Pla-
cebo 
Rela-
tive 
(95% 
CI) 
Absolute 
(95% CI) 
Annualised relapse rate 
2  ran-
domis
ed tri-
als  
not 
seri-
ous  
serious  1 not 
seri-
ous  2 
not se-
rious  
none  -/673  -/358  RR 
0.30 
(0.25 
to 
0.36)  
0 fewer per 1000 (from 0 fewer to 0 
fewer)  ⨁⨁⨁◯ 
MODER-
ATE  1 2 
 
Disease Progression 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  3 
not 
seri-
ous  4 
seri-
ous  5 
none  107/627 
(17.1%)  
91/315 
(28.9%)  
RR 
0.59 
(0.42 
to 
0.84)  
118 fewer per 1000 (from 46 fewer 
to 168 fewer)  ⨁⨁⨁◯ 
MODER-
ATE  3 4 5 
 
Withdrawal due to adverse events 
2  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  
not 
seri-
ous  2 
very 
seri-
ous  5 6 
none  38/673 
(5.6%)  
15/358 
(4.2%)  
RR 
1.22 
(0.50 
to 
2.74)  
9 more per 1000 (from 21 fewer to 
73 more)  ⨁⨁◯◯ 
LOW  2 5 6 
 
MD – mean difference, RR – relative risk  
1. Heterogeneity may be explained by differences in study setting. One study compared natalizumab with placebo over a two years period while the 
other tested treatment interruption in natalizumab users 
2. One study compared natalizumab with placebo over a two years period while the other tested treatment interruption in natalizumab users 
3. Only one study, not possible to check for inconsistency 
4. Patients’ treatment history was unclear.  
5. Optimal information size (OIS) not met. For example, at least 200 events are required to meet OIS, based on a 25% relative risk reduction and 
control group risks of approximately 50% or greater (ref GRADE 6 paper). 
6. The confidence interval (CI) includes both no effect, and the 25% threshold for appreciable benefit or harm. This corresponds to a CI that includes 
both 1.00, and 0.75 or 1.25 (ref GRADE 6 paper). 
  
 
 
 
 
185 
Interferon beta-1b 250 mcg SC every other day compared to Placebo for 
RRMS  
  
Quality assessment № of patients Effect 
Quality Im-portance № of stud-
ies 
Study 
de-
sign 
Risk 
of 
bias 
Incon-
sistency 
Indi-
rectn
ess 
Impre-
cision 
Other 
con-
sider-
ations 
Inter-
feron 
beta-1b 
250 mcg 
SC every 
other 
day 
Pla-
cebo 
Rela-
tive 
(95% 
CI) 
Absolute 
(95% CI) 
Annualised relapse rate 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  1 
not 
seri-
ous  2 
seri-
ous  3 
none  -/124  -/122  RR 
0.65 
(0.51 
to 
0.83)  
0 fewer per 1000 (from 0 fewer to 0 
fewer)  ⨁⨁⨁◯ 
MODER-
ATE  1 2 3 
 
Disease Progression 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  1 
not 
seri-
ous  2 
very 
seri-
ous  4 5 
none  43/122 
(35.2%)  
56/122 
(45.9%)  
RR 
0.77 
(0.50 
to 
1.17)  
106 fewer per 1000 (from 78 more 
to 230 fewer)  ⨁⨁◯◯ 
LOW  1 2 4 5 
 
Withdrawal due to adverse events 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  1 
not 
seri-
ous  2 
very 
seri-
ous  4 6 
none  1/124 
(0.8%)  
10/122 
(8.2%)  
RR 
0.070 
(0.003 
to 
0.480)  
76 fewer per 1000 (from 43 fewer to 
82 fewer)  ⨁⨁◯◯ 
LOW  1 2 4 6 
 
MD – mean difference, RR – relative risk  
1. Only one study, not possible to check for inconsistency 
2. Patients were treatment naïve.  
3. For continuous outcomes, a sample size of approximately 400 may not be sufficient to insure prognostic balance (ref GRADE 6 paper). 
4. Optimal information size (OIS) not met. For example, at least 200 events are required to meet OIS, based on a 25% relative risk reduction and 
control group risks of approximately 50% or greater (ref GRADE 6 paper). 
5. The confidence interval (CI) includes both no effect, and the 25% threshold for appreciable benefit or harm. This corresponds to a CI that includes 
both 1.00, and 0.75 or 1.25 (ref GRADE 6 paper). 
6. The effect estimate and the confidence interval are not robust. Minor variations in number of events would change the results. 
  
 
 
 
 
186 
Alemtuzumab 24 mg IV q.d compared to Alemtuzumab 12 mg IV q.d for 
RRMS  
  
Quality assessment № of patients Effect 
Quality Im-portance № of stud-
ies 
Study 
de-
sign 
Risk 
of 
bias 
Incon-
sistency 
Indi-
rectne
ss 
Impre-
cision 
Other 
con-
sider-
ations 
Alemtu-
zumab 
24 mg 
IV q.d 
Alemtu-
zumab 
12 mg 
IV q.d 
Rela-
tive 
(95% 
CI) 
Absolute 
(95% CI) 
Annualised relapse rate 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  1 
seri-
ous  2 3 
seri-
ous  4 
none  -/110  -/112  RR 
0.55 
(0.35 
to 
0.86)  
0 fewer per 1000 (from 0 fewer to 0 
fewer)  ⨁⨁◯◯ 
LOW  1 2 3 4 
 
Disease Progression (disability sustained for 6 months) 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  1 
seri-
ous  2 3 
very 
seri-
ous  5 6 
none  10/110 
(9.1%)  
8/112 
(7.1%)  
RR 
0.85 
(0.40 
to 
1.65)  
11 fewer per 1000 (from 43 fewer to 
46 more)  ⨁◯◯◯ 
VERY 
LOW  1 2 3 5 6 
 
Withdrawal due to adverse events 
2  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  
not se-
rious  7 
very 
seri-
ous  5 6 
none  7/280 
(2.5%)  
16/539 
(3.0%)  
RR 
0.88 
(0.30 
to 
2.31)  
4 fewer per 1000 (from 21 fewer to 
39 more)  ⨁⨁◯◯ 
LOW  5 6 7 
 
MD – mean difference, RR – relative risk  
1. Only one study, not possible to check for inconsistency 
2. Few patients could have received the intended three treatments’s rounds. Alemtuzumab arms were suspended from 2005 as immune thrombocyto-
penic purpura developed in three patients, and one of them died (patients were recruited from 2002 to 2004). 
3. Patients were treatment naïve.  
4. For continuous outcomes, a sample size of approximately 400 may not be sufficient to insure prognostic balance (ref GRADE 6 paper). 
5. Optimal information size (OIS) not met. For example, at least 200 events are required to meet OIS, based on a 25% relative risk reduction and 
control group risks of approximately 50% or greater (ref GRADE 6 paper). 
6. The confidence interval (CI) includes both no effect, and the 25% threshold for appreciable benefit or harm. This corresponds to a CI that includes 
both 1.00, and 0.75 or 1.25 (ref GRADE 6 paper). 
7. In the minor contributing study patients were treatment naïve. In the major contributing study patients were treatment experienced. 
  
 
 
 
 
187 
Interferon beta-1a 44 mcg compared to Alemtuzumab 12 mg IV q.d for 
RRMS  
  
Quality assessment № of patients Effect 
Quality Im-portance № of stud-
ies 
Study 
de-
sign 
Risk 
of 
bias 
Incon-
sistency 
Indi-
rectne
ss 
Im-
pre-
cisio
n 
Other 
con-
sider-
ations 
Inter-
feron 
beta-1a 
44 mcg 
Alemtu-
zumab 
12 mg 
IV q.d 
Rela-
tive 
(95% 
CI) 
Absolute 
(95% CI) 
Annualised relapse rate 
3  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  1 
not se-
ri-
ous  2 3 
not 
seri-
ous  
none  -/500  -/924  RR 
2.22 
(1.89 
to 
2.63)  
0 fewer per 1000 (from 0 fewer to 0 
fewer)  ⨁⨁⨁⨁ 
HIGH  1 2 3  
Disease Progression 
3  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  
not se-
ri-
ous  2 3 
seri-
ous  4 
none  113/529 
(21.4%)  
102/924 
(11.0%)  
RR 
1.95 
(1.45 
to 
2.59)  
105 more per 1000 (from 50 more to 
176 more)  ⨁⨁⨁◯ 
MODER-
ATE  2 3 4 
 
Withdrawal due to adverse events 
3  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  
not se-
ri-
ous  2 3 
seri-
ous  4 
none  39/500 
(7.8%)  
21/924 
(2.3%)  
RR 
3.60 
(1.88 
to 
7.34)  
59 more per 1000 (from 20 more to 
144 more)  ⨁⨁⨁◯ 
MODER-
ATE  2 3 4 
 
MD – mean difference, RR – relative risk  
1. Some inconsistency. It might be explained by the fact that in one study alemtuzumab arms were suspended.  
2. Included approximately the same proportion of treatment naïve and experienced patients. 
3. In the minor contributing study, alemtuzumab arms were suspended from 2005 as immune thrombocytopenic purpura developed in three patients, 
and one of them died (Patients were recruited from 2002 to 2004). 
4. Optimal information size (OIS) not met. For example, at least 200 events are required to meet OIS, based on a 25% relative risk reduction and 
control group risks of approximately 50% or greater (ref GRADE 6 paper). 
  
 
 
 
 
188 
Interferon beta-1a 44 mcg compared to Alemtuzumab 24 mg IV q.d for 
RRMS  
  
Quality assessment № of patients Effect 
Quality Im-portance № of stud-
ies 
Study 
de-
sign 
Risk 
of 
bias 
Incon-
sistency 
Indi-
rectne
ss 
Impre-
cision 
Other 
con-
sider-
ations 
Inter-
feron 
beta-1a 
44 mcg 
Alem-
tuzu-
mab 24 
mg IV 
q.d 
Rela-
tive 
(95% 
CI) 
Absolute 
(95% CI) 
Annualised relapse rate 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  1 
seri-
ous  2 3 
seri-
ous  4 
none  -/111  -/110  RR 
3.33 
(1.94 
to 
5.79)  
0 fewer per 1000 (from 0 fewer to 0 
fewer)  ⨁⨁◯◯ 
LOW  1 2 3 4 
 
Disease Progression 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  1 
seri-
ous  2 3 
very 
seri-
ous  5 6 
none  24/111 
(21.6%)  
10/110 
(9.1%)  
RR 
2.15 
(1.10 
to 
4.55)  
105 more per 1000 (from 9 more to 
323 more)  ⨁◯◯◯ 
VERY 
LOW  1 2 3 5 6 
 
Withdrawal due to adverse events 
2  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  
seri-
ous  7 8 
very 
seri-
ous  5 6 
none  28/313 
(8.9%)  
7/280 
(2.5%)  
RR 
4.08 
(1.69 
to 
11.42)  
77 more per 1000 (from 17 more to 
261 more)  ⨁◯◯◯ 
VERY 
LOW  5 6 7 8 
 
MD – mean difference, RR – relative risk  
1. Only one study, not possible to check for inconsistency 
2. Few patients could have received the intended three treatments’s rounds. Alemtuzumab arms were suspended from 2005 as immune thrombocyto-
penic purpura developed in three patients, and one of them died (Patients were recruited from 2002 to 2004). 
3. Patients were treatment naïve.  
4. For continuous outcomes, a sample size of approximately 400 may not be sufficient to insure prognostic balance (ref GRADE 6 paper). 
5. Optimal information size (OIS) not met. For example, at least 200 events are required to meet OIS, based on a 25% relative risk reduction and 
control group risks of approximately 50% or greater (ref GRADE 6 paper). 
6. The effect estimate and the confidence interval are not robust. Minor variations in number of events would change the results. 
7. In one of the two studies, few patients could have received the intended three treatments’s rounds. Alemtuzumab arms were suspended from 2005 
as immune thrombocytopenic purpura developed in three patients, and one of them died (Patients were recruited from 2002 to 2004). 
8. In the minor contributing study patients were treatment naïve. In the major contributing study patients were treatment experienced. 
  
 
 
 
 
189 
Interferon beta-1a 44 mcg compared to Interferon beta-1a 22 mcg for 
RRMS  
  
Quality assessment № of patients Effect 
Quality Im-portance № of stud-
ies 
Study 
de-
sign 
Risk 
of 
bias 
Incon-
sistency 
Indi-
rectn
ess 
Impre-
cision 
Other 
con-
sider-
ations 
Inter-
feron 
beta-1a 
44 mcg 
Inter-
feron 
beta-1a 
22 mcg 
Rela-
tive 
(95% 
CI) 
Absolute 
(95% CI) 
Annualised relapse rate 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  1 
not 
seri-
ous  2 
seri-
ous  3 
none  -/184  -/189  RR 
0.68 
(0.56 
to 
0.83)  
0 fewer per 1000 (from 0 fewer to 0 
fewer)  ⨁⨁⨁◯ 
MODER-
ATE  1 2 3 
 
Disease Progression 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  1 
not 
seri-
ous  2 
very 
seri-
ous  4 5 
none  54/184 
(29.3%)  
64/189 
(33.9%)  
RR 
0.92 
(0.65 
to 
1.30)  
27 fewer per 1000 (from 102 more 
to 119 fewer)  ⨁⨁◯◯ 
LOW  1 2 4 5 
 
Withdrawal due to advers events 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  1 
not 
seri-
ous  2 
very 
seri-
ous  4 5 
none  9/184 
(4.9%)  
6/189 
(3.2%)  
RR 
1.31 
(0.40 
to 
4.36)  
10 more per 1000 (from 19 fewer to 
107 more)  ⨁⨁◯◯ 
LOW  1 2 4 5 
 
MD – mean difference, RR – relative risk  
1. Only one study, not possible to check for inconsistency 
2. Patients were treatment naïve.  
3. For continuous outcomes, a sample size of approximately 400 may not be sufficient to insure prognostic balance (ref GRADE 6 paper). 
4. Optimal information size (OIS) not met. For example, at least 200 events are required to meet OIS, based on a 25% relative risk reduction and 
control group risks of approximately 50% or greater (ref GRADE 6 paper). 
5. The confidence interval (CI) includes both no effect, and the 25% threshold for appreciable benefit or harm. This corresponds to a CI that includes 
both 1.00, and 0.75 or 1.25 (ref GRADE 6 paper). 
  
 
 
 
 
190 
Interferon beta-1a 44 mcg compared to Interferon beta-1a 30 mcg for 
RRMS  
  
Quality assessment № of patients Effect 
Quality Im-portance № of stud-
ies 
Study 
de-
sign 
Risk 
of 
bias 
Incon-
sistency 
Indi-
rectn
ess 
Impre-
cision 
Other 
con-
sider-
ations 
Inter-
feron 
beta-1a 
44 mcg 
Inter-
feron 
beta-1a 
30 mcg 
Rela-
tive 
(95% 
CI) 
Absolute 
(95% CI) 
Annualised relapse rate 
3  ran-
domis
ed tri-
als  
not 
seri-
ous  1 
not seri-
ous  
not 
seri-
ous  2 
not se-
rious  
none  -/424  -/423  RR 
0.76 
(0.63 
to 
0.93)  
0 fewer per 1000 (from 0 fewer to 0 
fewer)  ⨁⨁⨁⨁ 
HIGH  1 2  
Disease Progression 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  3 
not 
seri-
ous  4 
very 
seri-
ous  5 6 
none  43/339 
(12.7%)  
49/338 
(14.5%)  
RR 
0.89 
(0.55 
to 
1.38)  
16 fewer per 1000 (from 55 more to 
65 fewer)  ⨁⨁◯◯ 
LOW  3 4 5 6 
 
Withdrawal due to adverse events 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  3 
not 
seri-
ous  4 
very 
seri-
ous  5 6 
none  16/339 
(4.7%)  
14/337 
(4.2%)  
RR 
1.15 
(0.43 
to 
3.10)  
6 more per 1000 (from 24 fewer to 
87 more)  ⨁⨁◯◯ 
LOW  3 4 5 6 
 
MD – mean difference, RR – relative risk  
1. The major contributing study had no risk of bias issue. 
2. Patients' treatment history was unclear in all three studies 
3. Only one study, not possible to check for inconsistency 
4. Patients' treatment history was unclear 
5. Optimal information size (OIS) not met. For example, at least 200 events are required to meet OIS, based on a 25% relative risk reduction and 
control group risks of approximately 50% or greater (ref GRADE 6 paper). 
6. The confidence interval (CI) includes both no effect, and the 25% threshold for appreciable benefit or harm. This corresponds to a CI that includes 
both 1.00, and 0.75 or 1.25 (ref GRADE 6 paper). 
  
 
 
 
 
191 
Interferon beta-1a 60 mcg compared to Interferon beta-1a 30 mcg for 
RRMS  
  
Quality assessment № of patients Effect 
Quality Im-portance № of stud-
ies 
Study 
de-
sign 
Risk 
of 
bias 
Incon-
sistency 
Indi-
rectn
ess 
Impre-
cision 
Other 
con-
sider-
ations 
Inter-
feron 
beta-1a 
60 mcg 
Inter-
feron 
beta-1a 
30 mcg 
Rela-
tive 
(95% 
CI) 
Absolute 
(95% CI) 
Annualised relapse rate 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  1 
not 
seri-
ous  2 
seri-
ous  3 
none  -/400  -/402  RR 
1.05 
(0.88 
to 
1.25)  
0 fewer per 1000 (from 0 fewer to 0 
fewer)  ⨁⨁⨁◯ 
MODER-
ATE  1 2 3 
 
Disease Progression 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  1 
not 
seri-
ous  2 
very 
seri-
ous  3 4 
none  108/400 
(27.0%)  
109/402 
(27.1%)  
RR 
0.99 
(0.71 
to 
1.39)  
3 fewer per 1000 (from 79 fewer to 
106 more)  ⨁⨁◯◯ 
LOW  1 2 3 4 
 
Withdrawal due to adverse events 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  1 
not 
seri-
ous  2 
very 
seri-
ous  3 4 
none  64/400 
(16.0%)  
45/402 
(11.2%)  
RR 
1.43 
(0.66 
to 
3.11)  
48 more per 1000 (from 38 fewer to 
236 more)  ⨁⨁◯◯ 
LOW  1 2 3 4 
 
MD – mean difference, RR – relative risk  
1. Only one study, not possible to check for inconsistency 
2. Patients' treatment history was unclear 
3. The confidence interval (CI) includes both no effect, and the 25% threshold for appreciable benefit or harm. This corresponds to a CI that includes 
both 1.00, and 0.75 or 1.25 (ref GRADE 6 paper). 
4. Optimal information size (OIS) not met. For example, at least 200 events are required to meet OIS, based on a 25% relative risk reduction and 
control group risks of approximately 50% or greater (ref GRADE 6 paper). 
  
 
 
 
 
192 
Glatiramer acetate 20 mg compared to Interferon beta-1a 30 mcg for 
RRMS  
  
Quality assessment № of patients Effect 
Quality Im-portance № of stud-
ies 
Study 
de-
sign 
Risk 
of 
bias 
Incon-
sistency 
Indi-
rectn
ess 
Impre-
cision 
Other 
con-
sider-
ations 
Glati-
ramer 
acetate 
20 mg 
Inter-
feron 
beta-1a 
30 mcg 
Rela-
tive 
(95% 
CI) 
Absolute 
(95% CI) 
Annualised relapse rate 
2  ran-
domis
ed tri-
als  
not 
seri-
ous  1 
not seri-
ous  
not 
seri-
ous  2 
seri-
ous  3 
none  -/314  -/305  RR 
0.79 
(0.61 
to 
1.02)  
0 fewer per 1000 (from 0 fewer to 0 
fewer)  ⨁⨁⨁◯ 
MODER-
ATE  1 2 3 
 
Disease Progression 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  4 
not 
seri-
ous  5 
very 
seri-
ous  3 6 
none  74/259 
(28.6%)  
61/250 
(24.4%)  
RR 
1.18 
(0.81 
to 
1.75)  
44 more per 1000 (from 46 fewer to 
183 more)  ⨁⨁◯◯ 
LOW  3 4 5 6 
 
Withdrawal due to adverse events 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  4 
not 
seri-
ous  5 
very 
seri-
ous  3 6 
none  11/259 
(4.2%)  
17/250 
(6.8%)  
RR 
0.61 
(0.22 
to 
1.67)  
27 fewer per 1000 (from 46 more to 
53 fewer)  ⨁⨁◯◯ 
LOW  3 4 5 6 
 
MD – mean difference, RR – relative risk  
1. The major contributing study had no risk of bias issue 
2. Unclear treatment history in both studies. In the major contributing study patients were excluded if prior use of either interferon or glatiramer ace-
tate. 
3. The confidence interval (CI) includes both no effect, and the 25% threshold for appreciable benefit or harm. This corresponds to a CI that includes 
both 1.00, and 0.75 or 1.25 (ref GRADE 6 paper). 
4. Only one study, not possible to check for inconsistency 
5. Unclear treatment history, but patients were excluded if prior use of either interferon or glatiramer acetate. 
6. Optimal information size (OIS) not met. For example, at least 200 events are required to meet OIS, based on a 25% relative risk reduction and 
control group risks of approximately 50% or greater (ref GRADE 6 paper). 
  
 
 
 
 
193 
Fingolimod oral 0.5 mg compared to Interferon beta-1a 30 mcg for 
RRMS  
  
Quality assessment № of patients Effect 
Quality Im-portance № of stud-
ies 
Study 
de-
sign 
Risk 
of 
bias 
Incon-
sistency 
Indi-
rectn
ess 
Impre-
cision 
Other 
con-
sider-
ations 
Fin-
golimod 
oral 0.5 
mg 
Inter-
feron 
beta-1a 
30 mcg 
Rela-
tive 
(95% 
CI) 
Absolute 
(95% CI) 
Annualised relapse rate 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  1 
not 
seri-
ous  
not se-
rious  
none  -/431  -/435  RR 
0.48 
(0.35 
to 
0.64)  
0 fewer per 1000 (from 0 fewer to 0 
fewer)  ⨁⨁⨁⨁ 
HIGH  1  
Disease Progression 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  1 
not 
seri-
ous  
very 
seri-
ous  2 3 
none  27/431 
(6.3%)  
38/435 
(8.7%)  
RR 
0.72 
(0.42 
to 
1.17)  
24 fewer per 1000 (from 15 more to 
51 fewer)  ⨁⨁◯◯ 
LOW  1 2 3 
 
Withdrawal due to adverse events 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  1 
not 
seri-
ous  
very 
seri-
ous  2 3 
none  25/429 
(5.8%)  
34/431 
(7.9%)  
RR 
1.28 
(0.52 
to 
3.44)  
22 more per 1000 (from 38 fewer to 
192 more)  ⨁⨁◯◯ 
LOW  1 2 3 
 
MD – mean difference, RR – relative risk  
1. Only one study, not possible to check for inconsistency 
2. Optimal information size (OIS) not met. For example, at least 200 events are required to meet OIS, based on a 25% relative risk reduction and 
control group risks of approximately 50% or greater (ref GRADE 6 paper). 
3. The confidence interval (CI) includes both no effect, and the 25% threshold for appreciable benefit or harm. This corresponds to a CI that includes 
both 1.00, and 0.75 or 1.25 (ref GRADE 6 paper). 
  
 
 
 
 
194 
Fingolimod oral 1.25 mg compared to Interferon beta-1a 30 mcg for 
RRMS  
  
Quality assessment № of patients Effect 
Quality Im-portance № of stud-
ies 
Study 
de-
sign 
Risk 
of 
bias 
Incon-
sistency 
Indi-
rectn
ess 
Impre-
cision 
Other 
con-
sider-
ations 
Fin-
golimod 
oral 1.25 
mg 
Inter-
feron 
beta-1a 
30 mcg 
Rela-
tive 
(95% 
CI) 
Absolute 
(95% CI) 
Annualised relapse rate 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  1 
not 
seri-
ous  
not se-
rious  
none  -/426  -/435  RR 
0.63 
(0.46 
to 
0.90)  
0 fewer per 1000 (from 0 fewer to 0 
fewer)  ⨁⨁⨁⨁ 
HIGH  1  
Disease Progression 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  1 
not 
seri-
ous  
very 
seri-
ous  2 3 
none  34/426 
(8.0%)  
38/435 
(8.7%)  
RR 
0.99 
(0.58 
to 
1.60)  
1 fewer per 1000 (from 37 fewer to 
52 more)  ⨁⨁◯◯ 
LOW  1 2 3 
 
Withdrawal due to adverse events 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  1 
not 
seri-
ous  
very 
seri-
ous  3 4 
none  28/420 
(6.7%)  
34/431 
(7.9%)  
RR 
2.44 
(1.09 
to 
5.68)  
114 more per 1000 (from 7 more to 
369 more)  ⨁⨁◯◯ 
LOW  1 3 4 
 
MD – mean difference, RR – relative risk  
1. Only one study, not possible to check for inconsistency 
2. The confidence interval (CI) includes both no effect, and the 25% threshold for appreciable benefit or harm. This corresponds to a CI that includes 
both 1.00, and 0.75 or 1.25 (ref GRADE 6 paper). 
3. Optimal information size (OIS) not met. For example, at least 200 events are required to meet OIS, based on a 25% relative risk reduction and 
control group risks of approximately 50% or greater (ref GRADE 6 paper). 
4. The effect estimate and the confidence interval are not robust. Minor variations in number of events would change the results. 
 
  
 
 
 
 
195 
Interferon beta-1b 250 mcg SC every other day compared to Interferon 
beta-1a 30 mcg for RRMS  
  
Quality assessment № of patients Effect 
Quality Im-portance № of stud-
ies 
Study 
de-
sign 
Risk 
of 
bias 
Incon-
sistency 
Indi-
rectn
ess 
Im-
preci-
sion 
Other 
con-
sider-
ation
s 
Inter-
feron 
beta-1b 
250 mcg 
SC 
every 
other 
day 
Inter-
feron 
beta-1a 
30 mcg 
Rela-
tive 
(95% 
CI) 
Absolute 
(95% CI) 
Annualised relapse rate 
2  ran-
domis
ed tri-
als  
not 
seri-
ous  1 
not seri-
ous  
not 
seri-
ous  2 
seri-
ous  3 
none  -/126  -/126  RR 
0.71 
(0.53 to 
0.91)  
0 fewer per 1000 (from 0 fewer to 0 
fewer)  ⨁⨁⨁◯ 
MODER-
ATE  1 2 3 
 
Disease Progression 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  4 
not 
seri-
ous  5 
very 
seri-
ous  6 7 
none  13/96 
(13.5%)  
28/92 
(30.4%)  
RR 
0.44 
(0.23 to 
0.82)  
170 fewer per 1000 (from 55 fewer 
to 234 fewer)  ⨁⨁◯◯ 
LOW  4 5 6 7 
 
Withdrawal due to adverse events 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  4 
not 
seri-
ous  5 
very 
seri-
ous  6 8 
none  5/96 
(5.2%)  
1/92 
(1.1%)  
RR 
6.27 
(0.79 to 
172.30)  
57 more per 1000 (from 2 fewer to 
1000 more)  ⨁⨁◯◯ 
LOW  4 5 6 8 
 
MD – mean difference, RR – relative risk  
1. The major contributing study had no risk of bias issue 
2. In the major contributing study patients were treatment naïve. 
3. For continuous outcomes, a sample size of approximately 400 may not be sufficient to insure prognostic balance (ref GRADE 6 paper). 
4. Only one study, not possible to check for inconsistency 
5. Patients were treatment naïve.  
6. Optimal information size (OIS) not met. For example, at least 200 events are required to meet OIS, based on a 25% relative risk reduction and 
control group risks of approximately 50% or greater (ref GRADE 6 paper). 
7. The effect estimate and the confidence interval are not robust. Minor variations in number of events would change the results. 
8. The confidence interval (CI) includes both no effect, and the 25% threshold for appreciable benefit or harm. This corresponds to a CI that includes 
both 1.00, and 0.75 or 1.25 (ref GRADE 6 paper). 
  
 
 
 
 
196 
 Glatiramer acetate 20 mg compared to Interferon beta-1a 44 mcg for 
RRMS  
  
Quality assessment № of patients Effect 
Quality Im-portance № of stud-
ies 
Study 
de-
sign 
Risk 
of 
bias 
Incon-
sistency 
Indi-
rectn
ess 
Impre-
cision 
Other 
con-
sider-
ations 
Glati-
ramer 
acetate 
20 mg 
Inter-
feron 
beta-1a 
44 mcg 
Rela-
tive 
(95% 
CI) 
Absolute 
(95% CI) 
Annualised relapse rate 
2  ran-
domis
ed tri-
als  
not 
seri-
ous  1 
not seri-
ous  
not 
seri-
ous  2 
seri-
ous  3 
none  -/433  -/441  RR 
1.02 
(0.83 
to 
1.28)  
0 fewer per 1000 (from 0 fewer to 0 
fewer)  ⨁⨁⨁◯ 
MODER-
ATE  1 2 3 
 
Disease Progression 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  4 
not 
seri-
ous  5 
very 
seri-
ous  3 6 
none  33/378 
(8.7%)  
45/386 
(11.7%)  
RR 
0.75 
(0.46 
to 
1.21)  
29 fewer per 1000 (from 24 more to 
63 fewer)  ⨁⨁◯◯ 
LOW  3 4 5 6 
 
Withdrawal due to adverse events 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  4 
not 
seri-
ous  5 
very 
seri-
ous  3 6 
none  19/378 
(5.0%)  
23/386 
(6.0%)  
RR 
0.88 
(0.36 
to 
1.94)  
7 fewer per 1000 (from 38 fewer to 
56 more)  ⨁⨁◯◯ 
LOW  3 4 5 6 
 
MD – mean difference, RR – relative risk  
1. The major contributing study had no risk of bias issue 
2. In the major contributing study patients were treatment naïve. Treatment history was unclear in the other 
3. The confidence interval (CI) includes both no effect, and the 25% threshold for appreciable benefit or harm. This corresponds to a CI that includes 
both 1.00, and 0.75 or 1.25 (ref GRADE 6 paper). 
4. Only one study, not possible to check for inconsistency 
5. Patients were treatment naïve.  
6. Optimal information size (OIS) not met. For example, at least 200 events are required to meet OIS, based on a 25% relative risk reduction and 
control group risks of approximately 50% or greater (ref GRADE 6 paper). 
  
 
 
 
 
197 
Teriflunomide 7 mg oral compared to Interferon beta-1a 44 mcg SC t.i.w. 
for RRMS   
  
Quality assessment № of patients Effect 
Quality Im-portance № of stud-
ies 
Study 
de-
sign 
Risk 
of 
bias 
Incon-
sistency 
Indi-
rectn
ess 
Impre-
cision 
Other 
con-
sider-
ations 
Teri-
fluno-
mide 7 
mg 
oral 
Inter-
feron 
beta-1a 
44 mcg 
SC t.i.w. 
Rela-
tive 
(95% 
CI) 
Absolute 
(95% CI) 
Annualised relapse rate 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  1 
not 
seri-
ous  
seri-
ous  2 
none  -/109  -/104  RR 
1.72 
(1.24 
to 
2.44)  
0 fewer per 1000 (from 0 fewer to 0 
fewer)  ⨁⨁⨁◯ 
MODER-
ATE  1 2 
 
Withdrawal due to adverse events 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  1 
not 
seri-
ous  
very 
seri-
ous  3 4 
none  9/110 
(8.2%)  
22/101 
(21.8%)  
RR 
0.40 
(0.14 
to 
1.00)  
131 fewer per 1000 (from 0 fewer to 
187 fewer)  ⨁⨁◯◯ 
LOW  1 3 4 
 
MD – mean difference, RR – relative risk  
1. Only one study, not possible to check for inconsistency 
2. For continuous outcomes, a sample size of approximately 400 may not be sufficient to insure prognostic balance (ref GRADE 6 paper). 
3. Optimal information size (OIS) not met. For example, at least 200 events are required to meet OIS, based on a 25% relative risk reduction and 
control group risks of approximately 50% or greater (ref GRADE 6 paper). 
4. The confidence interval (CI) includes both no effect, and the 25% threshold for appreciable benefit or harm. This corresponds to a CI that includes 
both 1.00, and 0.75 or 1.25 (ref GRADE 6 paper). 
  
 
 
 
 
198 
Teriflunomide 14 mg oral compared to Interferon beta-1a 44 mcg SC 
t.i.w. for RRMS   
  
Quality assessment № of patients Effect 
Quality Im-portance № of stud-
ies 
Study 
de-
sign 
Risk 
of 
bias 
Incon-
sistency 
Indi-
rectn
ess 
Impre-
cision 
Other 
con-
sider-
ations 
Teri-
fluno-
mide 14 
mg oral 
Inter-
feron 
beta-1a 
44 mcg 
SC t.i.w. 
Rela-
tive 
(95% 
CI) 
Absolute 
(95% CI) 
Annualised relapse rate 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  1 
not 
seri-
ous  
very 
seri-
ous  2 3 
none  -/111  -/104  RR 
0.91 
(0.62 
to 
1.36)  
0 fewer per 1000 (from 0 fewer to 0 
fewer)  ⨁⨁◯◯ 
LOW  1 2 3 
 
Withdrawal due to adverse events 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  1 
not 
seri-
ous  
very 
seri-
ous  3 4 
none  12/110 
(10.9%)  
22/101 
(21.8%)  
RR 
0.54 
(0.20 
to 
1.38)  
100 fewer per 1000 (from 83 more 
to 174 fewer)  ⨁⨁◯◯ 
LOW  1 3 4 
 
MD – mean difference, RR – relative risk  
1. Only one study, not possible to check for inconsistency 
2. For continuous outcomes, a sample size of approximately 400 may not be sufficient to insure prognostic balance (ref GRADE 6 paper). 
3. The confidence interval (CI) includes both no effect, and the 25% threshold for appreciable benefit or harm. This corresponds to a CI that includes 
both 1.00, and 0.75 or 1.25 (ref GRADE 6 paper). 
4. Optimal information size (OIS) not met. For example, at least 200 events are required to meet OIS, based on a 25% relative risk reduction and 
control group risks of approximately 50% or greater (ref GRADE 6 paper). 
  
 
 
 
 
199 
Interferon beta-1b 250 mcg SC every other day compared to Interferon 
beta-1a 44 mcg SC t.i.w. for RRMS   
  
Quality assessment № of patients Effect 
Quality Im-portance № of stud-
ies 
Study 
de-
sign 
Risk 
of 
bias 
Incon-
sistency 
Indi-
rectn
ess 
Impre-
cision 
Other 
con-
sider-
ations 
Inter-
feron 
beta-1b 
250 mcg 
SC 
every 
other 
day 
Inter-
feron 
beta-
1a 44 
mcg 
SC 
t.i.w. 
Rela-
tive 
(95% 
CI) 
Absolute 
(95% CI) 
Annualised relapse rate 
1  ran-
domis
ed tri-
als  
seri-
ous  1 
not seri-
ous  2 
not 
seri-
ous  3 
very 
seri-
ous  4 5 
none  -/30  -/30  RR 
0.81 
(0.46 
to 
1.43)  
0 fewer per 1000 (from 0 fewer to 0 
fewer)  ⨁◯◯◯ 
VERY 
LOW  1 2 3 4 5 
 
MD – mean difference, RR – relative risk  
1. Insufficient reporting for randomization, and differences in baseline characteristics between groups 
2. Only one study, not possible to check for inconsistency 
3. Patients' treatment history was unclear. 
4. For continuous outcomes, a sample size of approximately 400 may not be sufficient to insure prognostic balance (ref GRADE 6 paper). 
5. The confidence interval (CI) includes both no effect, and the 25% threshold for appreciable benefit or harm. This corresponds to a CI that includes 
both 1.00, and 0.75 or 1.25 (ref GRADE 6 paper). 
  
 
 
 
 
200 
Dimethyl fumarate 240 mg two times daily compared to Glatiramer ace-
tate 20 mg for RRMS   
  
Quality assessment № of patients Effect 
Quality Im-portance № of stud-
ies 
Study 
de-
sign 
Risk 
of 
bias 
Incon-
sistency 
Indi-
rect
ness 
Im-
preci-
sion 
Other 
con-
sider-
ation
s 
Dimethyl 
fumarate 
240 mg 
two times 
daily 
Glati-
ramer 
acetate 
20 mg 
Rela-
tive 
(95% 
CI) 
Absolute 
(95% CI) 
Annualised relapse rate 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  1 
not 
seri-
ous  
not 
seri-
ous  
none  -/359  -/351  RR 
0.59 
(0.38 
to 
0.90)  
0 fewer per 1000 (from 0 fewer to 0 
fewer)  ⨁⨁⨁⨁ 
HIGH  1  
Disease Progression 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  1 
not 
seri-
ous  
very 
seri-
ous  2 3 
none  47/359 
(13.1%)  
56/350 
(16.0%)  
RR 
0.78 
(0.52 
to 
1.18)  
35 fewer per 1000 (from 29 more to 
77 fewer)  ⨁⨁◯◯ 
LOW  1 2 3 
 
Withdrawal due to adverse events 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  1 
not 
seri-
ous  
very 
seri-
ous  2 3 
none  44/359 
(12.3%)  
35/351 
(10.0%)  
RR 
1.18 
(0.49 
to 
2.84)  
18 more per 1000 (from 51 fewer to 
183 more)  ⨁⨁◯◯ 
LOW  1 2 3 
 
MD – mean difference, RR – relative risk  
1. Only one study, not possible to check for inconsistency 
2. Optimal information size (OIS) not met. For example, at least 200 events are required to meet OIS, based on a 25% relative risk reduction and 
control group risks of approximately 50% or greater (ref GRADE 6 paper). 
3. The confidence interval (CI) includes both no effect, and the 25% threshold for appreciable benefit or harm. This corresponds to a CI that includes 
both 1.00, and 0.75 or 1.25 (ref GRADE 6 paper). 
  
 
 
 
 
201 
Dimethyl fumarate 240 mg three times daily compared to Glatiramer ac-
etate 20 mg for RRMS   
  
Quality assessment № of patients Effect 
Quality Im-portance № of stud-
ies 
Study 
de-
sign 
Risk 
of 
bias 
Incon-
sistency 
Indi-
rect
ness 
Im-
preci-
sion 
Other 
con-
sider-
ation
s 
Dimethyl 
fumarate 
240 mg 
three 
times 
daily 
Glati-
ramer 
acetate 
20 mg 
Rela-
tive 
(95% 
CI) 
Absolute 
(95% CI) 
Annualised relapse rate 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  1 
not 
seri-
ous  
not 
seri-
ous  
none  -/345  -/350  RR 
0.53 
(0.35 
to 
0.79)  
0 fewer per 1000 (from 0 fewer to 0 
fewer)  ⨁⨁⨁⨁ 
HIGH  1  
Disease Progression 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  1 
not 
seri-
ous  
very 
seri-
ous  2 3 
none  45/345 
(13.0%)  
56/350 
(16.0%)  
RR 
0.79 
(0.53 
to 
1.16)  
34 fewer per 1000 (from 26 more to 
75 fewer)  ⨁⨁◯◯ 
LOW  1 2 3 
 
Withdrawal due to adverse events 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  1 
not 
seri-
ous  
very 
seri-
ous  2 3 
none  41/344 
(11.9%)  
35/351 
(10.0%)  
RR 
1.15 
(0.52 
to 
2.56)  
15 more per 1000 (from 48 fewer to 
156 more)  ⨁⨁◯◯ 
LOW  1 2 3 
 
MD – mean difference, RR – relative risk  
1. Only one study, not possible to check for inconsistency 
2. Optimal information size (OIS) not met. For example, at least 200 events are required to meet OIS, based on a 25% relative risk reduction and 
control group risks of approximately 50% or greater (ref GRADE 6 paper). 
3. The confidence interval (CI) includes both no effect, and the 25% threshold for appreciable benefit or harm. This corresponds to a CI that includes 
both 1.00, and 0.75 or 1.25 (ref GRADE 6 paper).The confidence interval (CI) includes both no effect, and the 25% threshold for appreciable benefit 
or harm. This corresponds to a CI that includes both 1.00, and 0.75 or 1.25 (ref GRADE 6 paper). 
  
 
 
 
 
202 
Interferon beta-1b 250 mcg SC every other day compared to Glatiramer 
acetate 20mg for RRMS   
  
Quality assessment № of patients Effect 
Quality Im-portance № of stud-
ies 
Study 
de-
sign 
Risk 
of 
bias 
Incon-
sistency 
Indi-
rectn
ess 
Impre-
cision 
Other 
con-
sider-
ations 
Inter-
feron 
beta-1b 
250 mcg 
SC every 
other day 
Glati-
ramer 
acetate 
20mg 
Rela-
tive 
(95% 
CI) 
Absolute 
(95% CI) 
Annualised relapse rate 
2  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  
not 
seri-
ous  1 
seri-
ous  2 
none  -/933  -/487  RR 
1.07 
(0.90 
to 
1.27)  
0 fewer per 1000 (from 0 fewer to 0 
fewer)  ⨁⨁⨁◯ 
MODER-
ATE  1 2 
 
Disease Progression 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  3 
not 
seri-
ous  1 
seri-
ous  2 
none  188/897 
(21.0%)  
90/448 
(20.1%)  
RR 
1.04 
(0.74 
to 
1.46)  
8 more per 1000 (from 52 fewer to 
92 more)  ⨁⨁⨁◯ 
MODER-
ATE  1 2 3 
 
Withdrawal due to adverse events 
2  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  
not 
seri-
ous  1 
very 
seri-
ous  2 4 
none  17/933 
(1.8%)  
12/487 
(2.5%)  
RR 
0.91 
(0.37 
to 
2.27)  
2 fewer per 1000 (from 16 fewer to 
31 more)  ⨁⨁◯◯ 
LOW  1 2 4 
 
MD – mean difference, RR – relative risk  
1. Patients were treatment naïve.  
2. The confidence interval (CI) includes both no effect, and the 25% threshold for appreciable benefit or harm. This corresponds to a CI that includes 
both 1.00, and 0.75 or 1.25 (ref GRADE 6 paper). 
3. Only one study, not possible to check for inconsistency 
4. Optimal information size (OIS) not met. For example, at least 200 events are required to meet OIS, based on a 25% relative risk reduction and 
control group risks of approximately 50% or greater (ref GRADE 6 paper). 
  
 
 
 
 
203 
Interferon beta-1b 500 mcg SC every other day compared to Glatiramer 
acetate 20mg for RRMS   
  
Quality assessment № of patients Effect 
Quality Im-portance № of stud-
ies 
Study 
de-
sign 
Risk 
of 
bias 
Incon-
sistency 
Indi-
rectn
ess 
Impre-
cision 
Other 
con-
sider-
ations 
Inter-
feron 
beta-1b 
500 mcg 
SC every 
other day 
Glati-
ramer 
acetate 
20mg 
Rela-
tive 
(95% 
CI) 
Absolute 
(95% CI) 
Annualised relapse rate 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  1 
not 
seri-
ous  2 
seri-
ous  3 
none  -/899  -/448  RR 
0.95 
(0.80 
to 
1.12)  
0 fewer per 1000 (from 0 fewer to 0 
fewer)  ⨁⨁⨁◯ 
MODER-
ATE  1 2 3 
 
Disease Progression 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  1 
not 
seri-
ous  2 
seri-
ous  3 
none  198/899 
(22.0%)  
90/448 
(20.1%)  
RR 
1.01 
(0.74 
to 
1.36)  
2 more per 1000 (from 52 fewer to 
72 more)  ⨁⨁⨁◯ 
MODER-
ATE  1 2 3 
 
Withdrawal due to adverse events 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  1 
not 
seri-
ous  2 
very 
seri-
ous  3 4 
none  20/899 
(2.2%)  
8/448 
(1.8%)  
RR 
1.16 
(0.46 
to 
3.05)  
3 more per 1000 (from 10 fewer to 
37 more)  ⨁⨁◯◯ 
LOW  1 2 3 4 
 
MD – mean difference, RR – relative risk  
1. Only one study, not possible to check for inconsistency 
2. Patients were treatment naïve.  
3. The confidence interval (CI) includes both no effect, and the 25% threshold for appreciable benefit or harm. This corresponds to a CI that includes 
both 1.00, and 0.75 or 1.25 (ref GRADE 6 paper). 
4. Optimal information size (OIS) not met. For example, at least 200 events are required to meet OIS, based on a 25% relative risk reduction and 
control group risks of approximately 50% or greater (ref GRADE 6 paper). 
  
 
 
 
 
204 
Dimethyl fumarate 240 mg three times daily compared to Dimethyl 
fumarate 240 mg two times daily for RRMS   
  
Quality assessment № of patients Effect 
Quality Im-portance № of stud-
ies 
Study 
de-
sign 
Risk 
of 
bias 
Incon-
sistency 
Indi-
rect
ness 
Im-
preci-
sion 
Other 
con-
sider-
ation
s 
Dimethyl 
fumarate 
240 mg 
three 
times 
daily 
Dimethyl 
fumarate 
240 mg 
two times 
daily 
Rel-
ative 
(95% 
CI) 
Absolute 
(95% CI) 
Annualised relapse rate 
2  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  
not 
seri-
ous  
seri-
ous  1 
none  -/760  -/769  RR 
1.01 
(0.82 
to 
1.23)  
0 fewer per 1000 (from 0 fewer to 0 
fewer)  ⨁⨁⨁◯ 
MODER-
ATE  1 
 
Disease Progression 
2  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  
not 
seri-
ous  
very 
seri-
ous  1 2 
none  120/761 
(15.8%)  
113/768 
(14.7%)  
RR 
1.06 
(0.78 
to 
1.42)  
9 more per 1000 (from 32 fewer to 
62 more)  ⨁⨁◯◯ 
LOW  1 2 
 
Withdrawal due to adverse events 
2  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  
not 
seri-
ous  
very 
seri-
ous  1 2 
none  109/760 
(14.3%)  
109/769 
(14.2%)  
RR 
1.01 
(0.58 
to 
1.73)  
1 more per 1000 (from 60 fewer to 
103 more)  ⨁⨁◯◯ 
LOW  1 2 
 
MD – mean difference, RR – relative risk  
1. The confidence interval (CI) includes both no effect, and the 25% threshold for appreciable benefit or harm. This corresponds to a CI that includes 
both 1.00, and 0.75 or 1.25 (ref GRADE 6 paper). 
2. Optimal information size (OIS) not met. For example, at least 200 events are required to meet OIS, based on a 25% relative risk reduction and 
control group risks of approximately 50% or greater (ref GRADE 6 paper). 
  
 
 
 
 
205 
Teriflunomide oral 14 mg compared to Teriflunomide oral 7 mg for 
RRMS   
  
Quality assessment № of patients Effect 
Quality Im-portance № of stud-
ies 
Study 
de-
sign 
Risk 
of 
bias 
Incon-
sistency 
Indi-
rectn
ess 
Impre-
cision 
Other 
con-
sider-
ations 
Teri-
fluno-
mide 
oral 14 
mg 
Teri-
fluno-
mide 
oral 7 
mg 
Rela-
tive 
(95% 
CI) 
Absolute 
(95% CI) 
Annualised relapse rate 
4  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  
not 
seri-
ous  1 
seri-
ous  2 
none  -/935  -/912  RR 
0.86 
(0.74 
to 
1.00)  
0 fewer per 1000 (from 0 fewer to 0 
fewer)  ⨁⨁⨁◯ 
MODER-
ATE  1 2 
 
Disease Progression 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  3 
not 
seri-
ous  
very 
seri-
ous  2 4 
none  72/358 
(20.1%)  
79/365 
(21.6%)  
RR 
0.92 
(0.64 
to 
1.35)  
17 fewer per 1000 (from 76 more to 
78 fewer)  ⨁⨁◯◯ 
LOW  2 3 4 
 
Withdrawal due to adverse events 
4  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  
not 
seri-
ous  1 
seri-
ous  2 4 
none  112/934 
(12.0%)  
106/912 
(11.6%)  
RR 
1.12 
(0.73 
to 
1.85)  
14 more per 1000 (from 31 fewer to 
99 more)  ⨁⨁⨁◯ 
MODER-
ATE  1 2 4 
 
MD – mean difference, RR – relative risk  
1. In the minor contributing study, patients were treatment naïve 
2. The confidence interval (CI) includes both no effect, and the 25% threshold for appreciable benefit or harm. This corresponds to a CI that includes 
both 1.00, and 0.75 or 1.25 (ref GRADE 6 paper). 
3. Only one study, not possible to check for inconsistency 
4. Optimal information size (OIS) not met. For example, at least 200 events are required to meet OIS, based on a 25% relative risk reduction and 
control group risks of approximately 50% or greater (ref GRADE 6 paper). 
  
 
 
 
 
206 
Fingolimod oral 1.25 mg compared to Fingolomid oral 0.5 mg for RRMS   
  
Quality assessment № of patients Effect 
Quality Im-portance № of stud-
ies 
Study 
de-
sign 
Risk 
of 
bias 
Incon-
sistency 
Indi-
rectn
ess 
Im-
pre-
cisio
n 
Other 
con-
sider-
ations 
Fin-
golimod 
oral 1.25 
mg 
Fingol-
omid oral 
0.5 mg 
Rela-
tive 
(95% 
CI) 
Absolute 
(95% CI) 
Annualised relapse rate 
4  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  1 
not 
seri-
ous  2 
seri-
ous  3 
none  -/1273  -/1269  RR 
0.98 
(0.83 
to 
1.17)  
0 fewer per 1000 (from 0 fewer to 0 
fewer)  ⨁⨁⨁◯ 
MODER-
ATE  1 2 3 
 
Disease Progression 
3  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  
not 
seri-
ous  
seri-
ous  3 
none  153/1225 
(12.5%)  
151/1214 
(12.4%)  
RR 
1.01 
(0.78 
to 
1.32)  
1 more per 1000 (from 27 fewer to 
40 more)  ⨁⨁⨁◯ 
MODER-
ATE  3 
 
Withdrawal due to adverse events 
4  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  
not 
seri-
ous  2 
seri-
ous  3 
none  181/1273 
(14.2%)  
128/1269 
(10.1%)  
RR 
1.43 
(0.94 
to 
2.21)  
43 more per 1000 (from 6 fewer to 
122 more)  ⨁⨁⨁◯ 
MODER-
ATE  2 3 
 
MD – mean difference, RR – relative risk  
1. Some inconsistency. It may be explained by different definitions of relapse in studies 
2. In the minor contributing study, patients’ treatment history was unclear.  
3. The confidence interval (CI) includes both no effect, and the 25% threshold for appreciable benefit or harm. This corresponds to a CI that includes 
both 1.00, and 0.75 or 1.25 (ref GRADE 6 paper). 
  
 
 
 
 
207 
Peg-interferon beta-1a 125 mcg once every four weeks compared to Peg-
interferon beta-1a 125 mcg once every two weeks for RRMS   
  
Quality assessment № of patients Effect 
Quality Im-portance № of stud-
ies 
Study 
de-
sign 
Risk 
of 
bias 
Incon-
sistency 
Indi-
rectn
ess 
Impre-
cision 
Other 
con-
sider-
ations 
Peg-in-
terferon 
beta-1a 
125 mcg 
once 
every 
four 
weeks 
Peg-in-
terferon 
beta-1a 
125 mcg 
once 
every 
two 
weeks 
Rela-
tive 
(95% 
CI) 
Absolute 
(95% CI) 
Annualised relapse rate 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  1 
not 
seri-
ous  
seri-
ous  2 
none  -/500  -/512  RR 
1.13 
(0.84 
to 
1.52)  
0 fewer per 1000 (from 0 fewer to 0 
fewer)  ⨁⨁⨁◯ 
MODER-
ATE  1 2 
 
Disease Progression 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  1 
not 
seri-
ous  
very 
seri-
ous  2 3 
none  31/500 
(6.2%)  
31/512 
(6.1%)  
RR 
1.02 
(0.61 
to 
1.74)  
1 more per 1000 (from 24 fewer to 
45 more)  ⨁⨁◯◯ 
LOW  1 2 3 
 
Withdrawal due to adverse events 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  1 
not 
seri-
ous  
very 
seri-
ous  2 3 
none  24/500 
(4.8%)  
25/512 
(4.9%)  
RR 
0.98 
(0.41 
to 
2.37)  
1 fewer per 1000 (from 29 fewer to 
67 more)  ⨁⨁◯◯ 
LOW  1 2 3 
 
MD – mean difference, RR – relative risk  
1. Only one study, not possible to check for inconsistency 
2. The confidence interval (CI) includes both no effect, and the 25% threshold for appreciable benefit or harm. This corresponds to a CI that includes 
both 1.00, and 0.75 or 1.25 (ref GRADE 6 paper). 
3. Optimal information size (OIS) not met. For example, at least 200 events are required to meet OIS, based on a 25% relative risk reduction and 
control group risks of approximately 50% or greater (ref GRADE 6 paper). 
  
 
 
 
 
208 
Interferon beta-1b 250 mcg SC every other day compared to Natalizumab 
300 mg intravenous every 4 weeks for RRMS   
  
Quality assessment № of patients Effect 
Quality Im-portance № of stud-
ies 
Study 
de-
sign 
Risk 
of 
bias 
Incon-
sistency 
Indi-
rectn
ess 
Impre-
cision 
Other 
con-
sider-
ations 
Inter-
feron 
beta-1b 
250 
mcg SC 
every 
other 
day 
Natali-
zumab 
300 mg 
intrave-
nous 
every 4 
weeks 
Rela-
tive 
(95% 
CI) 
Absolute 
(95% CI) 
Annualised relapse rate 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  1 
seri-
ous  2 
very 
seri-
ous  3 4 
none  -/9  -/10  not 
esti-
mabl
e  
 ⨁◯◯◯ 
VERY 
LOW  1 2 3 4 
 
MD – mean difference, RR – relative risk  
1. Only one study, not possible to check for inconsistency 
2. Study included only patients treated with natalizumab randomised to continue natalizumab or to switch to interferon. Patients selected into the 
studies may be different from the general MS population. 
3. No meaningful information was given to be able to estimate the relative risk (the RR was 1.65*10^8(4510 to 2.52*10^9)  
4. For continuous outcomes, a sample size of approximately 400 may not be sufficient to insure prognostic balance (ref GRADE 6 paper). 
  
 
 
 
 
209 
 
Interferon beta-1b 500 mcg SC every other day compared to Interferon 
beta-1b 250 mcg SC every other day for RRMS   
  
Quality assessment № of patients Effect 
Quality Im-portance № of stud-
ies 
Study 
de-
sign 
Risk 
of 
bias 
Incon-
sistency 
Indi-
rectn
ess 
Impre-
cision 
Other 
con-
sider-
ations 
Inter-
feron 
beta-1b 
500 mcg 
SC every 
other 
day 
Inter-
feron 
beta-1b 
250 mcg 
SC every 
other 
day 
Rela-
tive 
(95% 
CI) 
Absolute 
(95% CI) 
Annualised relapse rate 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  1 
not 
seri-
ous  2 
seri-
ous  3 
none  -/899  -/897  RR 
0.93 
(0.80 
to 
1.10)  
0 fewer per 1000 (from 0 fewer to 0 
fewer)  ⨁⨁⨁◯ 
MODER-
ATE  1 2 3 
 
Disease Progression 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  1 
not 
seri-
ous  2 
seri-
ous  3 
none  198/899 
(22.0%)  
188/897 
(21.0%)  
RR 
1.10 
(0.84 
to 
1.51)  
21 more per 1000 (from 34 fewer to 
107 more)  ⨁⨁⨁◯ 
MODER-
ATE  1 2 3 
 
Withdrawal due to adverse events 
1  ran-
domis
ed tri-
als  
not 
seri-
ous  
not seri-
ous  1 
not 
seri-
ous  2 
very 
seri-
ous  3 4 
none  20/899 
(2.2%)  
13/897 
(1.4%)  
RR 
1.63 
(0.66 
to 
4.11)  
9 more per 1000 (from 5 fewer to 45 
more)  ⨁⨁◯◯ 
LOW  1 2 3 4 
 
MD – mean difference, RR – relative risk  
1. Only one study, not possible to check for inconsistency 
2. Patients were treatment naïve.  
3. The confidence interval (CI) includes both no effect, and the 25% threshold for appreciable benefit or harm. This corresponds to a CI that includes 
both 1.00, and 0.75 or 1.25 (ref GRADE 6 paper) 
4. Optimal information size (OIS) not met. For example, at least 200 events are required to meet OIS, based on a 25% relative risk reduction and 
control group risks of approximately 50% or greater (ref GRADE 6 paper). 
  
 
 
 
 
210 
Appendix 6: Full network meta-analysis results 
A6.1: Annualised relapse rate 
 
 
 
  
Treatment Placebo
Alem tuzum ab 1 2  m g 
IV q.d
Alem tuzum ab 24 
mg IV q.d
Interferon beta-1 a 22  
m cg SC t.i.w
Interferon beta-1 a 3 0 
m cg IM q.w
Interferon beta-1 a 44 
m cg SC t.i.w
Interferon beta-1 a 
60 mcg IM q.w
glatiram er acetate 
20mg q.d
glatiram er acetate 
40mg t.i.w
dim ethy l fum arate 
240 m g two times 
daily
dimethy l fum arate 
240 mg three times 
daily
Teriflunom ide oral 
7  m g 
Teriflunom ide oral 
1 4 m g
Fingolim od oral 
0.5 m g 
Fingolim od oral 1 .25 
m g  
Peginterferon beta-1 a 
1 25 m cg once ev ery  
2 weeks 
peginterferon beta-
1 a 1 25 mcg once 
ev ery  4 weeks Natalizum ab
Interferon beta-
1 b 250 mcg SC 
ev ery  other day
Interferon 
beta-1 b 500 
m cg SC ev ery  
other day
Placebo 1
Alem tuzum ab 1 2  mg IV q.d 0.29 (0.23 to 0.3 5) 1
Alem tuzum ab 24 m g IV q.d 0.1 6  (0.1  to 0.25) 0.55 (0.3 5 to 0.86) 1
Interferon beta-1 a 22  m cg SC t.i.w 0.69 (0.57  to 0.83 ) 2.4  (1 .9  to 3 .1 2) 4.3 5 (2 .7 1  to 7 .1 3 ) 1
Interferon beta-1 a 30 m cg IM q.w 0.82 (0.7 3 to 0.91 ) 2.82 (2.3 3 to 3.59) 5.1 5 (3 .24 to 8.29) 1 .1 8 (0.97  to 1 .46) 1
Interferon beta-1 a 44 m cg SC t.i.w 0.64 (0.56 to 0.7 2) 2.21  (1 .9  to 2.64) 4.02 (2.6  to 6 .34) 0.92 (0.7 6 to 1 .1 1 ) 0.7 8 (0.68 to 0.89) 1
Interferon beta-1 a 60 m cg IM q.w 0.86 (0.7  to 1 .06) 2.96 (2.3 1  to 4.02) 5.41  (3.3  to 8.99) 1 .24 (0.96 to 1 .63) 1 .05 (0.88 to 1 .25) 1 .34 (1 .09 to 1 .7 ) 1
glatiram er acetate 20m g q.d 0.65 (0.59 to 0.7 3) 2.25 (1 .85 to 2.87 ) 4.1  (2.59 to 6 .63 ) 0.94 (0.7 7  to 1 .1 6) 0.8 (0.7  to 0.91 ) 1 .02 (0.9 to 1 .1 8) 0.7 6 (0.61  to 0.94) 1
glatiram er acetate 40m g t.i.w 0.66 (0.52  to 0.82) 2.27  (1 .7  to 3.1 4) 4.1 4  (2 .47  to 6 .95) 0.95 (0.7 2  to 1 .27 ) 0.8 (0.62 to 1 .02) 1 .03 (0.8 to 1 .33) 0.7 7  (0.56 to 1 .03) 1 .01  (0.7 8 to 1 .28) 1
dimethy l fum arate 240 mg two tim es daily 0.5 (0.42 to 0.6) 1 .7 3  (1 .3 5 to 2.31 ) 3.1 5 (1 .92  to 5.23) 0.7 2 (0.56 to 0.93 ) 0.61  (0.49 to 0.7 5) 0.7 8 (0.63 to 0.97 ) 0.58 (0.44 to 0.7 6) 0.7 7  (0.63 to 0.93) 0.7 6 (0.57  to 1 .01 ) 1
dimethy l fum arate 240 mg three times daily 0.5 (0.42 to 0.6) 1 .7 3  (1 .3 5 to 2.33) 3.1 6  (1 .93 to 5.28) 0.7 2 (0.57  to 0.94) 0.62  (0.5 to 0.7 5) 0.7 9 (0.64 to 0.98) 0.58 (0.45 to 0.7 6) 0.7 7  (0.64 to 0.93) 0.7 7  (0.58 to 1 .02) 1 .01  (0.82 to 1 .23 ) 1
Teriflunomide oral 7  m g 0.7 7  (0.68 to 0.9) 2.68 (2.1 3  to 3.53) 4.89 (3.03 to 7 .93) 1 .1 2 (0.9  to 1 .42) 0.95 (0.8 to 1 .1 3 ) 1 .21  (1 .02 to 1 .47 ) 0.9 (0.7 1  to 1 .1 6) 1 .1 9 (1 . to 1 .42) 1 .1 8 (0.91  to 1 .55) 1 .55 (1 .24 to 1 .96) 1 .54 (1 .23  to 1 .94) 1
Teriflunomide oral 1 4 m g 0.67  (0.58 to 0.7 7 ) 2.3  (1 .83 to 3.03) 4.1 9  (2 .6 to 6.9) 0.96 (0.7 7  to 1 .22) 0.82  (0.68 to 0.98) 1 .04 (0.87  to 1 .27 ) 0.7 8 (0.6 to 0.99) 1 .02  (0.85 to 1 .22) 1 .02  (0.7 8 to 1 .3 3) 1 .3 3 (1 .06 to 1 .68) 1 .33  (1 .05 to 1 .67 ) 0.86 (0.7 4 to 1 .) 1
Fingolim od oral 0.5 m g 0.46 (0.3 9 to 0.54) 1 .6 (1 .25 to 2 .09) 2.91  (1 .7 9 to 4.7 9) 0.67  (0.53  to 0.85) 0.57  (0.47  to 0.67 ) 0.7 2 (0.6  to 0.88) 0.54 (0.42 to 0.68) 0.7 1  (0.59 to 0.85) 0.7  (0.54 to 0.92) 0.92  (0.7 3  to 1 .1 7 ) 0.92 (0.7 3 to 1 .1 6) 0.6 (0.48 to 0.7 3) 0.69 (0.56 to 0.85) 1
Fingolim od oral 1 .25 m g  0.45 (0.39 to 0.53) 1 .57  (1 .23 to 2.06) 2.86 (1 .7 6  to 4 .66) 0.65 (0.52 to 0.83) 0.55 (0.47  to 0.66) 0.7 1  (0.58 to 0.87 ) 0.53 (0.41  to 0.67 ) 0.69 (0.57  to 0.83 ) 0.69 (0.53  to 0.9) 0.9 (0.7 1  to 1 .1 5) 0.9  (0.7 1  to 1 .1 4) 0.59 (0.47  to 0.7 1 ) 0.68 (0.55 to 0.84) 0.98 (0.83 to 1 .1 7 ) 1
Peginterferon beta-1 a 1 25 mcg once ev ery  2 weeks 0.65 (0.49 to 0.85) 2.23 (1 .6 to 3 .1 9) 4.07  (2.3 3 to 7 .07 ) 0.93 (0.67  to 1 .29) 0.7 9 (0.58 to 1 .06) 1 .01  (0.7 4  to 1 .3 6) 0.7 5 (0.53 to 1 .05) 0.99 (0.7 3 to 1 .32) 0.98 (0.69 to 1 .41 ) 1 .29 (0.93 to 1 .8) 1 .29 (0.92  to 1 .7 7 ) 0.83 (0.6 to 1 .1 3 ) 0.97  (0.7  to 1 .32) 1 .4 (1 .02  to 1 .92) 1 .43 (1 .03  to 1 .95) 1
peginterferon beta-1 a 1 25 mcg once ev ery  4 weeks 0.7 3 (0.56 to 0.95) 2.52  (1 .83 to 3 .59) 4.59 (2 .68 to 7 .94) 1 .06 (0.7 6 to 1 .46) 0.89 (0.66 to 1 .2) 1 .1 4  (0.85 to 1 .54) 0.85 (0.6  to 1 .1 9) 1 .1 2 (0.83 to 1 .5) 1 .1 1  (0.7 8 to 1 .58) 1 .46 (1 .06 to 2.01 ) 1 .45 (1 .05 to 1 .99) 0.94 (0.69 to 1 .27 ) 1 .1  (0.8 to 1 .49) 1 .58 (1 .1 6 to 2.1 6) 1 .61  (1 .1 8 to 2.2) 1 .1 3  (0.84 to 1 .52) 1
Natalizumab 0.3  (0.24 to 0.36) 1 .03  (0.7 9 to 1 .3 7 ) 1 .88 (1 .1 4  to 3 .09) 0.43 (0.33 to 0.56) 0.36 (0.29 to 0.45) 0.47  (0.3 7  to 0.59) 0.35 (0.26 to 0.46) 0.46 (0.3 6 to 0.57 ) 0.45 (0.34 to 0.61 ) 0.59 (0.45 to 0.7 7 ) 0.59 (0.45 to 0.7 7 ) 0.39 (0.3  to 0.49) 0.45 (0.3 5 to 0.56) 0.65 (0.5 to 0.83 ) 0.66 (0.51  to 0.84) 0.46 (0.33  to 0.25) 0.41  (0.29 to 0.57 ) 1
Interferon beta-1 b 250 m cg SC ev ery  other day 0.66 (0.57  to 0.7 6) 2.28 (1 .84 to 2.94) 4.1 5 (2.6  to 6 .7 1 ) 0.95 (0.7 7  to 1 .1 9) 0.81  (0.69 to 0.93) 1 .03 (0.88 to 1 .22) 0.7 7  (0.61  to 0.96) 1 .01  (0.88 to 1 .1 6) 1 .01  (0.7 8 to 1 .3) 1 .3 2 (1 .06 to 1 .65) 1 .32  (1 .06 to 1 .63 ) 0.86 (0.69 to 1 .03 ) 0.99 (0.81  to 1 .2) 1 .44 (1 .1 7  to 1 .7 5) 1 .46 (1 .1 9 to 1 .7 8) 1 .02 (0.7 5 to 0.83) 0.91  (0.66 to 1 .22) 2 .22  (1 .7 6 to 2.81 ) 1
Interferon beta-1 b 500 m cg SC ev ery  other day 0.62 (0.51  to 0.7 4) 2.1 3  (1 .67  to 2 .84) 3.87  (2.3 9 to 6.41 ) 0.89 (0.69 to 1 .1 5) 0.7 6 (0.62  to 0.91 ) 0.96 (0.7 9 to 1 .1 9) 0.7 2  (0.55 to 0.93) 0.95 (0.8 to 1 .1 2) 0.94 (0.7  to 1 .26) 1 .24 (0.96 to 1 .59) 1 .23  (0.96 to 1 .57 ) 0.8 (0.62 to 1 .) 0.93  (0.7 3  to 1 .1 7 ) 1 .34 (1 .06 to 1 .69) 1 .3 7  (1 .07  to 1 .7 2) 0.96 (0.69 to 0.91 ) 0.85 (0.61  to 1 .1 7 ) 2 .07  (1 .6  to 2 .7 3 ) 0.93 (0.8 to 1 .1 ) 1
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A6.2: Disability progression 
 
 
 
 
  
Treatment Placebo
Alemtuzumab 12 
mg IV q.d
Alemtuzumab 24 
mg IV q.d
Interferon beta‐1a 
22 mcg SC t.i.w
Interferon beta‐1a 
30 mcg IM q.w
Interferon beta‐1a 
44 mcg SC t.i.w
Interferon beta‐
1a 60 mcg IM q.w
glatiramer 
acetate 20mg q.d
dimethyl fumarate 
240 mg two times 
daily
dimethyl fumarate 
240 mg three 
times daily
Teriflunomide oral 
7 mg 
Teriflunomide oral 
14 mg
Fingolimod oral 
0.5 mg 
Fingolimod oral 
1.25 mg  
Peginterferon 
beta‐1a 125 mcg 
once every 2 
weeks 
peginterferon 
beta‐1a 125 mcg 
once every 4 
weeks  Natalizumab
Interferon beta‐1b 
250 mcg SC every 
other day
Interferon beta‐
1b 500 mcg SC 
every other day
Placebo 1
Alemtuzumab 12 mg IV q.d 0.4 (0.27 to 0.6) 1
Alemtuzumab 24 mg IV q.d 0.36 (0.16 to 0.74) 0.91 (0.42 to 1.8) 1
Interferon beta‐1a 22 mcg SC t.i.w 0.84 (0.61 to 1.19) 2.12 (1.34 to 3.34) 2.33 (1.09 to 5.26) 1
Interferon beta‐1a 30 mcg IM q.w 0.8 (0.65 to 0.99) 2.01 (1.32 to 3.01) 2.21 (1.05 to 4.94) 0.95 (0.65 to 1.38) 1
Interferon beta‐1a 44 mcg SC t.i.w 0.77 (0.6 to 1.01) 1.95 (1.45 to 2.59) 2.15 (1.1 to 4.55) 0.92 (0.65 to 1.3) 0.97 (0.73 to 1.3) 1
Interferon beta‐1a 60 mcg IM q.w 0.79 (0.54 to 1.19) 2. (1.17 to 3.37) 2.22 (0.96 to 5.17) 0.94 (0.57 to 1.56) 0.99 (0.71 to 1.39) 1.03 (0.66 to 1.58) 1
glatiramer acetate 20mg q.d 0.78 (0.63 to 0.96) 1.97 (1.28 to 2.92) 2.17 (1.04 to 4.9) 0.93 (0.63 to 1.35) 0.98 (0.76 to 1.23) 1.01 (0.75 to 1.33) 0.99 (0.64 to 1.47) 1
dimethyl fumarate 240 mg two 
times daily 0.65 (0.49 to 0.85) 1.63 (1.01 to 2.57) 1.82 (0.81 to 4.18) 0.77 (0.5 to 1.17) 0.81 (0.58 to 1.13) 0.84 (0.58 to 1.2) 0.82 (0.51 to 1.29) 0.83 (0.61 to 1.15) 1
dimethyl fumarate 240 mg three 
times daily 0.68 (0.52 to 0.89) 1.73 (1.06 to 2.69) 1.9 (0.88 to 4.31) 0.81 (0.52 to 1.22) 0.86 (0.62 to 1.17) 0.89 (0.61 to 1.26) 0.86 (0.54 to 1.36) 0.88 (0.64 to 1.18) 1.06 (0.78 to 1.42) 1
Teriflunomide oral 7 mg  0.8 (0.55 to 1.13) 2. (1.15 to 3.35) 2.2 (0.99 to 5.4) 0.94 (0.57 to 1.52) 0.99 (0.65 to 1.48) 1.03 (0.65 to 1.58) 1.01 (0.58 to 1.69) 1.01 (0.67 to 1.53) 1.23 (0.78 to 1.91) 1.16 (0.74 to 1.81) 1
Teriflunomide oral 14 mg 0.73 (0.51 to 1.05) 1.85 (1.06 to 3.11) 2.03 (0.91 to 4.89) 0.87 (0.52 to 1.41) 0.93 (0.6 to 1.38) 0.95 (0.6 to 1.46) 0.92 (0.54 to 1.57) 0.94 (0.62 to 1.43) 1.13 (0.72 to 1.76) 1.07 (0.68 to 1.69) 0.92 (0.64 to 1.35) 1
Fingolimod oral 0.5 mg  0.71 (0.55 to 0.9) 1.78 (1.11 to 2.77) 1.96 (0.92 to 4.55) 0.83 (0.54 to 1.26) 0.89 (0.65 to 1.16) 0.91 (0.64 to 1.3) 0.89 (0.57 to 1.37) 0.9 (0.66 to 1.23) 1.09 (0.75 to 1.57) 1.03 (0.72 to 1.48) 0.89 (0.58 to 1.37) 0.97 (0.62 to 1.5) 1
Fingolimod oral 1.25 mg   0.71 (0.56 to 0.9) 1.8 (1.12 to 2.78) 1.96 (0.93 to 4.49) 0.85 (0.55 to 1.26) 0.89 (0.66 to 1.18) 0.92 (0.65 to 1.3) 0.9 (0.57 to 1.38) 0.91 (0.67 to 1.25) 1.1 (0.77 to 1.59) 1.04 (0.73 to 1.49) 0.9 (0.59 to 1.38) 0.97 (0.63 to 1.5) 1.01 (0.78 to 1.32) 1
Peginterferon beta‐1a 125 mcg once 
every 2 weeks  0.61 (0.36 to 0.98) 1.53 (0.8 to 2.87) 1.68 (0.69 to 4.18) 0.72 (0.39 to 1.28) 0.76 (0.43 to 1.27) 0.78 (0.44 to 1.36) 0.77 (0.4 to 1.4) 0.78 (0.45 to 1.31) 0.94 (0.53 to 1.62) 0.89 (0.5 to 1.55) 0.77 (0.41 to 1.4) 0.83 (0.44 to 1.49) 0.86 (0.49 to 1.49) 0.86 (0.49 to 1.47) 1
peginterferon beta‐1a 125 mcg once 
every 4 weeks  0.62 (0.38 to 1.01) 1.56 (0.84 to 2.86) 1.74 (0.71 to 4.23) 0.73 (0.4 to 1.33) 0.78 (0.46 to 1.33) 0.8 (0.46 to 1.38) 0.79 (0.41 to 1.44) 0.8 (0.47 to 1.37) 0.96 (0.55 to 1.66) 0.91 (0.52 to 1.57) 0.79 (0.43 to 1.43) 0.85 (0.46 to 1.55) 0.88 (0.51 to 1.54) 0.87 (0.51 to 1.53) 1.02 (0.61 to 1.74) 1
Natalizumab 0.59 (0.42 to 0.84) 1.49 (0.86 to 2.5) 1.65 (0.73 to 3.9) 0.7 (0.43 to 1.13) 0.74 (0.49 to 1.11) 0.76 (0.49 to 1.18) 0.75 (0.44 to 1.25) 0.75 (0.5 to 1.15) 0.91 (0.59 to 1.42) 0.86 (0.56 to 1.34) 0.74 (0.45 to 1.23) 0.8 (0.49 to 1.34) 0.84 (0.55 to 1.28) 0.83 (0.55 to 1.27) 0.97 (0.53 to 1.81) 0.94 (0.53 to 1.73) 1
Interferon beta‐1b 250 mcg SC every 
other day 0.72 (0.54 to 0.92) 1.8 (1.1 to 2.77) 1.97 (0.92 to 4.52) 0.85 (0.54 to 1.26) 0.9 (0.65 to 1.17) 0.93 (0.64 to 1.28) 0.9 (0.56 to 1.36) 0.92 (0.69 to 1.16) 1.1 (0.75 to 1.58) 1.05 (0.72 to 1.48) 0.9 (0.57 to 1.38) 0.98 (0.61 to 1.51) 1.02 (0.7 to 1.42) 1.01 (0.69 to 1.41) 1.17 (0.66 to 2.07) 1.16 (0.63 to 0.74) 1.22 (0.76 to 1.84) 1
Interferon beta‐1b 500 mcg SC every 
other day 0.79 (0.56 to 1.1) 1.99 (1.18 to 3.2) 2.18 (1. to 5.02) 0.94 (0.58 to 1.47) 0.99 (0.68 to 1.39) 1.02 (0.68 to 1.49) 1. (0.6 to 1.59) 1.01 (0.74 to 1.36) 1.22 (0.8 to 1.84) 1.15 (0.77 to 1.73) 1. (0.6 to 1.61) 1.08 (0.65 to 1.76) 1.12 (0.74 to 1.68) 1.11 (0.73 to 1.66) 1.3 (0.71 to 2.38) 1.27 (0.68 to 1.19) 1.34 (0.81 to 2.16) 1.1 (0.84 to 1.51) 1
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A6.3: Withdrawal due to adverse events 
 
 
  
Treatment Placebo
Alemtuzumab 12 
mg IV q.d
Alemtuzumab 24 
mg IV q.d
Interferon beta‐1a 
22 mcg SC t.i.w
Interferon beta‐1a 
30 mcg IM q.w
Interferon beta‐1a 
44 mcg SC t.i.w
Interferon beta‐
1a 60 mcg IM q.w
glatiramer 
acetate 20mg q.d
glatiramer 
acetate 40mg t.i.w
dimethyl fumarate 
240 mg two times 
daily
dimethyl fumarate 
240 mg three 
times daily
Teriflunomide oral 
7 mg 
Teriflunomide oral 
14 mg
Fingolimod oral 
0.5 mg 
Fingolimod oral 
1.25 mg  
Peginterferon 
beta‐1a 125 mcg 
once every 2 
weeks 
peginterferon 
beta‐1a 125 mcg 
once every 4 
weeks  Natalizumab
Interferon beta‐
1b 250 mcg SC 
every other day
Interferon 
beta‐1b 500 
mcg SC 
every other 
day
Placebo 1
Alemtuzumab 12 mg IV q.d 0.61 (0.25 to 1.47) 1
Alemtuzumab 24 mg IV q.d 0.54 (0.17 to 1.54) 0.88 (0.3 to 2.31) 1
Interferon beta‐1a 22 mcg SC t.i.w 1.68 (0.5 to 5.98) 2.78 (0.7 to 11.12) 3.16 (0.7 to 15.17) 1
Interferon beta‐1a 30 mcg IM q.w 1.33 (0.85 to 2.17) 2.18 (0.89 to 5.5) 2.46 (0.85 to 8.1) 0.8 (0.22 to 2.82) 1
Interferon beta‐1a 44 mcg SC t.i.w 2.2 (1.29 to 3.97) 3.6 (1.88 to 7.33) 4.08 (1.69 to 11.42) 1.31 (0.4 to 4.36) 1.65 (0.91 to 3.08) 1
Interferon beta‐1a 60 mcg IM q.w 1.9 (0.79 to 4.81) 3.1 (0.96 to 10.5) 3.5 (0.95 to 14.59) 1.14 (0.25 to 4.94) 1.43 (0.66 to 3.11) 0.86 (0.32 to 2.29) 1
glatiramer acetate 20mg q.d 1.17 (0.74 to 1.94) 1.91 (0.79 to 4.89) 2.16 (0.76 to 7.2) 0.7 (0.19 to 2.48) 0.88 (0.51 to 1.55) 0.53 (0.29 to 0.96) 0.62 (0.24 to 1.63) 1
glatiramer acetate 40mg t.i.w 2.5 (0.86 to 8.29) 4.08 (1.02 to 18.4) 4.7 (1.05 to 24.1) 1.47 (0.29 to 8.02) 1.87 (0.58 to 6.69) 1.13 (0.33 to 4.18) 1.32 (0.32 to 5.79) 2.13 (0.65 to 7.5) 1
dimethyl fumarate 240 mg two times 
daily 1.24 (0.74 to 2.13) 2.02 (0.75 to 5.59) 2.29 (0.74 to 8.12) 0.74 (0.19 to 2.73) 0.94 (0.47 to 1.82) 0.56 (0.27 to 1.15) 0.66 (0.23 to 1.81) 1.07 (0.56 to 1.92) 0.5 (0.14 to 1.64) 1
dimethyl fumarate 240 mg three times 
daily 1.25 (0.74 to 2.13) 2.03 (0.76 to 5.6) 2.32 (0.74 to 8.16) 0.75 (0.19 to 2.74) 0.94 (0.47 to 1.83) 0.57 (0.27 to 1.17) 0.66 (0.23 to 1.81) 1.07 (0.56 to 1.93) 0.5 (0.14 to 1.65) 1.01 (0.58 to 1.73) 1
Teriflunomide oral 7 mg  1.37 (0.82 to 2.21) 2.24 (0.87 to 5.55) 2.53 (0.85 to 8.25) 0.82 (0.22 to 2.84) 1.03 (0.52 to 1.91) 0.62 (0.31 to 1.12) 0.72 (0.25 to 1.9) 1.17 (0.57 to 2.16) 0.55 (0.15 to 1.74) 1.1 (0.52 to 2.19) 1.1 (0.52 to 2.19) 1
Teriflunomide oral 14 mg 1.53 (0.96 to 2.54) 2.51 (1.02 to 6.37) 2.85 (0.98 to 9.45) 0.9 (0.25 to 3.25) 1.15 (0.61 to 2.19) 0.69 (0.37 to 1.28) 0.81 (0.29 to 2.2) 1.31 (0.68 to 2.48) 0.62 (0.17 to 1.99) 1.23 (0.62 to 2.54) 1.23 (0.61 to 2.53) 1.12 (0.73 to 1.85) 1
Fingolimod oral 0.5 mg  1.54 (0.98 to 2.52) 2.52 (0.96 to 6.8) 2.85 (0.93 to 9.82) 0.91 (0.24 to 3.35) 1.16 (0.65 to 2.04) 0.7 (0.34 to 1.4) 0.81 (0.31 to 2.1) 1.31 (0.68 to 2.48) 0.62 (0.17 to 1.99) 1.24 (0.62 to 2.52) 1.24 (0.62 to 2.5) 1.12 (0.59 to 2.29) 1.01 (0.52 to 1.96) 1
Fingolimod oral 1.25 mg   2.21 (1.42 to 3.58) 3.62 (1.38 to 9.71) 4.09 (1.34 to 14.02) 1.31 (0.35 to 4.8) 1.66 (0.94 to 2.91) 1. (0.49 to 1.99) 1.16 (0.45 to 3.02) 1.88 (0.99 to 3.53) 0.89 (0.25 to 2.84) 1.78 (0.89 to 3.61) 1.77 (0.89 to 3.6) 1.6 (0.86 to 3.27) 1.45 (0.74 to 2.79) 1.43 (0.94 to 2.21) 1
Peginterferon beta‐1a 125 mcg once 
every 2 weeks  3.57 (1.27 to 11.14) 5.78 (1.51 to 24.42) 6.67 (1.5 to 33.69) 2.12 (0.41 to 11.18) 2.67 (0.85 to 9.09) 1.62 (0.49 to 5.69) 1.88 (0.47 to 7.82) 3.04 (0.95 to 10.19) 1.43 (0.29 to 6.88) 2.87 (0.9 to 9.95) 2.85 (0.9 to 9.93) 2.59 (0.84 to 9.15) 2.31 (0.73 to 8.02) 2.3 (0.73 to 7.85) 1.61 (0.51 to 5.43) 1
peginterferon beta‐1a 125 mcg once 
every 4 weeks  3.47 (1.25 to 10.9) 5.75 (1.48 to 24.35) 6.48 (1.48 to 33.07) 2.07 (0.4 to 10.92) 2.61 (0.83 to 8.91) 1.58 (0.48 to 5.61) 1.83 (0.46 to 7.75) 2.96 (0.94 to 10.) 1.4 (0.29 to 6.78) 2.8 (0.87 to 9.8) 2.78 (0.88 to 9.76) 2.54 (0.83 to 8.99) 2.28 (0.72 to 7.88) 2.27 (0.72 to 7.71) 1.59 (0.5 to 5.33) 0.98 (0.41 to 2.37) 1
Natalizumab 1.22 (0.5 to 2.74) 1.98 (0.56 to 6.49) 2.26 (0.56 to 8.94) 0.72 (0.15 to 3.06) 0.91 (0.32 to 2.31) 0.55 (0.18 to 1.44) 0.65 (0.17 to 2.1) 1.04 (0.36 to 2.6) 0.48 (0.11 to 1.84) 0.98 (0.34 to 2.52) 0.98 (0.33 to 2.53) 0.89 (0.32 to 2.3) 0.79 (0.28 to 2.) 0.79 (0.28 to 1.98) 0.55 (0.19 to 1.36) 0.34 (0.08 to 1.54) 0.34 (0.08 to 1.28) 1
Interferon beta‐1b 250 mcg SC every 
other day 0.84 (0.4 to 1.87) 1.36 (0.46 to 4.29) 1.56 (0.46 to 6.11) 0.49 (0.12 to 2.07) 0.63 (0.28 to 1.44) 0.38 (0.16 to 0.93) 0.44 (0.15 to 1.37) 0.72 (0.35 to 1.49) 0.33 (0.09 to 1.28) 0.68 (0.29 to 1.67) 0.67 (0.29 to 1.67) 0.61 (0.26 to 1.57) 0.55 (0.23 to 1.34) 0.54 (0.23 to 1.32) 0.38 (0.16 to 0.92) 0.23 (0.06 to 5.98) 0.24 (0.06 to 0.9) 0.7 (0.23 to 2.37) 1
Interferon beta‐1b 500 mcg SC every 
other day 1.37 (0.52 to 3.92) 2.25 (0.63 to 8.47) 2.55 (0.64 to 11.48) 0.8 (0.17 to 3.91) 1.03 (0.37 to 2.99) 0.62 (0.21 to 1.9) 0.72 (0.2 to 2.71) 1.16 (0.46 to 3.05) 0.54 (0.12 to 2.46) 1.1 (0.38 to 3.38) 1.09 (0.38 to 3.39) 1. (0.34 to 3.22) 0.89 (0.3 to 2.74) 0.89 (0.3 to 2.73) 0.62 (0.21 to 1.9) 0.38 (0.09 to 2.17) 0.39 (0.09 to 1.75) 1.13 (0.32 to 4.63)1.63 (0.66 to 4.11 1
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A6.4: Change in Expanded Disability Status Scale 
 
 
 
 
  
Treatment Placebo
Alemtuzumab 12 
mg IV q.d
Alemtuzumab 24 mg IV 
q.d
Interferon beta‐1a 
22 mcg SC t.i.w
Interferon beta‐1a 
30 mcg IM q.w
Interferon beta‐1a 
44 mcg SC t.i.w
Interferon beta‐
1a 60 mcg IM q.w
glatiramer 
acetate 20mg q.d
Teriflunomide oral 
7 mg 
Teriflunomide oral 
14 mg
Fingolimod oral 
0.5 mg 
Fingolimod oral 
1.25 mg  
Interferon beta‐1b 
250 mcg SC every 
other day
Placebo 1
Alemtuzumab 12 mg IV q.d ‐0.6 (‐1.02 to ‐0.24) 1
Alemtuzumab 24 mg IV q.d ‐0.91 (‐1.48 to ‐0.4) ‐0.31 (‐0.76 to 0.15) 1
Interferon beta‐1a 22 mcg SC t.i.w ‐0.27 (‐0.71 to 0.15) 0.33 (‐0.15 to 0.85) 0.64 (0.03 to 1.28) 1
Interferon beta‐1a 30 mcg IM q.w ‐0.22 (‐0.48 to 0.02) 0.38 (0.04 to 0.77) 0.69 (0.18 to 1.24) 0.05 (‐0.4 to 0.51) 1
Interferon beta‐1a 44 mcg SC t.i.w ‐0.28 (‐0.58 to ‐0.02) 0.32 (0.07 to 0.6) 0.63 (0.18 to 1.1) ‐0.01 (‐0.44 to 0.41) ‐0.06 (‐0.32 to 0.18) 1
Interferon beta‐1a 60 mcg IM q.w ‐0.25 (‐0.76 to 0.24) 0.35 (‐0.19 to 0.95) 0.66 (0. to 1.36) 0.02 (‐0.6 to 0.65) ‐0.03 (‐0.47 to 0.41) 0.03 (‐0.46 to 0.54) 1
glatiramer acetate 20mg q.d ‐0.13 (‐0.4 to 0.11) 0.47 (0.08 to 0.9) 0.78 (0.24 to 1.35) 0.14 (‐0.33 to 0.61) 0.09 (‐0.2 to 0.38) 0.15 (‐0.15 to 0.47) 0.12 (‐0.41 to 0.64) 1
Teriflunomide oral 7 mg  ‐0.05 (‐0.47 to 0.36) 0.55 (0.01 to 1.15) 0.86 (0.21 to 1.57) 0.22 (‐0.36 to 0.83) 0.17 (‐0.3 to 0.66) 0.23 (‐0.25 to 0.75) 0.19 (‐0.44 to 0.86) 0.08 (‐0.4 to 0.58) 1
Teriflunomide oral 14 mg ‐0.14 (‐0.56 to 0.27) 0.46 (‐0.08 to 1.06) 0.77 (0.12 to 1.48) 0.13 (‐0.46 to 0.74) 0.08 (‐0.39 to 0.57) 0.14 (‐0.34 to 0.66) 0.11 (‐0.53 to 0.77)‐0.01 (‐0.48 to 0.49) ‐0.09 (‐0.5 to 0.33) 1
Fingolimod oral 0.5 mg  ‐0.16 (‐0.41 to 0.1) 0.44 (0.04 to 0.91) 0.76 (0.21 to 1.36) 0.12 (‐0.36 to 0.61) 0.06 (‐0.22 to 0.36) 0.12 (‐0.2 to 0.48) 0.09 (‐0.42 to 0.63)‐0.03 (‐0.35 to 0.33) ‐0.1 (‐0.59 to 0.38) ‐0.02 (‐0.5 to 0.47) 1
Fingolimod oral 1.25 mg   ‐0.22 (‐0.47 to 0.04) 0.38 (‐0.02 to 0.85) 0.69 (0.14 to 1.3) 0.06 (‐0.42 to 0.55) 0. (‐0.28 to 0.3) 0.06 (‐0.26 to 0.42) 0.03 (‐0.48 to 0.56)‐0.09 (‐0.42 to 0.26) ‐0.17 (‐0.65 to 0.32) ‐0.08 (‐0.56 to 0.41) ‐0.06 (‐0.3 to 0.18) 1
Interferon beta‐1b 250 mcg SC every 
other day ‐0.58 (‐0.94 to ‐0.22) 0.02 (‐0.37 to 0.47) 0.33 (‐0.21 to 0.92) ‐0.31 (‐0.81 to 0.21)‐0.36 (‐0.64 to ‐0.06) ‐0.3 (‐0.61 to 0.04) ‐0.33 (‐0.84 to 0.2)‐0.45 (‐0.83 to ‐0.05)‐0.53 (‐1.08 to 0.02) ‐0.44 (‐0.99 to 0.11)‐0.42 (‐0.82 to ‐0.02)‐0.36 (‐0.76 to 0.04) 1
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A6.5: Serious adverse events 
 
 
 
  
Treatment Placebo
Alemtuzumab 12 
mg IV q.d
Alemtuzumab 24 
mg IV q.d
Interferon beta‐1a 
30 mcg IM q.w
Interferon beta‐1a 
44 mcg SC t.i.w
glatiramer 
acetate 20mg q.d
glatiramer 
acetate 40mg 
t.i.w
dimethyl fumarate 
240 mg two times 
daily
dimethyl fumarate 
240 mg three 
times daily
Teriflunomide oral 
7 mg 
Teriflunomide oral 
14 mg
Fingolimod oral 
0.5 mg 
Fingolimod oral 
1.25 mg  
Peginterferon 
beta‐1a 125 mcg 
once every 2 
weeks 
peginterferon 
beta‐1a 125 mcg 
once every 4 
weeks  Natalizumab
Interferon beta‐1b 
250 mcg SC every 
other day
Interferon beta‐1b 
500 mcg SC every 
other day
Placebo 1
Alemtuzumab 12 mg IV q.d 0.67 (0.37 to 1.28) 1
Alemtuzumab 24 mg IV q.d 0.79 (0.42 to 1.53) 1.18 (0.79 to 1.71) 1
Interferon beta‐1a 30 mcg IM q.w 0.77 (0.54 to 1.13) 1.14 (0.61 to 2.07) 0.97 (0.51 to 1.83) 1
Interferon beta‐1a 44 mcg SC t.i.w 0.86 (0.52 to 1.46) 1.28 (0.91 to 1.75) 1.09 (0.74 to 1.59) 1.12 (0.67 to 1.86) 1
glatiramer acetate 20mg q.d 0.78 (0.54 to 1.14) 1.16 (0.62 to 2.08) 0.99 (0.52 to 1.83) 1.01 (0.67 to 1.53) 0.91 (0.55 to 1.49) 1
glatiramer acetate 40mg t.i.w 0.99 (0.49 to 2.04) 1.47 (0.57 to 3.72) 1.25 (0.48 to 3.23) 1.28 (0.58 to 2.87) 1.15 (0.48 to 2.75) 1.27 (0.57 to 2.83) 1
dimethyl fumarate 240 mg two 
times daily 0.81 (0.56 to 1.19) 1.21 (0.59 to 2.36) 1.03 (0.49 to 2.07) 1.05 (0.63 to 1.72) 0.94 (0.51 to 1.71) 1.04 (0.65 to 1.63) 0.82 (0.36 to 1.81) 1
dimethyl fumarate 240 mg three 
times daily 0.72 (0.49 to 1.07) 1.08 (0.52 to 2.1) 0.92 (0.44 to 1.84) 0.94 (0.56 to 1.54) 0.84 (0.45 to 1.53) 0.93 (0.58 to 1.46) 0.73 (0.33 to 1.62) 0.89 (0.6 to 1.33) 1
Teriflunomide oral 7 mg  1.03 (0.71 to 1.51) 1.54 (0.77 to 2.92) 1.31 (0.64 to 2.58) 1.34 (0.8 to 2.2) 1.2 (0.67 to 2.12) 1.33 (0.79 to 2.19) 1.05 (0.46 to 2.31) 1.28 (0.75 to 2.16) 1.43 (0.84 to 2.44) 1
Teriflunomide oral 14 mg 1.07 (0.73 to 1.54) 1.58 (0.78 to 3.01) 1.35 (0.66 to 2.65) 1.38 (0.82 to 2.26) 1.24 (0.68 to 2.18) 1.37 (0.81 to 2.24) 1.08 (0.48 to 2.36) 1.32 (0.77 to 2.21) 1.48 (0.86 to 2.49) 1.03 (0.71 to 1.48) 1
Fingolimod oral 0.5 mg  0.96 (0.68 to 1.39) 1.43 (0.71 to 2.77) 1.22 (0.59 to 2.44) 1.25 (0.8 to 1.95) 1.12 (0.61 to 2.01) 1.24 (0.76 to 2.01) 0.97 (0.44 to 2.14) 1.19 (0.71 to 1.99) 1.33 (0.8 to 2.25) 0.93 (0.56 to 1.56) 0.9 (0.55 to 1.52) 1
Fingolimod oral 1.25 mg   1.22 (0.87 to 1.77) 1.81 (0.91 to 3.53) 1.54 (0.76 to 3.11) 1.58 (1.03 to 2.47) 1.41 (0.79 to 2.56) 1.56 (0.97 to 2.55) 1.23 (0.56 to 2.74) 1.5 (0.92 to 2.55) 1.68 (1.03 to 2.88) 1.18 (0.72 to 1.99) 1.14 (0.7 to 1.95) 1.26 (0.91 to 1.8) 1
Peginterferon beta‐1a 125 mcg once 
every 2 weeks  1.67 (0.94 to 2.94) 2.48 (1.04 to 5.55) 2.11 (0.88 to 4.9) 2.16 (1.08 to 4.21) 1.93 (0.88 to 4.1) 2.14 (1.06 to 4.16) 1.69 (0.68 to 4.13) 2.06 (1.03 to 4.07) 2.31 (1.16 to 4.57) 1.62 (0.81 to 3.16) 1.56 (0.79 to 3.1) 1.73 (0.87 to 3.34) 1.37 (0.69 to 2.62) 1
peginterferon beta‐1a 125 mcg once 
every 4 weeks  1.55 (0.88 to 2.74) 2.31 (0.97 to 5.19) 1.96 (0.81 to 4.57) 2.02 (1. to 3.95) 1.8 (0.82 to 3.85) 2. (0.99 to 3.89) 1.57 (0.63 to 3.84) 1.92 (0.95 to 3.8) 2.15 (1.07 to 4.25) 1.5 (0.75 to 2.96) 1.45 (0.74 to 2.9) 1.61 (0.81 to 3.12) 1.28 (0.64 to 2.43) 0.93 (0.54 to 1.61) 1
Natalizumab 0.81 (0.49 to 1.39) 1.21 (0.53 to 2.62) 1.03 (0.45 to 2.31) 1.06 (0.56 to 1.99) 0.95 (0.46 to 1.93) 1.04 (0.56 to 1.95) 0.82 (0.34 to 1.97) 1.01 (0.53 to 1.92) 1.13 (0.6 to 2.15) 0.79 (0.42 to 1.5) 0.76 (0.41 to 1.47) 0.85 (0.46 to 1.59) 0.67 (0.36 to 1.23) 0.49 (0.23 to 1.07) 0.52 (0.25 to 1.15) 1
Interferon beta‐1b 250 mcg SC every 
other day 0.66 (0.35 to 1.26) 0.99 (0.43 to 2.18) 0.84 (0.36 to 1.9) 0.86 (0.43 to 1.68) 0.77 (0.36 to 1.61) 0.85 (0.49 to 1.45) 0.67 (0.25 to 1.72) 0.82 (0.4 to 1.64) 0.92 (0.45 to 1.86) 0.64 (0.31 to 1.33) 0.62 (0.3 to 1.31) 0.69 (0.33 to 1.41) 0.55 (0.26 to 1.09) 0.4 (0.17 to 0.94) 0.43 (0.18 to 1.02) 0.82 (0.36 to 1.78) 1
Interferon beta‐1b 500 mcg SC every 
other day 0.93 (0.49 to 1.8) 1.38 (0.6 to 3.05) 1.18 (0.5 to 2.67) 1.21 (0.61 to 2.36) 1.08 (0.51 to 2.25) 1.19 (0.69 to 2.06) 0.94 (0.36 to 2.43) 1.15 (0.57 to 2.33) 1.29 (0.64 to 2.63) 0.9 (0.43 to 1.9) 0.87 (0.42 to 1.85) 0.97 (0.46 to 2.) 0.77 (0.36 to 1.55) 0.56 (0.24 to 1.34) 0.6 (0.25 to 1.44) 1.14 (0.5 to 1.53) 1.4 (0.83 to 2.4) 1
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A6.6: Mortality 
 
 
  
Treatment Placebo
Alemtuzumab 12 
mg IV q.d
Alemtuzumab 24 
mg IV q.d
Interferon beta‐1a 
22 mcg SC t.i.w
Interferon beta‐1a 
30 mcg IM q.w
Interferon beta‐1a 
44 mcg SC t.i.w
Interferon beta‐
1a 60 mcg IM q.w
glatiramer 
acetate 20mg q.d
glatiramer 
acetate 40mg t.i.w
dimethyl fumarate 
240 mg two times 
daily
dimethyl fumarate 
240 mg three 
times daily
Teriflunomide oral 
7 mg 
Teriflunomide oral 
14 mg
Fingolimod oral 
0.5 mg 
Fingolimod oral 
1.25 mg  
Peginterferon 
beta‐1a 125 mcg 
once every 2 
weeks 
peginterferon 
beta‐1a 125 mcg 
once every 4 
weeks  Natalizumab
Interferon beta‐
1b 250 mcg SC 
every other day
Interferon 
beta‐1b 500 
mcg SC 
every other 
day
Placebo 1
Alemtuzumab 12 mg IV q.d 2.81 (0.08 to 168.2) 1
Alemtuzumab 24 mg IV q.d 2.08 (0.04 to 125.5) 0.73 (0.06 to 5.88) 1
Interferon beta‐1a 22 mcg SC t.i.w 1.6 (0.07 to 34.77) 0.55 (0.01 to 24.67) 0.78 (0.01 to 51.33) 1
Interferon beta‐1a 30 mcg IM q.w 2.1 (0.26 to 24.45) 0.82 (0.01 to 40.09) 1.09 (0.01 to 84.65) 1.4 (0.04 to 55.3) 1
Interferon beta‐1a 44 mcg SC t.i.w 0.97 (0.06 to 17.15) 0.35 (0.02 to 2.55) 0.46 (0.02 to 6.62) 0.62 (0.02 to 14.92) 0.43 (0.01 to 12.35) 1
Interferon beta‐1a 60 mcg IM q.w 2.28 (0.03 to 222.1) 0.88 (0. to 177.5) 1.15 (0. to 358.5) 1.51 (0.01 to 308.9) 1.01 (0.02 to 55.64) 2.48 (0.01 to 420.6) 1
glatiramer acetate 20mg q.d 0.9 (0.11 to 7.85) 0.33 (0.01 to 10.23) 0.44 (0.01 to 19.73) 0.55 (0.02 to 22.44) 0.42 (0.03 to 4.39) 0.97 (0.06 to 14.14) 0.41 (0. to 42.93) 1
glatiramer acetate 40mg t.i.w 0.08 (0. to 3.54) 0.02 (0. to 4.79) 0.04 (0. to 8.96) 0.05 (0. to 7.02) 0.04 (0. to 2.97) 0.08 (0. to 9.45) 0.03 (0. to 14.21) 0.09 (0. to 7.16) 1
dimethyl fumarate 240 mg two 
times daily 0.52 (0.04 to 5.34) 0.18 (0. to 10.34) 0.24 (0. to 19.9) 0.32 (0.01 to 14.89) 0.24 (0.01 to 4.56) 0.51 (0.02 to 16.38) 0.22 (0. to 29.21) 0.57 (0.03 to 7.89) 6.69 (0.06 to 7441.) 1
dimethyl fumarate 240 mg three 
times daily 0.89 (0.09 to 8.41) 0.3 (0. to 16.87) 0.42 (0. to 32.89) 0.53 (0.01 to 25.59) 0.42 (0.02 to 7.26) 0.9 (0.03 to 26.01) 0.4 (0. to 46.87) 0.98 (0.08 to 11.73) 1.07 (0.13 to 11810 1.69 (0.18 to 18.19) 1
Teriflunomide oral 7 mg  2.59 (0.12 to 82.51) 0.93 (0. to 126.9) 1.36 (0. to 242.8) 1.66 (0.02 to 167.7) 1.16 (0.03 to 67.28) 2.73 (0.04 to 238.5)1.08 (0.01 to 383.4 2.88 (0.07 to 196.5) 6.05 (0.27 to 53180 5.18 (0.12 to 307.1) 3.08 (0.07 to 174.6) 1
Teriflunomide oral 14 mg 0.94 (0.02 to 37.74) 0.33 (0. to 56.46) 0.48 (0. to 98.06) 0.58 (0. to 88.85) 0.45 (0. to 34.11) 0.99 (0.01 to 105.1) 0.42 (0. to 157.2) 1.05 (0.01 to 71.67) 2.64 (0.05 to 19540 1.88 (0.02 to 147.7) 1.1 (0.01 to 79.34) 0.39 (0.01 to 7.5) 1
Fingolimod oral 0.5 mg  0.1 (0. to 2.57) 0.03 (0. to 4.24) 0.04 (0. to 8.67) 0.05 (0. to 5.39) 0.04 (0. to 2.2) 0.08 (0. to 8.4) 0.04 (0. to 12.77) 0.1 (0. to 5.12) 1.03 (0. to 1842.) 0.17 (0. to 12.01) 0.1 (0. to 6.16) 0.03 (0. to 3.64) 0.09 (0. to 18.86) 1
Fingolimod oral 1.25 mg   0.52 (0.02 to 6.76) 0.17 (0. to 13.59) 0.24 (0. to 24.79) 0.31 (0. to 17.09) 0.24 (0.01 to 6.36) 0.5 (0.01 to 23.87) 0.22 (0. to 40.74) 0.57 (0.01 to 15.09) 6.57 (0.05 to 8530.) 0.98 (0.02 to 36.2) 0.59 (0.01 to 17.31) 0.19 (0. to 9.23) 0.5 (0. to 63.23) 5.46 (0.12 to 4103.) 1
Peginterferon beta‐1a 125 mcg once 
every 2 weeks  0.41 (0.01 to 8.87) 0.13 (0. to 12.73) 0.18 (0. to 25.17) 0.25 (0. to 19.58) 0.17 (0. to 8.06) 0.41 (0. to 22.98) 0.17 (0. to 38.09) 0.43 (0.01 to 19.38) 5.11 (0.02 to 7408.) 0.79 (0.01 to 44.58) 0.44 (0.01 to 21.56) 0.15 (0. to 11.05) 0.42 (0. to 71.51) 4.72 (0.02 to 4890.) 0.79 (0.01 to 65.78) 1
peginterferon beta‐1a 125 mcg once 
every 4 weeks  0.4 (0.01 to 10.22) 0.13 (0. to 14.86) 0.18 (0. to 26.14) 0.24 (0. to 19.82) 0.17 (0. to 8.86) 0.39 (0. to 24.78) 0.16 (0. to 42.68) 0.42 (0. to 20.5) 4.75 (0.02 to 7254.) 0.78 (0.01 to 43.94) 0.45 (0. to 21.3) 0.14 (0. to 10.48) 0.4 (0. to 69.74) 4.66 (0.03 to 5197.) 0.74 (0.01 to 66.19) 1. (0.02 to 44.74) 1
Natalizumab 4.34 (0.16 to 2761.) 1.73 (0.01 to 2475.) 2.19 (0.01 to 4596.) 3.03 (0.04 to 3566.) 2.21 (0.03 to 2092.) 5.17 (0.06 to 4779.)2.53 (0.01 to 3792. 5.25 (0.1 to 4005.) 9.25 (0.34 to 2017009.32 (0.14 to 8262.) 5.45 (0.09 to 4151.) 1.88 (0.02 to 1428.) 5.75 (0.03 to 5626.)6.43 (0.48 to 3403009.91 (0.14 to 10330.12.92 (0.12 to 125.513.91 (0.12 to 23380 1
Interferon beta‐1b 250 mcg SC every 
other day 0.07 (0. to 6.65) 0.02 (0. to 4.5) 0.03 (0. to 7.49) 0.04 (0. to 8.89) 0.03 (0. to 3.51) 0.08 (0. to 8.68) 0.03 (0. to 16.62) 0.08 (0. to 3.74) 0.93 (0. to 1388.) 0.14 (0. to 17.77) 0.08 (0. to 9.03) 0.02 (0. to 6.09) 0.07 (0. to 25.39) 0.8 (0. to 1492.) 0.14 (0. to 31.76) 0.18 (0. to 34.77) 0.17 (0. to 154.9) 0.01 (0. to 4.83) 1
Interferon beta‐1b 500 mcg SC every 
other day 0.08 (0. to 5.9) 0.02 (0. to 4.32) 0.04 (0. to 8.01) 0.05 (0. to 8.57) 0.03 (0. to 3.12) 0.08 (0. to 7.76) 0.03 (0. to 13.35) 0.09 (0. to 3.55) 0.95 (0. to 2803.) 0.15 (0. to 17.67) 0.09 (0. to 8.48) 0.03 (0. to 5.52) 0.08 (0. to 31.17) 0.87 (0. to 1764.) 0.15 (0. to 31.31) 0.19 (0. to 24.45) 0.19 (0. to 128.) 0.01 (0. to 4.47) 1.08 (0. to 863.8) 1
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Appendix 7: Results for direct pairwise meta-analyses 
 
A7.1 Annual relapse for multiple sclerosis treatments compared to pla-
cebo  
 
Interventions RR (95% CI) 
Natalizumab 0.31 (0.26 to 0.36) 
Fingolimod oral 1.25 mg   0.44 (0.38 to 0.51) 
Fingolimod oral 0.5 mg  0.45 (0.41 to 0.56) 
Dimethyl fumarate 240 mg two times daily 0.51 (0.44 to 0.60) 
Dimethyl fumarate 240 mg three times daily 0.51 (0.44 to 0.60) 
Interferon beta-1a 44 mcg SC t.i.w. 0.67 (0.58 to 0.77) 
Peg-interferon beta-1a 125 mcg once every 2 weeks  0.64 (0.50 to 0.82) 
Glatiramer acetate 20mg q.d. 0.71 (0.62 to 0.80) 
Glatiramer acetate 40mg t.i.w. 0.66 (0.55 to 0.78) 
Interferon beta-1b 250 mcg SC every other day 0.65 (0.54 to 0.79) 
Teriflunomide oral 14 mg 0.66 (0.58 to 0.75) 
Interferon beta-1a 22 mcg SC t.i.w. 0.71 (0.62 to 0.82) 
Peg-interferon beta-1a 125 mcg once every 4 weeks  0.73 (0.57 to 0.92) 
Teriflunomide oral 7 mg  0.73 (0.65 to 0.82) 
Interferon beta-1a 30 mcg IM q.w. 0.79 (0.69 to 0.89) 
RR= relative ratio, CI= confidence interval, mg= milligrams, mcg= micrograms, SC= subcutaneous, 
IM= intra muscular, q.d.= once daily, q.w.=once weekly, t.i.w.= three times weekly,  
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A7.2: Disability progression for multiple sclerosis treatments compared 
to placebo 
 
 
Interventions  RR (95% CI) 
Natalizumab 0.59 (0.46, 0.75) 
Peg-interferon beta-1a 125 mcg once every 2 
weeks  0.61 (0.39, 0.93) 
Peg-interferon beta-1a 125 mcg once every 4 
weeks  0.62 (0.40, 0.95) 
Dimethyl fumarate 240 mg two times daily 0.66 (0.52, 0.84) 
Dimethyl fumarate 240 mg three times daily 0.70 (0.57, 0.86) 
Fingolimod oral 0.5 mg  0.75 (0.60, 0.92) 
Fingolimod oral 1.25 mg   0.70 (0.57, 0.87) 
Interferon beta-1b 250 mcg SC every other day 0.77 (0.56, 1.04) 
Teriflunomide oral 14 mg 0.74 (0.57, 0.96) 
Interferon beta-1a 44 mcg SC t.i.w 0.71 (0.54, 0.95) 
Glatiramer acetate 20mg q.d 0.92 (0.70, 1.20) 
Teriflunomide oral 7 mg  0.79 (0.61, 1.03) 
Interferon beta-1a 30 mcg IM q.w 0.69 (0.52, 0.91) 
Interferon beta-1a 22 mcg SC t.i.w 0.82 (0.63, 1.07) 
RR= relative ratio, CI= confidence interval, mg= milligrams, mcg= micrograms, SC= subcutaneous, 
IM= intra muscular, q.d.= once daily, q.w.=once weekly, t.i.w.= three times weekly,  
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A7.3: Withdrawal due to adverse events for multiple sclerosis treatments 
compared to placebo 
 
Interventions RR (95% CI) 
Interferon beta-1b 250 mcg SC every other day 0.10 (0.01, 0.76) 
Glatiramer acetate 20mg q.d 1.20 (0.59, 2.43) 
Dimethyl fumarate 240 mg two times daily 1.21 (0.93, 1.57) 
Dimethyl fumarate 240 mg three times daily 1.18 (0.91, 1.53) 
Interferon beta-1a 30 mcg IM q.w 1.55 (0.91, 2.65) 
Teriflunomide oral 7 mg  1.54 (0.81, 2.94) 
Teriflunomide oral 14 mg 1.70 (1.25, 2.33) 
Fingolimod oral 0.5 mg  1.41 (0.89, 2.24) 
Interferon beta-1a 22 mcg SC t.i.w 2.97 (0.61, 14.52) 
Glatiramer acetate 40mg t.i.w 2.36 (0.99, 5.65) 
Interferon beta-1a 44 mcg SC t.i.w 4.57 (1.00, 20.88) 
Fingolimod oral 1.25 mg  1.87 (1.43, 2.45) 
Peg-interferon beta-1a 125 mcg once every 4 weeks  3.43 (1.49, 7.88) 
Peg-interferon beta-1a 125 mcg once every 2 weeks  3.49 (1.52, 7.99) 
RR= relative ratio, CI= confidence interval, mg= milligrams, mcg= micrograms, SC= subcutaneous, 
IM= intra muscular, q.d.= once daily, q.w.=once weekly, t.i.w.= three times weekly,  
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Appendix 8 Monitorings costs 
 
8.1: Monitoring costs associated with each of the treatments (1. year) 
 
Drug NAB-analyses Infusion costs 
Eye examina-
tions 
Startup 
costs 
Medical 
consulta-
tions 
MRI 
Blood 
tests 
(outpatient 
visits) 
Travel 
costs  Total 
Alemtuzumab 
(Lemtrada) 0 
9777 
(5/year) 
0 0 
7350 
(4/year) 
1 
(!/year) 
1008 
(9/year) 
2000 a 22,735 
Dimethyl 
fumarate 
(Tecifidera) 
0 0 0 0 
7350 
(4/year) 
2600 
(1/year) 
0 1600 b 11,550 
Fingolimod  
(Gilenya) 0 0 
2500 
(1/year) 
3750 c 
7350 
(4/year) 
2600 
(1/year) 
112 
(1/year) 
1600 b 17,912 
Glatiramer  ace-
tate 
(Copaxone) 
0 0 0 0 
7350 
(4/year) 
2600 
(1/year) 
0 1600 b 11,550 
Interferon beta-
1a (Avonex) 
7716 
(2/year) 
0 0 0 
7350 
(4/year) 
2600 
(1/year) 
0 1600 b 19,266 
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Interferon beta-
1a 44 mcg 
(Rebif) 
7716 
(2/year) 
0 0 0 
7350 
(4/year) 
2600 
(1/year) 
0 1600 b 19,266 
Interferon beta-
1a 22 mcg 
(Rebif) 
7716 
(2/year) 
0 0 0 
7350 
(4/year) 
2600 
(1/year) 
0 1600 b 19,266 
Interferon beta-
1b (Betaferon) 
7716 
(2/year) 
0 0 0 
7350 
(4/year) 
2600 
(1/year) 
0 1600 b 19,266 
Interferon beta-
1b (Extavia) 
7716 
(2/year) 
0 0 0 
7350 
(4/year) 
2600 
(1/year) 
0 1600 b 19,266 
Natalizumab 
(Tysabri) 
1840 
(2/year) 
16,250 
(13/year) 
0 0 
7350 
(4/year) 
2600 
(1/year) 
0 5200 a 33,240 
Peg-interferon  
beta-1a 
(Plegridy) 
7716 
(2/year) 
0 0 0 
7350 
(4/year) 
2600 
(1/year) 
0 1600 b 19,266 
Teriflunomide 
(Aubagio) 0 0 0 0 
7350 
(4/year) 
2600 
(1/year) 
1344 d 1600 b 12,894 
a Analyses, MR, medical consultations and infusions will be done at the same day. 
b Analyses, MR,  and medical consultations will be done at the same day (4/year). 
c 6 hours observation 
d  Every 14 days for 6 months, then every other month (numbers of medical consultations were deducted) 
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8.2: Monitoring costs associated with each of the treatments (2. year) 
 
Drug NAB-analyses Infusion costs 
Eye examina-
tions 
Startup 
costs 
Medical 
consulta-
tions 
MRI 
Blood 
tests 
(outpatient 
visits) 
Travel 
costs  Total 
Alemtuzumab 
(Lemtrada) 0 
5866 
(3/year) 
0 0 
3675 
(2/year) 
2600 
(1/year) 
1232 
(11/year) 
1200 a 14,573 
Dimethyl 
fumarate 
(Tecifidera) 
0 0 0 0 
3675 
(2/year) 
2600 
(1/year) 
0 800 b 7075 
Fingolimod  
(Gilenya) 0 0 0 0 
3675 
(2/year) 
2600 
(1/year) 
0 800 b 7075 
Glatiramer   
acetate 
(Copaxone) 
0 0 0 0 
3675 
(2/year) 
2600 
(1/year) 
0 800 b 7075 
Interferon beta-
1a (Avonex) 
7716 
(2/year) 
0 0 0 
3675 
(2/year) 
2600 
(1/year) 
0 800 b 14,791 
Interferon beta-
1a 44 mcg 
(Rebif) 
7716 
(2/year) 
0 0 0 
3675 
(2/year) 
2600 
(1/year) 
0 800 b 14,791 
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Interferon beta-
1a 22 mcg 
(Rebif) 
7716 
(2/year) 
0 0 0 
3675 
(2/year) 
2600 
(1/year) 
0 800 b 14,791 
Interferon beta-
1b (Betaferon) 
7716 
(2/year) 
0 0 0 
3675 
(2/year) 
2600 
(1/year) 
0 800 b 14,791 
Interferon beta-
1b (Extavia) 
7716 
(2/year) 
0 0 0 
3675 
(2/year) 
2600 
(1/year) 
0 800 b 14,791 
Natalizumab 
(Tysabri) 0 
16,250 
(13/year) 
0 0 
3675 
(2/year) 
2600 
(1/year) 
0 5200 a 27,725 
Peg-interferon  
beta-1a 
(Plegridy) 
7716 
(2/year) 
0 0 0 
3675 
(2/year) 
2600 
(1/year) 
0 800 b 14,791 
Teriflunomide 
(Aubagio) 0 0 0 0 
3675 
(2/year) 
2600 
(1/year) 
448 c 800 b 7523 
a Analyses, MR, medical consultations and infusions will be done at the same day. 
b Analyses, MR,  and medical consultations will be done at the same day (2/year). 
c Every other month (numbers of medical consultations were deducted) 
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8.3: Monitoring costs associated with each of the treatments (beyond 2. year) 
 
Drug NAB-analyses Infusion costs 
Eye examina-
tions 
Startup 
costs 
Medical 
consulta-
tions 
MRI 
Blood 
tests 
(outpatient 
visits) 
Travel 
costs  Total 
Alemtuzumab a 
(Lemtrada) 0 0 0 0 
3675 
(2/year) 
2600 
(1/year) 
1232 
(11/year; 
only for 3.-5. 
year) 
800 b 
8307 (3.-
5.year) 
7075 
(+5.year) 
Dimethyl 
fumarate 
(Tecifidera) 
0 0 0 0 
3675 
(2/year) 
2600 
(1/year) 
0 800 b 7075 
Fingolimod  
(Gilenya) 0 0 0 0 
3675 
(2/year) 
2600 
(1/year) 
0 800 b 7075 
Glatiramer   
acetate 
(Copaxone) 
0 0 0 0 
3675 
(2/year) 
2600 
(1/year) 
0 800 b 7075 
Interferon beta-
1a (Avonex) 0 0 0 0 
3675 
(2/year) 
2600 
(1/year) 
0 800 b 7075 
Interferon beta-
1a 44 mcg 
(Rebif) 
0 0 0 0 
3675 
(2/year) 
2600 
(1/year) 
0 800 b 7075 
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Interferon beta-
1a 22 mcg 
(Rebif) 
0 0 0 0 
3675 
(2/year) 
2600 
(1/year) 
0 800 b 7075 
Interferon beta-
1b (Betaferon) 0 0 0 0 
3675 
(2/year) 
2600 
(1/year) 
0 800 b 7075 
Interferon beta-
1b (Extavia) 0 0 0 0 
3675 
(2/year) 
2600 
(1/year) 
0 800 b 7075 
Natalizumab 
(Tysabri) 0 
16,250 
(13/year) 
0 0 
3675 
(2/year) 
2600 
(1/year) 
0 5200 c 27,725 
Peg-interferon  
beta-1a 
(Plegridy) 
0 0 0 0 
3675 
(2/year) 
2600 
(1/year) 
0 800 b 7075 
Teriflunomide 
(Aubagio) 0 0 0 0 
3675 
(2/year) 
2600 
(1/year) 
448 d 800 b 7523 
a The majority of patients receiving Alemtuzumab would not need new treatment after 5 –year treatment. It was assumed that 20% of patients 
need extra treatment (12 mg/day for 3 days) (expert opinion). 
b Analyses, MR, medical consultations and infusions will be done at the same day. 
c Analyses, MR,  and medical consultations will be done at the same day (2/year). 
d Every other month (numbers of medical consultations were deducted) 
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Appendix 9 Scenario analyses 
 
9.1:  The results of sensitivity analysis regarding stopping rule at EDSS=7 
(discounted)* 
Drugs 
Total costs 
(NOK) 
Effects 
(QALYs) 
Versus Interferon beta-1b 250 mg (Extavia) 
Sequential 
ICER  
(NOK/QALY) Incremental 
cost (NOK) 
  Incremental 
effect  
(QALYs) 
ICER 
(NOK/QALY) 
Interferon  
beta-1b (Extavia) 
6,026,196 7.45     
Peg-interferon  
beta-1a 
(Plegridy) 
6,290,635 7.64 264,439 0.19 1,424,765 1,424,765 
Natalizumab 
(Tysabri) 
6,956,053 7.71 92,857 0.26 3,549,122 8,710,280 
Dominated therapies 
Interferon 
beta-1b (Beta-
feron) 
6,083,022 7.45 56,826 - 
Dominated by 
interferon 
beta-1b  (Ex-
tavia) 
Dominated by  
interferon beta-
1b (Extavia) 
Glatiramer ace-
tate (Copaxone) 
6,252,584 7.35 226,388 -0.10 Dominated 
Dominated by  
interferon beta-
1b (Extavia) and  
interferon beta-
1b (Betaferon) 
Teriflunomide 
(Aubagio) 
6,332,238 7.42 306,042 -0.03 Dominated 
Dominated by  
interferon beta-
1b (Extavia), in-
terferon beta-1b 
(Betaferon) and 
peg-interferon 
beta-1a 
Interferon  
beta-1a 22 mcg 
(Rebif) 
6,500,898 7.24 474,702 -0.21 Dominated 
Dominated by  
interferon beta-
1b (Extavia), in-
terferon beta-1b 
(Betaferon), peg-
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QALY: quality-adjusted life year; ICER: incremental cost-effectiveness ratio; mcg: mi-
crogram; mg: milligram  
* Alemtuzumab still was more effective (QALYS: 8.22) and less costly (Costs: 4,828,145) rel-
ative to other treatments (dominant strategy). 
  
interferon beta-
1a, glatiramer 
acetate and teri-
flunomide 
Interferon beta-
1a 30 mcg 
(Avonex) 
6,542,166 7.3 515,970 -0.15 Dominated 
Dominated by  
interferon beta-
1b (Extavia), in-
terferon beta-1b 
(Betaferon), peg-
interferon beta-
1a, glatiramer 
acetate and teri-
flunomide 
Interferon 
beta-1a 44 mcg 
(Rebif) 
6,572,277 7.36 546,081 -0.09 Dominated 
Dominated by  
interferon beta-
1b (Extavia), in-
terferon beta-1b 
(Betaferon),  
peg-interferon 
beta-1a, glati-
ramer acetate 
and teriflunomide 
Dimethyl 
fumarate 
(Tecifidera) 
6,692,516 7.58 666,319 0.13 4,953,711 
Dominated by 
peg-interferon 
beta-1a  
Fingolimod 
(Gilenya) 
7,034,538 7.47 1,008,342 0.03 40,301,928 
Dominated by 
peg-interferon 
beta-1a, dimethyl 
fumarate and na-
talizumab  
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9.2: The results of sensitivity analysis using a 30-year time horizon of 
analysis (discounted) * 
Drugs 
Total costs 
(NOK) 
Effects 
 (QALYs) 
Versus Interferon beta-1b 250 mg (Extavia) 
Sequential 
ICER 
(NOK/QALY) Incremental 
cost (NOK) 
  Incremental 
effect  
(QALYs) 
ICER 
(NOK/QALY) 
Interferon  
beta-1b (Extavia) 
8,026,896 8.29     
Peg-interferon  
beta-1a 
(Plegridy) 
8,276,892 8.55 249,995 0.26 960,134 960,134 
Natalizumab 
(Tysabri) 
9,033,436 8.64 1,006,540 0.36 2,818796 7,823,148 
Dominated therapies 
Interferon 
beta-1b (Beta-
feron) 
8,090,003 8.29 255,409 - 
Dominated by 
interferon 
beta-1b  
(Extavia) 
Dominated by  
interferon 
beta-1b (Exta-
via) 
Glatiramer  ace-
tate (Copaxone) 
8,282,305 8.17 331,284 -0.11 Dominated 
Dominated by  
interferon 
beta-1b (Exta-
via), interferon 
beta-1b (Beta-
feron) and 
peg-interferon 
beta-1a 
Teriflunomide 
(Aubagio) 
8,358,180 8.26 565,095 -0.02 Dominated 
Dominated by  
interferon 
beta-1b (Exta-
via), interferon 
beta-1b (Beta-
feron) and 
peg-interferon 
beta-1a 
Interferon  
beta-1a 22 mcg 
(Rebif) 
8,591,992 8.02 576,680 -0.327 Dominated 
Dominated by  
interferon 
beta-1b (Exta-
via), interferon 
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QALY: quality-adjusted life year; ICER: incremental cost-effectiveness ratio; mcg: mi-
crogram; mg: milligram 
* Alemtuzumab still was more effective (QALYS: 9.24) and less costly (Costs: 6,541,067) rela-
tive to other treatments (dominant strategy). 
 
 
  
beta-1b (Beta-
feron), peg-in-
terferon beta-
1a, glatiramer 
acetate and 
teriflunomide 
Interferon beta-1a 
30 mg (Avonex) 
8,603,576 8.12 611,852 -0.16 Dominated  
Dominated by  
interferon 
beta-1b (Exta-
via), interferon 
beta-1b (Beta-
feron), peg-in-
terferon beta-
1a, glatiramer 
acetate and 
teriflunomide 
Interferon 
beta-1a 44 mcg 
(Rebif) 
8,638,748 8.19 717,167 -0.10 Dominated  
Dominated by  
interferon 
beta-1b (Exta-
via), interferon 
beta-1b (Beta-
feron),  peg-in-
terferon beta-
1a, glatiramer 
acetate and 
teriflunomide 
Dimethyl fumarate 
(Tecifidera) 
8,744,063 8.48 255,409 0.19 3,690,151 
Dominated 
peg-interferon 
beta-1a  
Fingolimod 
(Gilenya) 
9162,932 8.32 1,136,036 0.03 37,196,628 
Dominated by 
peg-interferon 
beta-1a, dime-
thyl fumarate 
and natali-
zumab  
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9.3: The results of sensitivity analysis regarding “no EDSS improve-
ment” (discounted) * 
Drugs 
Total costs 
(NOK) 
Effects 
 (QALYs) 
Versus Interferon beta-1b 250 mg (Extavia) 
Sequential 
ICER 
(NOK/QALY) Incremental 
cost (NOK) 
  Incremental 
effect  
(QALYs) 
ICER 
(NOK/QALY) 
Interferon  
beta-1b (Extavia) 
6,902,178 6.57     
Peg-interferon  
beta-1a 
(Plegridy) 
7,109,166 6.73 
206,988 
 0.16 
1,309,477 
 
1,309,477 
 
Natalizumab 
(Tysabri) 
7,706,752 6.78 
804,573 
 0.20 
3,935,743 
 
12,890,581 
 
Dominated therapies 
Interferon 
beta-1b (Beta-
feron) 
6,951,138 6.57 48,960 - 
Dominated by 
interferon 
beta-1b 
(Extavia) 
Dominated by  
interferon 
beta-1b (Exta-
via) 
Glatiramer acetate 
(Copaxone) 
7,104,889 6.49 202,710 -0.08 Dominated 
Dominated by  
interferon 
beta-1b (Exta-
via), interferon 
beta-1b (Beta-
feron) and 
peg-interferon 
beta-1a 
Teriflunomide 
(Aubagio) 
7,176,103 6.54 273,925 -0.03 Dominated 
Dominated by  
interferon 
beta-1b (Exta-
via), interferon 
beta-1b (Beta-
feron) and 
peg-interferon 
beta-1a 
Interferon  
beta-1a 22 mcg 
(Rebif) 
7,329,592 6.4 427,413 -0.17 Dominated 
Dominated by  
interferon 
beta-1b (Exta-
via), interferon 
 
 
 
 
230 
QALY: quality-adjusted life year; ICER: incremental cost-effectiveness ratio; mcg: mi-
crogram; mg: milligram 
* Alemtuzumab still was more effective (QALYS: 7.18) and less costly (Costs: 5,820,891) rela-
tive to other treatments (dominant strategy). 
 
 
  
beta-1b (Beta-
feron), peg-in-
terferon beta-
1a, glatiramer 
acetate and 
teriflunomide 
Interferon beta-1a 
30 mg (Avonex) 
7,362,604 6.45 460,425 -0.12 Dominated 
Dominated by  
interferon 
beta-1b (Exta-
via), interferon 
beta-1b (Beta-
feron), peg-in-
terferon beta-
1a, glatiramer 
acetate and 
teriflunomide 
Interferon 
beta-1a 44 mcg 
(Rebif) 
7,380,177 6,5 477,998 -0.07 Dominated 
Dominated by  
interferon 
beta-1b (Exta-
via), interferon 
beta-1b (Beta-
feron),  peg-in-
terferon beta-
1a, glatiramer 
acetate and 
teriflunomide 
Dimethyl fumarate 
(Tecifidera) 
7,470,947 6.68 568,769 0.11 
5,111,539 
 
Dominated 
peg-interferon 
beta-1a  
Fingolimod 
(Gilenya) 
7,768,104 
 6.60 
865,925 
 0.03 
28,491,096 
 
Dominated by 
peg-interferon 
beta-1a, dime-
thyl fumarate 
and natali-
zumab  
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9.4: The results of sensitivity analysis regarding utility values (dis-
counted) * 
Drugs 
Total costs 
(NOK) 
Effects 
 (QALYs) 
Versus Interferon beta-1b 250 mg (Extavia) 
Sequential 
ICER 
(NOK/QALY) Incremental 
cost (NOK) 
  Incremental 
effect  
(QALYs) 
ICER 
(NOK/QALY) 
Interferon  
beta-1b (Extavia) 
6,035,711 7.88     
Peg-interferon  
beta-1a 
(Plegridy) 
6,324,629 8.02 
288,918 
 0.15 
1,967,737 
 
1,967,737 
 
Natalizumab 
(Tysabri) 
7,000,849 8.08 
965,138 
 0.21 
4,649,607 
 
11,131,827 
 
Dominated therapies 
Interferon 
beta-1b (Beta-
feron) 
6,094,252 7.88 58,541 - 
Dominated by 
interferon 
beta-1b  
(Extavia) 
Dominated by  
interferon 
beta-1b (Exta-
via) 
Glatiramer acetate 
(Copaxone) 
6,259,628 7.79 223,917 -0.08 Dominated 
Dominated by  
interferon 
beta-1b (Exta-
via), interferon 
beta-1b (Beta-
feron) and 
peg-interferon 
beta-1a 
Teriflunomide 
(Aubagio) 
6,353,620 7.84 317,909 -0.03 Dominated 
Dominated by  
interferon 
beta-1b (Exta-
via), interferon 
beta-1b (Beta-
feron) and 
peg-interferon 
beta-1a 
Interferon  
beta-1a 22 mcg 
(Rebif) 
6,511,148 7.69 475,437 -0.19 Dominated 
Dominated by  
interferon 
beta-1b (Exta-
via), interferon 
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QALY: quality-adjusted life year; ICER: incremental cost-effectiveness ratio; mcg: mi-
crogram; mg: milligram 
* Alemtuzumab still was more effective (QALYS: 8.46) and less costly (Costs: 4,985,254) rel-
ative to other treatments (dominant strategy). 
beta-1b (Beta-
feron), peg-in-
terferon beta-
1a, glatiramer 
acetate and 
teriflunomide 
Interferon beta-1a 
30 mg (Avonex) 
6,556,702 7.74 520,991 -0.13 Dominated 
Dominated by 
interferon 
beta-1b (Exta-
via), interferon 
beta-1b (Beta-
feron), peg-in-
terferon beta-
1a, glatiramer 
acetate and 
teriflunomide 
Interferon 
beta-1a 44 mcg 
(Rebif) 
6,586,671 7.79 550,959 -0.08 Dominated 
Dominated by 
interferon 
beta-1b (Exta-
via), interferon 
beta-1b (Beta-
feron),  peg-in-
terferon beta-
1a, glatiramer 
acetate and 
teriflunomide 
Dimethyl fumarate 
(Tecifidera) 
6,715,056 7.99 679,345 0.11 
6,182,526 
 
Dominated 
peg-interferon 
beta-1a  
Fingolimod 
(Gilenya) 
7,059,978 
 7.89 
1,024,267 
 0.01 
78,665,232 
 
Dominated by 
peg-interferon 
beta-1a, dime-
thyl fumarate 
and natali-
zumab  
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